
<html lang="en"     class="pb-page"  data-request-id="e9205053-ae0f-494a-8cdc-685ad74dcc2e"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2016.59.issue-14;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.6b00608"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="4-Oxo-1,4-dihydroquinoline-3-carboxamide Derivatives as New Axl Kinase Inhibitors" /></meta><meta name="dc.Creator" content="Li  Tan" /></meta><meta name="dc.Creator" content="Zhang  Zhang" /></meta><meta name="dc.Creator" content="Donglin  Gao" /></meta><meta name="dc.Creator" content="Jinfeng  Luo" /></meta><meta name="dc.Creator" content="Zheng-Chao  Tu" /></meta><meta name="dc.Creator" content="Zhengqiu  Li" /></meta><meta name="dc.Creator" content="Lijie  Peng" /></meta><meta name="dc.Creator" content="Xiaomei  Ren" /></meta><meta name="dc.Creator" content="Ke  Ding" /></meta><meta name="dc.Description" content="Axl is a new potential target for anticancer drug discovery. A series of 4-oxo-1,4-dihydroquinoline-3-carboxamides were designed and synthesized as highly potent Axl kinase inhibitors. One of the m..." /></meta><meta name="Description" content="Axl is a new potential target for anticancer drug discovery. A series of 4-oxo-1,4-dihydroquinoline-3-carboxamides were designed and synthesized as highly potent Axl kinase inhibitors. One of the m..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 19, 2016" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b00608" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2016 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00608" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b00608" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00608" /></link>
        
    
    

<title>4-Oxo-1,4-dihydroquinoline-3-carboxamide Derivatives as New Axl Kinase Inhibitors | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b00608" /></meta><meta property="og:title" content="4-Oxo-1,4-dihydroquinoline-3-carboxamide Derivatives as New Axl Kinase Inhibitors" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/large/jm-2016-00608n_0014.jpeg" /></meta><meta property="og:description" content="Axl is a new potential target for anticancer drug discovery. A series of 4-oxo-1,4-dihydroquinoline-3-carboxamides were designed and synthesized as highly potent Axl kinase inhibitors. One of the most promising compounds, 9im, tightly bound with Axl protein and potently inhibited its kinase function with a Kd value of 2.7 nM and an IC50 value of 4.0 nM, respectively, while was obviously less potent against most of the 403 wild-type kinases evaluated at a relatively high concentration. The compound dose-dependently inhibited the TGF-β1-induced epithelial–mesenchymal transition (EMT) and suppressed the migration and invasion of MDA-MB-231 breast cancer cells. In addition, 9im also demonstrated reasonable pharmacokinetics properties in rats and exhibited in vivo therapeutic effect on hepatic metastasis in a xenograft model of highly metastatic 4T1 murine breast cancer cells. Compound 9im may serve as a lead compound for new anticancer drug discovery and a valuable research probe for further biological investigation on Axl." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b00608"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b00608">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b00608&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b00608&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b00608&amp;href=/doi/10.1021/acs.jmedchem.6b00608" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2016</span><span class="cit-fg-volume">, 59</span><span class="cit-fg-issue">, 14</span><span class="cit-fg-pageRange">, 6807-6825</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/59/14" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.6b00562" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.6b00639" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">4-Oxo-1,4-dihydroquinoline-3-carboxamide Derivatives as New Axl Kinase Inhibitors</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Li++Tan">Li Tan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Zhang++Zhang">Zhang Zhang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Donglin++Gao">Donglin Gao</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jinfeng++Luo">Jinfeng Luo</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Zheng-Chao++Tu">Zheng-Chao Tu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Zhengqiu++Li">Zhengqiu Li</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lijie++Peng">Lijie Peng</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xiaomei++Ren">Xiaomei Ren</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ke++Ding">Ke Ding</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">State Key Laboratory of Respiratory Diseases, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, 190 Kaiyuan Avenue, Guangzhou 510530, China</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">School of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">University of Chinese Academy of Sciences, 19 Yuquan Road, Beijing 100049, China</span></div><div class="corresp-info"><strong>*</strong>Tel: +86-20-85228025. Fax: +86-20-85224766. E-mail: <a href="/cdn-cgi/l/email-protection#a7c3cec9c0ccc2e7cdc9d289c2c3d289c4c9"><span class="__cf_email__" data-cfemail="5c3835323b37391c36322972393829723f32">[email protected]</span></a> (K.D.).</div><div class="corresp-info"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#6113040f3e1908000e0c040821060803094f00024f020f"><span class="__cf_email__" data-cfemail="e496818abb9c8d858b89818da4838d868cca8587ca878a">[email protected]</span></a> (R.M.).</div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00608&amp;href=/doi/10.1021%2Facs.jmedchem.6b00608" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2016</span></span><span class="cit-volume">, 59</span><span class="cit-issue">, 14</span><span class="cit-pageRange">, 6807–6825</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">July 5, 2016</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>20 April 2016</li><li><span class="item_label"><b>Published</b> online</span>19 July 2016</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 28 July 2016</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b00608" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00608</a></div><div class="article_header-article-copyright"><strong>Copyright © 2016 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D6807%26pageCount%3D19%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DLi%2BTan%252C%2BZhang%2BZhang%252C%2BDonglin%2BGao%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D59%26issueNum%3D14%26contentID%3Dacs.jmedchem.6b00608%26title%3D4-Oxo-1%252C4-dihydroquinoline-3-carboxamide%2BDerivatives%2Bas%2BNew%2BAxl%2BKinase%2BInhibitors%26numPages%3D19%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D6825%26publicationDate%3DJuly%2B2016">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b00608"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2906</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">24</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b00608" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;4-Oxo-1,4-dihydroquinoline-3-carboxamide Derivatives as New Axl Kinase Inhibitors&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Li&quot;,&quot;last_name&quot;:&quot;Tan&quot;},{&quot;first_name&quot;:&quot;Zhang&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Donglin&quot;,&quot;last_name&quot;:&quot;Gao&quot;},{&quot;first_name&quot;:&quot;Jinfeng&quot;,&quot;last_name&quot;:&quot;Luo&quot;},{&quot;first_name&quot;:&quot;Zheng-Chao&quot;,&quot;last_name&quot;:&quot;Tu&quot;},{&quot;first_name&quot;:&quot;Zhengqiu&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Lijie&quot;,&quot;last_name&quot;:&quot;Peng&quot;},{&quot;first_name&quot;:&quot;Xiaomei&quot;,&quot;last_name&quot;:&quot;Ren&quot;},{&quot;first_name&quot;:&quot;Ke&quot;,&quot;last_name&quot;:&quot;Ding&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2016&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;19&quot;,&quot;issue&quot;:&quot;14&quot;,&quot;volume&quot;:&quot;59&quot;,&quot;pages&quot;:&quot;6807-6825&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b00608&quot;},&quot;abstract&quot;:&quot;Axl is a new potential target for anticancer drug discovery. A series of 4-oxo-1,4-dihydroquinoline-3-carboxamides were designed and synthesized as highly potent Axl kinase inhibitors. One of the most promising compounds, 9im, tightly bound with Axl protein and potently inhibited its kinase function with a Kd value of 2.7 nM and an IC50 value of 4.0 nM, respectively, while was obviously less potent against most of the 403 wild-type kinases evaluated at a relatively high concentration. The compound dose-dependently inhibited the TGF-β1-induced epithelial–mesenchymal transition (EMT) and suppressed the migration and invasion of MDA-MB-231 breast cancer cells. In addition, 9im also demonstrated reasonable pharmacokinetics properties in rats and exhibited in vivo therapeutic effect on hepatic metastasis in a xenograft model of highly metastatic 4T1 murine breast cancer cells. Compound 9im may serve as a lead compound for new anticancer drug discovery and a valuable research probe for further biological investigat&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00608&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00608" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00608&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00608" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00608&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00608" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00608&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00608&amp;href=/doi/10.1021/acs.jmedchem.6b00608" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b00608" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b00608" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00608&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b00608%26sid%3Dliteratum%253Aachs%26pmid%3D27379978%26genre%3Darticle%26aulast%3DTan%26date%3D2016%26atitle%3D4-Oxo-1%252C4-dihydroquinoline-3-carboxamide%2BDerivatives%2Bas%2BNew%2BAxl%2BKinase%2BInhibitors%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D59%26issue%3D14%26spage%3D6807%26epage%3D6825%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/59/14" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/jmcmar.2016.59.issue-14/20160728/jmcmar.2016.59.issue-14.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/medium/jm-2016-00608n_0014.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/large/jm-2016-00608n_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00608&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Axl is a new potential target for anticancer drug discovery. A series of 4-oxo-1,4-dihydroquinoline-3-carboxamides were designed and synthesized as highly potent Axl kinase inhibitors. One of the most promising compounds, <b>9im</b>, tightly bound with Axl protein and potently inhibited its kinase function with a <i>K</i><sub>d</sub> value of 2.7 nM and an IC<sub>50</sub> value of 4.0 nM, respectively, while was obviously less potent against most of the 403 wild-type kinases evaluated at a relatively high concentration. The compound dose-dependently inhibited the TGF-β1-induced epithelial–mesenchymal transition (EMT) and suppressed the migration and invasion of MDA-MB-231 breast cancer cells. In addition, <b>9im</b> also demonstrated reasonable pharmacokinetics properties in rats and exhibited <i>in vivo</i> therapeutic effect on hepatic metastasis in a xenograft model of highly metastatic 4T1 murine breast cancer cells. Compound <b>9im</b> may serve as a lead compound for new anticancer drug discovery and a valuable research probe for further biological investigation on Axl.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28554" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28554" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Axl is a member of the receptor tyrosine kinase TAM (i.e., Tyro3, Axl, and c-mer proto-oncogene tyrosine kinase (Mer)) subfamily, which was originally identified as a transforming gene in cells from chronic myeloid leukemia (CML) patients.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Upon activation by the ligand growth arrest-specific 6 (Gas6),<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Axl demonstrates pivotal roles in many fundamental cellular processes, including survival,<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> proliferation,<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> differentiation,<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> migration, invasion, angiogenesis, etc.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Dysregulation of Axl signaling has been implicated in various types of human cancers as well as inflammation and autoimmune, vascular, and kidney diseases.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Overexpression of Axl is frequently detected and closely correlated to the poor prognosis in lung cancer,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> breast cancer,<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> hepatic cellular cancer (HCC),<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> pancreatic cancer,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> squamous-cell carcinoma (SCC),<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> prostate carcinoma,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> gastrointestinal stromal tumors (GIST),<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> melanomas,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> renal cell carcinoma (RCC),<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> leukemia,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> colorectal carcinoma (CRC),<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> ovarian cancer,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> and others.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Collective studies have suggested that abnormal activation of Axl signaling is one prominent mechanism by which tumor cells undergo epithelial–mesenchymal transition (EMT)<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> and develop drug resistance to both targeted therapies and chemotherapy.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> For instance, a high level of Axl is an important hallmark in invasive estrogen receptor positive (ER<sup>+</sup>) breast cancer cells, while it is generally expressed at low concentration in healthy breast tissue.<a onclick="showRef(event, 'cit9a'); return false;" href="javascript:void(0);" class="ref cit9a">(9a)</a> Axl was also identified as an essential EMT-induced regulator of metastasis to mediate the clinical resistance against lapatinib and traztuzumab in human epidermal growth factor receptor 2 positive (Her2<sup>+</sup>) and/or ER<sup>+</sup> breast cancer patients.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Thus, Axl becomes a new promising molecular target for anticancer drug discovery.</div><div class="NLM_p">Several well-characterized receptor tyrosine kinase inhibitors (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) were discovered to nonselectively inhibit Axl with low nM IC<sub>50</sub> values, among which <b>1</b> (Cabozantinib),<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a><i>(R)</i>-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1<i>H</i>-pyrazol-4-yl)pyridin-2-amine (Crizotinib),<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a><i>N</i>-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine (Bosutinib),<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> and <i>(Z)</i>-<i>N</i>-(2-(diethylamino)ethyl)-5-(5-fluoro-2-oxo-2,3-dihydro-1<i>H</i>-indol-3-ylidenemethyl)-2,4-dimethyl-1<i>H</i>-pyrrole-3-carboxamide (Sunitinib)<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> have been approved by U.S. Food and Drug Administration (FDA) for clinical management of different human cancers. Other molecules, such as <b>2</b> (Foretinib),<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a><b>3</b> (Merestinib),<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> 6-ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-(tetrahydro-2<i>H</i>-pyran-4-ylamino)pyrazine-2-carboxamide (Gilteritinib),<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a><i>(Z)</i>-3-((3-((4-(morpholinomethyl)-1<i>H</i>-pyrrol-2-yl)methylene)-2-oxoindolin-5-yl)methyl)thiazolidine-2,4-dione (S49076),<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a><b>4</b> (BMS777607),<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a><b>5</b> (MGCD265),<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> and <b>6</b> (NPS-1034),<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> are also in different stages of clinical investigation. However, none of these inhibitors were developed by using Axl as the primary target. Only recently, <b>7</b> (R428, BGB324)<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> was disclosed as the first selective Axl inhibitor to potently inhibit the kinase with an IC<sub>50</sub> value of 14.0 nM and demonstrated promising therapeutic efficacy against various human cancer models. The molecule has been advanced into phase I clinical trial and was granted as “orphan-drug” designation for treatment of acute myeloid leukemia (AML). Compound <b>8</b> (TP-0903),<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> another selective Axl inhibitor, also displayed promising therapeutic potential in preclinical evaluations. However, given the fact that no selective Axl inhibitor has been approved for clinical application, it is highly desirable to discover new Axl inhibitors with distinct chemical scaffolds and improved target selectivity. In this Article, we report a series of 4-oxo-1,4-dihydroquinoline-3-carboxamides as new Axl inhibitors.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/medium/jm-2016-00608n_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/large/jm-2016-00608n_0002.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of reported selective and nonselective Axl inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/large/jm-2016-00608n_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00608&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Molecular Design</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01787" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01787" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">There is no X-ray crystal structure of Axl kinase domain reported to date. Structural feature analysis of the reported selective/nonselective Axl inhibitors (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) revealed that most of the compounds consist of several key structural elements which might form crucial interactions with the protein:<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> (1) a heterocyclic moiety (so-called “head region”) possibly binding to the adenine pocket and forming hydrogen bond network with residues in the hinge region of the kinase; (2) a dual hydrogen bond acceptor (DHBA) moiety (e.g., 1,3-diketone) which might form additional hydrogen bond networks with back pocket of the protein (“DHBA group”); and (3) a 1,4-disubstituted phenyl group as a potential linker between the “head region” and the “DHBA group” (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). Based on this observation, a series of 4-oxo-1,4-dihydroquinoline-3-carboxamide derivatives were designed as new potential selective Axl inhibitors in which a privileged quinolone scaffold, which has been widely applied in a number of FDA approved antibacterial drugs (e.g., ciprofloxacin<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> and levofloxacin<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a>), was utilized as the “DHBA group”.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/medium/jm-2016-00608n_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/large/jm-2016-00608n_0003.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Design strategy of the potential new selective Axl inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/large/jm-2016-00608n_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00608&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04336" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04336" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Synthesis of the designed compounds is outlined in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Briefly, commercially available 4-chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>10</b>) was reacted with substituted 4-nitrophenols (<b>11</b>) under microwave to yield compounds <b>12</b>, which were further iodinated and subsequently protected with (2-(chloromethoxy)ethyl)trimethylsilane (SEMCl) to produce intermediates <b>14</b>. Suzuki coupling<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> of compounds <b>14</b> with different substituted phenylboronic acids (<b>15</b>) under air-free condition produced the corresponding products <b>16</b>. Reduction of <b>16</b> yielded the key intermediates <b>17</b>, which were condensed with quinolonic acids <b>29</b> to afford compounds <b>18</b>. Deprotection of <b>18</b> under standard conditions produced the final products <b>9</b> in good or moderate yields.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/medium/jm-2016-00608n_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/large/jm-2016-00608n_0008.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>9</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/large/jm-2016-00608n_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00608&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) ethyl diisopropylamine (DIPEA), 1-methyl-2-pyrrolidinone (NMP), microwave, 200 °C, 1.0 h, 30–85%; (b) iodine, KOH, <i>N,N</i>-dimethylformamide (DMF), 0 °C, 4.0 h, 75–80%; (c) SEMCl, NaOH, DMF, room temperature (rt), overnight, 70–78%; (d) Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, toluene, 90 °C, overnight, 65–75%; (e) NiCl<sub>2</sub>·6H<sub>2</sub>O, NaBH<sub>4</sub>, tetrahydrofuran (THF), MeOH, rt, 2.0 h, 60–72%; (f) 2-(7-aza-1<i>H</i>-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU), DIPEA, DMF, rt, overnight, 68–85%; (g) trifluoroacetic acid (F<sub>3</sub>CCOOH), dichloromethane (DCM), rt, overnight, 85–90%; (h) NaOH, THF–H<sub>2</sub>O, rt, overnight, 80–90%.</p></p></figure><div class="NLM_p">The key intermediates <b>29</b> were synthesized via two different methods (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>) by starting from 2-aminobenzoic acids (<b>20</b>) or anilines <b>25</b>, respectively. Substituted 2-aminobenzoic acids (<b>20</b>) reacted with triphosgene to produce compounds <b>21</b>, which was subsequently <i>N</i>-alkalized and condensed with alkyl 3-oxobutanoate <b>22</b> to yield intermediates <b>24</b>. Compounds <b>24</b> were hydrolyzed under base conditions to obtain the intermediates <b>29</b>. Alternatively, substituted anilines <b>25</b> reacted with diethyl 2-acetylmalonate or diethyl 2-(ethoxymethylene)malonate to produce intermediates <b>27</b>. Compounds <b>27</b> were alkylated to yield esters <b>28</b>, which were hydrolyzed to produce quinolonic acids <b>29</b> in good yields.</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/medium/jm-2016-00608n_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/large/jm-2016-00608n_0009.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Intermediates <b>29</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/large/jm-2016-00608n_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00608&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) triphosgene, pyridine, acetonitrile (MeCN), 0–55 °C, 2.0 h, 82–94%; (j) R<sub>2</sub>I, DIPEA, DMF, 40 °C, overnight, 75–82%; (k) <b>22</b>, NaH, DMF, 120 °C, overnight, 70–85%; (l) diethyl 2-acetylmalonate or diethyl 2-(ethoxymethylene)malonate, <i>p</i>-toluenesulfonic acid, H<sub>2</sub>O, pentane, reflux, overnight, 75–90%; (m) diphenyl oxide, 200 °C, 2.0 h, or polyphosphoric acid (PPA), 100 °C, overnight, 75–90%; (n) MeI, K<sub>2</sub>CO<sub>3</sub>, DMF, 50 °C, overnight, 78–88%; (o) NaOH, THF–H<sub>2</sub>O, reflux, overnight, 84–93%.</p></p></figure><div class="NLM_p last">Compound <b>9im</b> was prepared by utilizing commercially available 4-chloro-6,7-dimethoxyquinazoline as the starting material and following the procedures of the other designed molecules.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82354" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82354" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Axl inhibitory activities of the designed compounds <b>9</b> were preliminarily evaluated via a well-established fluorescence resonance energy transfer (FRET)-based Z′-Lyte assays according to the manufactory’s instructions (Invitrogen, Carsbad, USA).<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Two well characterized Axl inhibitors <b>4</b> and <b>7</b> were included as the positive controls to validate the screening conditions. Under the experimental conditions, both of the compounds displayed strong inhibition against Axl with IC<sub>50</sub> values of 6.0 and 5.0 nM, respectively, which are similar to the previously reported data.<a onclick="showRef(event, 'ref32 ref35'); return false;" href="javascript:void(0);" class="ref ref32 ref35">(32, 35)</a></div><div class="NLM_p">We initially investigated if the quinolone moiety is suitable to serve as a “DHBA group” to demonstrate Axl inhibition. Therefore, a bivalent 5-phenyl-7<i>H</i>-pyrrolo-[2,3-<i>d</i>]pyrimidinyl group was applied as the potential hinge binding “head region” based on the chemical structure of compound <b>6</b> in the newly designed compounds <b>9</b>. A generally utilized 2-fluoro-1,4-substituted phenyl linker was also adopted from the newly reported inhibitors. Although the R<sub>1</sub>-unsubstituted dihydroquinoline derivative <b>9a</b> did not show obvious inhibition against Axl at 10.0 μM (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>), a 4-chloro substitution at the quinolone scaffold (<b>9c</b>) significantly improved the kinase inhibitory potency. Compound <b>9c</b> displayed an IC<sub>50</sub> value of 1.89 μM. Though this compound is approximately 500 times less potent than the reference molecules <b>4</b> and <b>7</b>, it could provide a starting point for further structural optimization. Further investigation also suggested that the 4-position of the quinolone is optimal for substitution. When the R<sub>1</sub>-chloro group was introduced at the 3- or 5-position, the resulting compounds (<b>9b</b> and <b>9d</b>, respectively) were totally inactive. Thus, a variety of substituted groups were introduced in the 4-position with the aim of improving the Axl inhibitory activity. It was shown that 4-substituent had significant and diversified impact on the Axl kinase inhibitory activity. Although the 4-bromo compound <b>9f</b> displayed comparable Axl inhibitory effect to that of compound <b>9c</b>, the 4-fluoro derivative (<b>9e</b>) totally abolished its potency. Encouragingly, when the 4-chloro group in <b>9c</b> was replaced by 4-methyl (<b>9h</b>) or 4-trifluoromethyl (<b>9g</b>), the Axl inhibitory activity was obviously improved by 12–19-fold. The IC<sub>50</sub> values of the corresponding compounds were 0.10 and 0.15 μM, respectively. Further investigation also revealed that the 4-choro group in <b>9c</b> could also be replaced by 4-cyclopropyl (<b>9j</b>), 4-isopropyl (<b>9k</b>), 4-prop-1-en-2-yl (<b>9l</b>), 4-<i>n</i>-propyl (<b>9m</b>), 4-<i>tert</i>-butyl (<b>9n</b>), 4-cyclopentyl (<b>9o</b>), 4-methoxyl (<b>9s</b>) or 4-trifluoromethoxyl (<b>9t</b>) substituent to obviously improve the potency. The compounds exhibited IC<sub>50</sub> values ranged from 0.23 to 0.026 μM. Significantly, 4-ethyl compound (<b>9i</b>) demonstrated the strongest potency with an IC<sub>50</sub> value of 6.0 nM against Axl kinase, which is equally potent to the positive controls <b>7</b> and <b>4</b>. However, when a phenyl (<b>9q</b>) or methoxy carbonyl (<b>9u</b>) was introduced at the 4-position, the resulting compounds totally abolished their Axl inhibitory activities. A cyclopent-1-en-1-yl substitution at the 4-position also caused a 2-fold potency loss. A 1-oxo-1,4-dihydrobenzo[<i>f</i>]quinoline-2-carboxamide derivative (<b>9r</b>) was also designed and synthesized to display no inhibition against Axl at 10.0 μM.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. <i>In Vitro</i> Axl Kinase Inhibitory Activities of Inhibitors <b>9a</b>–<b>9ic</b><a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/medium/jm-2016-00608n_0010.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/medium/jm-2016-00608n_0011.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">Axl kinase inhibition was determined by using a FRET-based Z′-Lyte assay according to the manufactory’s instructions (Invitrogen, Carsbad, USA).<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> The compounds were incubated with the kinase reaction mixture for 1–1.5 h before measurement. Reported data are means from two independent experiments in which the variation is less than 20%.</p></div></div><div></div></div><div class="NLM_p">Potential impact of R<sub>2</sub> or R<sub>3</sub> substituent on the Axl inhibition was also investigated. It was shown that the <i>N</i>-methyl (R<sub>2</sub>) group in <b>9h</b> was able to be replaced by an ethyl group (<b>9hb</b>) without obviously affecting the Axl inhibitory potency. However, when the R<sub>2</sub> position was introduced with a large hydrophobic group such as an <i>n</i>-propyl (<b>9hc</b>), <i>n</i>-butyl (<b>9hd</b>) or phenyl (<b>9he</b>) moiety, the potency was decreased by about 4–5-fold. The investigation also revealed that R<sub>3</sub> position is well tolerated to either small or large hydrophobic group without obviously affecting the kinase inhibitory activity. For instance, compounds <b>9hf</b>, <b>9hg</b>, and <b>9hh</b> displayed IC<sub>50</sub> values of 0.15, 0.078, and 0.078 μM, respectively, which are almost identical to that of <b>9h</b>.</div><div class="NLM_p">Further investigation also suggested that the 2′-fluoro substituent was critical to the strong Axl inhibition of compound <b>9i</b>. When the 2′-fluoro group was removed (<b>9ib</b>) or merged to 3′ position (<b>9ia</b>), the resulting compounds displayed 5–16-fold potency loss. It was noteworthy that the 2′-methyl compound <b>9ic</b> also showed significantly decreased Axl inhibitory activity, with an IC<sub>50</sub> value of 1.12 μM, which is approximately 170-fold less potent than the parental compound <b>9i</b>.</div><div class="NLM_p">We further investigated contribution of the potential hinge binding 7<i>H</i>-pyrrolo[2,3-<i>d</i>] pyrimidine group to the Axl kinase inhibition by replacing it with a variety of heterocyclic groups by using <b>9i</b> as the template molecule. It was found that the 7″-phenyl group is important for the strong Axl kinase inhibition of <b>9i</b> (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). When the 7″-phenyl group was removed (<b>9id</b>) or replaced with a 1-methyl-1<i>H</i>-pyrazol-4-yl (<b>9ie</b>) group, the resulting compounds exhibited 6–26-fold lower potency. The replacement of 5-phenyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl hinge binding moiety with a 3-phenyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-4-yl group (<b>9if</b>) also caused a 5-time potency loss. The IC<sub>50</sub> value of <b>9if</b> was 0.03 μM against Axl. More significantly, the 3-phenyl benzofuran-4-yl derivative displayed an IC<sub>50</sub> value of 0.19 μM, which is 32 times less potent than the parental compound <b>9i</b>. The potential hinge binding group was further changed to various monocyclic pyridinyl moieties, such as 2-chloropyridinyl (<b>9ih</b>), 2-aminopyridinyl (<b>9ii</b>), 2-aminocarbonatepyridinyl (<b>9ij</b>), 2-amino-3-chloropyridinyl (<b>9ik</b>), or 2-aminocarbonate-3-choloropyridinyl (<b>9il</b>). All of the resulting compounds displayed significantly lower potencies than the original molecule <b>9i</b>. Particularly, compounds <b>9ih</b> and <b>9il</b> totally abolished the Axl inhibitory potencies. Interestingly, when a 6,7-dimethoxyquinazolin-4-yl group was utilized as the potential hinge binding moiety, the resulting compound <b>9im</b> displayed an IC<sub>50</sub> value of 4.0 nM against Axl, making it equally potent to compound <b>9i</b>. Thus, compounds <b>9i</b> and <b>9im</b> represented the most potent Axl inhibitors for further biological investigation.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. <i>In Vitro</i> Axl Kinase Inhibitory Activities of Inhibitors <b>9id</b>–<b>9im</b><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/medium/jm-2016-00608n_0012.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/medium/jm-2016-00608n_0013.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">Axl kinase inhibition was determined by uing an FRET-based Z′-Lyte assay according to the manufactory’s instructions (Invitrogen, Carsbad, USA).<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> The compounds were incubated with the kinase reaction mixture for 1–1.5 h before measurement. Reported data are means from two independent experiments in which the variation is less than 20%.</p></div></div><div></div></div><div class="NLM_p">The binding of compounds <b>9i</b> and <b>9im</b> with Axl protein was further determined by using an active-site-dependent competition binding assay (conducted by DiscoveRx Corp., San Diego, USA).<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> It was found that the compounds tightly bound to ATP-binding site of the kinase with binding constant (<i>K</i><sub>d</sub>) values of 1.2 and 2.7 nM, respectively, which validated their strong kinase inhibition against Axl. To demonstrate the target selectivity of the compounds, a kinase selectivity profiling study was conducted against a panel of 468 kinases (including 403 nonmutated kinases) at 1.0 μM by using the DiscovRx screening platform. It was shown that both <b>9i</b> and <b>9im</b> displayed good target selectivity (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>). For instance, <b>9im</b> exhibited S(1), S(10), and S(35) scores of 0.005, 0.037, and 0.082, respectively, while the corresponding S(1), S(10), and S(35) scores of the clinical investigated inhibitor <b>7</b> were 0.032, 0.117, and 0.243, respectively, at the same concentration (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>).<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> These data implied that compound <b>9im</b> might achieve a better target selectivity than the positive control <b>7</b>.</div><div class="NLM_p">In addition to its primary target Axl, compound <b>9im</b> also displayed obvious binding with several tyrosine or serine/threonine kinases including abelson murine leukemia viral oncogene (Abl), Aurora A, Aurora B, B lymphoid tyrosine kinase (BLK), cyclin-dependent-kinase 11 (CDK 11), CDK 8, discoidin domain receptor 1 (DDR1), DDR2, death-associated protein kinase related 1 (DRAK1), FMS-like tyrosine kinase 3 (Flt3), homeodomain interacting protein kinase 4 (HIPK4), v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homologue (Kit), serine/threonine kinase 10 (LOK), mitogen-activated protein kinase kinase 5 (MEK1), Ste-like kinase (SLK), nerve growth factor receptor A (TrkA) and TrkB etc. The binding affinities (<i>K</i><sub>d</sub>) or kinase inhibitory activities (IC<sub>50</sub>) of compound <b>9im</b> against these “off targets” were further determined by using DiscoveRx’s platform or our in-house kinase assays (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). It was shown that compound <b>9im</b> displayed approximately 25–430-fold higher potency against Axl than most of the “off target” kinases. However, it also exhibited strong potencies against several human cancer-related kinases such as DDR1, Flt3, LOK, MEK5, Met, Trk A, and Trk B with <i>K</i><sub>d</sub> or IC<sub>50</sub> values below 100 nM.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> It is noteworthy that some of these kinases (e.g., Flt3, Met, and MEK5) have been well validated as molecular targets for new anticancer drug discovery.<a onclick="showRef(event, 'cit43b cit43c cit43d'); return false;" href="javascript:void(0);" class="ref cit43b cit43c cit43d">(43b, 43d, 43e)</a> However, strong inhibition against the “off targets” may also raise some potential toxicity concern about the further development of this compound. The binding affinities of <b>9im</b> with the other TAM tyrosine kinase members (Tyro3 and Mer) were also determined. It was shown that <b>9im</b> exhibited a similar potency to Mer with a <i>K</i><sub>d</sub> value of 1.4 nM, while it was less potent to Tyro3 with a <i>K</i><sub>d</sub> value of 58 nM.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Binding Affinities or Kinase Inhibition of Compound <b>9im</b> against a Panel of “Off-Target” Kinases</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col /></col><col align="left" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center"><i>K</i><sub>d</sub> or IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center"><i>K</i><sub>d</sub> or IC<sub>50</sub>(nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ALK</td><td class="colsep0 rowsep0" align="center">>1000<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" rowspan="10" align="center"> </td><td class="colsep0 rowsep0" align="left">HIPK4</td><td class="colsep0 rowsep0" align="center">11.0<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Axl</td><td class="colsep0 rowsep0" align="center">2.7<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a> (4.0<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a>)</td><td class="colsep0 rowsep0" align="left">Kit</td><td class="colsep0 rowsep0" align="center">1673<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BLK</td><td class="colsep0 rowsep0" align="center">200<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">LOK</td><td class="colsep0 rowsep0" align="center">10<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Aurora A</td><td class="colsep0 rowsep0" align="center">192.4<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">MEK5</td><td class="colsep0 rowsep0" align="center">38<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Aurora B</td><td class="colsep0 rowsep0" align="center">114.4<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">Mer</td><td class="colsep0 rowsep0" align="center">1.4<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK11</td><td class="colsep0 rowsep0" align="center">470<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">Met</td><td class="colsep0 rowsep0" align="center">79.0<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK8</td><td class="colsep0 rowsep0" align="center">>1000<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">SLK</td><td class="colsep0 rowsep0" align="center">240<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DDR1</td><td class="colsep0 rowsep0" align="center">22.2<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">TrkA</td><td class="colsep0 rowsep0" align="center">50<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DDR2</td><td class="colsep0 rowsep0" align="center">349.6<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">TrkB</td><td class="colsep0 rowsep0" align="center">54<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Flt3</td><td class="colsep0 rowsep0" align="center">4.0<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a> (<10.0<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a>)</td><td class="colsep0 rowsep0" align="left">Tyro3</td><td class="colsep0 rowsep0" align="center">58<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">The binding affinities (<i>K</i><sub>d</sub>) were determined by using DiscoveRx’s platform.</p></div><div class="footnote" id="t3fn2"><sup>b</sup><p class="last">The kinase inhibitory activities (IC<sub>50</sub>) were evaluated by using “in-house” kinase assays. Reported data are means from two independent experiments in which the variation is less than 20%.</p></div></div></div><div class="NLM_p">The inhibitory effect of compounds <b>9i</b> and <b>9im</b> on the activation of Axl and downstream Akt signal in MDA-MB-231 breast cancer cells was also investigated to validate its strong Axl kinase inhibition (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>). Previous studies reported that MDA-MB-231 cancer cells harbor a high level of Axl,<a onclick="showRef(event, 'cit9b cit22e ref44'); return false;" href="javascript:void(0);" class="ref cit9b cit22e ref44">(9b, 22e, 44)</a> and the phosphorylation of Akt becomes one of the significant consequent signal responses upon Axl activation in various human cancer cells.<a onclick="showRef(event, 'cit8d cit12c ref44 ref45'); return false;" href="javascript:void(0);" class="ref cit8d cit12c ref44 ref45">(8d, 12c, 44, 45)</a> The results revealed that both compound <b>9i</b> and <b>9im</b> dose-dependently inhibited the phosphorylation of Axl (pAxl (Tyr<sup>702</sup>)) and the downstream Akt without obvious effect on their total proteins in MDA-MB-231 cancer cells, with potencies similar to that of the clinical candidate <b>7</b>.</div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/medium/jm-2016-00608n_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/large/jm-2016-00608n_0004.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Inhibitors <b>9i</b>, <b>9im</b>, and <b>7</b> suppress the Axl signaling pathway in MDA-MB-231 breast cancer cells. (A) Compound <b>7</b> inhibits activation of Axl and downstream signaling in MDA-MB-231 cells after 6-h treatments. (B) Compound <b>9i</b> inhibits phosphorylation of Axl and downstream signaling in MDA-MB-231 cells after 6-h treatments. (C) Compound <b>9im</b> inhibits phosphorylation of Axl and downstream signaling in MDA-MB-231 cells after 6-h treatments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/large/jm-2016-00608n_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00608&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Antiproliferative effect of the compounds was also evaluated. It was shown that both compound <b>9i</b> and <b>9im</b> demonstrated poor antiproliferative activities against MDA-MB-231 human breast cancer cells and Axl overexpressing 4T1 murine breast cancer cells with IC<sub>50</sub> values greater than 10.0 μM, which is similar to the previous observation on <b>7</b>.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> The relatively low cell growth inhibitory activities suggested that Axl might not be the “driving force” for proliferation of the cancer cells.</div><div class="NLM_p">Given their promising <i>in vitro</i> Axl inhibitory activities, the <i>in vivo</i> pharmacokinetic (PK) profiles of compounds <b>9i</b> and <b>9im</b> were further investigated in Sprague–Dawley (SD) rats (see <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). Plasma levels of the compounds were monitored after a single oral dose of 25 mg/kg or an i.v. dose of 2.5 mg/kg (<b>9i</b>) or 5.0 mg/kg (<b>9im</b>). It was disappointing that compound <b>9i</b> exhibited low exposure with an AUC value of 505.7 μg/L·h and a poor oral bioavailability of 1.2% after an oral administration. Encouragingly, compound <b>9im</b> demonstrated reasonable PK profiles with an oral AUC value of 31 505 μg/L·h, a <i>T</i><sub>1/2</sub> value of 10.2 h, and an oral bioavailability of 14.9%. In addition, a <i>C</i><sub>max</sub> value of 1967 μg/L (3.62 μM) was achieved in plasma after it was orally administrated at a dosage of 25 mg/kg, which was over 900 times higher than its <i>in vitro</i> IC<sub>50</sub> value against Axl kinase.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Pharmacokinetic Profile of Compounds <b>9i</b> and <b>9im</b> in Rats<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center"><b>9i</b></th><th class="rowsep1 colsep0" colspan="2" align="center"><b>9im</b></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">oral 25 mg/kg</th><th class="colsep0 rowsep0" align="center">i.v. 2.5 mg/kg</th><th class="colsep0 rowsep0" align="center">oral 25 mg/kg</th><th class="colsep0 rowsep0" align="center">i.v. 5 mg/kg</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC(0–∞) (μg/L·h)</td><td class="colsep0 rowsep0" align="center">505.7</td><td class="colsep0 rowsep0" align="center">3029.6</td><td class="colsep0 rowsep0" align="center">31 505</td><td class="colsep0 rowsep0" align="center">42 325</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="center">3.72</td><td class="colsep0 rowsep0" align="center">0.87</td><td class="colsep0 rowsep0" align="center">10.2</td><td class="colsep0 rowsep0" align="center">25.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub> (h)</td><td class="colsep0 rowsep0" align="center">0.67</td><td class="colsep0 rowsep0" align="center">–</td><td class="colsep0 rowsep0" align="center">6.0</td><td class="colsep0 rowsep0" align="center">–</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (μg/L)</td><td class="colsep0 rowsep0" align="center">121.74</td><td class="colsep0 rowsep0" align="center">2910.13</td><td class="colsep0 rowsep0" align="center">1967</td><td class="colsep0 rowsep0" align="center">1168</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL (L/h/kg)</td><td class="colsep0 rowsep0" align="center">–</td><td class="colsep0 rowsep0" align="center">0.83</td><td class="colsep0 rowsep0" align="center">0.90</td><td class="colsep0 rowsep0" align="center">0.10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BA (%)</td><td class="colsep0 rowsep0" align="center">1.2</td><td class="colsep0 rowsep0" align="center">–</td><td class="colsep0 rowsep0" align="center">14.9</td><td class="colsep0 rowsep0" align="center">–</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">SD rats (male, three animals per group) weighing 190–230 g were used for the study.</p></div></div></div><div class="NLM_p">Collective results have suggested that Axl is closely involved in the tumor cell EMT transition, which has been gradually accepted as a potential mechanism underlying cancer progression, invasion, and metastasis.<a onclick="showRef(event, 'cit9c cit9d'); return false;" href="javascript:void(0);" class="ref cit9c cit9d">(9c, 9d)</a> The Axl-mediated EMT also contributes greatly to the clinical acquired resistance against both targeted therapies and chemotherapy in different cancer patients.<a onclick="showRef(event, 'ref21 cit22a cit22e'); return false;" href="javascript:void(0);" class="ref ref21 cit22a cit22e">(21, 22a, 22e)</a> Therefore, the potential suppressing effect of compound <b>9im</b> against EMT was further investigated in MDA-MB-231 breast cancer cells which are characterized to be highly metastatic. Transforming growth factor beta receptor (TGF-β1) has been well documented as an EMT inducer.<a onclick="showRef(event, 'cit21b cit22e'); return false;" href="javascript:void(0);" class="ref cit21b cit22e">(21b, 22e)</a> The treatment of TGF-β1 obviously induced EMT as determined by repressing the level of epithelial cell biomarker E-cadherin while elevating the level of mesenchymal cell marker N-cadherin in the cells (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). It was also noteworthy that the treatment of TGF-β1 resulted in an elevation of phosphorylation of Axl. Not surprisingly, the treatment of inhibitor <b>9im</b> dose-dependently restores the protein levels of E-cadherin and N-cadherin back to the control levels, as determined by both Western blot analysis and immunofluorescence microscopy evaluation, suggesting the blockage of <b>9im</b> on the TGF-β1-induced EMT process. The TGF-β1-induced Axl activation was also inhibited by <b>9im</b> in a dose-dependent manner.</div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/medium/jm-2016-00608n_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/large/jm-2016-00608n_0005.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Compound <b>9im</b> blocks TGF-β1-induced EMT process in MDA-MB-231 breast cancer cells. (A) Compound <b>9im</b> reverses TGF-β1-induced expression level changes of E-cadherin (an epithelial marker) and N-cadherin (a meschenchymal marker) EMT markers in MDA-MB-231 cells, as determined by optical and immunofluorescence microscopy. (B) Compound <b>9im</b> reverses TGF-β1-induced changes of the EMT markers expression in MDA-MB-231 cells as determined by Western blot analysis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/large/jm-2016-00608n_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00608&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Encouraged by its promising suppression on the TGF-β1-induced EMT transition, the migration inhibitory effect of <b>9im</b> on MDA-MB-231 breast cancer cells was initially investigated by using a well-established wound healing assay.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> It was shown that treatment of compound <b>9im</b> moderately inhibited the migrating process in MDA-MB-231 cells, suppressing the TGF-β1 (10 ng/mL)-induced wound closure by ∼24.2%, ∼50.6%, and ∼58.4% at concentrations of 0.2, 1.0, and 5.0 μM (<i>p</i> < 0.01), respectively, compared with the untreated control (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>A,C). The migration inhibitory potency of <b>9im</b> against MDA-MB-231 breast cancer cells was also validated by a well-established transwell assay (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>B).<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> We further evaluated the inhibitory effect of <b>9im</b> on the invasiveness of MDA-MB-231 breast cancer cells by using a matrigel-mediated Boyden chamber assay.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Matrigel was applied to the filter membrane, and the numbers of MDA-MB-231 cells that penetrated through the matrigel and migrated to the other side of the filter membrane were quantified. It was shown that compound <b>9im</b> dose-dependently inhibited the invasiveness of MDA-MB-231 cancer cells, while did not exhibited much cytotoxicity on the proliferation of the cells. Treatment of <b>9im</b> at 0.04, 0.2, 1.0, or 5.0 μM for 24 h inhibited cancer cell invasion by ∼48.5%, ∼52.1%, ∼73.5%, or ∼78.1%, respectively (<i>P</i> < 0.05, compared to the TGF-β1 (10 ng/mL) treatment; <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>B,D). These results collectively suggested the promising potential of compound <b>9im</b> to serve as a lead compound for drug discovery.</div><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/medium/jm-2016-00608n_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/large/jm-2016-00608n_0006.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Compound <b>9im</b> suppresses migration and invasion of MDA-MB-231 cells. (A) Effect of <b>9im</b> on the wound healing induced by TGF-β1 in MDA-MB-231 cells. (B) Compound <b>9im</b> suppresses migration and invasion induced by TGF-β1 (10 ng/mL) of MDA-MB-231 cells. (C–E) Quantitative analysis of wound healing (C), migration (D), and invasion (E). The results are presented as the mean ± standard deviation, *<i>P</i> < 0.05 (compared with TGF-β1 treatment).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/large/jm-2016-00608n_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00608&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Development of metastasis is the most cause for collapse of anticancer therapies. Liver is one of the most common sites of breast cancer metastasis. Thus, the potential <i>in vivo</i> therapeutic effect of <b>9im</b> on hepatic metastasis was further investigated by using a xenograft model of highly metastatic 4T1 murine breast cancer cells. Mice were randomized into treatment groups (<i>n</i> = 10) after 24 h of inoculation. Inhibitor <b>9im</b> (30 or 90 mg/kg/day, qd) or vehicle was orally administrated for 21 continuous days. The mice were then sacrificed, and liver organs were collected for hematoxylin–eosin (H&E) staining analysis (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>A). It was shown that 4T1 cells metastasis coloned aggressively in liver 3 weeks after the implantation. Although <b>9im</b> did not show an obvious effect on growth of the primary tumor, which is consistent with its poor <i>in vitro</i> antiproliferative activity, the compound dose-dependently suppressed both size and number of liver metastases (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>B). The metastasis number was about 27.8 ± 5.4 in the vehicle group, while the corresponding numbers are 21.3 ± 4.2 and 13.0 ± 3.3 in the 30 and 90 mg/kg dosing groups, respectively.</div><figure id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/medium/jm-2016-00608n_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/large/jm-2016-00608n_0007.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Compound <b>9im</b> reduces hepatic metastasis of 4T1 murine breast cancer cells. (A) H&E staining showed that <b>9im</b> decreased the size and number of the metastatic colons in liver (×100). Arrow indicates the tumor metastasis (B) Quantity analysis of the micrometastases in panel A. (C) Photos of the isolated tumor tissues after administration of <b>9im</b> for 21 continuous days. The results are presented as the mean ± standard deviation, *<i>P</i> < 0.05 (compare with untreated group).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/large/jm-2016-00608n_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00608&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32025" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32025" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, a series of 4-oxo-1,4-dihydroquinoline-3-carboxamides were designed and synthesized as new potent and highly selective Axl kinase inhibitors. One of the most promising compounds <b>9im</b> tightly bound with Axl protein and potently inhibited its kinase function with a <i>K</i><sub>d</sub> value of 2.7 nM and an IC<sub>50</sub> value of 4.0 nM, respectively. Furthermore, the compound was obviously less potent against most of the 468 kinases (including 403 nonmutated kinases) evaluated at 1.0 μM (which is approximately 370 times its <i>K</i><sub>d</sub> value against Axl), indicating its good target selectivity. The compound also exhibited moderate PK profiles and potently inhibited the TGF-β1-induced EMT process and suppressed the migration and invasion of MDA-MB-231 cancer breast cancer cells. Furthermore, the compound demonstrated <i>in vivo</i> therapeutic effect on hepatic metastasis in a xenograft model of highly metastatic 4T1 murine breast cancer cells. Compound <b>9im</b> may serve as a new lead compound for anticancer drug discovery, as well as a valuable research probe for further biological investigation on Axl.</div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31533" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31533" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> General Methods for Chemistry</h3><div class="NLM_p">All reagents and solvents were used as purchased from commercial sources without further purification. Flash chromatography was performed using 300 mesh silica gel. All reactions were monitored by thin-layer chromatography using silica gel plates with fluorescence F254 and UV light visualization. <sup>1</sup>H NMR spectra were recorded on a Bruker AV-400 spectrometer at 400 MHz or a Bruker AV-500 spectrometer at 500 MHz. <sup>13</sup>C NMR spectra were recorded on a Bruker AV-500 spectrometer at 125 MHz. Coupling constants (<i>J</i>) are expressed in hertz (Hz). Chemical shifts (δ) of NMR are reported in parts per million (ppm) units relative to an internal standard (TMS). Low-resolution electrospray ionization (ESI) mass spectra were recorded on an Agilent 1200 HPLC-MSD mass spectrometer and high-resolution ESI-MS on an Applied Biosystems Q-STAR Elite ESI-LC-MS/MS mass spectrometer. Purity of compounds was determined by reverse-phase high-performance liquid chromatography [HPLC, Dionex Summit HPLC; column: Diamonsil C18, 5.0 μm, 4.6 × 250 mm (Dikma Technologies); detector: PDA-100 photodiode array; injector: ASI-100 autoinjector; pump: p-680A] to be >95%. A flow rate of 1.0 mL/min was used with mobile phase of MeOH in H<sub>2</sub>O with 0.1% modifier (ammonia, v/v).</div><div id="sec6_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i14" class="anchor-spacer"></div><h4 class="article-section__title" id="_i14"> <i>N</i>-(3-Fluoro-4-((5-phenyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)phenyl)-1,2-dimethyl-4-oxo-1,4-dihydroquinoline-3-carboxamide (<b>9a</b>)</h4><div class="NLM_p last">The compound was prepared by following a procedure similar to that of <b>9h</b>. White solid (35 mg, 65%, <i>R</i><sub><i>f</i></sub> = 0.33, DCM:methanol = 20:1). <sup>1</sup>H NMR (500 MHz, <i>d</i><sub>6</sub>-DMSO): δ 10.91 (s, 1 H), 8.32 (s, 1 H), 8.25 (dd, <i>J</i><sub>1</sub> = 1.0 Hz, <i>J</i><sub>2</sub> = 8.0 Hz, 1 H),  7.91–7.87 (m, 2 H), 7.80 (dd, <i>J</i><sub>1</sub> = 1.5 Hz, <i>J</i><sub>2</sub> = 7.0 Hz, 1 H), 7.76 (d, <i>J</i> = 7.5 Hz, 2 H), 7.74 (s, 1 H),  7.48–7.44 (m, 2 H),  7.42–7.38 (m, 3 H), 7.26 (t, <i>J</i> = 7.0 Hz, 1 H), 3.83 (s, 3 H), 2.62 (s, 3 H). <sup>13</sup>C NMR (125 MHz, <i>d</i><sub>6</sub>-DMSO): δ 174.0, 166.0, 161.7, 154.8, 154.1 (d, <i>J</i> = 242.6 Hz, 1 C), 152.6, 150.6, 141.4, 138.5 (d, <i>J</i> = 9.5 Hz, 1 C), 135.1 (d, <i>J</i> = 12.8 Hz, 1 C), 134.7, 133.2, 128.9, 128.7, 126.7, 126.3, 126.1, 124.9, 124.5, 124.3, 119.7, 117.5, 116.0 (d, <i>J</i> = 5.6 Hz, 1 C), 108.0 (d, <i>J</i> = 23.4 Hz, 1 C), 102.3, 35.6, 30.9, 19.6. HRMS (ESI) for C<sub>30</sub>H<sub>22</sub>FN<sub>5</sub>O<sub>3</sub>   [M+H] <sup>+</sup>, calcd 520.1779, found 520.1778. HPLC analysis: MeOH–H <sub>2</sub>O (80:20), 7.00 min, 99.44% purity. Melting point:   248.4–250.1 °C.</div></div><div id="sec6_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15"> 5-Chloro-<i>N</i>-(3-fluoro-4-((5-phenyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)phenyl)-1,2-dimethyl-4-oxo-1,4-dihydroquinoline-3-carboxamide (<b>9b</b>)</h4><div class="NLM_p last">The compound was prepared by following a procedure similar to that of <b>9h</b>. Beige solid (68 mg, 52%; <i>R</i><sub><i>f</i></sub> = 0.43, DCM:methanol = 20:1). <sup>1</sup>H NMR (500 MHz, <i>d</i><sub>6</sub>-DMSO): δ 10.61 (s, 1 H), 8.31 (s, 1 H), 7.88 (d, <i>J</i> = 12.5 Hz, 1 H), 7.82 (d, <i>J</i> = 9.0 Hz,1 H),  7.78–7.75 (m, 3 H),  7.69–7.66 (t,  <i>J</i> = 8.0 Hz, 1 H), 7.46–7.39 (m, 5 H), 7.25 (t, <i>J</i> = 7.5 Hz, 1 H), 3.78 (s, 3 H), 2.54 (s, 3 H). <sup>13</sup>C NMR (125 MHz, <i>d</i><sub>6</sub>-DMSO): δ 173.3, 165.8, 161.7, 155.1, 154.1 (d, <i>J</i> = 242.5 Hz, 1 C), 150.4, 150.2, 144.1, 138.4 (d, <i>J</i> = 10.4 Hz, 1 C), 135.2 (d, <i>J</i> = 12.5 Hz, 1 C), 134.8, 133.2, 132.5, 128.8, 128.7, 127.1, 126.6, 125.0, 122.7, 122.5, 116.9, 115.9, 107.9 (d, <i>J</i> = 23.1 Hz, 1 C), 102.4, 36.5, 19.3. HRMS (ESI) for C<sub>30</sub>H<sub>21</sub>ClFN<sub>5</sub>O<sub>3</sub>  [M+H]<sup>+</sup>, calcd 554.1390, found 554.1389. HPLC analysis: MeOH–H <sub>2</sub>O (85:15), 4.30 min, 97.76% purity. Melting point:   269.4–271.1 °C.</div></div><div id="sec6_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16"> 6-Chloro-<i>N</i>-(3-fluoro-4-((5-phenyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)phenyl)-1,2-dimethyl-4-oxo-1,4-dihydroquinoline-3-carboxamide (<b>9c</b>)</h4><div class="NLM_p last">The compound was prepared by following a procedure similar to that of <b>9h</b>. White solid (115 mg, 75%; <i>R</i><sub><i>f</i></sub> = 0.48, DCM:methanol = 10:1). <sup>1</sup>H NMR (500 MHz, <i>d</i><sub>6</sub>-DMSO): δ 12.53 (s, 1 H), 10.80 (s, 1 H), 8.33 (s, 1 H), 8.15 (d, <i>J</i> = 2.5 Hz, 1 H), 7.93–7.89 (m, 2 H), 7.81 (dd, <i>J</i><sub>1</sub> = 2.5 Hz, <i>J</i><sub>2</sub> = 9.0 Hz, 1 H), 7.77 (m, 3 H), 7.46 (dd, <i>J</i><sub>1</sub> = 1.5 Hz, <i>J</i><sub>2</sub> = 9.0 Hz, 1 H),  7.43–7.39 (m, 3 H), 7.27 (t, <i>J</i> = 7.5 Hz, 1 H), 3.83 (s, 3 H), 2.62 (s, 3 H). <sup>13</sup>C NMR (125 MHz, <i>d</i><sub>6</sub>-DMSO): δ 172.7, 165.6, 161.7, 154.6, 154.1 (d, <i>J</i> = 242.9 Hz, 1 C), 152.7, 150.7, 150.5, 140.1, 138.4 (d, <i>J</i> = 9.8 Hz, 1 C), 135.2 (d, <i>J</i> = 13.0 Hz, 1 C), 134.6, 132.9, 129.2, 128.9, 128.7, 127.4, 126.8, 125.0, 124.8, 124.2, 120.4, 120.2, 116.0 (d, <i>J</i> = 2.5 Hz, 1 C), 108.0 (d, <i>J</i> = 23.2 Hz, 1 C), 102.3, 35.9, 19.5. HRMS (ESI) for C<sub>30</sub>H<sub>21</sub>ClFN<sub>5</sub>O<sub>3</sub> [M+H]<sup>+</sup>, calcd 554.1390, found 554.1386. HPLC analysis: MeOH–H<sub>2</sub>O (75:25), 5.18 min, 95.02% purity. Melting point: >300.0 °C.</div></div><div id="sec6_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> 7-Chloro-<i>N</i>-(3-fluoro-4-((5-phenyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)phenyl)-1,2-dimethyl-4-oxo-1,4-dihydroquinoline-3-carboxamide (<b>9d</b>)</h4><div class="NLM_p last">The compound was prepared by following a procedure similar to that of <b>9h</b>. White solid (108 mg, 72%; <i>R</i><sub><i>f</i></sub> = 0.52, DCM:methanol = 10:1). <sup>1</sup>H NMR (500 MHz, <i>d</i><sub>6</sub>-DMSO): δ 10.81 (s, 1 H), 8.31 (s, 1 H), 8.22 (d, <i>J</i> = 8.5 Hz, 1 H), 7.97 (s, 1 H), 7.92–7.89 (dd, <i>J</i><sub>1</sub> = 2.0 Hz, <i>J</i><sub>2</sub> = 13.0 Hz, 1 H), 7.77 (m, 2 H), 7.75 (s, 1 H), 7.49–7.46 (m, 2 H), 7.42–7.38 (m, 3 H), 7.25 (t, <i>J</i> = 7.5 Hz, 1 H), 3.81 (s, 3 H), 2.60 (s, 3 H). <sup>13</sup>C NMR (125 MHz, <i>d</i><sub>6</sub>-DMSO): δ 173.7, 166.1, 162.1, 155.5, 154.6 (d, <i>J</i> = 242.6 Hz, 1 C) 153.1, 150.9, 142.6, 138.8 (d, <i>J</i> = 9.9 Hz, 1 C), 138.6, 135.7 (d, <i>J</i> = 12.8 Hz, 1 C), 135.2, 129.3, 129.1, 128.6, 127.0, 125.4, 125.3, 125.0, 121.2, 117.7, 116.4, 116.3, 108.4 (d, <i>J</i> = 23.1 Hz, 1 C), 102.8, 36.3, 20.0. HRMS (ESI) for C<sub>30</sub>H<sub>21</sub>ClFN<sub>5</sub>O<sub>3</sub> [M+H]<sup>+</sup>, calcd 554.1390, found 554.1385. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 5.09 min, 97.88% purity. Melting point: >300.0 °C.</div></div><div id="sec6_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> 6-Fluoro-<i>N</i>-(3-fluoro-4-((5-phenyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)phenyl)-1,2-dimethyl-4-oxo-1,4-dihydroquinoline-3-carboxamide (<b>9e</b>)</h4><div class="NLM_p last">The compound was prepared by following a procedure similar to that of <b>9h</b>. White solid (96 mg, 64%; <i>R</i><sub><i>f</i></sub> = 0.36, DCM:methanol = 20:1). <sup>1</sup>H NMR (500 MHz, <i>d</i><sub>6</sub>-DMSO): δ 10.85 (s, 1 H), 8.32 (s, 1 H), 7.99 (dd, <i>J</i><sub>1</sub> = 4.0 Hz, <i>J</i><sub>2</sub> = 9.5 Hz, 1 H), 7.89 (m, 2 H), 7.76 (m, 3 H), 7.73–7.69 (m, 1 H), 7.45 (m, 1 H), 7.40 (m, 3 H), 7.26 (m, 1 H), 3.86 (s, 3 H), 2.63 (s, 3 H). <sup>13</sup>C NMR (125 MHz, <i>d</i><sub>6</sub>-DMSO): δ 173.0, 165.8, 161.7, 160.0, 158.1, 154.9, 154.1 (d, <i>J</i> = 243.0 Hz, 1 C), 152.5, 150.5, 138.4 (d, <i>J</i> = 9.9 Hz, 1 C), 138.2, 135.2 (d, <i>J</i> = 12.8 Hz, 1 C), 134.7, 128.9, 128.7, 127.8, 127.7, 126.7, 125.0, 124.8, 121.5, 121.3, 120.8, 120.7, 119.5, 115.9 (d, <i>J</i> = 5.8 Hz, 1 C), 110.3, 110.1, 108.0 (d, <i>J</i> = 23.1 Hz, 1 C), 102.3, 36.1, 19.5. HRMS (ESI) for C<sub>30</sub>H<sub>21</sub>F<sub>2</sub>N<sub>5</sub>O<sub>3</sub> [M+H]<sup>+</sup>, calcd 538.1685, found 538.1680. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 4.56 min, 98.56% purity. Melting point: 298.8–300.1 °C.</div></div><div id="sec6_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> 6-Bromo-<i>N</i>-(3-fluoro-4-((5-phenyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)phenyl)-1,2-dimethyl-4-oxo-1,4-dihydroquinoline-3-carboxamide (<b>9f</b>)</h4><div class="NLM_p last">The compound was prepared by following a procedure similar to that of <b>9h</b>. White solid (102 mg, 70%; <i>R</i><sub><i>f</i></sub> = 0.29, DCM:methanol = 20:1). <sup>1</sup>H NMR (500 MHz, <i>d</i><sub>6</sub>-DMSO): δ 12.52 (s, 1 H), 10.79 (s, 1 H), 8.33 (s, 1 H), 8.30 (d, <i>J</i> = 1.5 Hz, 1 H), 7.94–7.86 (m, 3 H), 7.77 (t, <i>J</i> = 7.5 Hz, 3 H), 7.45 (d, <i>J</i> = 9.0 Hz, 1 H), 7.40 (t, <i>J</i> = 8.0 Hz, 3 H), 7.28–7.26 (t, <i>J</i> = 7.5 Hz, 1 H), 3.83 (s, 3 H), 2.61 (s, 3 H). <sup>13</sup>C NMR (125 MHz, <i>d</i><sub>6</sub>-DMSO): δ 172.5, 165.6, 161.7, 154.7, 154.1 (d, <i>J</i> = 242.8 Hz, 1 C), 152.6, 150.7, 140.4, 138.4 (d, <i>J</i> = 10.0 Hz, 1 C), 135.6, 135.2 (d, <i>J</i> = 13.0 Hz, 1 C), 134.6, 128.9, 128.7, 128.1, 127.8, 126.8, 126.7, 125.0, 124.3, 120.5, 120.4, 117.2, 116.0, 115.9 (d, <i>J</i> = 2.5 Hz, 1 C), 108.0 (d, <i>J</i> = 23.4 Hz, 1 C), 102.3, 35.9, 19.6. HRMS (ESI) for C<sub>30</sub>H<sub>21</sub>BrFN<sub>5</sub>O<sub>3</sub> [M+H]<sup>+</sup>, calcd 598.0885, found 598.0877. HPLC analysis: MeOH–H<sub>2</sub>O (75:25), 5.41 min, 95.02% purity. Melting point: 286.2–288.1 °C.</div></div><div id="sec6_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> <i>N</i>-(3-Fluoro-4-((5-phenyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)phenyl)-1,2-dimethyl-4-oxo-6-(trifluoromethyl)-1,4-dihydroquinoline-3-Carboxamide (<b>9g</b>)</h4><div class="NLM_p last">The compound was prepared by following a procedure similar to that of <b>9h</b>. Beige solid (90 mg, 71%; <i>R</i><sub><i>f</i></sub> = 0.31, DCM:methanol = 20:1). <sup>1</sup>H NMR (500 MHz, <i>d</i><sub>6</sub>-DMSO): δ 12.54 (s, 1 H), 10.74 (s, 1 H), 8.50 (s, 1 H), 8.33 (s, 1 H), 8.11 (s, 2 H), 7.89 (d, <i>J</i> = 12.5 Hz, 1 H), 7.77 (m, 3 H), 7.43 (m, 4 H), 7.28 (s, 1 H), 3.89 (s, 3 H), 2.64 (s, 3 H). <sup>13</sup>C NMR (125 MHz, <i>d</i><sub>6</sub>-DMSO): δ 173.0, 165.3, 161.6, 154.5, 154.0 (d, <i>J</i> = 243.8 Hz, 1 C), 153.0, 150.5, 143.4, 138.2 (d, <i>J</i> = 9.9 Hz, 1 C), 135.1 (d, <i>J</i> = 13.0 Hz, 1 C), 134.4, 128.8, 128.6, 126.6, 125.7, 124.9, 124.3 (q, <i>J</i> = 33.2 Hz, 1 C), 123.3 (q, <i>J</i> = 4.4 Hz, 1 C), 122.3 (q, <i>J</i> = 260.1 Hz, 1 C), 115.8 (d, <i>J</i> = 5.0 Hz, 1 C), 107.9 (d, <i>J</i> = 23.7 Hz, 1 C), 107.8, 102.1, 35.8, 19.5. HRMS (ESI) for C<sub>31</sub>H<sub>21</sub>F<sub>4</sub>N<sub>5</sub>O<sub>3</sub> [M+H]<sup>+</sup>, calcd 588.1653, found 588.1644. HPLC analysis: MeOH–H<sub>2</sub>O (75:25), 11.65 min, 95.52% purity. Melting point: 297.3–299.2 °C.</div></div><div id="sec6_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> <i>N</i>-(3-Fluoro-4-((5-phenyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)phenyl)-1,2,6-trimethyl-4-oxo-1,4-dihydroquinoline-3-carboxamide (<b>9h</b>)</h4><div class="NLM_p">To a solution of <b>18h</b> (250 mg, 0.4 mmol) in THF (10 mL) and water (8 mL) was added NaOH (71 mg, 1.8 mmol). The resulting mixture was stirred at rt overnight. The solvent was removed under reduced pressure. Next, ice water was added to the mixture, and the precipitate was filtrated. The filter cake was washed with methanol and dried in a vacuum oven to give the title product <b>9a</b> as white solid (220 mg, 94%, <i>R</i><sub><i>f</i></sub> = 0.25, DCM:methanol = 20:1). <sup>1</sup>H NMR (500 MHz, <i>d</i><sub>6</sub>-DMSO): δ 12.52 (s, 1 H), 11.00 (s, 1 H), 8.33 (s, 1 H), 8.05 (s, 1 H), 7.91 (d, <i>J</i> = 13.0 Hz, 1 H), 7.79–7.75 (m, 4 H), 7.61(d, <i>J</i> = 8.5 Hz, 1 H), 7.46 (d, <i>J</i> = 8.5 Hz, 1 H), 7.41 (m, 3 H), 7.27 (t, <i>J</i> = 7.0 Hz, 1 H), 3.81 (s, 3 H), 2.63 (s, 3 H), 2.45 (s, 3 H). <sup>13</sup>C NMR (125 MHz, <i>d</i><sub>6</sub>-DMSO): δ 174.0, 166, 161.7, 154.6, 154.1 (d, <i>J</i> = 247.5 Hz, 1 C), 152.9, 150.6, 139.5, 138.4 (d, <i>J</i> = 9.0 Hz, 1 C), 135.1 (d, <i>J</i> = 12.8 Hz, 1 C), 134.5, 134.4, 133.8, 128.8, 128.6, 126.7, 126.2, 125.5, 124.8, 124.1, 118.6, 117.3, 116.1, 116.0 (d, <i>J</i> = 1.9 Hz, 1 C), 108.1 (d, <i>J</i> = 23.1 Hz, 1 C), 102.4, 35.6, 20.8, 19.4. HRMS (ESI) for C<sub>31</sub>H<sub>24</sub>FN<sub>5</sub>O<sub>3</sub> [M+H]<sup>+</sup>, calcd 534.1936, found 534.1934. HPLC analysis: MeOH–H<sub>2</sub>O (75:25), 4.92 min, 95.33% purity. Melting point: >300.0 °C.</div><div class="NLM_p last">The other designed inhibitors were prepared by following a similar procedure.</div></div><div id="sec6_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> 6-Ethyl-<i>N</i>-(3-fluoro-4-((5-phenyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)phenyl)-1,2-dimethyl-4-oxo-1,4-dihydroquinoline-3-carboxamide (<b>9i</b>)</h4><div class="NLM_p last">White solid (225 mg, 72%; <i>R</i><sub><i>f</i></sub> = 0.44, DCM:methanol = 10:1).  <sup>1</sup>H NMR (500 MHz, <i>d</i><sub>6</sub>-DMSO): δ 11.02 (s, 1 H), 8.33 (s, 1 H), 8.09 (s, 1 H), 7.93 (d, <i>J</i> = 1.5 Hz, 1 H), 7.91–7.76 (m, 4 H), 7.65 (m, 1 H), 7.46 (d, <i>J</i> = 9.5 Hz, 1 H), 7.41 (m, 3 H), 7.26 (m, 1 H), 3.82 (s, 3 H), 2.75 (q, <i>J</i> = 7.5 Hz, 2 H), 2.65 (s, 3 H), 1.24 (t, <i>J</i> = 7.5 Hz, 3 H). <sup>13</sup>C NMR (125 MHz, <i>d</i><sub>6</sub>-DMSO): δ 174.0, 166.1, 161.7, 154.8, 154.1 (d, <i>J</i> = 242.6 Hz, 1 C), 152.4, 150.5, 139.9, 139.6, 138.5 (d, <i>J</i> = 9.8 Hz, 1 C), 135.0 (d, <i>J</i> = 13.1 Hz, 1 C), 133.3, 128.8, 128.6, 126.6, 126.2, 124.9, 124.6, 124.1, 119.0, 117.5, 115.9, 107.9 (d, <i>J</i> = 23.8 Hz, 1 C), 102.3, 35.6, 27.9, 19.4, 15.9. HRMS (ESI) for C<sub>32</sub>H<sub>26</sub>FN<sub>5</sub>O<sub>3</sub> [M+H]<sup>+</sup>, calcd 548.2092, found 548.2089. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 5.61 min, 97.02% purity. Melting point: 283.8–285.1 °C.</div></div><div id="sec6_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> 6-Cyclopropyl-<i>N</i>-(3-fluoro-4-((5-phenyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)phenyl)-1,2-dimethyl-4-oxo-1,4-dihydroquinoline-3-carboxamide (<b>9j</b>)</h4><div class="NLM_p last">White solid (65 mg, 58%; <i>R</i><sub><i>f</i></sub> = 0.24, DCM:methanol = 20:1).  <sup>1</sup>H NMR (500 MHz, <i>d</i><sub>6</sub>-DMSO): δ 11.02 (s, 1 H), 8.29 (s, 1 H), 7.95 (d, <i>J</i> = 2.0 Hz, 1 H), 7.90 (dd, <i>J</i><sub>1</sub> = 2.0 Hz, <i>J</i><sub>2</sub> = 12.5 Hz, 1 H), 7.79–7.77 (m, 3 H), 7.73 (s, 1 H), 7.51 (dd, <i>J</i><sub>1</sub> = 2.0 Hz, <i>J</i><sub>2</sub> = 8.5 Hz, 1 H), 7.45 (dd, <i>J</i><sub>1</sub> = 2.0 Hz, <i>J</i><sub>2</sub> = 9.5 Hz, 1 H), 7.41–7.37 (m, 3 H), 7.24 (t, <i>J</i> = 7.0 Hz, 1 H), 3.82 (s, 3 H), 2.64 (s, 3 H), 2.14–2.09 (m, 1 H), 1.04 (m, 2 H), 0.76 (m, 2 H). <sup>13</sup>C NMR (125 MHz, <i>d</i><sub>6</sub>-DMSO): δ 173.8, 166.1, 161.6, 154.2 (d, <i>J</i> = 242.8 Hz, 1 C), 152.4, 150.1, 140.1, 139.4, 138.4 (d, <i>J</i> = 9.9 Hz, 1 C), 135.2 (d, <i>J</i> = 13.1 Hz, 1 C), 135.0, 130.9, 128.8, 128.7, 126.4, 126.3, 125.0, 121.8, 119.0, 117.6, 115.9, 115.6, 108.0 (d, <i>J</i> = 23.4 Hz, 1 C), 102.4, 35.7, 19.5, 15.0, 10.2. HRMS (ESI) for C<sub>33</sub>H<sub>26</sub>FN<sub>5</sub>O<sub>3</sub> [M+H]<sup>+</sup>, calcd 560.2092, found 560.2081. HPLC analysis: MeOH–H<sub>2</sub>O (75:25), 5.63 min, 95.14% purity. Melting point: 270.4–272.6 °C.</div></div><div id="sec6_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> <i>N</i>-(3-Fluoro-4-((5-phenyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)phenyl)-6-isopropyl-1,2-dimethyl-4-oxo-1,4-dihydroquinoline-3-carboxamide (<b>9k</b>)</h4><div class="NLM_p last">White solid (106 mg, 50%; <i>R</i><sub><i>f</i></sub> = 0.32, DCM:methanol = 20:1).  <sup>1</sup>H NMR (500 MHz, <i>d</i><sub>6</sub>-DMSO): δ 11.02 (s, 1 H), 8.31 (s, 1 H), 8.12 (s, 1 H), 7.90 (d, <i>J</i> = 12.5 Hz, 1 H), 7.84–7.72 (m, 5 H), 7.46–7.27 (m, 4 H), 7.27 (d, <i>J</i> = 6.5 Hz, 1 H), 3.84 (s, 3 H), 3.07 (m, 1 H), 2.66 (s, 3 H), 1.27 (m, 6 H). <sup>13</sup>C NMR (125 MHz, <i>d</i><sub>6</sub>-DMSO): δ 174.1, 166.1, 161.7, 154.2 (d, <i>J</i> = 246.0 Hz, 1 C), 152.5, 150.4, 144.5, 139.8, 138.5 (d, <i>J</i> = 9.1 Hz, 1 C), 135.1 (d, <i>J</i> = 12.6 Hz, 1 C), 134.8, 132.1, 128.8, 128.7, 126.6, 126.2, 125.1, 125.0, 122.6, 119.0, 117.6, 115.9, 115.8, 108.0 (d, <i>J</i> = 23.3 Hz, 1 C), 102.4, 35.7, 33.2, 24.2, 19.5. HRMS (ESI) for C<sub>33</sub>H<sub>28</sub>FN<sub>5</sub>O<sub>3</sub> [M+H]<sup>+</sup>, calcd 562.2249, found 562.2253. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 6.28 min, 98.65% purity. Melting point: 268.9–270.2 °C.</div></div><div id="sec6_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> <i>N</i>-(3-Fluoro-4-((5-phenyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)phenyl)-1,2-dimethyl-4-oxo-6-(prop-1-en-2-yl)-1,4-dihydroquinoline-3-carboxamide (<b>9l</b>)</h4><div class="NLM_p last">White solid (34 mg, 55%; <i>R</i><sub><i>f</i></sub> = 0.25, DCM:methanol = 20:1).  <sup>1</sup>H NMR (400 MHz, <i>d</i><sub>6</sub>-DMSO): δ 12.53 (s, 1 H), 10.93 (s, 1 H), 8.32 (d, <i>J</i> = 11.2 Hz, 1 H), 8.01 (d, <i>J</i> = 8.4 Hz, 1 H), 7.92–7.87 (m, 2 H), 7.79–7.76 (m, 3 H), 7.45–7.41 (m, 4 H), 7.27 (t, <i>J</i> = 6.8 Hz, 1 H), 5.62 (s, 1 H), 5.23 (s, 1 H), 3.86 (s, 3 H), 2.65 (s, 3 H), 2.20 (s, 3 H). <sup>13</sup>C NMR (125 MHz, <i>d</i><sub>6</sub>-DMSO): δ 174.0, 166.0, 161.8, 154.6, 154.1 (d, <i>J</i> = 242.3 Hz, 1 C), 152.5, 150.7, 141.6, 140.7, 138.5 (d, <i>J</i> = 9.6 Hz, 1 C), 135.9, 135.1 (d, <i>J</i> = 12.8 Hz, 1 C), 134.6, 130.2, 128.9, 128.7, 126.8, 126.0, 125.0, 124.3, 122.1, 119.7, 117.7, 116.0, 113.9, 108.0 (d, <i>J</i> = 21.9 Hz, 1 C), 102.3, 35.7, 21.8, 19.5. HRMS (ESI) for C<sub>33</sub>H<sub>26</sub>FN<sub>5</sub>O<sub>3</sub> [M+H]<sup>+</sup>, calcd 560.2092, found 560.2081. HPLC analysis: MeOH–H<sub>2</sub>O (90:10), 8.13 min, 97.79% purity. Melting point: 233.3–235.8 °C.</div></div><div id="sec6_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> <i>N</i>-(3-Fluoro-4-((5-phenyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)phenyl)-1,2-dimethyl-4-oxo-6-propyl-1,4-dihydroquinoline-3-carboxamide (<b>9m</b>)</h4><div class="NLM_p last">White solid (88 mg, 77%; <i>R</i><sub><i>f</i></sub> = 0.23, DCM:methanol = 20:1).  <sup>1</sup>H NMR (500 MHz, <i>d</i><sub>6</sub>-DMSO): δ 11.00 (s, 1 H), 8.30 (s, 1 H), 8.06 (d, <i>J</i> = 2.0 Hz, 1 H), 7.91 (dd, <i>J</i><sub>1</sub> = 2.0 Hz, <i>J</i><sub>2</sub> = 12.5 Hz, 1 H), 7.81–7.77 (m, 3 H), 7.74 (s, 1 H), 7.64 (dd, <i>J</i><sub>1</sub> = 2.0 Hz, <i>J</i><sub>2</sub> = 9.0 Hz, 1 H), 7.45 (dd, <i>J</i><sub>1</sub> = 1.5 Hz, <i>J</i><sub>2</sub> = 9.0 Hz, 1 H), 7.41–7.38 (m, 3 H), 7.25 (m, 1 H), 3.83 (s, 3 H), 2.71 (t, <i>J</i> = 7.2 Hz, 2 H), 2.64 (s, 3 H), 1.69–1.61 (q, <i>J</i> = 7.1 Hz, 2 H), 0.89 (t, <i>J</i> = 7.0 Hz, 3 H). <sup>13</sup>C NMR (125 MHz, <i>d</i><sub>6</sub>-DMSO): δ 174.0, 166.1, 161.6, 155.4, 154.2 (d, <i>J</i> = 242.8 Hz, 1 C), 152.4, 150.3, 139.7, 138.5 (d, <i>J</i> = 9.8 Hz, 1 C), 138.3, 135.2 (d, <i>J</i> = 12.8 Hz, 1 C), 134.9, 133.8, 128.8, 128.7, 126.5, 126.2, 125.5, 125.0, 119.1, 117.5, 115.9 (d, <i>J</i> = 2.6 Hz, 1 C), 115.7, 108.0 (d, <i>J</i> = 23.1 Hz, 1 C), 102.4, 36.9, 35.7, 24.4, 19.5, 13.9. HRMS (ESI) for C<sub>33</sub>H<sub>28</sub>FN<sub>5</sub>O<sub>3</sub> [M+H]<sup>+</sup>, calcd 562.2249, found 562.2249. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 6.60 min, 95.83% purity. Melting point: 271.5–273.2 °C.</div></div><div id="sec6_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 6-(<i>Tert</i>-butyl)-<i>N</i>-(3-fluoro-4-((5-phenyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)phenyl)-1,2-dimethyl-4-oxo-1,4-dihydroquinoline-3-carboxamide (<b>9n</b>)</h4><div class="NLM_p last">White solid (55 mg, 75%; <i>R</i><sub><i>f</i></sub> = 0.24, DCM:methanol = 20:1).  <sup>1</sup>H NMR (500 MHz, <i>d</i><sub>6</sub>-DMSO): δ 11.03 (s, 1 H), 8.32 (s, 1 H), 8.25 (d, <i>J</i> = 2.0 Hz, 1 H), 7.92–7.87 (m, 2 H), 7.83 (m, 1 H), 7.78 (d, <i>J</i> = 7.5 Hz, 2 H), 7.75 (s,1 H), 7.45 (dd, <i>J</i><sub>1</sub> = 2.0 Hz, <i>J</i><sub>2</sub> = 8.5 Hz, 1 H), 7.42–7.38 (m, 3 H), 7.26 (t, <i>J</i> = 7.5 Hz, 1 H), 3.84 (s, 3 H), 2.66 (s, 3 H), 1.36 (s, 9 H). <sup>13</sup>C NMR (125 MHz, <i>d</i><sub>6</sub>-DMSO): δ 174.2, 166.1, 161.7, 154.8, 154.1 (d, <i>J</i> = 242.6 Hz, 1 C), 152.7, 150.6 146.8, 139.4, 138.5 (d, <i>J</i> = 9.8 Hz, 1 C), 135.0 (d, <i>J</i> = 13.0 Hz, 1 C), 134.7, 131.1, 128.9, 128.7, 126.7, 125.8, 125.0, 124.6, 121.5, 118.9, 117.5, 115.9, 108.0 (d, <i>J</i> = 23.4 Hz, 1 C), 102.3, 35.6, 34.8, 31.5, 19.5. HRMS (ESI) for C<sub>34</sub>H<sub>30</sub>FN<sub>5</sub>O<sub>3</sub> [M+H]<sup>+</sup>, calcd 576.2405, found 576.2411. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 7.12 min, 97.03% purity. Melting point: 272.7–274.3 °C.</div></div><div id="sec6_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 6-Cyclopentyl-<i>N</i>-(3-fluoro-4-((5-phenyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)phenyl)-1,2 -dimethyl-4-oxo-1,4-dihydroquinoline-3-carboxamide (<b>9o</b>)</h4><div class="NLM_p last">White solid (25 mg, 59%; <i>R</i><sub><i>f</i></sub> = 0.36, DCM:methanol = 20:1). <sup>1</sup>H NMR (500 MHz, <i>d</i><sub>6</sub>-DMSO): δ 11.03 (s, 1 H), 8.33 (d, <i>J</i> = 2.0 Hz, 1 H), 8.12 (d, <i>J</i> = 1.5 Hz, 1 H), 7.91 (dd, <i>J</i><sub>1</sub> = 2.0 Hz, <i>J</i><sub>2</sub> = 12.5 Hz, 1 H), 7.82–7.75 (m, 4 H), 7.69 (dd, <i>J</i><sub>1</sub> = 2.0 Hz, <i>J</i><sub>2</sub> = 9.0 Hz, 1 H), 7.45 (dd, <i>J</i><sub>1</sub> = 1.5 Hz, <i>J</i><sub>2</sub> = 9.0 Hz, 1 H), 7.42–7.38 (m, 3 H), 7.27 (m, 1 H), 3.83 (s, 3 H), 3.15 (m, 1 H), 2.65 (s, 3 H), 2.10–2.06 (m, 2 H), 1.82–1.78 (m, 2 H), 1.71–1.68 (m, 2 H), 1.62–1.56 (m, 2 H). <sup>13</sup>C NMR (125 MHz, <i>d</i><sub>6</sub>-DMSO): δ 174.0, 166.1, 161.7, 154.7, 154.1 (d, <i>J</i> = 242.5 Hz, 1 C), 152.6, 150.6, 142.2, 139.7, 138.5 (d, <i>J</i> = 9.9 Hz, 1 C), 135.0 (d, <i>J</i> = 12.8 Hz, 1 C), 134.6, 132.6, 128.9, 128.8, 128.7, 126.7, 126.1, 125.4 124.9, 124.4, 123.3, 118.9, 117.5, 116.0, 115.9 (d, <i>J</i> = 2.8 Hz, 1 C), 108.0 (d, <i>J</i> = 23.0 Hz, 1 C), 102.3, 45.0, 35.7, 34.6, 30.9, 25.5, 19.5. HRMS (ESI) for C<sub>35</sub>H<sub>30</sub>FN<sub>5</sub>O<sub>3</sub> [M+H]<sup>+</sup>, calcd 588.2405, found 588.2394. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 8.40 min, 96.84% purity. Melting point: 286.8–288.1 °C.</div></div><div id="sec6_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 6-(Cyclopent-1-en-1-yl)-<i>N</i>-(3-fluoro-4-((5-phenyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy) phenyl)-1,2-dimethyl-4-oxo-1,4-dihydroquinoline-3-carboxamide (<b>9p</b>)</h4><div class="NLM_p last">Beige solid (64 mg, 52%; <i>R</i><sub><i>f</i></sub> = 0.21, DCM:methanol = 20:1).  <sup>1</sup>H NMR (400 MHz, <i>d</i><sub>6</sub>-DMSO): δ 10.95 (s, 1 H), 8.32 (s, 1 H), 8.16 (s, 1 H), 8.00 (d, <i>J</i> = 8.4 Hz, 1 H), 7.92–7.84 (m, 2 H), 7.78–7.75 (m, 3 H), 7.47–7.39 (m, 4 H), 7.27 (t, <i>J</i> = 7.2 Hz, 1 H), 6.45 (s, 1 H), 3.85 (s, 3 H), 2.75 (m, 2 H), 2.64 (s, 3 H), 2.54 (m, 2 H), 2.01 (m, 2 H). <sup>13</sup>C NMR (125 MHz, <i>d</i><sub>6</sub>-DMSO): δ 174.0, 166.0, 161.8, 154.6, 154.1 (d, <i>J</i> = 243.0 Hz, 1 C), 152.4, 151.9, 150.7, 141.2, 140.3, 139.6, 138.5 (d, <i>J</i> = 10.0 Hz, 1 C), 135.1 (d, <i>J</i> = 12.6 Hz, 1 C), 134.6, 132.1, 130.7, 128.9, 128.7, 127.5, 127.8, 126.8, 126.2, 125.4, 124.9, 124.2, 122.0, 119.5, 117.7, 116.0 (d, <i>J</i> = 2.1 Hz, 1 C), 108.0 (d, <i>J</i> = 23.3 Hz, 1 C), 102.3, 67.5, 35.7, 34.8, 33.6, 33.2,30.9, 25.6, 23.3, 21.5, 19.5. HRMS (ESI) for C<sub>35</sub>H<sub>28</sub>FN<sub>5</sub>O<sub>3</sub> [M+H]<sup>+</sup>, calcd 586.2249, found 586.2243. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 11.32 min, 97.72% purity. Melting point: 279.2–281.8 °C.</div></div><div id="sec6_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> <i>N</i>-(3-Fluoro-4-((5-phenyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)phenyl)-1,2-dimethyl-4-oxo-6-phenyl-1,4-dihydroquinoline-3-carboxamide (<b>9q</b>)</h4><div class="NLM_p last">White solid (55 mg, 62%; <i>R</i><sub><i>f</i></sub> = 0.26, DCM:methanol = 20:1).  <sup>1</sup>H NMR (500 MHz, <i>d</i><sub>6</sub>-DMSO): δ 10.94 (s, 1 H), 8.51 (d, <i>J</i> = 2.0 Hz, 1 H), 8.31 (s, 1 H), 8.13 (dd, <i>J</i><sub>1</sub> = 2.5 Hz, <i>J</i><sub>2</sub> = 9.0 Hz, 1 H), 7.99 (d, <i>J</i> = 9.0 Hz, 1 H), 7.91 (dd, <i>J</i><sub>1</sub> = 2.0 Hz, <i>J</i><sub>2</sub> = 13.0 Hz, 1 H), 7.78 (m, 4 H), 7.75 (s, 1 H), 7.52 (t, <i>J</i> = 7.5 Hz, 2 H), 7.47 (dd, <i>J</i><sub>1</sub> = 2 Hz, <i>J</i><sub>2</sub> = 9 Hz, 1 H), 7.43–7.39 (m, 4 H), 7.26 (t, <i>J</i> = 7.5 Hz, 1 H), 3.88 (s, 3 H), 2.65 (s, 3 H). <sup>13</sup>C NMR (125 MHz, <i>d</i><sub>6</sub>-DMSO): δ 174.0, 166.0, 161.7, 155.2, 154.2 (d, <i>J</i> = 242.9 Hz, 1 C), 152.5, 150.4, 140.8, 139.2, 138.4 (d, <i>J</i> = 9.8 Hz, 1 C), 135.9, 135.2 (d, <i>J</i> = 12.9 Hz, 1 C), 134.8, 131.5, 129.7, 128.8, 128.7, 128.3, 127.1, 126.6, 125.0, 123.3, 119.9, 118.4, 116.0 (d, <i>J</i> = 2.9 Hz, 1 C), 115.8, 108.0 (d, <i>J</i> = 23.0 Hz, 1 C), 102.4, 35.8, 19.5. HRMS (ESI) for C<sub>36</sub>H<sub>26</sub>FN<sub>5</sub>O<sub>3</sub> [M+H]<sup>+</sup>, calcd 596.2092, found 596.2089. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 6.78 min, 95.15% purity. Melting point: 255.4–257.7 °C.</div></div><div id="sec6_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> <i>N</i>-(3-Fluoro-4-((5-phenyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)phenyl)-1,2-dimethyl-4-oxo-1,4-dihydrobenzo[g]quinoline-3-carboxamide (<b>9r</b>)</h4><div class="NLM_p last">Yellow solid (46 mg, 68%; <i>R</i><sub><i>f</i></sub> = 0.23, DCM:methanol = 20:1).  <sup>1</sup>H NMR (500 MHz, <i>d</i><sub>6</sub>-DMSO): δ 10.91 (s, 1 H), 8.91 (s, 1 H), 8.40 (s, 1 H), 8.34 (s, 1 H), 8.2 (d, <i>J</i> = 8.0 Hz, 1 H), 8.12 (d, <i>J</i> = 8.0 Hz, 1 H), 7.93 (d, <i>J</i> = 12.0 Hz, 1 H), 7.79–7.76 (m, 3 H), 7.68–7.65 (t, <i>J</i> = 7.5 Hz, 1 H), 7.55 (d, <i>J</i> = 7.5 Hz, 1 H), 7.48 (d, <i>J</i> = 8.5 Hz, 1 H), 7.43–7.40 (m, 3 H), 7.27 (t, <i>J</i> = 7.5 Hz, 1 H), 3.92 (s, 3 H), 2.69 (s, 3 H). <sup>13</sup>C NMR (125 MHz, <i>d</i><sub>6</sub>-DMSO): δ 174.9, 166.1, 161.8, 154.6, 154.2, 154.1 (d, <i>J</i> = 242.3 Hz, 1 C), 150.7, 138.6 (d, <i>J</i> = 8.5 Hz, 1 C), 135.4, 135.0 (d, <i>J</i> = 12.6 Hz, 1 C), 134.6, 129.5, 129.4, 128.9, 128.8, 128.7, 128.2, 126.8, 126.7, 126.3, 125.3, 125.0, 124.3, 117.6, 116.0, 115.9 (d, <i>J</i> = 2.8 Hz, 1 C), 114.5, 107.9 (d, <i>J</i> = 22.6 Hz, 1 C), 102.3, 35.8, 19.9. HRMS (ESI) for C<sub>34</sub>H<sub>24</sub>FN<sub>5</sub>O<sub>3</sub> [M+H]<sup>+</sup>, calcd 570.1936, found 570.1931. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 6.37 min, 95.08% purity. Melting point: 278.3–280.5 °C.</div></div><div id="sec6_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> <i>N</i>-(3-Fluoro-4-((5-phenyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)phenyl)-6-methoxy-1,2-dimethyl-4-oxo-1,4-dihydroquinoline-3-carboxamide (<b>9s</b>)</h4><div class="NLM_p last">Beige solid (43 mg, 56%; <i>R</i><sub><i>f</i></sub> = 0.28, DCM:methanol = 20:1).  <sup>1</sup>H NMR (400 MHz, <i>d</i><sub>6</sub>-DMSO): δ 11.10 (s, 1 H), 8.30 (s, 1 H), 7.92 (dd, <i>J</i><sub>1</sub> = 2.0 Hz, <i>J</i><sub>2</sub> = 12.8 Hz, 1 H), 7.85 (d, <i>J</i> = 9.6 Hz, 1 H), 7.75–7.78 (m, 3 H), 7.67 (d, <i>J</i> = 3.2 Hz, 1 H), 7.46 (dd, <i>J</i><sub>1</sub> = 1.6 Hz, <i>J</i><sub>2</sub> = 8.8 Hz, 1 H), 7.42–7.38 (m, 4 H), 7.25 (m, 1 H), 3.87 (s, 3 H), 3.83 (s, 3 H), 2.65 (s, 3 H). <sup>13</sup>C NMR (125 MHz, <i>d</i><sub>6</sub>-DMSO): δ 173.3, 166.1, 161.6, 156.3, 154.2 (d, <i>J</i> = 242.3 Hz, 1 C), 151.9, 150.2, 138.4 (d, <i>J</i> = 9.4 Hz, 1 C), 135.9, 135.1 (d, <i>J</i> = 13.6 Hz, 1 C), 134.8, 128.7, 128.6, 127.5, 126.4, 125.4, 124.9, 122.6, 119.4, 118.2, 115.9, 115.7, 107.9 (d, <i>J</i> = 22.6 Hz, 1 C), 105.9, 102.3, 55.9, 35.8, 19.4. HRMS (ESI) for C<sub>31</sub>H<sub>24</sub>FN<sub>5</sub>O<sub>4</sub> [M+H]<sup>+</sup>, calcd 550.1885, found 550.1881. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 4.69 min, 95.04% purity. Melting point: 271.4–273.5 °C.</div></div><div id="sec6_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> <i>N</i>-(3-Fluoro-4-((5-phenyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)phenyl)-1,2-dimethyl-4-oxo-6-(trifluoromethoxy)-1,4-dihydroquinoline-3-Carboxamide (<b>9t</b>)</h4><div class="NLM_p last">White solid (67 mg, 67%; <i>R</i><sub><i>f</i></sub> = 0.30, DCM:methanol = 20:1).  <sup>1</sup>H NMR (500 MHz, <i>d</i><sub>6</sub>-DMSO): δ 12.53 (s, 1 H), 10.76 (s,1 H), 8.33 (s, 1 H), 8.09 (m, 2 H), 7.89 (d, <i>J</i> = 12.5 Hz, 1 H), 7.82–7.76 (m, 4 H), 7.46–7.40 (m, 4 H), 7.27 (m, 1 H), 3.87 (s, 3 H), 2.63 (s, 3 H). <sup>13</sup>C NMR (125 MHz, <i>d</i><sub>6</sub>-DMSO): δ 172.9, 165.6, 161.7, 154.6, 154.1 (d, <i>J</i> = 242.8 Hz, 1 C), 152.8, 150.7, 144.9, 140.1, 138.4 (d, <i>J</i> = 9.8 Hz, 1C), 135.2 (d, <i>J</i> = 12.5 Hz, 1 C), 134.6, 128.9, 128.7, 126.8, 126.2, 125.0, 124.3, 121.7, 120.7, 120.3, 119.6, 116.8, 116.0, 115.9, 108.0 (d, <i>J</i> = 23.4 Hz, 1 C), 102.3, 36.0, 19.6. HRMS (ESI) for C<sub>31</sub>H21F<sub>4</sub>N<sub>5</sub>O<sub>4</sub> [M+H]<sup>+</sup>, calcd 604.1602, found 604.1597. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 5.31 min, 97.59% purity. Melting point: 284.1–286.8 °C.</div></div><div id="sec6_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> Methyl-3-((3-fluoro-4-((5-phenyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)phenyl)carbamoyl)-1,2-dimethyl-4-oxo-1,4-dihydroquinoline-6-carboxylate (<b>9u</b>)</h4><div class="NLM_p last">A mixture of <b>9f</b> (200 mg, 0.3 mmol), PdCl<sub>2</sub>(dppf) (24 mg, 0.033 mmol), and triethylamine in methanol (15 mL) and DMF (50 μL) was stirred at 95 °C overnight under the pressure of CO and then cooled to rt. The mixture was filtratead, the filtrate was concentrated in vacuo and further purified by flash chromatography on silica gel to get the product as a yellow solid (60 mg, 33%; <i>R</i><sub><i>f</i></sub> = 0.29, DCM:methanol = 10:1). <sup>1</sup>H NMR (500 MHz, <i>d</i><sub>6</sub>-DMSO): δ 12.52 (s, 1 H), 10.76 (s, 1 H), 8.82 (d, <i>J</i> = 2.0 Hz, 1 H), 8.33 (s, 1 H), 8.25 (dd, <i>J</i><sub>1</sub> = 2.0 Hz, <i>J</i><sub>2</sub> = 9.0 Hz, 1 H), 8.00 (d, <i>J</i> = 9.0 Hz, 1 H), 7.91–7.88 (dd, <i>J</i><sub>1</sub> = 2.0 Hz, <i>J</i><sub>2</sub> = 12.5 Hz, 1 H), 7.77 (m, 3 H), 7.46 (dd, <i>J</i><sub>1</sub> = 1.0 Hz, <i>J</i><sub>2</sub> = 9.0 Hz, 1 H), 7.41 (m, 3 H), 7.28 (t, <i>J</i> = 7.0 Hz, 1 H), 3.92 (s, 3 H), 3.86 (s, 3 H), 2.62 (s, 3 H). <sup>13</sup>C NMR (125 MHz, <i>d</i><sub>6</sub>-DMSO): δ 173.7, 166.0, 165.5, 161.7, 154.6, 154.1 (d, <i>J</i> = 242.8 Hz, 1 C), 152.8, 150.7, 144.2, 138.3 (d, <i>J</i> = 10.0 Hz, 1 C), 135.2 (d, <i>J</i> = 12.8 Hz, 1 C), 134.7, 132.7, 128.9, 128.7, 128.1, 126.8, 125.8, 125.0, 124.9, 124.3, 121.4, 118.3, 116.0, 115.9 (d, <i>J</i> = 2.5 Hz, 1 C), 108.0 (d, <i>J</i> = 23.0 Hz, 1 C), 102.3, 52.8, 35.9, 19.6. HRMS (ESI) for C<sub>32</sub>H<sub>24</sub>FN<sub>5</sub>O<sub>5</sub> [M+H]<sup>+</sup>, calcd 578.1834, found 578.1833. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 4.26 min, 96.31% purity. Melting point: >300.0 °C.</div></div><div id="sec6_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> <i>N</i>-(3-Fluoro-4-((5-phenyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)phenyl)-2,6-dimethyl-4-oxo-1,4-dihydroquinoline-3-carboxamide (<b>9ha</b>)</h4><div class="NLM_p last">White solid (65 mg, 73%; <i>R</i><sub><i>f</i></sub> = 0.26, DCM:methanol = 20:1).  <sup>1</sup>H NMR (500 MHz, <i>d</i><sub>6</sub>-DMSO): δ 12.96 (s, 1 H), 12.52 (s, 1 H), 8.34 (s, 1 H), 8.03 (s, 1 H), 7.97 (dd, <i>J</i><sub>1</sub> = 2.0 Hz, <i>J</i><sub>2</sub> = 14.0 Hz, 1 H), 7.78 (dd, <i>J</i><sub>1</sub> = 1.0 Hz, <i>J</i><sub>2</sub> = 8.0 Hz, 2 H), 7.75 (s, 1 H), 7.59–7.54 (m, 2 H), 7.43–7.38 (m, 4 H), 7.27 (t, <i>J</i> = 7.5 Hz, 1 H), 2.83 (s, 3 H), 2.44 (s 3 H). <sup>13</sup>C NMR (125 MHz, <i>d</i><sub>6</sub>-DMSO): δ 176.6, 165.2, 161.8, 156.2, 154.6, 154.2 (d, <i>J</i> = 242.4 Hz, 1 C), 150.7, 138.4 (d, <i>J</i> = 9.4 Hz, 1 C), 136.9, 134.8 (d, <i>J</i> = 12.4 Hz, 1 C), 134.6, 128.9, 128.7, 126.8, 125.1, 125.0, 124.2, 118.8, 116.2 (d, <i>J</i> = 2.6 Hz, 1 C), 116.0, 110.7, 108.3 (d, <i>J</i> = 23.3 Hz, 1 C), 102.3, 22.0, 21.3. HRMS (ESI) for C<sub>30</sub>H<sub>22</sub>FN<sub>5</sub>O<sub>3</sub> [M+H]<sup>+</sup>, calcd 520.1779, found 520.1784. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 8.86 min, 98.25% purity. Melting point: 292.3–293.5 °C.</div></div><div id="sec6_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 1-Ethyl-<i>N</i>-(3-fluoro-4-((5-phenyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)phenyl)-2,6-dimethyl-4-oxo-1,4-dihydroquinoline-3-carboxamide (<b>9hb</b>)</h4><div class="NLM_p last">White solid (87 mg, 66%; <i>R</i><sub><i>f</i></sub> = 0.29, DCM:methanol = 20:1). <sup>1</sup>H NMR (500 MHz, <i>d</i><sub>6</sub>-DMSO): δ 10.87 (s, 1 H), 8.32 (s, 1 H), 8.07 (s, 1 H), 7.92 (d, <i>J</i> = 2.0 Hz, 1 H), 7.89–7.76 (m, 4 H), 7.62 (dd, <i>J</i><sub>1</sub> = 1.0 Hz, <i>J</i><sub>2</sub> = 8.5 Hz, 1 H), 7.45 (m, 1 H), 7.40 (m, 3 H), 7.26 (m, 1 H), 4.38 (q, <i>J</i> = 6.5 Hz, 2 H), 2.62 (s, 3 H), 2.45 (s, 3 H), 1.35 (t, <i>J</i> = 6.5 Hz, 3 H). <sup>13</sup>C NMR (125 MHz, <i>d</i><sub>6</sub>-DMSO): δ 173.7, 166.2, 161.7, 154.9, 154.1 (d, <i>J</i> = 242.5 Hz, 1 C), 150.8, 150.5, 138.5 (d, <i>J</i> = 9.6 Hz, 1 C), 138.3, 135.1 (d, <i>J</i> = 12.6 Hz, 1 C), 134.7, 134.6, 133.7, 128.9, 128.7, 126.7, 126.5, 125.7, 125.0, 124.8, 119.9, 117.3, 115.9 (d, <i>J</i> = 3.8 Hz, 1 C), 107.9 (d, <i>J</i> = 23.0 Hz, 1 C), 102.3, 42.3, 20.9, 18.6, 14.1. HRMS (ESI) for C<sub>32</sub>H<sub>26</sub>FN<sub>5</sub>O<sub>3</sub> [M+H]<sup>+</sup>, calcd 548.2092, found 548.2085. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 5.32 min, 98.32% purity. Melting point: 273.7–274.8 °C.</div></div><div id="sec6_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> <i>N</i>-(3-Fluoro-4-((5-phenyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)phenyl)-2,6-dimethyl-4-oxo-1-propyl-1,4-dihydroquinoline-3-carboxamide (<b>9hc</b>)</h4><div class="NLM_p last">White solid (70 mg, 73%; <i>R</i><sub><i>f</i></sub> = 0.37, DCM:methanol = 20:1).  <sup>1</sup>H NMR (500 MHz, <i>d</i><sub>6</sub>-DMSO): δ 10.85 (s, 1 H), 8.29 (s, 1 H), 8.06 (s, 1 H), 7.91 (d, <i>J</i> = 2.0 Hz, 1 H), 7.89–7.75 (m, 4 H), 7.61 (dd, <i>J</i><sub>1</sub> = 2.0 Hz, <i>J</i><sub>2</sub> = 9.0 Hz, 1 H), 7.45 (m, 1 H), 7.44–7.38 (m, 3 H), 7.25 (m, 1 H), 4.25 (t, <i>J</i> = 7.5 Hz, 2 H), 2.61 (s, 3 H), 2.45 (s, 3 H), 1.77–1.73 (m, 2 H), 1.02 (t, <i>J</i> = 7.5 Hz, 3 H). <sup>13</sup>C NMR (125 MHz, <i>d</i><sub>6</sub>-DMSO): δ 173.6, 166.2, 161.7, 155.3, 154.1 (d, <i>J</i> = 242.4 Hz, 1 C), 150.8, 150.3, 138.5 (d, <i>J</i> = 14.3 Hz, 1 C), 135.1 (d, <i>J</i> = 12.6 Hz, 1 C), 134.9, 134.5, 133.7, 128.8, 128.7, 126.5, 126.5, 125.6, 125.3, 125.0, 120.0, 117.5, 115.9 (d, <i>J</i> = 2.5 Hz,1 C), 115.8, 107.9 (d, <i>J</i> = 22.9 Hz, 1 C), 102.3, 48.5, 22.0, 20.9, 18.7, 11.1. HRMS (ESI) for C<sub>33</sub>H<sub>28</sub>FN<sub>5</sub>O<sub>3</sub> [M+H]<sup>+</sup>, calcd 562.2249, found 562.2245. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 6.12 min, 98.11% purity. Melting point: 267.9–269.2 °C.</div></div><div id="sec6_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 1-Butyl-<i>N</i>-(3-fluoro-4-((5-phenyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)phenyl)-2,6-dimethyl-4-oxo-1,4-dihydroquinoline-3-carboxamide (<b>9hd</b>)</h4><div class="NLM_p last">White solid (87 mg, 75%; <i>R</i><sub><i>f</i></sub> = 0.27, DCM:methanol = 20:1). <sup>1</sup>H NMR (500 MHz, <i>d</i><sub>6</sub>-DMSO): δ 10.87 (s, 1 H), 8.28 (s, 1 H), 8.06 (s, 1 H), 7.92 (dd, <i>J</i><sub>1</sub> = 2.0 Hz, <i>J</i><sub>2</sub> = 13.0 Hz, 1 H), 7.78–7.74 (m, 4 H), 7.61 (dd, <i>J</i><sub>1</sub> = 1.5 Hz, <i>J</i><sub>2</sub> = 8.5 Hz, 1 H), 7.45 (dd, <i>J</i><sub>1</sub> = 1.0 Hz, <i>J</i><sub>2</sub> = 9.0 Hz, 1 H), 7.41–7.38 (m, 3 H), 7.24 (t, <i>J</i> = 7.5 Hz, 1 H), 4.31–4.27 (t, <i>J</i> = 8.0 Hz, 2 H), 2.61 (s, 3 H), 2.45 (s, 3 H), 1.69 (m, 2 H), 1.50–1.45 (q, <i>J</i> = 7.5 Hz, 2 H), 0.97 (t, <i>J</i> = 7.5 Hz, 3 H). <sup>13</sup>C NMR (125 MHz, <i>d</i><sub>6</sub>-DMSO): δ 173.6, 166.2, 161.6, 155.8, 154.2 (d, <i>J</i> = 242.6 Hz, 1 C), 150.7, 150.0, 138.5, 138.4 (d, <i>J</i> = 10.0 Hz, 1 C), 135.3 (d, <i>J</i> = 12.9 Hz, 1 C), 135.1, 134.5, 133.6, 128.7, 128.6, 126.5, 126.3, 126.1, 125.6, 125.0, 120.0, 117.4, 115.8 (d, <i>J</i> = 2.3 Hz, 1 C), 115.5, 107.9 (d, <i>J</i> = 23.1 Hz, 1 C), 102.4, 46.9, 30.7, 26.0, 20.9, 19.7, 18.7, 14.1. HRMS (ESI) for C<sub>34</sub>H<sub>30</sub>FN<sub>5</sub>O<sub>3</sub> [M+H]<sup>+</sup>, calcd 576.2405, found 576.2407. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 7.46 min, 98.19% purity. Melting point: 260.4–261.6 °C.</div></div><div id="sec6_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> <i>N</i>-(3-Fluoro-4-((5-phenyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)phenyl)-2,6-dimethyl-4-oxo-1-phenyl-1,4-dihydroquinoline-3-carboxamide (<b>9he</b>)</h4><div class="NLM_p last">White solid (96 mg, 71%; <i>R</i><sub><i>f</i></sub> = 0.37, DCM:methanol = 20:1).  <sup>1</sup>H NMR (500 MHz, <i>d</i><sub>6</sub>-DMSO): δ 11.25 (s, 1 H), 8.29 (s, 1 H), 8.11 (s, 1 H), 7.90–7.93 (dd, <i>J</i><sub>1</sub> = 2.0 Hz, <i>J</i><sub>2</sub> = 12.5 Hz, 1 H), 7.78–7.68 (m, 6 H), 7.47 (m, 3 H), 7.38–7.44 (m, 4 H), 7.25 (t, <i>J</i> = 7.5 Hz, 1 H), 6.57 (d, <i>J</i> = 9.0 Hz, 1 H), 2.42 (s, 3 H), 2.22 (s, 3 H). <sup>13</sup>C NMR (125 MHz, <i>d</i><sub>6</sub>-DMSO): δ 175.0, 165.9, 162.0, 156.0, 154.6 (d, <i>J</i> = 242.8 Hz, 1 C), 152.2, 150.6, 140.7, 139.4, 138.7 (d, <i>J</i> = 9.6 Hz, 1 C), 135.7 (d, <i>J</i> = 12.8 Hz, 1 C), 135.4, 134.7, 134.6, 131.6, 130.8, 129.8, 129.2, 129.1, 126.8, 126.1, 125.9, 125.6, 125.4, 118.9, 118.8, 116.4, 116.0, 108.5 (d, <i>J</i> = 23.5 Hz, 1 H), 102.8, 21.3, 20.8. HRMS (ESI) for C<sub>36</sub>H<sub>26</sub>FN<sub>5</sub>O<sub>3</sub> [M+H]<sup>+</sup>, calcd 596.2092, found 596.2098. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 8.93 min, 97.96% purity. Melting point: 278.8–280.3 °C.</div></div><div id="sec6_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> <i>N</i>-(3-Fluoro-4-((5-phenyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)phenyl)-1,6-dimethyl-4-oxo-1,4-dihydroquinoline-3-carboxamide (<b>9hf</b>)</h4><div class="NLM_p last">White solid (55 mg, 66%; <i>R</i><sub><i>f</i></sub> = 0.20, DCM:methanol = 20:1).  <sup>1</sup>H NMR (500 MHz, <i>d</i><sub>6</sub>-DMSO): δ 12.67 (s, 1 H), 8.97 (s, 1 H), 8.30 (s, 1 H), 8.20 (s, 1 H), 7.99–7.97 (d, <i>J</i> = 12.5 Hz, 1 H), 7.80–7.74 (m, 5 H), 7.42–7.38 (m, 4 H), 7.25 (m,1 H), 4.06 (s, 3 H), 2.49 (s, 3 H). <sup>13</sup>C NMR (125 MHz, <i>d</i><sub>6</sub>-DMSO): δ 176.0, 163.5, 161.6, 155.3, 154.3 (d, <i>J</i> = 242.5 Hz, 1 C), 150.3, 149.4, 138.6, 137.7 (d, <i>J</i> = 9.6 Hz, 1 C), 135.8, 135.3 (d, <i>J</i> = 12.9 Hz, 1 C), 135.1, 134.9, 128.8, 128.7, 127.1, 126.5, 125.8, 125.2, 118.2, 116.3 (d, <i>J</i> = 2.9 Hz, 1C), 115.8, 110.2, 108.5 (d, <i>J</i> = 23.3 Hz, 1 C), 102.4, 41.9, 21.1. HRMS (ESI) for C<sub>31</sub>H<sub>24</sub>FN<sub>5</sub>O<sub>3</sub> [M+H]<sup>+</sup>, calcd 534.1936, found 534.19324. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 3.78 min, 97.54% purity. Melting point: 280.1–281.7 °C.</div></div><div id="sec6_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 2-Ethyl-<i>N</i>-(3-fluoro-4-((5-phenyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)phenyl)-1,6-dimethyl-4-oxo-1,4-dihydroquinoline-3-carboxamide (<b>9hg</b>)</h4><div class="NLM_p last">White solid (76 mg, 70%; <i>R</i><sub><i>f</i></sub> = 0.19, DCM:methanol = 20:1). <sup>1</sup>H NMR (500 MHz, <i>d</i><sub>6</sub>-DMSO): δ 10.84 (s, 1 H), 8.29 (s, 1 H), 8.05 (s, 1 H), 7.90 (dd, <i>J</i><sub>1</sub> = 2.5 Hz, <i>J</i><sub>2</sub> = 13.0 Hz, 1 H), 7.79–7.76 (m, 3 H), 7.74 (s, 1 H), 7.62 (dd, <i>J</i><sub>1</sub> = 2.0 Hz, <i>J</i><sub>2</sub> = 9.0 Hz, 1 H), 7.45 (dd, <i>J</i><sub>1</sub> = 2.0 Hz, <i>J</i><sub>2</sub> = 9.0 Hz, 1 H), 7.41–7.37 (m, 3 H), 7.24 (t, <i>J</i> = 7.0 Hz, 1 H), 3.84 (s, 3 H), 2.96 (d, <i>J</i> = 7.0 Hz, 2 H), 2.46 (s, 3 H), 1.30 (t, <i>J</i> = 7.0 Hz, 3 H). <sup>13</sup>C NMR (125 MHz, <i>d</i><sub>6</sub>-DMSO): δ 174.0, 166.2, 161.6, 155.7, 155.5, 154.2 (d, <i>J</i> = 242.0 Hz, 1 C), 150.1, 139.8, 138.4 (d, <i>J</i> = 9.9 Hz, 1 C), 135.2 (d, <i>J</i> = 13.6 Hz, 1 C), 135.0, 134.4, 133.8, 128.8, 128.7, 126.4, 126.3, 125.9, 125.3, 125.0, 119.6, 117.7, 115.9 (d, <i>J</i> = 2.5 Hz, 1 C), 115.6, 107.9 (d, <i>J</i> = 22.5 Hz, 1 C), 102.4, 35.3, 25.2, 20.9, 13.7. HRMS (ESI) for C<sub>32</sub>H<sub>26</sub>FN<sub>5</sub>O<sub>3</sub> [M+H]<sup>+</sup>, calcd 548.2092, found 548.2080. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 5.08 min, 95.14% purity. Melting point: 292.2–294.5 °C.</div></div><div id="sec6_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> <i>N</i>-(3-Fluoro-4-((5-phenyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)phenyl)-1,6-dimethyl-4-oxo-2-phenyl-1,4-dihydroquinoline-3-carboxamide (<b>9hh</b>)</h4><div class="NLM_p last">White solid (58 mg, 60%; <i>R</i><sub><i>f</i></sub> = 0.36, DCM:methanol = 20:1).  <sup>1</sup>H NMR (500 MHz, <i>d</i><sub>6</sub>-DMSO): δ 10.60 (s, 1 H), 8.27 (s, 1 H), 8.14 (s, 1 H), 7.78 (d, <i>J</i> = 9.0 Hz, 1 H), 7.74 (d, <i>J</i> = 8.5 Hz, 3 H), 7.71–7.69 (dd, <i>J</i><sub>1</sub> = 2.0 Hz, <i>J</i><sub>2</sub> = 9.0 Hz, 1 H), 7.55–7.50 (m, 6 H), 7.39–7.36 (m, 2 H), 7.30–7.27 (m, 1 H), 7.23 (t, <i>J</i> = 7.5 Hz, 1 H), 7.19 (dd, <i>J</i><sub>1</sub> = 1.5 Hz, <i>J</i><sub>2</sub> = 8.5 Hz, 1 H), 3.50 (s, 3 H), 2.51 (s, 3 H). <sup>13</sup>C NMR (125 MHz, <i>d</i><sub>6</sub>-DMSO): δ 173.8, 164.7, 161.5, 155.6, 154.0 (d, <i>J</i> = 242.4 Hz, 1 C), 152.6, 150.1, 139.5, 138.1 (d, <i>J</i> = 9.8 Hz, 1 C), 135.0 (d, <i>J</i> = 12.8 Hz, 1 C), 134.7, 134.2, 134.1, 130.0, 129.1, 128.9, 128.7, 128.6, 126.7, 126.4, 125.3, 124.8, 120.8, 118.0, 115.6 (d, <i>J</i> = 2.5 Hz, 1 C), 115.5, 107.6 (d, <i>J</i> = 22.9 Hz, 1 C), 102.3, 37.6, 21.0. HRMS (ESI) for C<sub>36</sub>H<sub>26</sub>FN<sub>5</sub>O<sub>3</sub> [M+H]<sup>+</sup>, calcd 596.2092, found 596.2096. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 5.14 min, 98.3% purity. Melting point: 281.2–282.6 °C.</div></div><div id="sec6_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 6-Ethyl-<i>N</i>-(2-fluoro-4-((5-phenyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)phenyl)-1,2-dimethyl-4-oxo-1,4-dihydroquinoline-3-carboxamide (<b>9ia</b>)</h4><div class="NLM_p last">White solid (180 mg, 77%; <i>R</i><sub><i>f</i></sub> = 0.35, DCM:methanol = 20:1).  <sup>1</sup>H NMR (400 MHz, <i>d</i><sub>6</sub>-DMSO): δ 12.13 (s, 1 H), 8.29 (s, 1 H), 8.24 (t, <i>J</i> = 8.8 Hz, 1 H), 8.17 (s, 1 H), 7.88 (d, <i>J</i> = 8.8 Hz, 1 H), 7.76 (d, <i>J</i> = 7.6 Hz, 2 H), 7.71–7.69 (m, 2 H), 7.40–7.34 (m, 3 H), 7.22 (t, <i>J</i> = 8.0 Hz, 1 H), 7.10 (d, <i>J</i> = 7.2 Hz, 1 H), 3.90 (s, 3 H), 2.91 (s, 3 H), 2.79 (q, <i>J</i> = 7.6 Hz, 2 H), 1.26 (t, <i>J</i> = 7.6 Hz, 3 H). <sup>13</sup>C NMR (125 MHz, <i>d</i><sub>6</sub>-DMSO): δ 175.6, 165.9, 162.4, 157.4, 156.2, 153.9 (d, <i>J</i> = 244.0 Hz, 1 C), 150.5, 149.3 (d, <i>J</i> = 10.5 Hz, 1 C), 141.1, 139.7, 135.6, 134.1, 129.3, 129.0, 126.7, 126.5, 126.4, 125.0 (d, <i>J</i> = 11.1 Hz, 1 C), 124.8, 124.1, 118.7, 118.2, 116.0, 115.2, 110.9 (d, <i>J</i> = 22.3 Hz, 1 C), 103.5, 36.6, 28.4, 20.3, 16.3. HRMS (ESI) for C<sub>32</sub>H<sub>26</sub>FN<sub>5</sub>O<sub>3</sub> [M+H]<sup>+</sup>, calcd 548.2092, found 548.2098. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 7.37 min, 95.08% purity. Melting point: 241.1–243.7 °C.</div></div><div id="sec6_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 6-Ethyl-1,2-dimethyl-4-oxo-<i>N</i>-(4-((5-phenyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)phenyl)-1,4-dihydroquinoline-3-carboxamide (<b>9ib</b>)</h4><div class="NLM_p last">White solid (66 mg, 73%; <i>R</i><sub><i>f</i></sub> = 0.32, DCM:methanol = 20:1). <sup>1</sup>H NMR (500 MHz, <i>d</i><sub>6</sub>-DMSO): δ 10.81 (s, 1 H), 8.29 (s, 1 H), 8.09 (s, 1 H), 7.81 (d, <i>J</i> = 9.0 Hz, 1 H), 7.78–7.75 (m, 4 H), 7.70 (s, 1 H), 7.65 (dd, <i>J</i><sub>1</sub> = 1.5 Hz, <i>J</i><sub>2</sub> = 8.5 Hz, 1 H), 7.38 (m, 2 H),   7.26–7.21 (m, 3 H), 3.83 (s, 3 H),  2.79–274 (q,  <i>J</i> = 7.5 Hz, 2 H), 2.64 (s, 3 H), 1.24 (t, <i>J</i> = 7.5 Hz, 3 H). <sup>13</sup>C NMR (125 MHz, <i>d</i><sub>6</sub>-DMSO): δ 174.9, 174.0, 165.8, 162.5, 152.2, 150.4, 148.5, 139.9, 139.7, 137.0, 135.1, 133.3, 128.9, 128.6, 126.4, 126.3, 124.2, 122.6, 120.9, 119.5, 117.5, 115.8, 103.0, 35.6, 27.9, 19.5, 16.0. HRMS (ESI) for C<sub>32</sub>H<sub>27</sub>N<sub>5</sub>O<sub>3</sub> [M+H]<sup>+</sup>, calcd 530.2187, found 530.2182. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 5.25 min, 97.83% purity. Melting point: 271.8–273.2 °C.</div></div><div id="sec6_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 6-Ethyl-1,2-dimethyl-<i>N</i>-(3-methyl-4-((5-phenyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)phenyl-4-oxo-1,4-dihydroquinoline-3-carboxamide (<b>9ic</b>)</h4><div class="NLM_p last">White solid (45 mg, 56%; <i>R</i><sub><i>f</i></sub> = 0.19, DCM:methanol = 20:1).  <sup>1</sup>H NMR (500 MHz, <i>d</i><sub>6</sub>-DMSO): δ 10.79 (s, 1 H), 8.28 (s, 1 H), 8.09 (s, 1 H), 7.80 (m, 3 H), 7.71-.65 (m, 3 H), 7.53 (d, <i>J</i> = 7.5 Hz, 1 H), 7.40 (t, <i>J</i> = 7.5 Hz, 2 H), 7.26 (t, <i>J</i> = 7.5 Hz, 1 H), 7.11 (d, <i>J</i> = 8.5 Hz, 1 H), 3.83 (s, 3 H), 2.76 (q, <i>J</i> = 7.5 Hz, 2 H), 2.65 (s, 3 H), 2.09 (s, 3 H), 1.24 (t, <i>J</i> = 7.5 Hz, 3 H). <sup>13</sup>C NMR (125 MHz, <i>d</i><sub>6</sub>-DMSO): δ 174.0, 165.7, 162.2, 154.7, 152.3, 150.7, 147.0, 139.9, 139.7, 137.2, 134.8, 133.3, 130.7, 128.9, 128.6, 126.6, 126.3, 124.2, 123.0, 122.2, 119.3, 118.6, 117.5, 116.1, 102.6, 35.6, 27.9, 19.5, 16.9, 15.9. HRMS (ESI) for C<sub>33</sub>H<sub>29</sub>N<sub>5</sub>O<sub>3</sub> [M+H]<sup>+</sup>, calcd 544.2343, found 544.2348. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 5.74 min, 96.04% purity. Melting point: 263.3–265.2 °C.</div></div><div id="sec6_1_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> <i>N</i>-(4-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)-3-fluorophenyl)-6-ethyl-1,2-dimethyl-4-oxo-1,4-dihydroquinoline-3-carboxamide (<b>9id</b>)</h4><div class="NLM_p last">Yellow solid (65 mg, 72%; <i>R</i><sub><i>f</i></sub> = 0.18, DCM:methanol = 20:1).  <sup>1</sup>H NMR (500 MHz, <i>d</i><sub>6</sub>-DMSO): δ 12.28 (s, 1 H), 10.98 (s, 1 H), 8.30 (d, <i>J</i> = 2.0 Hz, 1 H), 7.92 (dd, <i>J</i><sub>1</sub> = 2.0 Hz, <i>J</i><sub>2</sub> = 12.5 Hz, 1 H), 7.81 (d, <i>J</i> = 9.0 Hz, 1 H), 7.66 (dd, <i>J</i><sub>1</sub> = 2.0 Hz, <i>J</i><sub>2</sub> = 9.0 Hz, 1 H), 7.51 (m, 1 H), 7.87 (dd, <i>J</i><sub>1</sub> = 2.0 Hz, <i>J</i><sub>2</sub> = 9.0 Hz, 1 H), 7.39 (m, 1 H), 6.59 (m, 1 H), 3.83 (s, 3 H), 2.79–2.75 (q, <i>J</i> = 7.5 Hz, 2 H), 2.64 (s, 3 H), 1.24 (t, <i>J</i> = 7.5 Hz, 3 H). <sup>13</sup>C NMR (125 MHz, <i>d</i><sub>6</sub>-DMSO): δ 174.0, 166.2, 161.5, 154.2 (d, <i>J</i> = 242.9 Hz, 1 C), 154.1, 152.3, 150.5, 140.0, 138.6 (d, <i>J</i> = 9.9 Hz, 1 C), 135.1 (d, <i>J</i> = 12.9 Hz, 1 C), 133.4, 126.3, 126.0, 124.9, 124.2, 119.2, 117.6, 115.9 (d, <i>J</i> = 2.6 Hz, 1 C), 108.0 (d, <i>J</i> = 23.2 Hz, 1 C), 104.5, 98.3, 35.7, 27.9, 19.5, 16.0. HRMS (ESI) for C<sub>26</sub>H<sub>22</sub>FN<sub>5</sub>O<sub>3</sub> [M+H]<sup>+</sup>, calcd 472.1779, found 472.1776. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 3.99 min, 96.56% purity. Melting point: 253.9–255.6 °C.</div></div><div id="sec6_1_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 6-Ethyl-<i>N</i>-(3-fluoro-4-((5-(1-methyl-1<i>H</i>-pyrazol-4-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)phenyl)-1,2-dimethyl-4-oxo-1,4-dihydroquinoline-3-carboxamide (<b>9ie</b>)</h4><div class="NLM_p last">White solid (180 mg, 73%; <i>R</i><sub><i>f</i></sub> = 0.19, DCM:methanol = 20:1).  <sup>1</sup>H NMR (400 MHz, <i>d</i><sub>6</sub>-DMSO): δ 12.30 (s, 1 H), 11.00 (s, 1 H), 8.28 (s, 1 H), 8.09 (s, 1 H), 8.00 (s, 1 H), 7.90 (m, 1 H), 7.83 (m, 2 H), 7.66 (m, 2 H), 7.49–7.42 (m, 2 H), 3.85 (s, 3 H), 3.84 (s, 3 H), 2.78 (q, <i>J</i> = 7.5 Hz, 2 H), 2.65 (s, 3 H), 1.2 (t, <i>J</i> = 7.5 Hz, 3 H). <sup>13</sup>C NMR (125 MHz, <i>d</i><sub>6</sub>-DMSO): δ 174.4, 166.6, 162.1, 154.7 (d. <i>J</i> = 242.5 Hz, 1 C), 154.5, 152.8, 151.0, 140.4, 140.1, 139.0 (d, <i>J</i> = 10.0 Hz, 1 C), 138.4, 135.4 (d, <i>J</i> = 12.5 Hz, 1 C), 133.8, 129.4, 126.7, 125.4, 124.6, 122.5, 119.5, 118.0, 116.4 (d, <i>J</i> = 1.3 Hz, 1 C), 115.6, 108.4 (d, <i>J</i> = 22.5 Hz, 1 C), 107.4, 102.6, 40.0, 39.5, 36.1,28.2, 19.9, 16.4. HRMS (ESI) for C<sub>30</sub>H<sub>26</sub>FN<sub>7</sub>O<sub>3</sub> [M+H]<sup>+</sup>, calcd 552.2154, found 552.2156. HPLC analysis: MeOH–H<sub>2</sub>O (75:25), 5.34 min, 99.20% purity. Melting point: >300.0 °C.</div></div><div id="sec6_1_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 6-Ethyl-<i>N</i>-(3-fluoro-4-((3-phenyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-4-yl)oxy)phenyl)-1,2-dimethyl-4-oxo-1,4-dihydroquinoline-3-carboxamide (<b>9if</b>)</h4><div class="NLM_p last">White solid (62 mg, 68%; <i>R</i><sub><i>f</i></sub> = 0.25, DCM:methanol = 20:1).  <sup>1</sup>H NMR (500 MHz, <i>d</i><sub>6</sub>-DMSO): δ 12.03 (s, 1 H), 11.02 (s, 1 H), 8.08 (m, 2 H), 7.98–7.95 (d, <i>J</i> = 13.0 Hz, 2 H), 7.81 (d, <i>J</i> = 8.5 Hz, 1 H), 7.70 (d, <i>J</i> = 7.5 Hz, 2 H), 7.66 (d, <i>J</i> = 8.5 Hz, 1 H), 7.60 (s, 1 H), 7.47 (d, <i>J</i> = 9.0 Hz, 1 H), 7.54 (m, 3 H), 7.21 (t, <i>J</i> = 7 Hz, 1 H), 6.31 (d, <i>J</i> = 5.0 Hz, 1 H), 3.83 (s, 3 H), 2.79–2.74 (q, <i>J</i> = 7.5 Hz, 2 H), 2.64 (s, 3 H), 1.24 (t, <i>J</i> = 7.5 Hz, 3H). <sup>13</sup>C NMR (125 MHz, <i>d</i><sub>6</sub>-DMSO): δ 174.0, 166.2, 158.8, 153.9 (d, <i>J</i> = 243.8 Hz, 1 C), 152.4, 152.0, 145.1, 140.0, 139.7, 138.5 (d, <i>J</i> = 9.4 Hz, 1 C), 136.1 (d, <i>J</i> = 11.9 Hz, 1 C), 135.8, 133.4, 129.1, 128.4, 126.3, 126.2, 124.2, 119.1, 117.6, 116.4 (d, <i>J</i> = 2.6 Hz, 1 C), 115.6, 108.5 (d, <i>J</i> = 22.0 Hz, 1 C), 107.6, 101.1, 35.7, 27.9, 19.5, 16.0. HRMS (ESI) for C<sub>33</sub>H<sub>27</sub>FN<sub>4</sub>O<sub>3</sub> [M+H]<sup>+</sup>, calcd 547.214, found 547.2145. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 6.31 min, 95.08% purity. Melting point: 274.7–276.7 °C.</div></div><div id="sec6_1_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 6-Ethyl-<i>N</i>-(3-fluoro-4-((3-phenylfuro[2,3-<i>b</i>]pyridin-4-yl)oxy)phenyl)-1,2-dimethyl-4-oxo-1,4-dihydroquinoline-3-carboxamide (<b>9ig</b>)</h4><div class="NLM_p last">Beige solid (220 mg, 64%; <i>R</i><sub><i>f</i></sub> = 0.58, DCM:methanol = 20:1). <sup>1</sup>H NMR (400 MHz, <i>d</i><sub>6</sub>-DMSO): δ 11.04 (s, 1 H), 8.58 (s, 1 H), 8.51 (s, 1 H), 8.09 (s, 1 H), 7.94 (d, <i>J</i> = 13.2 Hz, 1 H), 7.83 (m, 3 H), 7.66 (dd, <i>J</i><sub>1</sub> = 1.6 Hz, <i>J</i><sub>2</sub> = 8.8 Hz, 1 H), 7.52–7.48 (m, 4 H), 7.41 (t, <i>J</i> = 7.2 Hz, 1 H), 3.84 (s, 3 H), 2.80-.74 (q, <i>J</i> = 7.6 Hz, 2 H), 2.65 (s, 3 H), 1.24 (t, <i>J</i> = 7.6 Hz, 3 H). <sup>13</sup>C NMR (125 MHz, <i>d</i><sub>6</sub>-DMSO): δ 174.0, 169.2, 166.2, 163.2, 153.9 (d, <i>J</i> = 243.8 Hz, 1 C), 153.4, 152.5, 142.3, 140.0, 139.7, 139.0 (d, <i>J</i> = 10.0 Hz, 1 C), 134.5 (d, <i>J</i> = 12.5 Hz, 1 C), 133.4, 130.2, 129.1, 128.9, 128.6, 126.3, 124.7, 124.1, 120.8, 119.0, 117.6, 116.0, 108.0 (d, <i>J</i> = 22.5 Hz, 1 C), 103.3, 35.7, 27.3, 19.49, 15.9. HRMS (ESI) for C<sub>32</sub>H<sub>25</sub>FN<sub>4</sub>O<sub>4</sub> [M+H]<sup>+</sup>, calcd 549.1933, found 549.1936. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 6.91 min, 97.17% purity. Melting point: 257.8–259.1 °C.</div></div><div id="sec6_1_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> <i>N</i>-(4-((2-Chloropyridin-4-yl)oxy)-3-fluorophenyl)-6-ethyl-1,2-dimethyl-4-oxo-1,4-dihydroquinoline-3-carboxamide (<b>9ih</b>)</h4><div class="NLM_p last">White solid (50 mg, 70%; <i>R</i><sub><i>f</i></sub> = 0.58, DCM:methanol = 20:1). <sup>1</sup>H NMR (500 MHz, <i>d</i><sub>6</sub>-DMSO): δ 11.06 (s, 1 H), 8.31 (d, <i>J</i> = 6.0 Hz, 1 H), 8.06 (d, <i>J</i> = 2.0 Hz, 1 H), 8.00 (dd, <i>J</i><sub>1</sub> = 2.0 Hz, <i>J</i><sub>2</sub> = 13.0 Hz, 1 H), 7.79 (d, <i>J</i> = 9.0 Hz, 1 H), 7.65 (dd, <i>J</i><sub>1</sub> = 2.0 Hz, <i>J</i><sub>2</sub> = 9.0 Hz, 1 H), 7.52 (dd, <i>J</i><sub>1</sub> = 1.0 Hz, <i>J</i><sub>2</sub> = 9.0 Hz, 1 H), 7.39 (t, <i>J</i> = 9.0 Hz, 1 H), 7.09 (d, <i>J</i> = 2.0 Hz, 1 H), 7.00 (dd, <i>J</i><sub>1</sub> = 2.0 Hz, <i>J</i><sub>2</sub> = 6.0 Hz, 1 H), 3.81 (s, 3 H), 2.78–2.74 (q, <i>J</i> = 7.5 Hz, 2 H), 2.63 (s, 3 H), 1.24 (t, <i>J</i> = 7.5 Hz, 3 H). <sup>13</sup>C NMR (125 MHz, <i>d</i><sub>6</sub>-DMSO): δ 174.2, 166.3, 166.1, 153.7 (d, <i>J</i> = 244.1 Hz, 1 C), 153.1, 152.1, 151.8, 140.1, 139.6, 139.2 (d, <i>J</i> = 9.8 Hz, 1 C), 135.2 (d, <i>J</i> = 12.3 Hz, 1 C), 133.3, 126.3, 124.2, 124.0, 118.3, 117.5, 116.6, 111.4, 111.2, 108.6 (d, <i>J</i> = 22.8 Hz, 1 C), 35.7, 27.9, 19.4, 15.7. HRMS (ESI) for C<sub>25</sub>H<sub>21</sub>ClFN<sub>3</sub>O<sub>3</sub> [M+H]<sup>+</sup>, calcd 466.1328, found 466.1325. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 5.44 min, 98.91% purity. Melting point: 193.6–194.7 °C.</div></div><div id="sec6_1_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> <i>N</i>-(4-((2-Aminopyridin-4-yl)oxy)-3-fluorophenyl)-6-ethyl-1,2-dimethyl-4-oxo-1,4-dihydroquinoline-3-carboxamide (<b>9ii</b>)</h4><div class="NLM_p last">To a solution of <b>9ij</b> (106 mg, 0.2 mmol) and pyridine (70 mg, 0.9 mmol) in 2 mL of DMF and H<sub>2</sub>O (11 mg, 0.6 mmol) was added (bis(trifluoro acetoxy)iodo)benzene (135 mg, 0.3 mmol), and the reaction was stirred at rt for 4.0 h. Next, water was added into the mixture, and the resulting solution was stirred for another 30 min. The mixture was filtrated, and the filter residue was diluted with EA (3 × 50 mL). The organic solution was washed with brine (2 × 50 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. The crude material was purified by flash chromatography on silica gel to get the product as a light yellow solid (38 mg, 38%; <i>R</i><sub><i>f</i></sub> = 0.35, DCM:methanol = 20:1).  <sup>1</sup>H NMR (400 MHz, <i>d</i><sub>6</sub>-DMSO): δ 10.94 (s, 1 H), 8.08 (s, 1 H), 7.95 (d, <i>J</i> = 13.2 Hz, 1 H), 7.81 (m, 2 H), 7.67 (m, 1 H), 7.48 (d, <i>J</i> = 8.8 Hz, 1 H), 7.30 (t, <i>J</i> = 8.8 Hz, 1 H), 6.19 (dd, <i>J</i><sub>1</sub> = 2.0 Hz, <i>J</i><sub>2</sub> = 5.6 Hz, 1 H), 5.95 (s, 2 H), 5.80 (s, 1 H), 3.83 (s, 3 H), 2.79-.74 (q, <i>J</i> = 7.6 Hz, 2 H), 2.62 (s, 3 H), 1.24 (t, <i>J</i> = 7.6 Hz, 3 H). <sup>13</sup>C NMR (125 MHz, <i>d</i><sub>6</sub>-DMSO): δ 174.4, 166.6, 166.2, 154.5 (d, <i>J</i> = 243.6 Hz, 1 C), 152.6, 150.3, 140.4, 140.1, 139.0 (d, <i>J</i> = 9.8 Hz, 1 C), 136.3 (d, <i>J</i> = 12.1 Hz, 1 C), 133.8, 126.7, 124.9, 124.6, 119.7, 118.0, 116.7, 108.7 (d, <i>J</i> = 23.1 Hz, 1 C), 102.1, 93.3, 28.4, 19.9, 16.4. HRMS (ESI) for C<sub>25</sub>H<sub>23</sub>FN<sub>4</sub>O<sub>3</sub> [M+H]<sup>+</sup>, calcd 447.1827, found 447.1822. HPLC analysis: MeOH–H<sub>2</sub>O (75:25), 4.92 min, 95.41% purity. Melting point: 204.5–206.8 °C.</div></div><div id="sec6_1_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> <i>N</i>-(4-((2-Carbamoylpyridin-4-yl)oxy)-3-fluorophenyl)-6-ethyl-1,2-dimethyl-4-oxo-1,4-dihydroquinoline-3-carboxamide (<b>9ij</b>)</h4><div class="NLM_p last">Brown solid (260 mg, 60%; <i>R</i><sub><i>f</i></sub> = 0.39, DCM:methanol = 20:1). <sup>1</sup>H NMR (400 MHz, <i>d</i><sub>6</sub>-DMSO): δ 11.06 (s, 1 H), 8.54 (d, <i>J</i> = 5.6 Hz, 1 H), 8.12 (s, 1 H), 8.08 (s, 1 H), 8.00 (d, <i>J</i> = 13.2 Hz, 1 H), 7.82 (d, <i>J</i> = 8.8 Hz, 1 H), 7.72 (s, 1 H), 7.67 (d, <i>J</i> = 8.0 Hz, 1 H), 7.53 (d, <i>J</i> = 8.8 Hz, 1 H), 7.41 (m, 2 H), 7.22 (m, 1 H), 3.84 (s, 3 H), 2.80–2.74 (q, <i>J</i> = 7.6 Hz, 2 H), 2.64 (s, 3 H), 1.24 (t, <i>J</i> = 7.6 Hz, 3 H). <sup>13</sup>C NMR (125 MHz, <i>d</i><sub>6</sub>-DMSO): δ 174.0, 166.3, 165.8, 165.7, 153.9 (d, <i>J</i> = 243.8 Hz, 1 C), 153.3, 152.4, 151.1, 140.0, 139.6, 139.2 (d, <i>J</i> = 10.0 Hz, 1 C), 135.2 (d, <i>J</i> = 12.5 Hz, 1 C), 133.4, 126.2, 124.4, 124.1, 119.0, 117.6, 116.6, 113.9, 108.7, 108.4 (d, <i>J</i> = 22.5 Hz, 1 C), 35.7, 27.9, 19.5, 15.9. HRMS (ESI) for C<sub>26</sub>H<sub>23</sub>FN<sub>4</sub>O<sub>4</sub> [M+H]<sup>+</sup>, calcd 475.1776, found 475.1772. HPLC analysis: MeOH–H<sub>2</sub>O (75:25), 4.92 min, 98.23% purity. Melting point: 250.4–251.8 °C.</div></div><div id="sec6_1_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> <i>N</i>-(4-((2-Amino-3-chloropyridin-4-yl)oxy)-3-fluorophenyl)-6-ethyl-1,2-dimethyl-4-oxo-1,4-dihydroquinoline-3-carboxamide (<b>9ik</b>)</h4><div class="NLM_p last">To a mixture of <b>9il</b> (100 mg, 0.2 mmol) in ethyl acetate (2.0 mL), CH<sub>3</sub>CN (2.0 mL), and H<sub>2</sub>O (1.0 mL) was added PhI(OCCH<sub>3</sub>)<sub>2</sub> (80 mg, 0.3 mmol), and the resulting solution was stirred at 0 °C overnight. The mixture was concentrated in vacuo and further purified by flash chromatography on silica gel to get the product as a beige solid (50 mg, 53%; <i>R</i><sub><i>f</i></sub> = 0.39, DCM:methanol = 20:1).  <sup>1</sup>H NMR (400 MHz, <i>d</i><sub>6</sub>-DMSO): δ 10.99 (s, 1 H), 8.08 (s, 1 H), 7.98–7.94 (dd, <i>J</i><sub>1</sub> = 2.4 Hz, <i>J</i><sub>2</sub> = 13.6 Hz,1 H), 7.82 (d, <i>J</i> = 8.8 Hz, 1 H), 7.75 (d, <i>J</i> = 5.6 Hz, 1 H), 7.68–7.65 (dd, <i>J</i><sub>1</sub> = 2.0 Hz, <i>J</i><sub>2</sub> = 8.8 Hz, 1 H), 7.48 (d, <i>J</i> = 9.6 Hz, 1 H), 7.42 (t, <i>J</i> = 8.8 Hz, 1 H), 6.40 (s, 2 H), 5.95 (d, <i>J</i> = 5.6 Hz, 1 H), 3.83 (s, 3 H), 2.80–2.74 (q, <i>J</i> = 7.2 Hz, 2 H), 2.63 (s, 3 H), 1.25 (t, <i>J</i> = 7.2 Hz, 3 H). <sup>13</sup>C NMR (125 MHz, <i>d</i><sub>6</sub>-DMSO): δ 174.4, 166.6, 160.7, 158.3, 154.1 (d, <i>J</i> = 243.8 Hz, 1 C), 152.8, 148.1, 140.4, 140.1 139.2 (d, <i>J</i> = 9.9 Hz, 1 C), 136.4 (d, <i>J</i> = 12.1 Hz, 1 C), 133.8, 126.6, 124.5, 124.3, 119.5, 118.0, 116.7, 108.7 (d, <i>J</i> = 22.8 Hz, 1 C), 101.1, 101.0, 36.1,28.3, 19.9, 16.3. HRMS (ESI) for C<sub>25</sub>H<sub>22</sub>ClFN<sub>4</sub>O<sub>3</sub> [M+H]<sup>+</sup>, calcd 481.1437, found 481.1435. HPLC analysis: MeOH–H<sub>2</sub>O (80:20), 5.43 min, 99.59% purity. Melting point: 230.6–231.7 °C.</div></div><div id="sec6_1_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> <i>N</i>-(4-((2-Carbamoyl-3-chloropyridin-4-yl)oxy)-3-fluorophenyl)-6-ethyl-1,2-dimethyl-4-oxo-1,4-dihydroquinoline-3-carboxamide (<b>9il</b>)</h4><div class="NLM_p last">Brown solid (162 mg, 62%; <i>R</i><sub><i>f</i></sub> = 0.31, DCM:methanol = 20:1).  <sup>1</sup>H NMR (400 MHz, <i>d</i><sub>6</sub>-DMSO): δ 11.05 (s, 1 H), 8.33 (d, <i>J</i> = 5.6 Hz, 1 H), 8.08–8.00 (m, 3 H), 7.83 (d, <i>J</i> = 8.8 Hz, 1 H), 7.74 (s, 1 H), 7.67 (m, 1 H), 7.53 (d, <i>J</i> = 8.8 Hz, 1 H), 7.42 (t, <i>J</i> = 8.8 Hz, 1 H), 6.87 (d, <i>J</i> = 5.2 Hz, 1 H), 3.84 (s, 3 H), 2.80–2.74 (q, <i>J</i> = 7.2 Hz, 2 H), 2.64 (s, 3 H), 1.25 (t, <i>J</i> = 7.2 Hz, 3 H). <sup>13</sup>C NMR (125 MHz, <i>d</i><sub>6</sub>-DMSO): δ 174.4, 167.4, 166.7, 161.0, 155.1, 153.9 (d, <i>J</i> = 244.3 Hz, 1 C), 152.8, 149.6, 140.5, 140.1, 139.8 (d, <i>J</i> = 9.5 Hz, 1 C), 135.6 (d, <i>J</i> = 12.4 Hz, 1 C), 133.8, 126.7, 124.6, 124.5, 119.5, 118.0, 117.3, 117.0, 111.6, 108.9 (d, <i>J</i> = 22.8 Hz, 1 C), 36.1,28.4, 19.9, 16.4. HRMS (ESI) for C<sub>26</sub>H<sub>22</sub>ClFN<sub>4</sub>O<sub>4</sub> [M+H]<sup>+</sup>, calcd 509.1386, found 509.1380. HPLC analysis: MeOH–H<sub>2</sub>O (70:30), 6.43 min, 99.81% purity. Melting point: 256.8–257.7 °C.</div></div><div id="sec6_1_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> <i>N</i>-(4-((6, 7-dimethoxyquinazolin-4-yl)oxy)-3-fluorophenyl)-6-ethyl-1,2-dimethyl-4-oxo-1,4-dihydroquinoline-3-carboxamide (<b>9im</b>)</h4><div class="NLM_p last">White solid (220 mg, 78%; <i>R</i><sub><i>f</i></sub> = 0.23, DCM:methanol = 20:1).  <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 12.69 (s, 1 H), 8.64 (s, 1 H), 8.34 (s, 1 H), 7.99 (dd, <i>J</i><sub>1</sub>= 2.0 Hz, <i>J</i><sub>2</sub> = 12.5 Hz, 1 H), 7.60 (m, 2 H), 7.53 (d, <i>J</i> = 8.5 Hz, 1 H), 7.45 (d, <i>J</i> = 8.5 Hz, 1 H), 7.36 (s, 1 H), 7.29–7.26 (m, 1 H), 4.09 (s, 3 H), 4.07 (s,3 H), 3.91 (s, 3 H), 3.08 (s, 3 H), 2.84–2.80 (q, <i>J</i> = 7.5 Hz, 2 H), 1.35–1.32 (t, <i>J</i> = 7.5 Hz, 3 H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 176.6, 165.0, 164.9, 158.2, 156.0, 154.3 (d, <i>J</i> = 245.6 Hz, 1 C), 152.9, 150.3, 149.4, 141.5, 138.7, 138.3 (d, <i>J</i> = 9.6 Hz, 1 C), 135.1 (d, <i>J</i> = 12.9 Hz, 1 C), 133.6, 126.4, 125.4, 125.3, 123.7, 123.7, 116.2 (d, <i>J</i> = 2.8 Hz, 1 C), 115.8, 113.6, 110.3, 109.4 (d, <i>J</i> = 22.9 Hz, 1 C), 106.8, 101.1, 56.4, 35.7, 28.3, 20.4, 15.3. HRMS (ESI) for C<sub>26</sub>H<sub>22</sub>ClFN<sub>4</sub>O<sub>4</sub> [M+H]<sup>+</sup>, calcd 543.2038, found 543.2035. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 5.03 min, 99.75%. Melting point: 260.7–261.6 °C.</div></div><div id="sec6_1_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 4-(2-Fluoro-4-nitrophenoxy)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>12h</b>)</h4><div class="NLM_p last">To a mixture of 4-chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (7.7 g, 50.0 mmol) and 2-fluoro-4-nitrophenol (11.0 g, 70.0 mmol) in 50 mL of 1-methyl-2-pyrrolidinone (NMP) was added <i>N,N</i>-diisopropylethylamine (DIPEA) (12.0 mL, 70.0 mmol). The reaction was heated to 200 °C under microwave irradiation and stirred for 1.0 h. The reaction mixture was cooled to rt and poured into ice water. The resulting mixture was filtrated, and the filter residue was rinsed with additional water (3 × 100 mL) and then dried in a vacuum oven to afford <b>12h</b> as a brown solid (12.0 g, 85%). <sup>1</sup>H NMR (400 MHz, <i>d</i><sub>6</sub>-DMSO): δ 12.42 (s, 1 H), 8.38 (dd,  <i>J</i><sub>1</sub> = 2.8 Hz, <i>J</i><sub>2</sub> = 10.4 Hz, 1 H), 8.33 (s, 1 H), 8.21 (m, 1 H), 7.81–7.77 (m, 1 H), 7.58 (t, <i>J</i> = 2.8 Hz, 1 H), 6.68 (dd, <i>J</i><sub>1</sub> = 1.6 Hz, <i>J</i><sub>2</sub> = 3.6 Hz, 1 H).</div></div><div id="sec6_1_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> 4-(2-Fluoro-4-nitrophenoxy)-5-iodo-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>13h</b>)</h4><div class="NLM_p last">To a solution of compound <b>12h</b> (11.2 g, 40.0 mmol) and KOH (6.7 g, 120.0 mmol) in 200 mL of DMF was added iodides (15.2 g, 60.0 mmol) over 10 min at 0 °C. The reaction mixture was stirred for 4.0 h at 0 °C and then poured into ice water. The precipitate was filtered, and the filter cake was rinsed with additional cool water and then dried in a vacuum oven to afford <b>13h</b> as a yellow solid (14.0 g, 88%). <sup>1</sup>H NMR (400 MHz, <i>d</i><sub>6</sub>-DMSO): δ 12.74 (s, 1 H), 8.38 (dd,  <i>J</i><sub>1</sub> = 2.4 Hz, <i>J</i><sub>2</sub> = 10.0 Hz, 1 H), 8.34 (s, 1 H), 8.21 (m, 1 H), 7.80 (m, 2 H).</div></div><div id="sec6_1_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> 4-(2-Fluoro-4-nitrophenoxy)-5-iodo-7-((2-(trimethylsilyl)ethoxy)methyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>14h</b>)</h4><div class="NLM_p last">To a solution of <b>13h</b> (12.2 g, 30.0 mmol) in DMF (150 mL) was added NaH (60%, 1.3 g, 33.0 mmol) under ice bath. The reaction was stirred at 0 °C for 15 min, then (2-(chloromethoxy)ethyl)trimethylsilane (5.8 mL, 33.0 mmol) was added to the mixture. The reaction solution was stirred at rt overnight and quenched with ice water. The mixture was extracted with DCM (4 × 300 mL). The combined organic layer was washed with brine (2 × 400 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated in vacuo, and further purified by flash chromatography on silica gel to get the product <b>14h</b> as a white solid (13.2 g, 83%). <sup>1</sup>H NMR (400 MHz, <i>d</i><sub>6</sub>-DMSO): δ 8.43 (s, 1 H), 8.39 (dd, <i>J</i><sub>1</sub> = 2.8 Hz, <i>J</i><sub>2</sub> = 10.4 Hz, 1 H), 8.22 (m, 1 H), 8.00 (s, 1 H), 7.82 (t, <i>J</i> = 8.4 Hz, 1 H), 5.61 (s, 2 H), 3.54 (t, <i>J</i> = 8.0 Hz, 2 H), 0.84 (t, <i>J</i> = 8.0 Hz, 2 H),  −0.08 (s, 9 H).</div></div><div id="sec6_1_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> 4-(2-Fluoro-4-nitrophenoxy)-5-phenyl-7-((2-(trimethylsilyl)ethoxy)methyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>16h</b>)</h4><div class="NLM_p last">To a solution of <b>14h</b> (<b>7</b>, 12.0 g, 22.7 mmol) and phenyl boronic acid (<b>15h</b>, 3.3 g, 27.2 mmol) in 200 mL of PhMe were added Pd(PPh<sub>3</sub>)<sub>4</sub> (1.3 g, 1.1 mmol) and Na<sub>2</sub>CO<sub>3</sub> (7.2 g, 68.1 mmol). The mixture was stirred at 90 °C under argon overnight and cooled to rt. The reaction mixture was filtrated, and the filtrate was extracted with DCM (3 × 400 mL). The combined organic layer was washed with brine (2 × 400 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. The crude material was purified by flash chromatography on silica gel to get the product as a yellow solid (<b>16h</b>, 8.3 g, 76%). <sup>1</sup>H NMR (400 MHz, <i>d</i><sub>6</sub>-DMSO): δ 8.45 (s, 1 H), 8.37 (dd, <i>J</i><sub>1</sub> = 2.8 Hz, <i>J</i><sub>2</sub> = 10.0 Hz, 1 H), 8.21 (m, 1 H), 8.01 (s, 1 H), 7.86–7.83 (t,  <i>J</i> = 8.0 Hz, 1 H), 7.76 (m, 2 H), 7.43 (t, <i>J</i> = 8.0 Hz, 1 H), 7.31 (m, 1 H), 5.70 (s, 2 H), 3.61 (t,  <i>J</i> = 8.0 Hz, 2 H), 0.86 (t, <i>J</i> = 8.0 Hz, 2 H),  −0.08 (s, 9 H).</div></div><div id="sec6_1_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> 3-Fluoro-4-((5-phenyl-7-((2-(trimethylsilyl)ethoxy)methyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)aniline (<b>17h</b>)</h4><div class="NLM_p last">To a solution of <b>16h</b> (8.0 g, 16.6 mmol) in 90 mL of THF and 30 mL of methanol were added NaBH<sub>4</sub> (3.8 g, 99.6 mmol) and NiCl<sub>2</sub>·6H<sub>2</sub>O (394 mg, 1.7 mmol). The mixture was stirred at rt for 2.0 h. The reaction mixture was quenched with water and filtrated, and the filtrate was concentrated in vacuo and further purified by flash chromatography on silica gel to get the product <b>17h</b> as a solid (5.3 g, 71%). <sup>1</sup>H NMR (400 MHz, <i>d</i><sub>6</sub>-DMSO): δ 8.39 (s, 1 H), 7.89 (s, 1 H), 7.74 (m, 2 H), 7.41 (t, <i>J</i> = 7.6 Hz, 2 H), 7.29 (t, <i>J</i> = 7.6 Hz, 1 H), 7.01 (t, <i>J</i> = 8.8 Hz, 1 H), 6.47 (dd, <i>J</i><sub>1</sub> = 2.4 Hz, <i>J</i><sub>2</sub> = 12.8 Hz, 1 H), 6.39 (dd, <i>J</i><sub>1</sub> = 2.0 Hz, <i>J</i><sub>2</sub> = 8.8 Hz, 1 H), 5.66 (s, 2 H), 3.59 (t, <i>J</i> = 8.0 Hz, 2 H), 0.85 (t, <i>J</i> = 8.0 Hz, 2 H), −0.08 (s, 9 H).</div></div><div id="sec6_1_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> <i>N</i>-(3-Fluoro-4-((5-phenyl-7-((2-(trimethylsilyl)ethoxy)methyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)phenyl)-1,2,6-trimethyl-4-oxo-1,4-dihydroquinoline-3-carboxamide (<b>18h</b>)</h4><div class="NLM_p last">A mixture of <b>17h</b> (450 mg, 1.0 mmol), <b>29h</b> (277 mg, 1.2 mmol), HATU (570 mg, 1.5 mmol), and DIEA (0.5 mL, 3.0 mmol) in DMF (30 mL) was stirred at rt overnight. Next, water was added to the mixture, and the precipitate was filtrated. The filter cake was washed with water, diluted with DCM, and concentrated in vacuo. The resulting residue was purified by flash chromatography on silica gel to get the product as a white solid (<b>18h</b>, 478 mg, 72%). <sup>1</sup>H NMR (400 MHz, <i>d</i><sub>6</sub>-DMSO): δ 11.01 (s, 1 H), 8.43 (s, 1 H), 8.07 (s, 1 H), 7.95 (s, 1 H), 7.94–7.90 (dd,  <i>J</i><sub>1</sub> = 2.0 Hz, <i>J</i><sub>2</sub> = 12.8 Hz, 1 H),   7.82–7.77 (m, 3 H), 7.63 (dd, <i>J</i><sub>1</sub> = 2.0 Hz, <i>J</i><sub>2</sub> = 8.8 Hz, 1 H),  7.48–7.40 (m, 4 H), 7.34 (m, 1 H), 5.70 (s, 2H), 3.84 (s, 3 H), 3.62 (t, <i>J</i> = 8.0 Hz, 2 H), 2.74 (s, 3 H), 2.46 (s, 3 H), 0.88 (t,  <i>J</i> = 8.0 Hz, 2 H), −0.06 (s, 9 H).</div></div><div id="sec6_1_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> <i>N</i>-(3-Fluoro-4-((7-(hydroxymethyl)-5-phenyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)phenyl)-1,2,6-trimethyl-4-oxo-1,4-dihydroquinoline-3-carboxamide (<b>19h</b>)</h4><div class="NLM_p last">To a solution of compound <b>18h</b> (400 mg, 0.6 mmol) in DCM (20 mL) was added trifluoroacetic acid (3 mL). The resulting mixture was stirred at rt overnight. The solvent was removed under reduced pressure, and water was added to the resulting residue. The precipitate was filtrated, and the filter cake was washed with methanol and dried in a vacuum oven to obtain the title product as a white solid (300 mg, 89%). <sup>1</sup>H NMR (400 MHz, <i>d</i><sub>6</sub>-DMSO): δ 11.00 (s, 1 H), 8.41 (s, 1 H), 8.07 (s, 1 H), 7.89 (d, <i>J</i> = 12.0 Hz, 1 H), 7.85 (s, 1 H),  7.81–7.76 (m, 3 H), 7.63 (d, <i>J</i> = 8.0 Hz, 1 H),  7.47–7.39 (m, 4 H), 7.31 (t, <i>J</i> = 8.0 Hz, 1 H), 5.68 (s, 2 H), 3.83 (s, 3 H), 2.64 (s, 3 H), 2.46 (s, 3 H).</div></div><div id="sec6_1_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> 6-Methyl-1<i>H</i>-benzo[<i>d</i>][1,3]oxazine-2,4-dione (<b>21h</b>)</h4><div class="NLM_p last">To a solution of 2-amino-5-methyl benzoic acid (<b>20h</b>, 3.6 g, 23.8 mmol) and pyridine (3.8 mL, 47.6 mmol) in MeCN (50 mL) was added triphosgene (2.4 g, 8.0 mmol) under an ice bath. The resulting solution was stirred at 55 °C for 2.0 h. After cooling to rt, the reaction was quenched with concentrated NaHCO<sub>3</sub>. The precipitate was filtrated, and the filter cake was washed with water and petroleum ether (PE) and then dried under vacuum to afford the title product (<b>21h</b>, 3.9 g, 94%). <sup>1</sup>H NMR (400 MHz, <i>d</i><sub>6</sub>-DMSO): δ 11.63 (s, 1 H), 7.72 (s, 1 H),  7.58–7.55 (dd,  <i>J</i><sub>1</sub> = 4.0 Hz, <i>J</i><sub>2</sub> = 8.0 Hz, 1 H), 7.06 (d, <i>J</i> = 8.0 Hz, 1 H), 2.33 (s, 3 H).</div></div><div id="sec6_1_51" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> 1,6-Dimethyl-1<i>H</i>-benzo[<i>d</i>][1,3]oxazine-2,4-dione (<b>23h</b>)</h4><div class="NLM_p last">To a solution of <b>21h</b> (3.0 g, 16.9 mmol) and DIEA (5.6 mL, 33.8 mmol) in DMF (50 mL) was added MeI (2.1 mL, 33.8 mmol) dropwise. The mixture was stirred at 40 °C overnight. After cooling to rt, the reaction was quenched with water. The precipitate was filtrated, the filter cake was washed with additional water. The crude material was purified by flash chromatography on silica gel to yield the product as a yellow solid (<b>23h</b>, 2.8 g, 88%). <sup>1</sup>H NMR (400 MHz, <i>d</i><sub>6</sub>-DMSO): δ 7.8 (s, 1 H), 7.68 (dd, <i>J</i><sub>1</sub> = 4.0 Hz, <i>J</i><sub>2</sub> = 8.0 Hz, 1 H), 7.34 (d, <i>J</i> = 8.0 Hz, 1 H), 3.44 (s, 3 H), 2.36 (s, 3 H).</div></div><div id="sec6_1_52" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> Methyl 1,2,6-Trimethyl-4-oxo-1,4-dihydroquinoline-3-carboxylate (<b>24h</b>)</h4><div class="NLM_p last">To a solution of <b>22h</b> (1.9 mL, 18.0 mmol) in DMF (50 mL) was added NaH (60%, 720 mg, 18.0 mmol) under ice bath. After stirring at rt for 30 min, <b>23h</b> (2.9 g, 15.0 mmol) was added to the reaction solution. The mixture was warmed to 120 °C and strried overnight. The reaction mixture was cooled to rt and quenched with ice water. The resulting residue was extracted with DCM (3 × 150 mL). The combined organic layer was washed with brine (2 × 150 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated in vacuo, and further purified by flash chromatography on silica gel to yield the title product (<b>24h</b>, 2.8 g, 60%). <sup>1</sup>H NMR (400 MHz, <i>d</i><sub>6</sub>-DMSO): δ 7.95 (s, 1 H), 7.74 (d, <i>J</i> = 8.0 Hz, 1 H), 7.58 (dd, <i>J</i><sub>1</sub> = 4.0 Hz, <i>J</i><sub>2</sub> = 8.0 Hz, 1 H), 3.77 (s, 3 H), 3.75 (s, 3 H), 2.44 (s, 3 H), 2.42 (s, 3 H).</div></div><div id="sec6_1_53" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> 1,2,6-Trimethyl-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid (<b>29h</b>)</h4><div class="NLM_p last">To a solution of <b>24h</b> (3.0 g, 12.2 mmol) in 40 mL of THF and 20 mL of water was added NaOH (2.0 g, 48.8 mmol). The mixture was refluxed overnight and then cooled to rt. The solvent was concentrated in vacuo, and the residue was diluted with water. The resulting solution was acidified to pH 6–7 with 1 N aqueous HCl. The precipitate was filtrated, and the filter cake was dried under vacuum to afford <b>29h</b> as a white solid (2.6 g, 92%). <sup>1</sup>HNMR (400 MHz, <i>d</i><sub>6</sub>-DMSO): δ 8.16 (s, 1 H), 7.99 (d, <i>J</i> = 8.0 Hz, 1 H), 7.77 (d, <i>J</i> = 8.0 Hz, 1 H), 3.96 (s, 3 H), 3.11 (s, 3 H), 2.49 (s, 3 H).</div></div></div><div id="sec6_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> Cell Culture</h3><div class="NLM_p last">MDA-MB-231 cells were purchased from American Type Culture Collection (ATCC). MDA-MB-231 cells were maintained in Roswell Park Memorial Institute (RPMI)-1640 supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, 50 mg/mL streptomycin, and 2 mmol/L glutamine in a humidified CO<sub>2</sub> incubator at 37 °C. All cells were passaged for less than 3 months before renewal from frozen, early-passage stocks obtained from the indicated sources.</div></div><div id="sec6_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> Reagents and Antibodies</h3><div class="NLM_p last">The compound was dissolved in dimethyl sulfoxide (DMSO, Sigma-Aldrich) at a concentration of 10 mmol/L and stored at −20 °C. Primary antibodies against Axl (8661), phosphor-Axl (Tyr<sup>702</sup>, 5724), E-cadherin (3195), N-cadherin (13116), glyceraldehyde-3-phosphate dehydrogenase (GAPDH, 2118), and anti-rabbit or anti-mouse IgG horseradish peroxidase (HRP)-linked secondary antibodies were purchased from Cell Signaling Technology (CST, Boston, MA, USA). Primary antibodies against v-akt murine thymoma viral oncogene homologue (AKT, SC8312), phosphor-AKT (SC16646R, SC7985R) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).</div></div><div id="sec6_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> <i>In Vitro</i> Enzymatic Activity Assay</h3><div class="NLM_p last">Axl and the Z′-Lyte Kinase Assay Kit were purchased from Invitrogen. The experiments were performed according to the instructions of the manufacturer. The concentrations of kinases were determined by optimization experiments, and the respective Axl (PV3971, Invitrogen) concentration was 0.22 μg/ μL.</div></div><div id="sec6_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> Western Blot Analysis</h3><div class="NLM_p last">The Western blot analysis was carried out by following the protocol described before. Briefly, after the indicated treatment, cell lysates were collected dissolving cells in 1× SDS sample lysis buffer (CST recommended). After being sonicated and boiled, the supernatant of cell lysate was used for Western blot analysis. Cell lysates were loaded to 8–12% SDS-PAGE and separated by electrophoresis. Separated proteins were then electrically transferred to a PVDF film. After being blocked with 1× TBS containing 0.5% Tween-20 and 5% nonfat milk, the film was incubated with corresponding primary antibody, followed by HRP-conjugated secondary antibody. The protein lanes were visualized using ECL Western Blotting Detection Kit (Thermo Scientific, USA).</div></div><div id="sec6_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> Cell Proliferation Assay</h3><div class="NLM_p last">Tumor cells were plated into 96-well plates (3000 cell/well) in complete medium. After incubation overnight, cells were exposed to various concentrations (0.016–50 μM) of the test compounds for 24, 48, or 72 h. Cell proliferation was evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay or Cell Counting Kit 8 (CCK8, CK04, Dojindo laboratories, Japan). IC<sub>50</sub> values were calculated by concentration–response curve-fitting using GraphPad Prism 5.0 software. Each IC<sub>50</sub> value was expressed as mean ± SD.</div></div><div id="sec6_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> Wound Healing Assay</h3><div class="NLM_p last">Cells were seeded in a 6-well plate and allowed to grow to nearly 100% confluence in culture medium. Subsequently, a cell-free line was manually created by scratching the confluent cell monolayers with a 200 μL pipet tip. The wounded cell monolayers were washed three times with PBS and incubated in RPMI-1640 (containing 2% FBS), with or without TGF-β1 of 10 ng/mL and different concentration of test compounds, for 24 h. Three scratched fields were randomly chosen, and the images were captured by bright-field microscopy (CKX41; Olympus). The percentage of wound closure was measured using Adobe Photoshop 7.0.1 (Adobe Systems Inc., San Jose, CA). The experiment was performed three times and in triplicate.</div></div><div id="sec6_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> Cell Migration and Invasion Assay</h3><div class="NLM_p last">Cell migration assays were evaluated in Transwell chambers (Corning Costar). Cell invasion assays were evaluated in Matrigel invasion chambers (Corning Costar). First, (0.2–1) × 10<sup>5</sup> tumor cells were plated in the top chamber with medium without FBS. RPMI-1640 medium containing 2% FBS with or without TGF-β1 of 10 ng/mL and test compound (0.04–5 μmol/L) was added to the bottom chamber. After incubation for 24 h at 37 °C, the cells were fixed in 100% methanol and stained with 0.25% crystal violet; the cells that had not migrated from the top surface of the filters were removed with cotton. Migrated cells were quantitated by counting cells in six randomly selected fields on each filter under a microscope at 200× magnification and graphed as the mean of three independent experiments.</div></div><div id="sec6_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> Immunofluorescence</h3><div class="NLM_p last">The cells were seeded on coverslips, which were placed in the 6-well plate in advance. Following treatment with or without TGF-β1 (10 ng/mL) and test compounds (0.04, 0.2, 1, and 5 μM) for 96–144 h, the cells were fixed with 4% paraformaldehyde for 15 min, permeabilized with 0.5% Triton X-100 for 10 min, then blocked with 3% normal goat serum albumin for 1.0 h at rt and incubated with anti-E-cadherin and anti-N-cadherin antibody at rt for 1.5 h. Subsequently, the cells were rinsed thoroughly with PBST and were then incubated with Alexa Fluor 555-conjugated goat anti-rabbit IgG (CST, USA) or Alexa Fluor 488-conjugated goat anti-mouse IgG (CST, USA) for 1.0 h at rt in the dark. ProLong Gold antifade reagent (Invitrogen, USA) was used to stain the nuclei for 5 min at rt. The cells were visualized with laser scanning confocal microscopy (Zeiss710; Germany).</div></div><div id="sec6_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> Determination of Pharmacokinetic Parameters in Rats</h3><div class="NLM_p last">Male Sprague–Dawley rats (190–230 g) were dosed with the test compounds intravenously (i.v.) at 2.5 or 5.0 mg/kg and by oral gavage (p.o.) at 25 mg/kg. The compounds was dissolved in mixed solvents (5% EtOH, 3% Tween, and a bit of 0.1 mol/L HCl). Blood samples (0.5 mL) were then obtained via orbital sinus puncture at 0.25, 0.75, 1.5, 3, 6, 12, 24, 36, 48, 60, 72, 84, and 96 h time points and collected into heparinized tubes. Samples were centrifuged for cell removal, and the plasma supernatant was then transferred to a clean vial and subsequently stored at −80 °C prior to analysis. Test sample concentrations were determined by LC/MS, and PK parameters were calculated using DAS 2.0 software.</div></div><div id="sec6_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> 4T1 Xenograft Model</h3><div class="NLM_p last">A total of 0.5 × 10<sup>6</sup> 4T1 cells were implanted in the right flank of female BALB/c mice. Twenty-four hours after inoculation, mice were randomized into different treatment groups (<i>n</i> = 10). <b>9im</b> (30, 90 mg/kg, qd) or vehicle were administrated orally through 21 days. Body weight and tumor size were measured every 2 days. After the mice died or were sacrificed at the end point, mice livers were collected by resection and fixed in 10% buffered formalin. After being paraffin embedded and sectioned, the liver tissue section slides were subjected for hematoxylin and eosin (H&E) staining. Two H&E-stained liver sections per animal were examined by microscope for micrometastases in at least three view fields. The numbers of liver micrometastases events were counted.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i77"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00608">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73666" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73666" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.6b00608" class="ext-link">10.1021/acs.jmedchem.6b00608</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Biological data, assay details, and <sup>1</sup>H and <sup>13</sup>C NMR spectra for final compounds and intermediates (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00608/suppl_file/jm6b00608_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">(<a href="/doi/suppl/10.1021/acs.jmedchem.6b00608/suppl_file/jm6b00608_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00608/suppl_file/jm6b00608_si_001.pdf">jm6b00608_si_001.pdf (8.93 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00608/suppl_file/jm6b00608_si_002.csv">jm6b00608_si_002.csv (4.41 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.6b00608" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56006" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56006" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaomei Ren</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Respiratory Diseases, Guangzhou Institutes of Biomedicine
and Health, Chinese Academy of Sciences, 190 Kaiyuan Avenue, Guangzhou 510530, China</span>; 
    <span class="hlFld-Affiliation affiliation">School
of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#cca8a5a2aba7a98ca6a2b9e2a9a8b9e2afa2"><span class="__cf_email__" data-cfemail="492d20272e222c0923273c672c2d3c672a27">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ke Ding</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Respiratory Diseases, Guangzhou Institutes of Biomedicine
and Health, Chinese Academy of Sciences, 190 Kaiyuan Avenue, Guangzhou 510530, China</span>; 
    <span class="hlFld-Affiliation affiliation">School
of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#5426313a0b2c3d353b39313d14333d363c7a35377a373a"><span class="__cf_email__" data-cfemail="9ceef9f2c3e4f5fdf3f1f9f5dcfbf5fef4b2fdffb2fff2">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Li Tan</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Respiratory Diseases, Guangzhou Institutes of Biomedicine
and Health, Chinese Academy of Sciences, 190 Kaiyuan Avenue, Guangzhou 510530, China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Chinese Academy of Sciences, 19 Yuquan Road, Beijing 100049, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhang Zhang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Respiratory Diseases, Guangzhou Institutes of Biomedicine
and Health, Chinese Academy of Sciences, 190 Kaiyuan Avenue, Guangzhou 510530, China</span>; 
    <span class="hlFld-Affiliation affiliation">School
of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Donglin Gao</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Respiratory Diseases, Guangzhou Institutes of Biomedicine
and Health, Chinese Academy of Sciences, 190 Kaiyuan Avenue, Guangzhou 510530, China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Chinese Academy of Sciences, 19 Yuquan Road, Beijing 100049, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jinfeng Luo</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Respiratory Diseases, Guangzhou Institutes of Biomedicine
and Health, Chinese Academy of Sciences, 190 Kaiyuan Avenue, Guangzhou 510530, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zheng-Chao Tu</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Respiratory Diseases, Guangzhou Institutes of Biomedicine
and Health, Chinese Academy of Sciences, 190 Kaiyuan Avenue, Guangzhou 510530, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhengqiu Li</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lijie Peng</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>L.T. and Z.Z. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d48e6555-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i79">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62273" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62273" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors are thankul for the financial support from National Natural Science Foundation of China (81425021 and 21572230), Guangzhou Science Technology and Innovation Commission (201508030036), and the Natural Science Foundation of Guangdong Province (2015A030312014).</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i80" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i80"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i81" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i81"> Abbreviations Used</h2><tr><td class="NLM_term">Mer</td><td class="NLM_def"><p class="first last">c-mer proto-oncogene tyrosine kinase</p></td></tr><tr><td class="NLM_term">CML</td><td class="NLM_def"><p class="first last">chronic myeloid leukemia</p></td></tr><tr><td class="NLM_term">Gas6</td><td class="NLM_def"><p class="first last">growth arrest-specific 6</p></td></tr><tr><td class="NLM_term">HCC</td><td class="NLM_def"><p class="first last">hepatic cellular cancer</p></td></tr><tr><td class="NLM_term">SCC</td><td class="NLM_def"><p class="first last">squamous-cell carcinoma</p></td></tr><tr><td class="NLM_term">GIST</td><td class="NLM_def"><p class="first last">gastrointestinal stromal tumors</p></td></tr><tr><td class="NLM_term">RCC</td><td class="NLM_def"><p class="first last">renal cell carcinoma</p></td></tr><tr><td class="NLM_term">CRC</td><td class="NLM_def"><p class="first last">colorectal carcinoma</p></td></tr><tr><td class="NLM_term">EMT</td><td class="NLM_def"><p class="first last">epithelial–mesenchymal transition</p></td></tr><tr><td class="NLM_term">ER<sup>+</sup></td><td class="NLM_def"><p class="first last">estrogen receptor positive</p></td></tr><tr><td class="NLM_term">Her2<sup>+</sup></td><td class="NLM_def"><p class="first last">Human epidermal growth factor receptor 2 positive</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">Food and Drug Administration</p></td></tr><tr><td class="NLM_term">AML</td><td class="NLM_def"><p class="first last">acute myeloid leukemia</p></td></tr><tr><td class="NLM_term">DHBA</td><td class="NLM_def"><p class="first last">dual hydrogen bond acceptor</p></td></tr><tr><td class="NLM_term">SEMCl</td><td class="NLM_def"><p class="first last">(2-(chloromethoxy)ethyl)trimethylsilane</p></td></tr><tr><td class="NLM_term">rt</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N,N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">NMP</td><td class="NLM_def"><p class="first last">1-methyl-2-pyrrolidinone</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N,N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">1-[bis(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo [4,5-<i>b</i>]pyridinium 3-oxide hexafluorophosphate</p></td></tr><tr><td class="NLM_term">F<sub>3</sub>CCOOH</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">MeCN</td><td class="NLM_def"><p class="first last">acetonitrile</p></td></tr><tr><td class="NLM_term">PPA</td><td class="NLM_def"><p class="first last">polyphosphoric acid</p></td></tr><tr><td class="NLM_term">FRET</td><td class="NLM_def"><p class="first last">fluorescence resonance energy transfer</p></td></tr><tr><td class="NLM_term">IC<sub>50</sub></td><td class="NLM_def"><p class="first last">half-maximal inhibitory concentration of a substance</p></td></tr><tr><td class="NLM_term"><i>K</i><sub>d</sub></td><td class="NLM_def"><p class="first last">binding constant</p></td></tr><tr><td class="NLM_term">Abl</td><td class="NLM_def"><p class="first last">abelson murine leukemia viral oncogene</p></td></tr><tr><td class="NLM_term">BLK</td><td class="NLM_def"><p class="first last">B lymphoid tyrosine kinase</p></td></tr><tr><td class="NLM_term">CDK</td><td class="NLM_def"><p class="first last">cyclin-dependent-kinase</p></td></tr><tr><td class="NLM_term">DDR</td><td class="NLM_def"><p class="first last">discoidin domain receptor</p></td></tr><tr><td class="NLM_term">DRAK1</td><td class="NLM_def"><p class="first last">death-associated protein kinase related 1</p></td></tr><tr><td class="NLM_term">Flt3</td><td class="NLM_def"><p class="first last">FMS-like tyrosine kinase 3</p></td></tr><tr><td class="NLM_term">HIPK</td><td class="NLM_def"><p class="first last">homeodomain interacting protein kinase</p></td></tr><tr><td class="NLM_term">Kit</td><td class="NLM_def"><p class="first last">v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homologue</p></td></tr><tr><td class="NLM_term">LOK</td><td class="NLM_def"><p class="first last">serine/threonine kinase 10</p></td></tr><tr><td class="NLM_term">MEK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase kinase</p></td></tr><tr><td class="NLM_term">Slk</td><td class="NLM_def"><p class="first last">Ste-like kinase</p></td></tr><tr><td class="NLM_term">Trk</td><td class="NLM_def"><p class="first last">nerve growth factor receptor</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">TGFβ</td><td class="NLM_def"><p class="first last">transforming growth factor β</p></td></tr><tr><td class="NLM_term">H&E</td><td class="NLM_def"><p class="first last">hematoxylin–eosin</p></td></tr><tr><td class="NLM_term">ATCC</td><td class="NLM_def"><p class="first last">American Type Culture Collection</p></td></tr><tr><td class="NLM_term">RPMI</td><td class="NLM_def"><p class="first last">Roswell Park Memorial Institute</p></td></tr><tr><td class="NLM_term">FBS</td><td class="NLM_def"><p class="first last">fetal bovine serum</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">ERK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase</p></td></tr><tr><td class="NLM_term">GAPDH</td><td class="NLM_def"><p class="first last">glyceraldehyde-3-phosphate dehydrogenase</p></td></tr><tr><td class="NLM_term">HRP</td><td class="NLM_def"><p class="first last">horseradish peroxidase</p></td></tr><tr><td class="NLM_term">AKT</td><td class="NLM_def"><p class="first last">v-akt murine thymoma viral oncogene homologue</p></td></tr><tr><td class="NLM_term">MTT</td><td class="NLM_def"><p class="first last">3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide</p></td></tr><tr><td class="NLM_term">CCK</td><td class="NLM_def"><p class="first last">Cell Counting Kit</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i82">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50076" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50076" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 48 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">O’Bryan, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frye, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cogswell, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neubauer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitch, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prokop, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Espinosa, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Beau, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Earp, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, E. T.</span><span> </span><span class="NLM_article-title">Axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">5016</span><span class="NLM_x">–</span> <span class="NLM_lpage">5031</span><span class="refDoi"> DOI: 10.1128/MCB.11.10.5016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1128%2FMCB.11.10.5016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1656220" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADyaK38XlvVGrsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1991&pages=5016-5031&author=J.+P.+O%E2%80%99Bryanauthor=R.+A.+Fryeauthor=P.+C.+Cogswellauthor=A.+Neubauerauthor=B.+Kitchauthor=C.+Prokopauthor=R.+Espinosaauthor=M.+M.+Le+Beauauthor=H.+S.+Earpauthor=E.+T.+Liu&title=Axl%2C+a+transforming+gene+isolated+from+primary+human+myeloid+leukemia+cells%2C+encodes+a+novel+receptor+tyrosine+kinase&doi=10.1128%2FMCB.11.10.5016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">axl, A transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase</span></div><div class="casAuthors">O'Bryan, John P.; Frye, Roy A.; Cogswell, Patricia C.; Neubauer, Andreas; Kitch, Barry; Prokop, Carol; Espinosa, Rafael, III; Le Beau, Michelle M.; Earp, H. Shelton; Liu, Edison T.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5016-31</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    </div><div class="casAbstract">A sensitive transfection-tumorigenicity assay was used to isolate a novel transforming gene from the DNA of 2 patients with chronic myelogenous leukemia.  Sequence anal. indicates that the product of this gene, axl, is a receptor tyrosine kinase.  Overexpression of axl cDNA in NIH 3T3 cells induces neoplastic transformation with the concomitant appearance of a 140-kDa axl tyrosine-phosphorylated protein.  Expression of axl cDNA in the baculovirus system results in the expression of the appropriate recombinant protein that is tyrosine kinase.  The juxtaposition of fibronectin type III and immunoglobulinlike repeats in the extracellular domain, as well as distinct amino acid sequences in the kinase domain, indicate that the axl protein represents a novel subclass of receptor tyrosine kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCIaouGK3RfrVg90H21EOLACvtfcHk0lhb2zDZx6Ug_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XlvVGrsLs%253D&md5=f244ff83822fdb98c22a35f918723d3a</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1128%2FMCB.11.10.5016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.11.10.5016%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Bryan%26aufirst%3DJ.%2BP.%26aulast%3DFrye%26aufirst%3DR.%2BA.%26aulast%3DCogswell%26aufirst%3DP.%2BC.%26aulast%3DNeubauer%26aufirst%3DA.%26aulast%3DKitch%26aufirst%3DB.%26aulast%3DProkop%26aufirst%3DC.%26aulast%3DEspinosa%26aufirst%3DR.%26aulast%3DLe%2BBeau%26aufirst%3DM.%2BM.%26aulast%3DEarp%26aufirst%3DH.%2BS.%26aulast%3DLiu%26aufirst%3DE.%2BT.%26atitle%3DAxl%252C%2520a%2520transforming%2520gene%2520isolated%2520from%2520primary%2520human%2520myeloid%2520leukemia%2520cells%252C%2520encodes%2520a%2520novel%2520receptor%2520tyrosine%2520kinase%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1991%26volume%3D11%26spage%3D5016%26epage%3D5031%26doi%3D10.1128%2FMCB.11.10.5016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Myers, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunton, V. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unciti-Broceta, A.</span><span> </span><span class="NLM_article-title">Axl inhibitors in cancer: a medicinal chemistry perspective</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">3593</span><span class="NLM_x">–</span> <span class="NLM_lpage">3608</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01273</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01273" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVWnsbnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=3593-3608&author=S.+H.+Myersauthor=V.+G.+Bruntonauthor=A.+Unciti-Broceta&title=Axl+inhibitors+in+cancer%3A+a+medicinal+chemistry+perspective&doi=10.1021%2Facs.jmedchem.5b01273"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective</span></div><div class="casAuthors">Myers, Samuel H.; Brunton, Valerie G.; Unciti-Broceta, Asier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3593-3608</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dysregulation of the AXL receptor tyrosine kinase has been assocd. with many types of cancer.  It has not been until recently, however, that targeting AXL has come under the spotlight because of ever accumulating evidence of its strong correlation with poor prognosis and drug resistance.  The entry of the first AXL-branded inhibitor in clin. trials in 2013 marked an important milestone for the clin. validation of AXL as an anticancer target.  Nevertheless, to weigh the current contribution and potential future impact of AXL inhibition in the clinic, it is fundamental to recognize that several kinase inhibitors approved or in clin. development have AXL as either a prominent secondary or even the primary target.  Through this review, the chem. and biol. properties of the main inhibitors targeting AXL (either intentionally or unintentionally) will be discussed, along with the prospects and challenges to translate AXL inhibitors into a bona fide therapeutic option.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7-ZTTNRD9LLVg90H21EOLACvtfcHk0lhb2zDZx6Ug_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVWnsbnI&md5=4643d9d9950251a14c3991c306c4cec0</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01273%26sid%3Dliteratum%253Aachs%26aulast%3DMyers%26aufirst%3DS.%2BH.%26aulast%3DBrunton%26aufirst%3DV.%2BG.%26aulast%3DUnciti-Broceta%26aufirst%3DA.%26atitle%3DAxl%2520inhibitors%2520in%2520cancer%253A%2520a%2520medicinal%2520chemistry%2520perspective%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D3593%26epage%3D3608%26doi%3D10.1021%2Facs.jmedchem.5b01273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Varnum, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartley, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridell, Y. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trail, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clogston, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toso, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yanagihara, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sylber, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merewether, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tseng, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Escobar, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamane, H. K.</span><span> </span><span class="NLM_article-title">Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">373</span><span class="NLM_x">, </span> <span class="NLM_fpage">623</span><span class="NLM_x">–</span> <span class="NLM_lpage">626</span><span class="refDoi"> DOI: 10.1038/373623a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1038%2F373623a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=7854420" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADyaK2MXjsl2mtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=1995&pages=623-626&author=B.+C.+Varnumauthor=C.+Youngauthor=G.+Elliottauthor=A.+Garciaauthor=T.+D.+Bartleyauthor=Y.+W.+Fridellauthor=R.+W.+Huntauthor=G.+Trailauthor=C.+Clogstonauthor=R.+J.+Tosoauthor=D.+Yanagiharaauthor=L.+Bennettauthor=M.+Sylberauthor=L.+A.+Merewetherauthor=A.+Tsengauthor=E.+Escobarauthor=E.+T.+Liuauthor=H.+K.+Yamane&title=Axl+receptor+tyrosine+kinase+stimulated+by+the+vitamin+K-dependent+protein+encoded+by+growth-arrest-specific+gene+6&doi=10.1038%2F373623a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Ax1 receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6</span></div><div class="casAuthors">Varnum, Brian C.; Young, Cynthia; Elliott, Gary; Garcia, Andy; Bartley, Timothy D.; Fridell, Yih-Woei; Hunt, Robert W.; Trail, Geraldine; Clogston, Chris; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">6515</span>),
    <span class="NLM_cas:pages">623-6</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">The Axl receptor tyrosine kinase was identified as a protein encoded by a transforming gene from primary human myeloid leukemia cells by DNA-mediated transformation of NIH 3T3 cells.  Ax1 is the founding member of a family of related receptors that includes Eyk, encoded by a chicken proto-oncogene originally described as a retroviral transforming gene, and c-Mer, encoded by a human proto-oncogene expressed in neoplastic B- and T-cell lines.  The transforming activity of Axl demonstrates that the receptor can drive cellular proliferation.  The function of Ax1 in non-transformed cells and tissues is unknown, but may involve the stimulation of cell proliferation in response to an appropriate signal, namely a ligand that activates the receptor.  We report here the purifn. of an Ax1 stimulatory factor, and its identification as the product of growth-arrest-specific gene 6.  This is, to our knowledge, the first description of a ligand for the Ax1 family of receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-4cxnEY4sPbVg90H21EOLACvtfcHk0lhb2zDZx6Ug_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXjsl2mtr4%253D&md5=0d8ecf55926f43384ca646ffa3692529</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1038%2F373623a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F373623a0%26sid%3Dliteratum%253Aachs%26aulast%3DVarnum%26aufirst%3DB.%2BC.%26aulast%3DYoung%26aufirst%3DC.%26aulast%3DElliott%26aufirst%3DG.%26aulast%3DGarcia%26aufirst%3DA.%26aulast%3DBartley%26aufirst%3DT.%2BD.%26aulast%3DFridell%26aufirst%3DY.%2BW.%26aulast%3DHunt%26aufirst%3DR.%2BW.%26aulast%3DTrail%26aufirst%3DG.%26aulast%3DClogston%26aufirst%3DC.%26aulast%3DToso%26aufirst%3DR.%2BJ.%26aulast%3DYanagihara%26aufirst%3DD.%26aulast%3DBennett%26aufirst%3DL.%26aulast%3DSylber%26aufirst%3DM.%26aulast%3DMerewether%26aufirst%3DL.%2BA.%26aulast%3DTseng%26aufirst%3DA.%26aulast%3DEscobar%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DE.%2BT.%26aulast%3DYamane%26aufirst%3DH.%2BK.%26atitle%3DAxl%2520receptor%2520tyrosine%2520kinase%2520stimulated%2520by%2520the%2520vitamin%2520K-dependent%2520protein%2520encoded%2520by%2520growth-arrest-specific%2520gene%25206%26jtitle%3DNature%26date%3D1995%26volume%3D373%26spage%3D623%26epage%3D626%26doi%3D10.1038%2F373623a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Nagata, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakano, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arita, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zong, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanafusa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mizuno, K.</span><span> </span><span class="NLM_article-title">Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">271</span><span class="NLM_x">, </span> <span class="NLM_fpage">30022</span><span class="NLM_x">–</span> <span class="NLM_lpage">30027</span><span class="refDoi"> DOI: 10.1074/jbc.271.47.30022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1074%2Fjbc.271.47.30022" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=271&publication_year=1996&pages=30022-30027&author=K.+Nagataauthor=K.+Ohashiauthor=T.+Nakanoauthor=H.+Aritaauthor=C.+Zongauthor=H.+Hanafusaauthor=K.+Mizuno&title=Identification+of+the+product+of+growth+arrest-specific+gene+6+as+a+common+ligand+for+Axl%2C+Sky%2C+and+Mer+receptor+tyrosine+kinases&doi=10.1074%2Fjbc.271.47.30022"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1074%2Fjbc.271.47.30022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.271.47.30022%26sid%3Dliteratum%253Aachs%26aulast%3DNagata%26aufirst%3DK.%26aulast%3DOhashi%26aufirst%3DK.%26aulast%3DNakano%26aufirst%3DT.%26aulast%3DArita%26aufirst%3DH.%26aulast%3DZong%26aufirst%3DC.%26aulast%3DHanafusa%26aufirst%3DH.%26aulast%3DMizuno%26aufirst%3DK.%26atitle%3DIdentification%2520of%2520the%2520product%2520of%2520growth%2520arrest-specific%2520gene%25206%2520as%2520a%2520common%2520ligand%2520for%2520Axl%252C%2520Sky%252C%2520and%2520Mer%2520receptor%2520tyrosine%2520kinases%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1996%26volume%3D271%26spage%3D30022%26epage%3D30027%26doi%3D10.1074%2Fjbc.271.47.30022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Hafizi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahlback, B.</span><span> </span><span class="NLM_article-title">Gas6 and protein S. Vitamin K-dependent ligands for the Axl receptor tyrosine kinase subfamily</span> <span class="citation_source-journal">FEBS J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">273</span><span class="NLM_x">, </span> <span class="NLM_fpage">5231</span><span class="NLM_x">–</span> <span class="NLM_lpage">5244</span><span class="refDoi"> DOI: 10.1111/j.1742-4658.2006.05529.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1111%2Fj.1742-4658.2006.05529.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=2006&pages=5231-5244&author=S.+Hafiziauthor=B.+Dahlback&title=Gas6+and+protein+S.+Vitamin+K-dependent+ligands+for+the+Axl+receptor+tyrosine+kinase+subfamily&doi=10.1111%2Fj.1742-4658.2006.05529.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2c&amp;dbid=16384&amp;doi=10.1111%2Fj.1742-4658.2006.05529.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1742-4658.2006.05529.x%26sid%3Dliteratum%253Aachs%26aulast%3DHafizi%26aufirst%3DS.%26aulast%3DDahlback%26aufirst%3DB.%26atitle%3DGas6%2520and%2520protein%2520S.%2520Vitamin%2520K-dependent%2520ligands%2520for%2520the%2520Axl%2520receptor%2520tyrosine%2520kinase%2520subfamily%26jtitle%3DFEBS%2520J.%26date%3D2006%26volume%3D273%26spage%3D5231%26epage%3D5244%26doi%3D10.1111%2Fj.1742-4658.2006.05529.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Stitt, T. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conn, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goret, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruno, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radzliejewski, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattsson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gies, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masiakowski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tobkes, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiStefano, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basilico, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldfarb, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemke, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glass, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yancopoulos, G. D.</span><span> </span><span class="NLM_article-title">The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x">, </span> <span class="NLM_fpage">661</span><span class="NLM_x">–</span> <span class="NLM_lpage">670</span><span class="refDoi"> DOI: 10.1016/0092-8674(95)90520-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1016%2F0092-8674%2895%2990520-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=7867073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADyaK2MXktV2it74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=1995&pages=661-670&author=T.+N.+Stittauthor=G.+Connauthor=M.+Goretauthor=C.+Laiauthor=J.+Brunoauthor=C.+Radzliejewskiauthor=K.+Mattssonauthor=J.+Fisherauthor=D.+R.+Giesauthor=P.+F.+Jonesauthor=P.+Masiakowskiauthor=T.+E.+Ryanauthor=N.+J.+Tobkesauthor=D.+H.+Chenauthor=P.+S.+DiStefanoauthor=G.+L.+Longauthor=C.+Basilicoauthor=M.+P.+Goldfarbauthor=G.+Lemkeauthor=D.+J.+Glassauthor=G.+D.+Yancopoulos&title=The+anticoagulation+factor+protein+S+and+its+relative%2C+Gas6%2C+are+ligands+for+the+Tyro+3%2FAxl+family+of+receptor+tyrosine+kinases&doi=10.1016%2F0092-8674%2895%2990520-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2dR"><div class="casContent"><span class="casTitleNuber">2d</span><div class="casTitle"><span class="NLM_cas:atitle">The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases</span></div><div class="casAuthors">Stitt, Trevor N.; Conn, Greg; Gore, Martin; Lai, Cary; Bruno, Joanne; Radziejewski, Czeslaw; Mattsson, Karen; Fisher, John; Gies, David R.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">661-70</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The authors report the identification of ligands for Tyro 3 (alternatively called Sky, rse, brt, or tif) and Axl (alternatively, Ark or UFO), members of a previously orphan family of receptor-like tyrosine kinases.  These ligands correspond to protein S, a protease regulator that is a potent anticoagulant, and Gas6, a protein related to protein S but lacking any known function.  The results are reminiscent of recent findings that the procoagulant thrombin, a protease that drives clot formation by cleaving fibrinogen to form fibrin, also binds and activates intracellular signaling via a G protein-coupled cell surface receptor.  Proteases and protease regulators that also activate specific cell surface receptors may serve to integrate coagulation with assocd. cellular responses required for tissue repair and growth, as well as to coordinate protease cascades and assocd. cellular responses in other systems, such as those involved in growth and remodeling of the nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0Kc6zOMgNobVg90H21EOLACvtfcHk0lg8-4xfOmPxRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXktV2it74%253D&md5=a12eece9ec055c4ee7927d97a9789fdb</span></div><a href="/servlet/linkout?suffix=cit2d&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2895%2990520-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252895%252990520-0%26sid%3Dliteratum%253Aachs%26aulast%3DStitt%26aufirst%3DT.%2BN.%26aulast%3DConn%26aufirst%3DG.%26aulast%3DGoret%26aufirst%3DM.%26aulast%3DLai%26aufirst%3DC.%26aulast%3DBruno%26aufirst%3DJ.%26aulast%3DRadzliejewski%26aufirst%3DC.%26aulast%3DMattsson%26aufirst%3DK.%26aulast%3DFisher%26aufirst%3DJ.%26aulast%3DGies%26aufirst%3DD.%2BR.%26aulast%3DJones%26aufirst%3DP.%2BF.%26aulast%3DMasiakowski%26aufirst%3DP.%26aulast%3DRyan%26aufirst%3DT.%2BE.%26aulast%3DTobkes%26aufirst%3DN.%2BJ.%26aulast%3DChen%26aufirst%3DD.%2BH.%26aulast%3DDiStefano%26aufirst%3DP.%2BS.%26aulast%3DLong%26aufirst%3DG.%2BL.%26aulast%3DBasilico%26aufirst%3DC.%26aulast%3DGoldfarb%26aufirst%3DM.%2BP.%26aulast%3DLemke%26aufirst%3DG.%26aulast%3DGlass%26aufirst%3DD.%2BJ.%26aulast%3DYancopoulos%26aufirst%3DG.%2BD.%26atitle%3DThe%2520anticoagulation%2520factor%2520protein%2520S%2520and%2520its%2520relative%252C%2520Gas6%252C%2520are%2520ligands%2520for%2520the%2520Tyro%25203%252FAxl%2520family%2520of%2520receptor%2520tyrosine%2520kinases%26jtitle%3DCell%26date%3D1995%26volume%3D80%26spage%3D661%26epage%3D670%26doi%3D10.1016%2F0092-8674%2895%2990520-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Axelrod, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pienta, K. J.</span><span> </span><span class="NLM_article-title">Axl as a mediator of cellular growth and survival</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">8818</span><span class="NLM_x">–</span> <span class="NLM_lpage">8852</span><span class="refDoi"> DOI: 10.18632/oncotarget.2422</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.18632%2Foncotarget.2422" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=8818-8852&author=H.+Axelrodauthor=K.+J.+Pienta&title=Axl+as+a+mediator+of+cellular+growth+and+survival&doi=10.18632%2Foncotarget.2422"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.2422&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.2422%26sid%3Dliteratum%253Aachs%26aulast%3DAxelrod%26aufirst%3DH.%26aulast%3DPienta%26aufirst%3DK.%2BJ.%26atitle%3DAxl%2520as%2520a%2520mediator%2520of%2520cellular%2520growth%2520and%2520survival%26jtitle%3DOncotarget%26date%3D2014%26volume%3D5%26spage%3D8818%26epage%3D8852%26doi%3D10.18632%2Foncotarget.2422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit3b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Lee, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hung, M. C.</span><span> </span><span class="NLM_article-title">Axl-Gas6 interaction counteracts E1A-mediated cell growth suppression and proapoptotic activity</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">8075</span><span class="NLM_x">–</span> <span class="NLM_lpage">8082</span><span class="refDoi"> DOI: 10.1128/MCB.19.12.8075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1128%2FMCB.19.12.8075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10567533" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADyaK1MXns1ygtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=1999&pages=8075-8082&author=W.+P.+Leeauthor=Y.+Liaoauthor=D.+Robinsonauthor=H.+J.+Kungauthor=E.+T.+Liuauthor=M.+C.+Hung&title=Axl-Gas6+interaction+counteracts+E1A-mediated+cell+growth+suppression+and+proapoptotic+activity&doi=10.1128%2FMCB.19.12.8075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3bR"><div class="casContent"><span class="casTitleNuber">3b</span><div class="casTitle"><span class="NLM_cas:atitle">Axl-Gas6 interaction counteracts E1A-mediated cell growth suppression and proapoptotic activity</span></div><div class="casAuthors">Lee, Wei-Ping; Liao, Yong; Robinson, Dan; Kung, Hsing-Jien; Liu, Edison T.; Hung, Mien-Chie</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">8075-8082</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The adenovirus type 5 early region 1A gene (E1A) has previously been known as an immortalization oncogene because E1A is required for transforming oncogenes, such as ras and E1B, to transform cells in primary cultures.  However, E1A has also been shown to downregulate the overexpression of the Her-2/neu oncogene, resulting in suppression of transformation and tumorigenesis induced by that oncogene.  In addn., E1A is able to promote apoptosis induced by anticancer drugs, irradn., and serum deprivation.  Many tyrosine kinases, such as the epidermal growth factor receptor, Her-2/Neu, Src, and Axl, are known to play a role in oncogenic signals in transformed cells.  To study the mechanism underlying the E1A-mediated tumor-suppressing function, we exploited a modified tyrosine kinase profile assay to identify potential tyrosine kinases regulated by E1A.  Reverse transcription (RT)-PCR products were synthesized with two degenerate primers derived from the conserved motifs of various tyrosine kinases.  A tyrosine kinase downregulated by E1A was identified by analyzing the AluI-digested RT-PCR products.  We isolated the DNA fragment of interest and found that E1A neg. regulated the expression of the transforming receptor tyrosine kinase Axl at the transcriptional level.  To study whether downregulation of the Axl receptor is involved in E1A-mediated growth suppression, we transfected axl cDNA into E1A-expressing cells (i.p.1-E1A) to establish cells that overexpressed Axl.  The Axl ligand Gas6 triggered a greater mitogenic effect in these i.p.1-E1A-Axl cells than in i.p.1-E1A control cells and protected the Axl-expressing cells from serum deprivation-induced apoptosis.  These results indicate that downregulation of the Axl receptor by E1A is involved in E1A-mediated growth suppression and E1A-induced apoptosis and thereby contributes to E1A's antitumor activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5bTvkTBbsorVg90H21EOLACvtfcHk0lg8-4xfOmPxRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXns1ygtrs%253D&md5=abce95b0399479189340f34a279fd6fc</span></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=10.1128%2FMCB.19.12.8075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.19.12.8075%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DLiao%26aufirst%3DY.%26aulast%3DRobinson%26aufirst%3DD.%26aulast%3DKung%26aufirst%3DH.%2BJ.%26aulast%3DLiu%26aufirst%3DE.%2BT.%26aulast%3DHung%26aufirst%3DM.%2BC.%26atitle%3DAxl-Gas6%2520interaction%2520counteracts%2520E1A-mediated%2520cell%2520growth%2520suppression%2520and%2520proapoptotic%2520activity%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1999%26volume%3D19%26spage%3D8075%26epage%3D8082%26doi%3D10.1128%2FMCB.19.12.8075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Valverde, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obin, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, A.</span><span> </span><span class="NLM_article-title">Role of Gas6/Axl signaling in lens epithelial cell proliferation and survival</span> <span class="citation_source-journal">Exp. Eye Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">78</span><span class="NLM_x">, </span> <span class="NLM_fpage">27</span><span class="NLM_x">–</span> <span class="NLM_lpage">37</span><span class="refDoi"> DOI: 10.1016/j.exer.2003.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1016%2Fj.exer.2003.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=14667825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BD3sXps1erur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2004&pages=27-37&author=P.+Valverdeauthor=M.+S.+Obinauthor=A.+Taylor&title=Role+of+Gas6%2FAxl+signaling+in+lens+epithelial+cell+proliferation+and+survival&doi=10.1016%2Fj.exer.2003.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Role of Gas6/Axl signaling in lens epithelial cell proliferation and survival</span></div><div class="casAuthors">Valverde, P.; Obin, M. S.; Taylor, A.</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Eye Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-37</span>CODEN:
                <span class="NLM_cas:coden">EXERA6</span>;
        ISSN:<span class="NLM_cas:issn">0014-4835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Axl is a receptor tyrosine kinase that is activated by Gas6, a growth factor that belongs to the vitamin K-dependent protein family.  Although Gas6 binding to Axl has been shown to transmit mitogenic and/or anti-apoptotic signals to a variety of cell types, the role of the Axl-Gas6 system in normal and pathol. lens biol. is not known.  We demonstrate for the first time that Axl protein is expressed in normal rat and bovine lens and that its ligand, Gas6, is present in bovine aq. humor.  In addn., we have detected tyrosine-phosphorylated Axl in normal rat and bovine lens epithelial tissues.  We further show that human recombinant Gas6 is able to act as a growth factor in cultured human lens epithelial cells by activating Axl and then the AKT signaling pathway.  Gas6 mediates a survival and anti-apoptotic response in cultured human lens epithelial cells subjected to serum-starvation (48-72 h), or treated with transforming growth factor β1 (5 ng ml-1, 48 h) or tumor necrosis factor α (100 ng ml-1, 48 h), as demonstrated by increased no. of viable cells, and decreased DNA condensation or caspase-3 activity.  In contrast, Gas6 is not able to block apoptosis induced by staurosporin (1 μm, 5-24 h) in human lens epithelial cells.  Taken together, these data suggest that the Gas6/Axl signaling plays an important role in the control of lens epithelial cell growth and survival and hence in the maintenance of lens homeostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrp-fUwE5As2bVg90H21EOLACvtfcHk0li4vJv2d4-wfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXps1erur0%253D&md5=5ee0b3ecd6319729b765e5a1fe178218</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.exer.2003.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.exer.2003.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DValverde%26aufirst%3DP.%26aulast%3DObin%26aufirst%3DM.%2BS.%26aulast%3DTaylor%26aufirst%3DA.%26atitle%3DRole%2520of%2520Gas6%252FAxl%2520signaling%2520in%2520lens%2520epithelial%2520cell%2520proliferation%2520and%2520survival%26jtitle%3DExp.%2520Eye%2520Res.%26date%3D2004%26volume%3D78%26spage%3D27%26epage%3D37%26doi%3D10.1016%2Fj.exer.2003.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Bauer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zagórska, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jurkin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasmin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Köffel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gesslbauer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemke, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strobl, H.</span><span> </span><span class="NLM_article-title">Identification of Axl as a downstream effector of TGF-β1 during Langerhans cell differentiation and epidermal homeostasis</span> <span class="citation_source-journal">J. Exp. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">209</span><span class="NLM_x">, </span> <span class="NLM_fpage">2033</span><span class="NLM_x">–</span> <span class="NLM_lpage">2047</span><span class="refDoi"> DOI: 10.1084/jem.20120493</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1084%2Fjem.20120493" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=209&publication_year=2012&pages=2033-2047&author=T.+Bauerauthor=A.+Zag%C3%B3rskaauthor=J.+Jurkinauthor=N.+Yasminauthor=R.+K%C3%B6ffelauthor=S.+Richterauthor=B.+Gesslbauerauthor=G.+Lemkeauthor=H.+Strobl&title=Identification+of+Axl+as+a+downstream+effector+of+TGF-%CE%B21+during+Langerhans+cell+differentiation+and+epidermal+homeostasis&doi=10.1084%2Fjem.20120493"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1084%2Fjem.20120493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20120493%26sid%3Dliteratum%253Aachs%26aulast%3DBauer%26aufirst%3DT.%26aulast%3DZag%25C3%25B3rska%26aufirst%3DA.%26aulast%3DJurkin%26aufirst%3DJ.%26aulast%3DYasmin%26aufirst%3DN.%26aulast%3DK%25C3%25B6ffel%26aufirst%3DR.%26aulast%3DRichter%26aufirst%3DS.%26aulast%3DGesslbauer%26aufirst%3DB.%26aulast%3DLemke%26aufirst%3DG.%26aulast%3DStrobl%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520Axl%2520as%2520a%2520downstream%2520effector%2520of%2520TGF-%25CE%25B21%2520during%2520Langerhans%2520cell%2520differentiation%2520and%2520epidermal%2520homeostasis%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2012%26volume%3D209%26spage%3D2033%26epage%3D2047%26doi%3D10.1084%2Fjem.20120493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Tai, K. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shieh, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiah, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, C. W.</span><span> </span><span class="NLM_article-title">Axl promotes cell invasion by inducing MMP-9 activity through activation of NF-κB and Brg-1</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">4044</span><span class="NLM_x">–</span> <span class="NLM_lpage">4055</span><span class="refDoi"> DOI: 10.1038/onc.2008.57</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1038%2Fonc.2008.57" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=4044-4055&author=K.+Y.+Taiauthor=Y.+S.+Shiehauthor=C.+S.+Leeauthor=S.+G.+Shiahauthor=C.+W.+Wu&title=Axl+promotes+cell+invasion+by+inducing+MMP-9+activity+through+activation+of+NF-%CE%BAB+and+Brg-1&doi=10.1038%2Fonc.2008.57"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1038%2Fonc.2008.57&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2008.57%26sid%3Dliteratum%253Aachs%26aulast%3DTai%26aufirst%3DK.%2BY.%26aulast%3DShieh%26aufirst%3DY.%2BS.%26aulast%3DLee%26aufirst%3DC.%2BS.%26aulast%3DShiah%26aufirst%3DS.%2BG.%26aulast%3DWu%26aufirst%3DC.%2BW.%26atitle%3DAxl%2520promotes%2520cell%2520invasion%2520by%2520inducing%2520MMP-9%2520activity%2520through%2520activation%2520of%2520NF-%25CE%25BAB%2520and%2520Brg-1%26jtitle%3DOncogene%26date%3D2008%26volume%3D27%26spage%3D4044%26epage%3D4055%26doi%3D10.1038%2Fonc.2008.57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Woo, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Min, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwon, T. K.</span><span> </span><span class="NLM_article-title">Axl is a novel target of withaferin A in the induction of apoptosis and the suppression of invasion</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">451</span><span class="NLM_x">, </span> <span class="NLM_fpage">455</span><span class="NLM_x">–</span> <span class="NLM_lpage">460</span><span class="refDoi"> DOI: 10.1016/j.bbrc.2014.08.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1016%2Fj.bbrc.2014.08.018" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=451&publication_year=2014&pages=455-460&author=S.+M.+Wooauthor=K.+J.+Minauthor=S.+Kimauthor=J.+W.+Parkauthor=D.+E.+Kimauthor=S.+H.+Kimauthor=Y.+H.+Choiauthor=T.+K.+Kwon&title=Axl+is+a+novel+target+of+withaferin+A+in+the+induction+of+apoptosis+and+the+suppression+of+invasion&doi=10.1016%2Fj.bbrc.2014.08.018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2014.08.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2014.08.018%26sid%3Dliteratum%253Aachs%26aulast%3DWoo%26aufirst%3DS.%2BM.%26aulast%3DMin%26aufirst%3DK.%2BJ.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DJ.%2BW.%26aulast%3DKim%26aufirst%3DD.%2BE.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DChoi%26aufirst%3DY.%2BH.%26aulast%3DKwon%26aufirst%3DT.%2BK.%26atitle%3DAxl%2520is%2520a%2520novel%2520target%2520of%2520withaferin%2520A%2520in%2520the%2520induction%2520of%2520apoptosis%2520and%2520the%2520suppression%2520of%2520invasion%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2014%26volume%3D451%26spage%3D455%26epage%3D460%26doi%3D10.1016%2Fj.bbrc.2014.08.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Abu-Thuraia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gauthier, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chidiac, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukui, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Screaton, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gratton, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Côté, J. F.</span><span> </span><span class="NLM_article-title">Axl phosphorylates Elmo scaffold proteins to promote Rac activation and cell invasion</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">76</span><span class="NLM_x">–</span> <span class="NLM_lpage">87</span><span class="refDoi"> DOI: 10.1128/MCB.00764-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1128%2FMCB.00764-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=25332238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslKktro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2015&pages=76-87&author=A.+Abu-Thuraiaauthor=R.+Gauthierauthor=R.+Chidiacauthor=Y.+Fukuiauthor=R.+A.+Screatonauthor=J.+P.+Grattonauthor=J.+F.+C%C3%B4t%C3%A9&title=Axl+phosphorylates+Elmo+scaffold+proteins+to+promote+Rac+activation+and+cell+invasion&doi=10.1128%2FMCB.00764-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6cR"><div class="casContent"><span class="casTitleNuber">6c</span><div class="casTitle"><span class="NLM_cas:atitle">Axl phosphorylates Elmo scaffold proteins to promote Rac activation and cell invasion</span></div><div class="casAuthors">Abu-Thuraia, Afnan; Gauthier, Rosemarie; Chidiac, Rony; Fukui, Yoshinori; Screaton, Robert A.; Gratton, Jean-Philippe; Cote, Jean-Francois</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">76-87/1-76-87/12, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">1098-5549</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The receptor tyrosine kinase Axl contributes to cell migration and invasion.  Expression of Axl correlates with metastatic progression in cancer patients, yet the specific signaling events promoting invasion downstream of Axl are poorly defined.  Herein, we report Elmo scaffolds to be direct substrates and binding partners of Axl.  Elmo proteins are established to interact with Dock family guanine nucleotide exchange factors to control Rac-mediated cytoskeletal dynamics.  Proteomics and mutagenesis studies reveal that Axl phosphorylates Elmo1/2 on a conserved carboxyl-terminal tyrosine residue.  Upon Gas6-dependent activation of Axl, endogenous Elmo2 becomes phosphorylated on Tyr-713 and enters into a phys. complex with Axl in breast cancer cells.  Interfering with Elmo2 expression prevented Gas6-induced Rac1 activation in breast cancer cells.  Similarly to blocking of Axl, Elmo2 knockdown or pharmacol. inhibition of Dock1 abolishes breast cancer cell invasion.  Interestingly, Axl or Elmo2 knockdown diminishes breast cancer cell proliferation.  Rescue of Elmo2 knockdown cells with the wild-type protein but not with Elmo2 harboring Tyr-713-Phe mutations restores cell invasion and cell proliferation.  These results define a new mechanism by which Axl promotes cell proliferation and invasion and identifies inhibition of the Elmo-Dock pathway as a potential therapeutic target to stop Axl-induced metastases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokdhdGfjbt6bVg90H21EOLACvtfcHk0li4vJv2d4-wfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslKktro%253D&md5=f89bc57cd15b039f2bb72b4eebcbc81c</span></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=10.1128%2FMCB.00764-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.00764-14%26sid%3Dliteratum%253Aachs%26aulast%3DAbu-Thuraia%26aufirst%3DA.%26aulast%3DGauthier%26aufirst%3DR.%26aulast%3DChidiac%26aufirst%3DR.%26aulast%3DFukui%26aufirst%3DY.%26aulast%3DScreaton%26aufirst%3DR.%2BA.%26aulast%3DGratton%26aufirst%3DJ.%2BP.%26aulast%3DC%25C3%25B4t%25C3%25A9%26aufirst%3DJ.%2BF.%26atitle%3DAxl%2520phosphorylates%2520Elmo%2520scaffold%2520proteins%2520to%2520promote%2520Rac%2520activation%2520and%2520cell%2520invasion%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2015%26volume%3D35%26spage%3D76%26epage%3D87%26doi%3D10.1128%2FMCB.00764-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Seitz, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camenisch, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemke, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Earp, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsushima, G. K.</span><span> </span><span class="NLM_article-title">Macrophages and dendritic cells use different Axl/Mertk/Tyro3 receptors in clearance of apoptotic cells</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">178</span><span class="NLM_x">, </span> <span class="NLM_fpage">5635</span><span class="NLM_x">–</span> <span class="NLM_lpage">5642</span><span class="refDoi"> DOI: 10.4049/jimmunol.178.9.5635</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.4049%2Fjimmunol.178.9.5635" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=178&publication_year=2007&pages=5635-5642&author=H.+M.+Seitzauthor=T.+D.+Camenischauthor=G.+Lemkeauthor=H.+S.+Earpauthor=G.+K.+Matsushima&title=Macrophages+and+dendritic+cells+use+different+Axl%2FMertk%2FTyro3+receptors+in+clearance+of+apoptotic+cells&doi=10.4049%2Fjimmunol.178.9.5635"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.178.9.5635&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.178.9.5635%26sid%3Dliteratum%253Aachs%26aulast%3DSeitz%26aufirst%3DH.%2BM.%26aulast%3DCamenisch%26aufirst%3DT.%2BD.%26aulast%3DLemke%26aufirst%3DG.%26aulast%3DEarp%26aufirst%3DH.%2BS.%26aulast%3DMatsushima%26aufirst%3DG.%2BK.%26atitle%3DMacrophages%2520and%2520dendritic%2520cells%2520use%2520different%2520Axl%252FMertk%252FTyro3%2520receptors%2520in%2520clearance%2520of%2520apoptotic%2520cells%26jtitle%3DJ.%2520Immunol.%26date%3D2007%26volume%3D178%26spage%3D5635%26epage%3D5642%26doi%3D10.4049%2Fjimmunol.178.9.5635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Rothlin, C. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zuniga, E. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oldstone, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemke, G.</span><span> </span><span class="NLM_article-title">TAM receptors are pleiotropic inhibitors of the innate immune response</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">131</span><span class="NLM_x">, </span> <span class="NLM_fpage">1124</span><span class="NLM_x">–</span> <span class="NLM_lpage">1136</span><span class="refDoi"> DOI: 10.1016/j.cell.2007.10.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1016%2Fj.cell.2007.10.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=18083102" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BD1cXksFGgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2007&pages=1124-1136&author=C.+V.+Rothlinauthor=S.+Ghoshauthor=E.+I.+Zunigaauthor=M.+B.+Oldstoneauthor=G.+Lemke&title=TAM+receptors+are+pleiotropic+inhibitors+of+the+innate+immune+response&doi=10.1016%2Fj.cell.2007.10.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">TAM receptors are pleiotropic inhibitors of the innate immune response</span></div><div class="casAuthors">Rothlin, Carla V.; Ghosh, Sourav; Zuniga, Elina I.; Oldstone, Michael B. A.; Lemke, Greg</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1124-1136</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The activation of Toll-like receptors (TLRs) in dendritic cells (DCs) triggers a rapid inflammatory response to pathogens.  However, this response must be tightly regulated because unrestrained TLR signaling generates a chronic inflammatory milieu that often leads to autoimmunity.  We have found that the TAM receptor tyrosine kinases-Tyro3, Axl, and Mer-broadly inhibit both TLR and TLR-induced cytokine-receptor cascades.  Remarkably, TAM inhibition of inflammation is transduced through an essential stimulator of inflammation-the type I interferon receptor (IFNAR)-and its assocd. transcription factor STAT1.  TLR induction of IFNAR-STAT1 signaling upregulates the TAM system, which in turn usurps the IFNAR-STAT1 cassette to induce the cytokine and TLR suppressors SOCS1 and SOCS3.  These results illuminate a self-regulating cycle of inflammation, in which the obligatory, cytokine-dependent activation of TAM signaling hijacks a proinflammatory pathway to provide an intrinsic feedback inhibitor of both TLR- and cytokine-driven immune responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWCPRBPKbiNrVg90H21EOLACvtfcHk0lhmx6QVdTFsGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXksFGgug%253D%253D&md5=32511c20288ef6f92b60d9a6bc94637d</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2007.10.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2007.10.034%26sid%3Dliteratum%253Aachs%26aulast%3DRothlin%26aufirst%3DC.%2BV.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DZuniga%26aufirst%3DE.%2BI.%26aulast%3DOldstone%26aufirst%3DM.%2BB.%26aulast%3DLemke%26aufirst%3DG.%26atitle%3DTAM%2520receptors%2520are%2520pleiotropic%2520inhibitors%2520of%2520the%2520innate%2520immune%2520response%26jtitle%3DCell%26date%3D2007%26volume%3D131%26spage%3D1124%26epage%3D1136%26doi%3D10.1016%2Fj.cell.2007.10.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Lemke, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rothlin, C. V.</span><span> </span><span class="NLM_article-title">Immunobiology of the TAM receptors</span> <span class="citation_source-journal">Nat. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">327</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span><span class="refDoi"> DOI: 10.1038/nri2303</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1038%2Fnri2303" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=18421305" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltFejsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=327-336&author=G.+Lemkeauthor=C.+V.+Rothlin&title=Immunobiology+of+the+TAM+receptors&doi=10.1038%2Fnri2303"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7cR"><div class="casContent"><span class="casTitleNuber">7c</span><div class="casTitle"><span class="NLM_cas:atitle">Immunobiology of the TAM receptors</span></div><div class="casAuthors">Lemke, Greg; Rothlin, Carla V.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">327-336</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Recent studies have revealed that the TAM receptor protein tyrosine kinases - TYRO3, AXL and MER - have pivotal roles in innate immunity.  They inhibit inflammation in dendritic cells and macrophages, promote the phagocytosis of apoptotic cells and membranous organelles, and stimulate the maturation of natural killer cells.  Each of these phenomena may depend on a cooperative interaction between TAM receptor and cytokine receptor signalling systems.  Although its importance was previously unrecognized, TAM signalling promises to have an increasingly prominent role in studies of innate immune regulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpW_CJak8Sc-LVg90H21EOLACvtfcHk0lhmx6QVdTFsGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltFejsbg%253D&md5=7726fd6ab58ce205941aa74f7bcdcf32</span></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=10.1038%2Fnri2303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2303%26sid%3Dliteratum%253Aachs%26aulast%3DLemke%26aufirst%3DG.%26aulast%3DRothlin%26aufirst%3DC.%2BV.%26atitle%3DImmunobiology%2520of%2520the%2520TAM%2520receptors%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2008%26volume%3D8%26spage%3D327%26epage%3D336%26doi%3D10.1038%2Fnri2303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Rothlin, C. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemke, G.</span><span> </span><span class="NLM_article-title">TAM receptor signaling and autoimmune disease</span> <span class="citation_source-journal">Curr. Opin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">740</span><span class="NLM_x">–</span> <span class="NLM_lpage">746</span><span class="refDoi"> DOI: 10.1016/j.coi.2010.10.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1016%2Fj.coi.2010.10.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=21030229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFaqsrjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2010&pages=740-746&author=C.+V.+Rothlinauthor=G.+Lemke&title=TAM+receptor+signaling+and+autoimmune+disease&doi=10.1016%2Fj.coi.2010.10.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7dR"><div class="casContent"><span class="casTitleNuber">7d</span><div class="casTitle"><span class="NLM_cas:atitle">TAM receptor signaling and autoimmune disease</span></div><div class="casAuthors">Rothlin, Carla V.; Lemke, Greg</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">740-746</span>CODEN:
                <span class="NLM_cas:coden">COPIEL</span>;
        ISSN:<span class="NLM_cas:issn">0952-7915</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The TAM receptor tyrosine kinases Tyro3, Axl, and Mer and their ligands Gas6 and Protein S are essential for the phagocytosis of apoptotic cells and membranes in the adult immune, nervous, and reproductive systems.  Genetic studies indicate that this receptor-ligand system is central to apoptotic cell engulfment that is triggered by the eat-me' signal phosphatidylserine (PtdSer).  At the same time, TAM signaling is normally activated by Toll-like receptor (TLR) and type I interferon signaling, as part of the innate inflammatory response in dendritic cells (DCs) and macrophages, where it inhibits this response.  Deficiencies in TAM signaling result in human retinal dystrophies and may contribute to lupus and other human autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNh1G6pHA1wrVg90H21EOLACvtfcHk0lhmx6QVdTFsGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFaqsrjN&md5=78794bcaf2dcb2dcf0e00409fae2c321</span></div><a href="/servlet/linkout?suffix=cit7d&amp;dbid=16384&amp;doi=10.1016%2Fj.coi.2010.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coi.2010.10.001%26sid%3Dliteratum%253Aachs%26aulast%3DRothlin%26aufirst%3DC.%2BV.%26aulast%3DLemke%26aufirst%3DG.%26atitle%3DTAM%2520receptor%2520signaling%2520and%2520autoimmune%2520disease%26jtitle%3DCurr.%2520Opin.%2520Immunol.%26date%3D2010%26volume%3D22%26spage%3D740%26epage%3D746%26doi%3D10.1016%2Fj.coi.2010.10.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Shibata, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habiel, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coelho, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunkel, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lukacs, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogaboam, C. M.</span><span> </span><span class="NLM_article-title">Axl receptor blockade ameliorates pulmonary pathology resulting from primary viral infection and viral exacerbation of asthma</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">192</span><span class="NLM_x">, </span> <span class="NLM_fpage">3569</span><span class="NLM_x">–</span> <span class="NLM_lpage">3581</span><span class="refDoi"> DOI: 10.4049/jimmunol.1302766</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.4049%2Fjimmunol.1302766" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=2014&pages=3569-3581&author=T.+Shibataauthor=D.+M.+Habielauthor=A.+L.+Coelhoauthor=S.+L.+Kunkelauthor=N.+W.+Lukacsauthor=C.+M.+Hogaboam&title=Axl+receptor+blockade+ameliorates+pulmonary+pathology+resulting+from+primary+viral+infection+and+viral+exacerbation+of+asthma&doi=10.4049%2Fjimmunol.1302766"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7e&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1302766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1302766%26sid%3Dliteratum%253Aachs%26aulast%3DShibata%26aufirst%3DT.%26aulast%3DHabiel%26aufirst%3DD.%2BM.%26aulast%3DCoelho%26aufirst%3DA.%2BL.%26aulast%3DKunkel%26aufirst%3DS.%2BL.%26aulast%3DLukacs%26aufirst%3DN.%2BW.%26aulast%3DHogaboam%26aufirst%3DC.%2BM.%26atitle%3DAxl%2520receptor%2520blockade%2520ameliorates%2520pulmonary%2520pathology%2520resulting%2520from%2520primary%2520viral%2520infection%2520and%2520viral%2520exacerbation%2520of%2520asthma%26jtitle%3DJ.%2520Immunol.%26date%3D2014%26volume%3D192%26spage%3D3569%26epage%3D3581%26doi%3D10.4049%2Fjimmunol.1302766" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Wimmel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glitz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraus, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roeder, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuermann, M.</span><span> </span><span class="NLM_article-title">Axl receptor tyrosine kinase expression in human lung cancer cell lines correlates with cellular adhesion</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">2264</span><span class="NLM_x">–</span> <span class="NLM_lpage">2274</span><span class="refDoi"> DOI: 10.1016/S0959-8049(01)00271-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1016%2FS0959-8049%2801%2900271-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2001&pages=2264-2274&author=A.+Wimmelauthor=D.+Glitzauthor=A.+Krausauthor=J.+Roederauthor=M.+Schuermann&title=Axl+receptor+tyrosine+kinase+expression+in+human+lung+cancer+cell+lines+correlates+with+cellular+adhesion&doi=10.1016%2FS0959-8049%2801%2900271-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1016%2FS0959-8049%2801%2900271-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0959-8049%252801%252900271-4%26sid%3Dliteratum%253Aachs%26aulast%3DWimmel%26aufirst%3DA.%26aulast%3DGlitz%26aufirst%3DD.%26aulast%3DKraus%26aufirst%3DA.%26aulast%3DRoeder%26aufirst%3DJ.%26aulast%3DSchuermann%26aufirst%3DM.%26atitle%3DAxl%2520receptor%2520tyrosine%2520kinase%2520expression%2520in%2520human%2520lung%2520cancer%2520cell%2520lines%2520correlates%2520with%2520cellular%2520adhesion%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2001%26volume%3D37%26spage%3D2264%26epage%3D2274%26doi%3D10.1016%2FS0959-8049%2801%2900271-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Shinh, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kao, Y. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiah, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, Y. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, C. W.</span><span> </span><span class="NLM_article-title">Expression of Axl in lung adenocarcinoma and correlation with tumor progression</span> <span class="citation_source-journal">Neoplasia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1058</span><span class="NLM_x">–</span> <span class="NLM_lpage">1064</span><span class="refDoi"> DOI: 10.1593/neo.05640</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1593%2Fneo.05640" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=16354588" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=1058-1064&author=Y.+S.+Shinhauthor=C.+Y.+Laiauthor=Y.+R.+Kaoauthor=S.+G.+Shiahauthor=Y.+W.+Chuauthor=H.+S.+Leeauthor=C.+W.+Wu&title=Expression+of+Axl+in+lung+adenocarcinoma+and+correlation+with+tumor+progression&doi=10.1593%2Fneo.05640"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=10.1593%2Fneo.05640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1593%252Fneo.05640%26sid%3Dliteratum%253Aachs%26aulast%3DShinh%26aufirst%3DY.%2BS.%26aulast%3DLai%26aufirst%3DC.%2BY.%26aulast%3DKao%26aufirst%3DY.%2BR.%26aulast%3DShiah%26aufirst%3DS.%2BG.%26aulast%3DChu%26aufirst%3DY.%2BW.%26aulast%3DLee%26aufirst%3DH.%2BS.%26aulast%3DWu%26aufirst%3DC.%2BW.%26atitle%3DExpression%2520of%2520Axl%2520in%2520lung%2520adenocarcinoma%2520and%2520correlation%2520with%2520tumor%2520progression%26jtitle%3DNeoplasia%26date%3D2005%26volume%3D7%26spage%3D1058%26epage%3D1064%26doi%3D10.1593%2Fneo.05640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Ishikawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sonobe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakayama, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kikuchi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitamura, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imamura, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Date, H.</span><span> </span><span class="NLM_article-title">Higher expression of receptor tyrosine kinase Axl, and differential expression of its ligand, Gas6, predict poor survival in lung adenocarcinoma patients</span> <span class="citation_source-journal">Ann. Surg. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">467</span><span class="NLM_x">–</span> <span class="NLM_lpage">476</span><span class="refDoi"> DOI: 10.1245/s10434-012-2795-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1245%2Fs10434-012-2795-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=467-476&author=M.+Ishikawaauthor=M.+Sonobeauthor=E.+Nakayamaauthor=M.+Kobayashiauthor=R.+Kikuchiauthor=J.+Kitamuraauthor=N.+Imamuraauthor=H.+Date&title=Higher+expression+of+receptor+tyrosine+kinase+Axl%2C+and+differential+expression+of+its+ligand%2C+Gas6%2C+predict+poor+survival+in+lung+adenocarcinoma+patients&doi=10.1245%2Fs10434-012-2795-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8c&amp;dbid=16384&amp;doi=10.1245%2Fs10434-012-2795-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1245%252Fs10434-012-2795-3%26sid%3Dliteratum%253Aachs%26aulast%3DIshikawa%26aufirst%3DM.%26aulast%3DSonobe%26aufirst%3DM.%26aulast%3DNakayama%26aufirst%3DE.%26aulast%3DKobayashi%26aufirst%3DM.%26aulast%3DKikuchi%26aufirst%3DR.%26aulast%3DKitamura%26aufirst%3DJ.%26aulast%3DImamura%26aufirst%3DN.%26aulast%3DDate%26aufirst%3DH.%26atitle%3DHigher%2520expression%2520of%2520receptor%2520tyrosine%2520kinase%2520Axl%252C%2520and%2520differential%2520expression%2520of%2520its%2520ligand%252C%2520Gas6%252C%2520predict%2520poor%2520survival%2520in%2520lung%2520adenocarcinoma%2520patients%26jtitle%3DAnn.%2520Surg.%2520Oncol.%26date%3D2013%26volume%3D20%26spage%3D467%26epage%3D476%26doi%3D10.1245%2Fs10434-012-2795-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Linger, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sather, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Migdall-Wilson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middleton, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baron, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franklin, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merrick, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jedlicka, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeRyckere, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heasley, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, D. K.</span><span> </span><span class="NLM_article-title">Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">3420</span><span class="NLM_x">–</span> <span class="NLM_lpage">3431</span><span class="refDoi"> DOI: 10.1038/onc.2012.355</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1038%2Fonc.2012.355" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2013&pages=3420-3431&author=R.+M.+Lingerauthor=R.+A.+Cohenauthor=C.+T.+Cummingsauthor=S.+Satherauthor=J.+Migdall-Wilsonauthor=D.+H.+Middletonauthor=X.+Luauthor=A.+E.+Baronauthor=W.+A.+Franklinauthor=D.+T.+Merrickauthor=P.+Jedlickaauthor=D.+DeRyckereauthor=L.+E.+Heasleyauthor=D.+K.+Graham&title=Mer+or+Axl+receptor+tyrosine+kinase+inhibition+promotes+apoptosis%2C+blocks+growth+and+enhances+chemosensitivity+of+human+non-small+cell+lung+cancer&doi=10.1038%2Fonc.2012.355"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8d&amp;dbid=16384&amp;doi=10.1038%2Fonc.2012.355&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2012.355%26sid%3Dliteratum%253Aachs%26aulast%3DLinger%26aufirst%3DR.%2BM.%26aulast%3DCohen%26aufirst%3DR.%2BA.%26aulast%3DCummings%26aufirst%3DC.%2BT.%26aulast%3DSather%26aufirst%3DS.%26aulast%3DMigdall-Wilson%26aufirst%3DJ.%26aulast%3DMiddleton%26aufirst%3DD.%2BH.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DBaron%26aufirst%3DA.%2BE.%26aulast%3DFranklin%26aufirst%3DW.%2BA.%26aulast%3DMerrick%26aufirst%3DD.%2BT.%26aulast%3DJedlicka%26aufirst%3DP.%26aulast%3DDeRyckere%26aufirst%3DD.%26aulast%3DHeasley%26aufirst%3DL.%2BE.%26aulast%3DGraham%26aufirst%3DD.%2BK.%26atitle%3DMer%2520or%2520Axl%2520receptor%2520tyrosine%2520kinase%2520inhibition%2520promotes%2520apoptosis%252C%2520blocks%2520growth%2520and%2520enhances%2520chemosensitivity%2520of%2520human%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DOncogene%26date%3D2013%26volume%3D32%26spage%3D3420%26epage%3D3431%26doi%3D10.1038%2Fonc.2012.355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Bivona, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okimoto, R.</span><span> </span><span class="NLM_article-title">AXL receptor tyrosine kinase as a therapeutic target in NSCLC</span> <span class="citation_source-journal">Lung Cancer: Targets Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">27</span><span class="NLM_x">–</span> <span class="NLM_lpage">34</span><span class="refDoi"> DOI: 10.2147/LCTT.S60438</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.2147%2FLCTT.S60438" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC28XosVCrsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=27-34&author=T.+Bivonaauthor=R.+Okimoto&title=AXL+receptor+tyrosine+kinase+as+a+therapeutic+target+in+NSCLC&doi=10.2147%2FLCTT.S60438"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8eR"><div class="casContent"><span class="casTitleNuber">8e</span><div class="casTitle"><span class="NLM_cas:atitle">AXL receptor tyrosine kinase as a therapeutic target in NSCLC</span></div><div class="casAuthors">Okimoto, Ross A.; Bivona, Trever G.</div><div class="citationInfo"><span class="NLM_cas:title">Lung Cancer: Targets and Therapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">27-34</span>CODEN:
                <span class="NLM_cas:coden">LCTTBI</span>;
        ISSN:<span class="NLM_cas:issn">1179-2728</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">The AXL receptor tyrosine kinase and its ligand, Gas6, regulate key processes in lung cancer growth, metastasis, and epithelial-mesenchymal transition-assocd. drug resistance.  Gas6 and AXL expression have been correlated with poor prognosis and advanced clin. stage in patients with lung cancer, and targeting the Gas6/AXL pathway demonstrates antitumor activity, decreases cellular invasion, and restores sensitivity in de novo and acquired drug resistance models.  These findings implicate AXL as a promising therapeutic target in lung cancer.  In this review, we explore the role of AXL in lung cancer progression, from tumor development to disseminated disease, and highlight the current clin. landscape of anti-AXL therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAZYZvs1l4vrVg90H21EOLACvtfcHk0ljHsyToip_q8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XosVCrsLs%253D&md5=23e221a3549d60126db8d2a9bd035932</span></div><a href="/servlet/linkout?suffix=cit8e&amp;dbid=16384&amp;doi=10.2147%2FLCTT.S60438&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FLCTT.S60438%26sid%3Dliteratum%253Aachs%26aulast%3DBivona%26aufirst%3DT.%26aulast%3DOkimoto%26aufirst%3DR.%26atitle%3DAXL%2520receptor%2520tyrosine%2520kinase%2520as%2520a%2520therapeutic%2520target%2520in%2520NSCLC%26jtitle%3DLung%2520Cancer%253A%2520Targets%2520Ther.%26date%3D2015%26volume%3D6%26spage%3D27%26epage%3D34%26doi%3D10.2147%2FLCTT.S60438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Berclaz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altermatt, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rohrbach, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kieffer, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dreher, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andres, A. C.</span><span> </span><span class="NLM_article-title">Estrogen dependent expression of the receptor tyrosine kinase axl in normal and malignant human breast</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">819</span><span class="NLM_x">–</span> <span class="NLM_lpage">824</span><span class="refDoi"> DOI: 10.1023/A:1011126330233</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1023%2FA%3A1011126330233" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=11484958" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A280%3ADC%252BD38%252FislSrtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2001&pages=819-824&author=G.+Berclazauthor=H.+J.+Altermattauthor=V.+Rohrbachauthor=I.+Kiefferauthor=E.+Dreherauthor=A.+C.+Andres&title=Estrogen+dependent+expression+of+the+receptor+tyrosine+kinase+axl+in+normal+and+malignant+human+breast&doi=10.1023%2FA%3A1011126330233"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9aR"><div class="casContent"><span class="casTitleNuber">9a</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogen dependent expression of the receptor tyrosine kinase axl in normal and malignant human breast</span></div><div class="casAuthors">Berclaz G; Altermatt H J; Rohrbach V; Kieffer I; Dreher E; Andres A C</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology / ESMO</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">819-24</span>
        ISSN:<span class="NLM_cas:issn">0923-7534</span>.
    </div><div class="casAbstract">BACKGROUND:  Axl, a member of a family of receptor tyrosine kinases characterized by an extracellular domain resembling cell adhesion molecules and an intracellular conserved tyrosine kinase domain has been reported to induce cell proliferation and transformation.  In mice, axl is expressed in the normal mammary gland and over-expressed in aggressive mammary tumors.  PATIENTS AND METHODS:  We have investigated the expression of axl immunohistochemically in 23 normal human breast samples and in 111 consecutive breast carcinomas.  Expression of axl was correlated with tumour characteristics (lymph node involvement, stage, grade) and immunohistochemical expression of ER, PR, Ki-67 and c-erbB-2.  RESULTS:  In normal tissue, axl localizes to the membrane of breast epithelial cells.  Axl protein shows membrane associated staining in high correlation (P = 0.004) with the expression of the estrogen receptor (ER).  Axl expression was found in a subset of breast carcinomas and was also correlated with high significance (P < 0.0001) with the presence of ER.  CONCLUSION:  Our results suggest that axl may serve as a mediator of estrogen stimulation preventing the completion of the breast epithelial life cycle and that estrogen induced axl expression may give a survival signal to cancerous cells, preventing them from dying through apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS4jH3dLUflJ91QT_1O5WBYfW6udTcc2eZ3WE8W4e_imrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38%252FislSrtw%253D%253D&md5=36a9041a5d19646e01b47ea4886e182e</span></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.1023%2FA%3A1011126330233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1011126330233%26sid%3Dliteratum%253Aachs%26aulast%3DBerclaz%26aufirst%3DG.%26aulast%3DAltermatt%26aufirst%3DH.%2BJ.%26aulast%3DRohrbach%26aufirst%3DV.%26aulast%3DKieffer%26aufirst%3DI.%26aulast%3DDreher%26aufirst%3DE.%26aulast%3DAndres%26aufirst%3DA.%2BC.%26atitle%3DEstrogen%2520dependent%2520expression%2520of%2520the%2520receptor%2520tyrosine%2520kinase%2520axl%2520in%2520normal%2520and%2520malignant%2520human%2520breast%26jtitle%3DAnn.%2520Oncol.%26date%3D2001%26volume%3D12%26spage%3D819%26epage%3D824%26doi%3D10.1023%2FA%3A1011126330233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Zhang, Y. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knyazev, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheburkin, Y. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knyazev, Y. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orfi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabadkai, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daub, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span> </span><span class="NLM_article-title">AXL is a potential target for therapeutic intervention in breast cancer progression</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">1905</span><span class="NLM_x">–</span> <span class="NLM_lpage">1915</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-2661</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1158%2F0008-5472.CAN-07-2661" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=1905-1915&author=Y.+X.+Zhangauthor=P.+G.+Knyazevauthor=Y.+V.+Cheburkinauthor=K.+Sharmaauthor=Y.+P.+Knyazevauthor=L.+Orfiauthor=I.+Szabadkaiauthor=H.+Daubauthor=G.+Keriauthor=A.+Ullrich&title=AXL+is+a+potential+target+for+therapeutic+intervention+in+breast+cancer+progression&doi=10.1158%2F0008-5472.CAN-07-2661"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-2661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-2661%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%2BX.%26aulast%3DKnyazev%26aufirst%3DP.%2BG.%26aulast%3DCheburkin%26aufirst%3DY.%2BV.%26aulast%3DSharma%26aufirst%3DK.%26aulast%3DKnyazev%26aufirst%3DY.%2BP.%26aulast%3DOrfi%26aufirst%3DL.%26aulast%3DSzabadkai%26aufirst%3DI.%26aulast%3DDaub%26aufirst%3DH.%26aulast%3DKeri%26aufirst%3DG.%26aulast%3DUllrich%26aufirst%3DA.%26atitle%3DAXL%2520is%2520a%2520potential%2520target%2520for%2520therapeutic%2520intervention%2520in%2520breast%2520cancer%2520progression%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D1905%26epage%3D1915%26doi%3D10.1158%2F0008-5472.CAN-07-2661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Gjerdrum, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiron, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoiby, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stefansson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haugen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandal, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collett, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCormack, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gjertsen, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Micklem, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akslen, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glackin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorens, J. B.</span><span> </span><span class="NLM_article-title">Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">1124</span><span class="NLM_x">–</span> <span class="NLM_lpage">1129</span><span class="refDoi"> DOI: 10.1073/pnas.0909333107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1073%2Fpnas.0909333107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=20080645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFyku7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=1124-1129&author=C.+Gjerdrumauthor=C.+Tironauthor=T.+Hoibyauthor=I.+Stefanssonauthor=H.+Haugenauthor=T.+Sandalauthor=K.+Collettauthor=S.+Liauthor=E.+McCormackauthor=B.+T.+Gjertsenauthor=D.+R.+Micklemauthor=L.+A.+Akslenauthor=C.+Glackinauthor=J.+B.+Lorens&title=Axl+is+an+essential+epithelial-to-mesenchymal+transition-induced+regulator+of+breast+cancer+metastasis+and+patient+survival&doi=10.1073%2Fpnas.0909333107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9cR"><div class="casContent"><span class="casTitleNuber">9c</span><div class="casTitle"><span class="NLM_cas:atitle">Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival</span></div><div class="casAuthors">Gjerdrum, Christine; Tiron, Crina; Hoeiby, Torill; Stefansson, Ingunn; Haugen, Hallvard; Sandal, Tone; Collett, Karin; Li, Shan; McCormack, Emmet; Gjertsen, Bjoern Tore; Micklem, David R.; Akslen, Lars A.; Glackin, Carlotta; Lorens, James B.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1124-1129, S1124/1-S1124/11</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Metastasis underlies the majority of cancer-related deaths.  Thus, furthering our understanding of the mol. mechanisms that enable tumor cell dissemination is a vital health issue.  Epithelial-to-mesenchymal transitions (EMTs) endow carcinoma cells with enhanced migratory and survival attributes that facilitate malignant progression.  Characterization of EMT effectors is likely to yield new insights into metastasis and novel avenues for treatment.  We show that the presence of the receptor tyrosine kinase Axl in primary breast cancers independently predicts strongly reduced overall patient survival, and that matched patient metastatic lesions show enhanced Axl expression.  We demonstrate that Axl is strongly induced by EMT in immortalized mammary epithelial cells that establishes an autocrine signaling loop with its ligand, Gas6.  Epiallelic RNA interference anal. in metastatic breast cancer cells delineated a distinct threshold of Axl expression for mesenchymal-like in vitro cell invasiveness and formation of tumors in foreign and tissue-engineered micro-environments in vivo.  Importantly, in two different optical imaging-based exptl. breast cancer models, Axl knockdown completely prevented the spread of highly metastatic breast carcinoma cells from the mammary gland to lymph nodes and several major organs and increased overall survival.  These findings suggest that Axl represents a downstream effector of the tumor cell EMT that is required for breast cancer metastasis.  Thus, the detection and targeted treatment of Axl-expressing tumors represents an important new therapeutic strategy for breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPiST_cnXhqrVg90H21EOLACvtfcHk0ljK6MVzlzUm4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFyku7s%253D&md5=dbd7113028010a800e22ff1f206b9337</span></div><a href="/servlet/linkout?suffix=cit9c&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0909333107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0909333107%26sid%3Dliteratum%253Aachs%26aulast%3DGjerdrum%26aufirst%3DC.%26aulast%3DTiron%26aufirst%3DC.%26aulast%3DHoiby%26aufirst%3DT.%26aulast%3DStefansson%26aufirst%3DI.%26aulast%3DHaugen%26aufirst%3DH.%26aulast%3DSandal%26aufirst%3DT.%26aulast%3DCollett%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DMcCormack%26aufirst%3DE.%26aulast%3DGjertsen%26aufirst%3DB.%2BT.%26aulast%3DMicklem%26aufirst%3DD.%2BR.%26aulast%3DAkslen%26aufirst%3DL.%2BA.%26aulast%3DGlackin%26aufirst%3DC.%26aulast%3DLorens%26aufirst%3DJ.%2BB.%26atitle%3DAxl%2520is%2520an%2520essential%2520epithelial-to-mesenchymal%2520transition-induced%2520regulator%2520of%2520breast%2520cancer%2520metastasis%2520and%2520patient%2520survival%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26spage%3D1124%26epage%3D1129%26doi%3D10.1073%2Fpnas.0909333107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Asiedu, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beauchamp-Perez, F. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingle, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behrens, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radisky, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knutson, K. L.</span><span> </span><span class="NLM_article-title">AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">1316</span><span class="NLM_x">–</span> <span class="NLM_lpage">1324</span><span class="refDoi"> DOI: 10.1038/onc.2013.57</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1038%2Fonc.2013.57" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=23474758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjslKlsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2014&pages=1316-1324&author=M.+K.+Asieduauthor=F.+D.+Beauchamp-Perezauthor=J.+N.+Ingleauthor=M.+D.+Behrensauthor=D.+C.+Radiskyauthor=K.+L.+Knutson&title=AXL+induces+epithelial-to-mesenchymal+transition+and+regulates+the+function+of+breast+cancer+stem+cells&doi=10.1038%2Fonc.2013.57"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9dR"><div class="casContent"><span class="casTitleNuber">9d</span><div class="casTitle"><span class="NLM_cas:atitle">AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells</span></div><div class="casAuthors">Asiedu, M. K.; Beauchamp-Perez, F. D.; Ingle, J. N.; Behrens, M. D.; Radisky, D. C.; Knutson, K. L.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1316-1324</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Despite significant progress in the treatment of breast cancer, particularly through the use of targeted therapy, relapse and chemoresistance remain a major hindrance to the fight to minimize the burden of the disease.  It is becoming increasingly clear that a rare subpopulation of cells known as cancer stem cells (CSC), able to be generated through epithelial-to-mesenchymal transition (EMT) and capable of tumor initiation and self-renewal, contributes to treatment resistance and metastases.  This means that a more effective therapy should target both the chemoresistant CSCs and the proliferating epithelial cells that give rise to them to reverse EMT and to attenuate their conversion to CSCs.  Here, we demonstrate a novel function of AXL in acting upstream to induce EMT in normal and immortalized human mammary epithelial cells in an apparent pos. feedback loop mechanism and regulate breast CSC (BCSC) self-renewal and chemoresistance.  Downregulation of AXL using MP470 (Amuvatinib) reversed EMT in mesenchymal normal human mammary epithelial cells and murine BCSCs attenuating self-renewal and restored chemosensitivity of the BCSCs.  AXL expression was also found to be assocd. with the expression of stem cell genes, regulation of metastases genes, increased tumorigenicity and was important for BCSC invasion and migration.  Inactivation of AXL also led to the downregulation of nuclear factor-κB pathway and reduced tumor formation in vivo.  Taken together, our data suggest that targeted therapy against AXL, in combination with systemic therapies, has the potential to improve response to anticancer therapies and to reduce breast cancer recurrence and metastases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqR3FaG5OgnVrVg90H21EOLACvtfcHk0liiW5I9ET7cxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjslKlsb0%253D&md5=a30463cda3288fbc2c92d712f7ef43a8</span></div><a href="/servlet/linkout?suffix=cit9d&amp;dbid=16384&amp;doi=10.1038%2Fonc.2013.57&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2013.57%26sid%3Dliteratum%253Aachs%26aulast%3DAsiedu%26aufirst%3DM.%2BK.%26aulast%3DBeauchamp-Perez%26aufirst%3DF.%2BD.%26aulast%3DIngle%26aufirst%3DJ.%2BN.%26aulast%3DBehrens%26aufirst%3DM.%2BD.%26aulast%3DRadisky%26aufirst%3DD.%2BC.%26aulast%3DKnutson%26aufirst%3DK.%2BL.%26atitle%3DAXL%2520induces%2520epithelial-to-mesenchymal%2520transition%2520and%2520regulates%2520the%2520function%2520of%2520breast%2520cancer%2520stem%2520cells%26jtitle%3DOncogene%26date%3D2014%26volume%3D33%26spage%3D1316%26epage%3D1324%26doi%3D10.1038%2Fonc.2013.57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">D’Alfonso, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hannah, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, S. J.</span><span> </span><span class="NLM_article-title">Axl receptor tyrosine kinase expression in breast cancer</span> <span class="citation_source-journal">J. Clin. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">690</span><span class="NLM_x">–</span> <span class="NLM_lpage">696</span><span class="refDoi"> DOI: 10.1136/jclinpath-2013-202161</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1136%2Fjclinpath-2013-202161" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=24904064" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslOqu77E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2014&pages=690-696&author=T.+M.+D%E2%80%99Alfonsoauthor=J.+Hannahauthor=Z.+M.+Chenauthor=Y.+F.+Liuauthor=P.+B.+Zhouauthor=S.+J.+Shin&title=Axl+receptor+tyrosine+kinase+expression+in+breast+cancer&doi=10.1136%2Fjclinpath-2013-202161"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9eR"><div class="casContent"><span class="casTitleNuber">9e</span><div class="casTitle"><span class="NLM_cas:atitle">Axl receptor tyrosine kinase expression in breast cancer</span></div><div class="casAuthors">D'Alfonso, Timothy M.; Hannah, Jeffrey; Chen, Zhengming; Liu, Yifang; Zhou, Pengbo; Shin, Sandra J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pathology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">690-696</span>CODEN:
                <span class="NLM_cas:coden">JCPAAK</span>;
        ISSN:<span class="NLM_cas:issn">0021-9746</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Aims Triple-neg. breast cancer comprises a clin. aggressive group of invasive carcinomas.  We examd. a published gene expression screen of a panel of breast cancer cell lines to identify a potential triple-neg. breast cancer-specific gene signature, and attempted to verify our findings by performing immunohistochem. anal. on tissue microarrays contg. a large cohort of invasive breast carcinomas.  Methods The microarray dataset for a panel of human breast cancer cell lines was interrogated for triple-neg. breast cancer-specific genes.  Membranous immunohistochem. expression of the protein product of the AXL gene was assessed semiquant. in 569 invasive breast carcinomas grouped according to mol. subgroup by immunohistochem.  Results AXL was significantly upregulated in triple-neg./basal B cell lines compared with luminal or basal A cell lines.  No significant difference was obsd. in the level of immunohistochem. expression of Axl protein between triple-neg. breast cancers and other mol. subgroups (p=0.257).  Axl expression was significantly assocd. with lymphovascular invasion (LVI) in all subgroups combined (p=0.033), and within the luminal A (p=0.002) and triple-neg. breast cancer subgroups (p=0.026).  Conclusions Despite preferential upregulation of AXL in triple-neg./basal B cell lines, anal. of Axl protein expression in a large series of patients' breast tumors revealed no assocn. between Axl expression and triple-neg. breast cancer or other subtype.  The assocn. of Axl expression with LVI supports previous work that implicates Axl as a promoter of invasiveness in breast cancer cell lines.  Further studies are necessary to explore whether Axl expression of individual breast cancer tumors can be clin. useful.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprcgtaivOWrLVg90H21EOLACvtfcHk0liiW5I9ET7cxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslOqu77E&md5=f856dcd153719c4f00c0d660d8bd85a4</span></div><a href="/servlet/linkout?suffix=cit9e&amp;dbid=16384&amp;doi=10.1136%2Fjclinpath-2013-202161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fjclinpath-2013-202161%26sid%3Dliteratum%253Aachs%26aulast%3DD%25E2%2580%2599Alfonso%26aufirst%3DT.%2BM.%26aulast%3DHannah%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DZ.%2BM.%26aulast%3DLiu%26aufirst%3DY.%2BF.%26aulast%3DZhou%26aufirst%3DP.%2BB.%26aulast%3DShin%26aufirst%3DS.%2BJ.%26atitle%3DAxl%2520receptor%2520tyrosine%2520kinase%2520expression%2520in%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Pathol.%26date%3D2014%26volume%3D67%26spage%3D690%26epage%3D696%26doi%3D10.1136%2Fjclinpath-2013-202161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Xu, M. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poon, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zender, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowe, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luk, J. M.</span><span> </span><span class="NLM_article-title">AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">1229</span><span class="NLM_x">–</span> <span class="NLM_lpage">1240</span><span class="refDoi"> DOI: 10.1038/onc.2010.504</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1038%2Fonc.2010.504" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=21076472" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVWmurjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2011&pages=1229-1240&author=M.+Z.+Xuauthor=S.+W.+Chanauthor=A.+M.+Liuauthor=K.+F.+Wongauthor=S.+T.+Fanauthor=J.+Chenauthor=R.+T.+Poonauthor=L.+Zenderauthor=S.+W.+Loweauthor=W.+Hongauthor=J.+M.+Luk&title=AXL+receptor+kinase+is+a+mediator+of+YAP-dependent+oncogenic+functions+in+hepatocellular+carcinoma&doi=10.1038%2Fonc.2010.504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10a</span><div class="casTitle"><span class="NLM_cas:atitle">AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma</span></div><div class="casAuthors">Xu, M. Z.; Chan, S. W.; Liu, A. M.; Wong, K. F.; Fan, S. T.; Chen, J.; Poon, R. T.; Zender, L.; Lowe, S. W.; Hong, W.; Luk, J. M.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1229-1240</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Yes-assocd. protein (YAP) is a downstream effector of the Hippo signaling pathway, which controls organ expansion and tissue development.  We have recently defined the tumorigenic potential and clin. significance of the YAP1 oncogene in human hepatocellular carcinoma (HCC).  The present study aims to define the tumorigenic properties of YAP in HCC and elucidate the related downstream signaling mechanism.  In a gain-of-function study, we demonstrated that ectopic increased expression of YAP in the immortalized non-tumorigenic hepatocyte cell line MIHA confers tumorigenic and metastatic potentials, as evidenced by (1) enhanced aptitudes in cell viability, anchorage-independent growth, migration and invasion; (2) tumor formation in a xenograft mouse model; and (3) induction of HCC biomarker α-fetoprotein and activation of mitogen-activated protein kinase.  Furthermore, we have identified AXL, a receptor tyrosine kinase, as a key downstream target that drives YAP-dependent oncogenic functions.  RNAi-mediated knockdown of AXL expression decreased the ability of YAP-expressing MIHA cells and of the primary HCC cell line to proliferate and invade.  These results indicate that AXL is a mediator of YAP-dependent oncogenic activities and implicates it as a potential therapeutic target for HCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhMeq35gO5yrVg90H21EOLACvtfcHk0liiW5I9ET7cxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVWmurjJ&md5=7d49124ddec8fafc084a336e55ecb80b</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1038%2Fonc.2010.504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2010.504%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DM.%2BZ.%26aulast%3DChan%26aufirst%3DS.%2BW.%26aulast%3DLiu%26aufirst%3DA.%2BM.%26aulast%3DWong%26aufirst%3DK.%2BF.%26aulast%3DFan%26aufirst%3DS.%2BT.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DPoon%26aufirst%3DR.%2BT.%26aulast%3DZender%26aufirst%3DL.%26aulast%3DLowe%26aufirst%3DS.%2BW.%26aulast%3DHong%26aufirst%3DW.%26aulast%3DLuk%26aufirst%3DJ.%2BM.%26atitle%3DAXL%2520receptor%2520kinase%2520is%2520a%2520mediator%2520of%2520YAP-dependent%2520oncogenic%2520functions%2520in%2520hepatocellular%2520carcinoma%26jtitle%3DOncogene%26date%3D2011%26volume%3D30%26spage%3D1229%26epage%3D1240%26doi%3D10.1038%2Fonc.2010.504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Lee, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeng, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, R. H.</span><span> </span><span class="NLM_article-title">Gas6/Axl pathway promotes tumor invasion through the transcriptional activation of Slug in hepatocellular carcinoma</span> <span class="citation_source-journal">Carcinogenesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">769</span><span class="NLM_x">–</span> <span class="NLM_lpage">775</span><span class="refDoi"> DOI: 10.1093/carcin/bgt372</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1093%2Fcarcin%2Fbgt372" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2014&pages=769-775&author=H.+J.+Leeauthor=Y.+M.+Jengauthor=Y.+L.+Chenauthor=L.+Chungauthor=R.+H.+Yuan&title=Gas6%2FAxl+pathway+promotes+tumor+invasion+through+the+transcriptional+activation+of+Slug+in+hepatocellular+carcinoma&doi=10.1093%2Fcarcin%2Fbgt372"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1093%2Fcarcin%2Fbgt372&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcarcin%252Fbgt372%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DH.%2BJ.%26aulast%3DJeng%26aufirst%3DY.%2BM.%26aulast%3DChen%26aufirst%3DY.%2BL.%26aulast%3DChung%26aufirst%3DL.%26aulast%3DYuan%26aufirst%3DR.%2BH.%26atitle%3DGas6%252FAxl%2520pathway%2520promotes%2520tumor%2520invasion%2520through%2520the%2520transcriptional%2520activation%2520of%2520Slug%2520in%2520hepatocellular%2520carcinoma%26jtitle%3DCarcinogenesis%26date%3D2014%26volume%3D35%26spage%3D769%26epage%3D775%26doi%3D10.1093%2Fcarcin%2Fbgt372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Reichl, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dengler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Zijl, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huber, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuhrlinger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reichel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sieghart, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peck-Radosavljevic, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grubinger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mikulits, W.</span><span> </span><span class="NLM_article-title">Axl activates autocrine transforming growth factor-beta signaling in hepatocellular carcinoma</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">930</span><span class="NLM_x">–</span> <span class="NLM_lpage">941</span><span class="refDoi"> DOI: 10.1002/hep.27492</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1002%2Fhep.27492" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=25251599" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtFejtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2015&pages=930-941&author=P.+Reichlauthor=M.+Denglerauthor=F.+van+Zijlauthor=H.+Huberauthor=G.+Fuhrlingerauthor=C.+Reichelauthor=W.+Sieghartauthor=M.+Peck-Radosavljevicauthor=M.+Grubingerauthor=W.+Mikulits&title=Axl+activates+autocrine+transforming+growth+factor-beta+signaling+in+hepatocellular+carcinoma&doi=10.1002%2Fhep.27492"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10cR"><div class="casContent"><span class="casTitleNuber">10c</span><div class="casTitle"><span class="NLM_cas:atitle">Axl activates autocrine transforming growth factor-β signaling in hepatocellular carcinoma</span></div><div class="casAuthors">Reichl, Patrick; Dengler, Mirko; van Zijl, Franziska; Huber, Heidemarie; Fuehrlinger, Gerhard; Reichel, Christian; Sieghart, Wolfgang; Peck-Radosavljevic, Markus; Grubinger, Markus; Mikulits, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">930-941</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">In hepatocellular carcinoma (HCC), intrahepatic metastasis frequently correlates with epithelial to mesenchymal transition (EMT) of malignant hepatocytes.  Several mechanisms have been identified to be essentially involved in hepatocellular EMT, among them transforming growth factor (TGF)-β signaling.  Here we show the up-regulation and activation of the receptor tyrosine kinase Axl in EMT-transformed hepatoma cells.  Knockdown of Axl expression resulted in abrogation of invasive and transendothelial migratory abilities of mesenchymal HCC cells in vitro and Axl overexpression-induced metastatic colonization of epithelial hepatoma cells in vivo.  Importantly, Axl knockdown severely impaired resistance to TGF-β-mediated growth inhibition.  Anal. of the Axl interactome revealed binding of Axl to 14-3-3ζ, which is essentially required for Axl-mediated cell invasion, transendothelial migration, and resistance against TGF-β.  Axl/14-3-3ζ signaling caused phosphorylation of Smad3 linker region (Smad3L) at Ser213, resulting in the up-regulation of tumor-progressive TGF-β target genes such as PAI1, MMP9, and Snail as well as augmented TGF-β1 secretion in mesenchymal HCC cells.  Accordingly, high Axl expression in HCC patient samples correlated with elevated vessel invasion of HCC cells, higher risk of tumor recurrence after liver transplantation, strong phosphorylation of Smad3L, and lower survival.  In addn., elevated expression of both Axl and 14-3-3ζ showed strongly reduced survival of HCC patients.  Conclusion: Our data suggest that Axl/14-3-3ζ signaling is central for TGF-β-mediated HCC progression and a promising target for HCC therapy. (Hepatol. 2015;61:930-941).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYINc0VpFLaLVg90H21EOLACvtfcHk0lj2ABR5znVmSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtFejtbo%253D&md5=9a7978862c05e63ad91bea57520c6c89</span></div><a href="/servlet/linkout?suffix=cit10c&amp;dbid=16384&amp;doi=10.1002%2Fhep.27492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.27492%26sid%3Dliteratum%253Aachs%26aulast%3DReichl%26aufirst%3DP.%26aulast%3DDengler%26aufirst%3DM.%26aulast%3Dvan%2BZijl%26aufirst%3DF.%26aulast%3DHuber%26aufirst%3DH.%26aulast%3DFuhrlinger%26aufirst%3DG.%26aulast%3DReichel%26aufirst%3DC.%26aulast%3DSieghart%26aufirst%3DW.%26aulast%3DPeck-Radosavljevic%26aufirst%3DM.%26aulast%3DGrubinger%26aufirst%3DM.%26aulast%3DMikulits%26aufirst%3DW.%26atitle%3DAxl%2520activates%2520autocrine%2520transforming%2520growth%2520factor-beta%2520signaling%2520in%2520hepatocellular%2520carcinoma%26jtitle%3DHepatology%26date%3D2015%26volume%3D61%26spage%3D930%26epage%3D941%26doi%3D10.1002%2Fhep.27492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Koorstra, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karikari, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldmann, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bisht, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rojas, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Offerhaus, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alvarez, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maitra, A.</span><span> </span><span class="NLM_article-title">The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target</span> <span class="citation_source-journal">Cancer Biol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">618</span><span class="NLM_x">–</span> <span class="NLM_lpage">626</span><span class="refDoi"> DOI: 10.4161/cbt.8.7.7923</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.4161%2Fcbt.8.7.7923" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=19252414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotFSjsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=618-626&author=J.+B.+Koorstraauthor=C.+A.+Karikariauthor=G.+Feldmannauthor=S.+Bishtauthor=P.+L.+Rojasauthor=G.+J.+Offerhausauthor=H.+Alvarezauthor=A.+Maitra&title=The+Axl+receptor+tyrosine+kinase+confers+an+adverse+prognostic+influence+in+pancreatic+cancer+and+represents+a+new+therapeutic+target&doi=10.4161%2Fcbt.8.7.7923"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11aR"><div class="casContent"><span class="casTitleNuber">11a</span><div class="casTitle"><span class="NLM_cas:atitle">The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target</span></div><div class="casAuthors">Koorstra, Jan-Bart M.; Karikari, Collins A.; Feldmann, Georg; Bisht, Savita; Rojas, Pamela Leal; Offerhaus, G. Johan A.; Alvarez, Hector; Maitra, Anirban</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">618-626</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1538-4047</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">Background: Pancreatic cancer is a near uniformly lethal disease and a better understanding of the mol. basis of this malignancy may lead to improved therapeutics.  The Axl receptor tyrosine kinase is implicated in cellular transformation and tumor progression, although its role in pancreatic cancer has not been previously documented.  Results: Axl labeling was present in 54 of 99 (55%), and was absent in 45 of 99 (45%) cases, resp.  Axl expression in pancreatic cancer was significantly assocd. with lymph node metastases (p < 0.01), and a shorter median survival (12 vs. 18 mo, p < 0.01), than in tumors with neg. labeling.  Stable knockdown of Axl resulted in significant redn. in cell viability (p < 0.001), anchorage independent growth (p = 0.0031), as well as attenuation of migratory (p < 0.001) and invasive properties (p < 0.005), compared to vector-transfected cells.  Profound inhibition of p42/p44 MAP kinase and PI-3kinase/Akt effector pathways was obsd. in MIAPaCa-2 cells with loss of Axl function.  The redn. in invasion and migration upon Axl knockdown was mirrored by a decrease in the amts. of activated (GTP-bound) GTPase proteins Rho and Rac, significant downregulation in transcript levels of the epithelial mesenchymal transition (EMT)-assocd. transcription factors slug, snail and twist, and significant decrease in matrix metalloproteinase MMP-9 mRNA levels.  Materials: The immunohistochem. expression of Axl protein was assessed in a panel of 99 archival pancreatic cancers.  Endogenous Axl expression was stably downregulated by lentiviral short hairpin shRNA directed against AXL mRNA in MIAPaCa-2 cells, and the effects on cell viability, anchorage independent growth, invasion, migration and intracellular effector pathways was assessed, by comparing to lentiviral vector-transfected cells.  Conclusion: Expression of Axl tyrosine kinase in pancreatic cancers confers an adverse prognostic influence, and represents a new therapeutic target in this malignancy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHVcT_EyeJ5LVg90H21EOLACvtfcHk0lj2ABR5znVmSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotFSjsLo%253D&md5=36b9836411f2b315629eb951b8765a72</span></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.4161%2Fcbt.8.7.7923&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.8.7.7923%26sid%3Dliteratum%253Aachs%26aulast%3DKoorstra%26aufirst%3DJ.%2BB.%26aulast%3DKarikari%26aufirst%3DC.%2BA.%26aulast%3DFeldmann%26aufirst%3DG.%26aulast%3DBisht%26aufirst%3DS.%26aulast%3DRojas%26aufirst%3DP.%2BL.%26aulast%3DOfferhaus%26aufirst%3DG.%2BJ.%26aulast%3DAlvarez%26aufirst%3DH.%26aulast%3DMaitra%26aufirst%3DA.%26atitle%3DThe%2520Axl%2520receptor%2520tyrosine%2520kinase%2520confers%2520an%2520adverse%2520prognostic%2520influence%2520in%2520pancreatic%2520cancer%2520and%2520represents%2520a%2520new%2520therapeutic%2520target%26jtitle%3DCancer%2520Biol.%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D618%26epage%3D626%26doi%3D10.4161%2Fcbt.8.7.7923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Leconet, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larbouret, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chardes, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neiveyans, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Busson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarlier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radosevic-Robin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pugniere, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernex, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penault-Llorca, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasquet, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelegrin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, B.</span><span> </span><span class="NLM_article-title">Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">5405</span><span class="NLM_x">–</span> <span class="NLM_lpage">5414</span><span class="refDoi"> DOI: 10.1038/onc.2013.487</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1038%2Fonc.2013.487" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2014&pages=5405-5414&author=W.+Leconetauthor=C.+Larbouretauthor=T.+Chardesauthor=G.+Thomasauthor=M.+Neiveyansauthor=M.+Bussonauthor=M.+Jarlierauthor=N.+Radosevic-Robinauthor=M.+Pugniereauthor=F.+Bernexauthor=F.+Penault-Llorcaauthor=J.+M.+Pasquetauthor=A.+Pelegrinauthor=B.+Robert&title=Preclinical+validation+of+AXL+receptor+as+a+target+for+antibody-based+pancreatic+cancer+immunotherapy&doi=10.1038%2Fonc.2013.487"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1038%2Fonc.2013.487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2013.487%26sid%3Dliteratum%253Aachs%26aulast%3DLeconet%26aufirst%3DW.%26aulast%3DLarbouret%26aufirst%3DC.%26aulast%3DChardes%26aufirst%3DT.%26aulast%3DThomas%26aufirst%3DG.%26aulast%3DNeiveyans%26aufirst%3DM.%26aulast%3DBusson%26aufirst%3DM.%26aulast%3DJarlier%26aufirst%3DM.%26aulast%3DRadosevic-Robin%26aufirst%3DN.%26aulast%3DPugniere%26aufirst%3DM.%26aulast%3DBernex%26aufirst%3DF.%26aulast%3DPenault-Llorca%26aufirst%3DF.%26aulast%3DPasquet%26aufirst%3DJ.%2BM.%26aulast%3DPelegrin%26aufirst%3DA.%26aulast%3DRobert%26aufirst%3DB.%26atitle%3DPreclinical%2520validation%2520of%2520AXL%2520receptor%2520as%2520a%2520target%2520for%2520antibody-based%2520pancreatic%2520cancer%2520immunotherapy%26jtitle%3DOncogene%26date%3D2014%26volume%3D33%26spage%3D5405%26epage%3D5414%26doi%3D10.1038%2Fonc.2013.487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Green, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikram, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vyas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proby, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghali, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leigh, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Toole, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storey, A.</span><span> </span><span class="NLM_article-title">Overexpression of the Axl tyrosine kinase receptor in cutaneous SCC-derived cell lines and tumours</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">1446</span><span class="NLM_x">–</span> <span class="NLM_lpage">1451</span><span class="refDoi"> DOI: 10.1038/sj.bjc.6603135</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1038%2Fsj.bjc.6603135" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=16641895" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BD28XksFKnurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2006&pages=1446-1451&author=J.+Greenauthor=M.+Ikramauthor=J.+Vyasauthor=N.+Patelauthor=C.+M.+Probyauthor=L.+Ghaliauthor=I.+M.+Leighauthor=E.+A.+O%E2%80%99Tooleauthor=A.+Storey&title=Overexpression+of+the+Axl+tyrosine+kinase+receptor+in+cutaneous+SCC-derived+cell+lines+and+tumours&doi=10.1038%2Fsj.bjc.6603135"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12aR"><div class="casContent"><span class="casTitleNuber">12a</span><div class="casTitle"><span class="NLM_cas:atitle">Overexpression of the Axl tyrosine kinase receptor in cutaneous SCC-derived cell lines and tumours</span></div><div class="casAuthors">Green, J.; Ikram, M.; Vyas, J.; Patel, N.; Proby, C. M.; Ghali, L.; Leigh, I. M.; O'Toole, E. A.; Storey, A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1446-1451</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The mol. mechanisms that underlie the development of squamous cell skin cancers (SSC) are poorly understood.  We have used oligonucleotide microarrays to compare the differences in cellular gene expression between a series of keratinocyte cell that mimic disease progression with the aim of identifying genes that may potentially contribute towards squamous cell carcinoma (SCC) progression in vivo, and in particular to identify markers that may serve as potential therapeutic targets for SCC treatment.  Gene expression differences were corroborated by polymerase chain reaction and Western blotting.  We identified Axl, a receptor tyrosine kinase with transforming potential that has also been shown to have a role in cell survival, adhesion and chemotaxis, was upregulated in vitro in SCC-derived cells compared to premalignant cells.  Extending the investigation to tumor biopsies showed that the Axl protein was overexpressed in vivo in a series of SCCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbYT3STDhQT7Vg90H21EOLACvtfcHk0lj2ABR5znVmSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XksFKnurc%253D&md5=c74bb75e82fee91be3fb8afcd22fa223</span></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6603135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6603135%26sid%3Dliteratum%253Aachs%26aulast%3DGreen%26aufirst%3DJ.%26aulast%3DIkram%26aufirst%3DM.%26aulast%3DVyas%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DN.%26aulast%3DProby%26aufirst%3DC.%2BM.%26aulast%3DGhali%26aufirst%3DL.%26aulast%3DLeigh%26aufirst%3DI.%2BM.%26aulast%3DO%25E2%2580%2599Toole%26aufirst%3DE.%2BA.%26aulast%3DStorey%26aufirst%3DA.%26atitle%3DOverexpression%2520of%2520the%2520Axl%2520tyrosine%2520kinase%2520receptor%2520in%2520cutaneous%2520SCC-derived%2520cell%2520lines%2520and%2520tumours%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2006%26volume%3D94%26spage%3D1446%26epage%3D1451%26doi%3D10.1038%2Fsj.bjc.6603135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit12b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Papadakis, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cichon, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vyas, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghali, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerio, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Toole, E. A.</span><span> </span><span class="NLM_article-title">Axl promotes cutaneous squamous cell carcinoma survival through negative regulation of pro-apoptotic Bcl-2 family members</span> <span class="citation_source-journal">J. Invest. Dermatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">131</span><span class="NLM_x">, </span> <span class="NLM_fpage">509</span><span class="NLM_x">–</span> <span class="NLM_lpage">517</span><span class="refDoi"> DOI: 10.1038/jid.2010.326</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1038%2Fjid.2010.326" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2011&pages=509-517&author=E.+S.+Papadakisauthor=M.+A.+Cichonauthor=J.+J.+Vyasauthor=N.+Patelauthor=L.+Ghaliauthor=R.+Cerioauthor=A.+Storeyauthor=E.+A.+O%E2%80%99Toole&title=Axl+promotes+cutaneous+squamous+cell+carcinoma+survival+through+negative+regulation+of+pro-apoptotic+Bcl-2+family+members&doi=10.1038%2Fjid.2010.326"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1038%2Fjid.2010.326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fjid.2010.326%26sid%3Dliteratum%253Aachs%26aulast%3DPapadakis%26aufirst%3DE.%2BS.%26aulast%3DCichon%26aufirst%3DM.%2BA.%26aulast%3DVyas%26aufirst%3DJ.%2BJ.%26aulast%3DPatel%26aufirst%3DN.%26aulast%3DGhali%26aufirst%3DL.%26aulast%3DCerio%26aufirst%3DR.%26aulast%3DStorey%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Toole%26aufirst%3DE.%2BA.%26atitle%3DAxl%2520promotes%2520cutaneous%2520squamous%2520cell%2520carcinoma%2520survival%2520through%2520negative%2520regulation%2520of%2520pro-apoptotic%2520Bcl-2%2520family%2520members%26jtitle%3DJ.%2520Invest.%2520Dermatol.%26date%3D2011%26volume%3D131%26spage%3D509%26epage%3D517%26doi%3D10.1038%2Fjid.2010.326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit12c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Lee, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yen, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiang, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiah, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shieh, Y. S.</span><span> </span><span class="NLM_article-title">Axl is a prognostic marker in oral squamous cell carcinoma</span> <span class="citation_source-journal">Ann. Surg. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">500</span><span class="NLM_x">–</span> <span class="NLM_lpage">508</span><span class="refDoi"> DOI: 10.1245/s10434-011-1985-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1245%2Fs10434-011-1985-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=500-508&author=C.+H.+Leeauthor=C.+Y.+Yenauthor=S.+Y.+Liuauthor=C.+K.+Chenauthor=C.+F.+Chiangauthor=S.+G.+Shiahauthor=P.+H.+Chenauthor=Y.+S.+Shieh&title=Axl+is+a+prognostic+marker+in+oral+squamous+cell+carcinoma&doi=10.1245%2Fs10434-011-1985-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12c&amp;dbid=16384&amp;doi=10.1245%2Fs10434-011-1985-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1245%252Fs10434-011-1985-8%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DC.%2BH.%26aulast%3DYen%26aufirst%3DC.%2BY.%26aulast%3DLiu%26aufirst%3DS.%2BY.%26aulast%3DChen%26aufirst%3DC.%2BK.%26aulast%3DChiang%26aufirst%3DC.%2BF.%26aulast%3DShiah%26aufirst%3DS.%2BG.%26aulast%3DChen%26aufirst%3DP.%2BH.%26aulast%3DShieh%26aufirst%3DY.%2BS.%26atitle%3DAxl%2520is%2520a%2520prognostic%2520marker%2520in%2520oral%2520squamous%2520cell%2520carcinoma%26jtitle%3DAnn.%2520Surg.%2520Oncol.%26date%3D2012%26volume%3D19%26spage%3D500%26epage%3D508%26doi%3D10.1245%2Fs10434-011-1985-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Sainaghi, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castello, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergamasco, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellosta, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avanzi, G. C.</span><span> </span><span class="NLM_article-title">Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor</span> <span class="citation_source-journal">J. Cell. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">204</span><span class="NLM_x">, </span> <span class="NLM_fpage">36</span><span class="NLM_x">–</span> <span class="NLM_lpage">44</span><span class="refDoi"> DOI: 10.1002/jcp.20265</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1002%2Fjcp.20265" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=15605394" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkvF2qsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=204&publication_year=2005&pages=36-44&author=P.+P.+Sainaghiauthor=L.+Castelloauthor=L.+Bergamascoauthor=M.+Gallettiauthor=P.+Bellostaauthor=G.+C.+Avanzi&title=Gas6+induces+proliferation+in+prostate+carcinoma+cell+lines+expressing+the+Axl+receptor&doi=10.1002%2Fjcp.20265"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor</span></div><div class="casAuthors">Sainaghi, Pier Paolo; Castello, Luigi; Bergamasco, Luca; Galletti, Margherita; Bellosta, Paola; Avanzi, Gian Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">204</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">36-44</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Axl is a Tyr kinase receptor and although it is expressed in malignancy such as leukemia, colon cancer, melanoma, endometrial, prostate and thyroid cancers, its role was not completely elucidated yet and appears to be complex.  The ligand of Axl, Gas6, is a 75 KDa multimodular protein with an N-terminal γ-carboxy-glutamic acid that is essential for binding.  Gas6 has a mitogenic effect on several normal cell lines.  The receptor Axl is expressed in primary prostate carcinoma and in prostate cancer cell lines as such as PC-3 and DU 145.  We demonstrated a mitogenic activity detd. by Gas6/Axl interaction in these undifferentiated metastatic human prostatic cancer cell lines.  This effect is proportional to Axl expression, not due to inhibition of apoptosis, and induces AKT and MAPK phosphorylation.  However, only MEK phosphorylation seems to be essential for growth signaling.  Our results suggest that Axl overexpression and activation by Gas6 could be involved in progression of prostate neoplastic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgNkOPWaojibVg90H21EOLACvtfcHk0ljIQtHAOo6Psw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkvF2qsr0%253D&md5=21e2ec8a6dab885ea9dcfed641c71f9c</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1002%2Fjcp.20265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.20265%26sid%3Dliteratum%253Aachs%26aulast%3DSainaghi%26aufirst%3DP.%2BP.%26aulast%3DCastello%26aufirst%3DL.%26aulast%3DBergamasco%26aufirst%3DL.%26aulast%3DGalletti%26aufirst%3DM.%26aulast%3DBellosta%26aufirst%3DP.%26aulast%3DAvanzi%26aufirst%3DG.%2BC.%26atitle%3DGas6%2520induces%2520proliferation%2520in%2520prostate%2520carcinoma%2520cell%2520lines%2520expressing%2520the%2520Axl%2520receptor%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2005%26volume%3D204%26spage%3D36%26epage%3D44%26doi%3D10.1002%2Fjcp.20265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Mahadevan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooke, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riley, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swart, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simons, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Della Croce, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wisner, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iorio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakalya, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garewal, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagle, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bearss, D.</span><span> </span><span class="NLM_article-title">A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">3909</span><span class="NLM_x">–</span> <span class="NLM_lpage">3919</span><span class="refDoi"> DOI: 10.1038/sj.onc.1210173</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1038%2Fsj.onc.1210173" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=3909-3919&author=D.+Mahadevanauthor=L.+Cookeauthor=C.+Rileyauthor=R.+Swartauthor=B.+Simonsauthor=K.+Della+Croceauthor=L.+Wisnerauthor=M.+Iorioauthor=K.+Shakalyaauthor=H.+Garewalauthor=R.+Nagleauthor=D.+Bearss&title=A+novel+tyrosine+kinase+switch+is+a+mechanism+of+imatinib+resistance+in+gastrointestinal+stromal+tumors&doi=10.1038%2Fsj.onc.1210173"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210173%26sid%3Dliteratum%253Aachs%26aulast%3DMahadevan%26aufirst%3DD.%26aulast%3DCooke%26aufirst%3DL.%26aulast%3DRiley%26aufirst%3DC.%26aulast%3DSwart%26aufirst%3DR.%26aulast%3DSimons%26aufirst%3DB.%26aulast%3DDella%2BCroce%26aufirst%3DK.%26aulast%3DWisner%26aufirst%3DL.%26aulast%3DIorio%26aufirst%3DM.%26aulast%3DShakalya%26aufirst%3DK.%26aulast%3DGarewal%26aufirst%3DH.%26aulast%3DNagle%26aufirst%3DR.%26aulast%3DBearss%26aufirst%3DD.%26atitle%3DA%2520novel%2520tyrosine%2520kinase%2520switch%2520is%2520a%2520mechanism%2520of%2520imatinib%2520resistance%2520in%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D3909%26epage%3D3919%26doi%3D10.1038%2Fsj.onc.1210173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Sensi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castellano, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicolini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alciato, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tragni, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Santis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bersani, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avanzi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomassetti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canevari, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anichini, A.</span><span> </span><span class="NLM_article-title">Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase</span> <span class="citation_source-journal">J. Invest. Dermatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">131</span><span class="NLM_x">, </span> <span class="NLM_fpage">2448</span><span class="NLM_x">–</span> <span class="NLM_lpage">2457</span><span class="refDoi"> DOI: 10.1038/jid.2011.218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1038%2Fjid.2011.218" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2011&pages=2448-2457&author=M.+Sensiauthor=M.+Cataniauthor=G.+Castellanoauthor=G.+Nicoliniauthor=F.+Alciatoauthor=G.+Tragniauthor=G.+De+Santisauthor=I.+Bersaniauthor=G.+Avanziauthor=A.+Tomassettiauthor=S.+Canevariauthor=A.+Anichini&title=Human+cutaneous+melanomas+lacking+MITF+and+melanocyte+differentiation+antigens+express+a+functional+Axl+receptor+kinase&doi=10.1038%2Fjid.2011.218"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.1038%2Fjid.2011.218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fjid.2011.218%26sid%3Dliteratum%253Aachs%26aulast%3DSensi%26aufirst%3DM.%26aulast%3DCatani%26aufirst%3DM.%26aulast%3DCastellano%26aufirst%3DG.%26aulast%3DNicolini%26aufirst%3DG.%26aulast%3DAlciato%26aufirst%3DF.%26aulast%3DTragni%26aufirst%3DG.%26aulast%3DDe%2BSantis%26aufirst%3DG.%26aulast%3DBersani%26aufirst%3DI.%26aulast%3DAvanzi%26aufirst%3DG.%26aulast%3DTomassetti%26aufirst%3DA.%26aulast%3DCanevari%26aufirst%3DS.%26aulast%3DAnichini%26aufirst%3DA.%26atitle%3DHuman%2520cutaneous%2520melanomas%2520lacking%2520MITF%2520and%2520melanocyte%2520differentiation%2520antigens%2520express%2520a%2520functional%2520Axl%2520receptor%2520kinase%26jtitle%3DJ.%2520Invest.%2520Dermatol.%26date%3D2011%26volume%3D131%26spage%3D2448%26epage%3D2457%26doi%3D10.1038%2Fjid.2011.218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit15b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Muller, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krijgsman, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsoi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hugo, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Possik, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornelissen-Steijger, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foppen, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kemper, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goding, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDermott, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blank, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haanen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graeber, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peeper, D. S.</span><span> </span><span class="NLM_article-title">Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma</span> <span class="citation_source-journal">Nat. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">5712</span><span class="refDoi"> DOI: 10.1038/ncomms6712</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1038%2Fncomms6712" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=25502142" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A280%3ADC%252BC2MvgtV2ksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=5712&author=J.+Mullerauthor=O.+Krijgsmanauthor=J.+Tsoiauthor=L.+Robertauthor=W.+Hugoauthor=C.+Songauthor=X.+Kongauthor=P.+A.+Possikauthor=P.+D.+Cornelissen-Steijgerauthor=M.+H.+Foppenauthor=K.+Kemperauthor=C.+R.+Godingauthor=U.+McDermottauthor=C.+Blankauthor=J.+Haanenauthor=T.+G.+Graeberauthor=A.+Ribasauthor=R.+S.+Loauthor=D.+S.+Peeper&title=Low+MITF%2FAXL+ratio+predicts+early+resistance+to+multiple+targeted+drugs+in+melanoma&doi=10.1038%2Fncomms6712"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15bR"><div class="casContent"><span class="casTitleNuber">15b</span><div class="casTitle"><span class="NLM_cas:atitle">Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma</span></div><div class="casAuthors">Muller Judith; Krijgsman Oscar; Possik Patricia A; Cornelissen-Steijger Paulien D M; Kemper Kristel; Peeper Daniel S; Tsoi Jennifer; Robert Lidia; Hugo Willy; Song Chunying; Kong Xiangju; Geukes Foppen Marnix H; Blank Christian; Haanen John; Goding Colin R; McDermott Ultan; Graeber Thomas G; Ribas Antoni; Lo Roger S</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">5712</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Increased expression of the Microphthalmia-associated transcription factor (MITF) contributes to melanoma progression and resistance to BRAF pathway inhibition.  Here we show that the lack of MITF is associated with more severe resistance to a range of inhibitors, while its presence is required for robust drug responses.  Both in primary and acquired resistance, MITF levels inversely correlate with the expression of several activated receptor tyrosine kinases, most frequently AXL.  The MITF-low/AXL-high/drug-resistance phenotype is common among mutant BRAF and NRAS melanoma cell lines.  The dichotomous behaviour of MITF in drug response is corroborated in vemurafenib-resistant biopsies, including MITF-high and -low clones in a relapsed patient.  Furthermore, drug cocktails containing AXL inhibitor enhance melanoma cell elimination by BRAF or ERK inhibition.  Our results demonstrate that a low MITF/AXL ratio predicts early resistance to multiple targeted drugs, and warrant clinical validation of AXL inhibitors to combat resistance of BRAF and NRAS mutant MITF-low melanomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRBPp9KggQbmfh3YQQtAhNufW6udTcc2eY1csLafYqlBLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MvgtV2ksw%253D%253D&md5=2617d6a0337c130696f3858827b1015c</span></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=10.1038%2Fncomms6712&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms6712%26sid%3Dliteratum%253Aachs%26aulast%3DMuller%26aufirst%3DJ.%26aulast%3DKrijgsman%26aufirst%3DO.%26aulast%3DTsoi%26aufirst%3DJ.%26aulast%3DRobert%26aufirst%3DL.%26aulast%3DHugo%26aufirst%3DW.%26aulast%3DSong%26aufirst%3DC.%26aulast%3DKong%26aufirst%3DX.%26aulast%3DPossik%26aufirst%3DP.%2BA.%26aulast%3DCornelissen-Steijger%26aufirst%3DP.%2BD.%26aulast%3DFoppen%26aufirst%3DM.%2BH.%26aulast%3DKemper%26aufirst%3DK.%26aulast%3DGoding%26aufirst%3DC.%2BR.%26aulast%3DMcDermott%26aufirst%3DU.%26aulast%3DBlank%26aufirst%3DC.%26aulast%3DHaanen%26aufirst%3DJ.%26aulast%3DGraeber%26aufirst%3DT.%2BG.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DLo%26aufirst%3DR.%2BS.%26aulast%3DPeeper%26aufirst%3DD.%2BS.%26atitle%3DLow%2520MITF%252FAXL%2520ratio%2520predicts%2520early%2520resistance%2520to%2520multiple%2520targeted%2520drugs%2520in%2520melanoma%26jtitle%3DNat.%2520Commun.%26date%3D2014%26volume%3D5%26spage%3D5712%26doi%3D10.1038%2Fncomms6712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Yu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yen, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krasnoperov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bove, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buscarini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parekh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gill, I. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tretiakova, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinn, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gill, P. S.</span><span> </span><span class="NLM_article-title">Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">616</span><span class="NLM_x">–</span> <span class="NLM_lpage">625</span><span class="refDoi"> DOI: 10.1038/bjc.2015.237</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1038%2Fbjc.2015.237" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=26180925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1WrtbrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2015&pages=616-625&author=H.+Yuauthor=R.+Liuauthor=B.+Maauthor=X.+Liauthor=H.+Y.+Yenauthor=Y.+Zhouauthor=V.+Krasnoperovauthor=Z.+Xiaauthor=X.+Zhangauthor=A.+M.+Boveauthor=M.+Buscariniauthor=D.+Parekhauthor=I.+S.+Gillauthor=Q.+Liaoauthor=M.+Tretiakovaauthor=D.+Quinnauthor=J.+Zhaoauthor=P.+S.+Gill&title=Axl+receptor+tyrosine+kinase+is+a+potential+therapeutic+target+in+renal+cell+carcinoma&doi=10.1038%2Fbjc.2015.237"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16aR"><div class="casContent"><span class="casTitleNuber">16a</span><div class="casTitle"><span class="NLM_cas:atitle">Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma</span></div><div class="casAuthors">Yu, H.; Liu, R.; Ma, B.; Li, X.; Yen, H.-Y.; Zhou, Y.; Krasnoperov, V.; Xia, Z.; Zhang, X.; Bove, A. M.; Buscarini, M.; Parekh, D.; Gill, I. S.; Liao, Q.; Tretiakova, M.; Quinn, D.; Zhao, J.; Gill, P. S.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">616-625</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: Axl plays multiple roles in tumorigenesis in several cancers.  Here we evaluated the expression and biol. function of Axl in renal cell carcinoma (RCC).  Methods: Axl expression was analyzed in a tissue microarray of 174 RCC samples by immunostaining and a panel of 11 normal tumor pairs of human RCC tissues by western blot, as well as in RCC cell lines by both western blot and quant. PCR.  The effects of Axl knockdown in RCC cells on cell growth and signalling were investigated.  The efficacy of a humanized Axl targeting monoclonal antibody hMAb173 was tested in histoculture and tumor xenograft.  Results: We have detd. by immunohistochem. (IHC) that Axl is expressed in 59% of RCC array samples with moderate to high in 20% but not expressed in normal kidney tissue.  Western blot anal. of 11 pairs of tumor and adjacent normal tissue show high Axl expression in 73% of the tumors but not normal tissue.  Axl is also expressed in RCC cell lines in which Axl knockdown reduces cell viability and PI3K/Akt signalling.  The Axl antibody hMAb173 significantly induced RCC cell apoptosis in histoculture and inhibited the growth of RCC tumor in vivo by 78%.  The hMAb173-treated tumors also had significantly reduced Axl protein levels, inhibited PI3K signalling, decreased proliferation, and induced apoptosis.  Conclusions: Axl is highly expressed in RCC and crit. for RCC cell survival.  Targeting Axl is a potential approach for RCC treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwKf4yyaQhWrVg90H21EOLACvtfcHk0lgFGrHpddGIxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1WrtbrO&md5=3f916c7beaa150038cbc5ed35594be29</span></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2015.237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2015.237%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DMa%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DYen%26aufirst%3DH.%2BY.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DKrasnoperov%26aufirst%3DV.%26aulast%3DXia%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DBove%26aufirst%3DA.%2BM.%26aulast%3DBuscarini%26aufirst%3DM.%26aulast%3DParekh%26aufirst%3DD.%26aulast%3DGill%26aufirst%3DI.%2BS.%26aulast%3DLiao%26aufirst%3DQ.%26aulast%3DTretiakova%26aufirst%3DM.%26aulast%3DQuinn%26aufirst%3DD.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DGill%26aufirst%3DP.%2BS.%26atitle%3DAxl%2520receptor%2520tyrosine%2520kinase%2520is%2520a%2520potential%2520therapeutic%2520target%2520in%2520renal%2520cell%2520carcinoma%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2015%26volume%3D113%26spage%3D616%26epage%3D625%26doi%3D10.1038%2Fbjc.2015.237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit16b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Rankin, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castellini, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viswanathan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finger, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diep, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaGory, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kariolis, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindgren, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Axelson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miao, Y. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krieg, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giaccia, A. J.</span><span> </span><span class="NLM_article-title">Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">13373</span><span class="NLM_x">–</span> <span class="NLM_lpage">13378</span><span class="refDoi"> DOI: 10.1073/pnas.1404848111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1073%2Fpnas.1404848111" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=13373-13378&author=E.+B.+Rankinauthor=K.+C.+Fuhauthor=L.+Castelliniauthor=K.+Viswanathanauthor=E.+C.+Fingerauthor=A.+N.+Diepauthor=E.+L.+LaGoryauthor=M.+S.+Kariolisauthor=A.+Chanauthor=D.+Lindgrenauthor=H.+Axelsonauthor=Y.+R.+Miaoauthor=A.+J.+Kriegauthor=A.+J.+Giaccia&title=Direct+regulation+of+GAS6%2FAXL+signaling+by+HIF+promotes+renal+metastasis+through+SRC+and+MET&doi=10.1073%2Fpnas.1404848111"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1404848111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1404848111%26sid%3Dliteratum%253Aachs%26aulast%3DRankin%26aufirst%3DE.%2BB.%26aulast%3DFuh%26aufirst%3DK.%2BC.%26aulast%3DCastellini%26aufirst%3DL.%26aulast%3DViswanathan%26aufirst%3DK.%26aulast%3DFinger%26aufirst%3DE.%2BC.%26aulast%3DDiep%26aufirst%3DA.%2BN.%26aulast%3DLaGory%26aufirst%3DE.%2BL.%26aulast%3DKariolis%26aufirst%3DM.%2BS.%26aulast%3DChan%26aufirst%3DA.%26aulast%3DLindgren%26aufirst%3DD.%26aulast%3DAxelson%26aufirst%3DH.%26aulast%3DMiao%26aufirst%3DY.%2BR.%26aulast%3DKrieg%26aufirst%3DA.%2BJ.%26aulast%3DGiaccia%26aufirst%3DA.%2BJ.%26atitle%3DDirect%2520regulation%2520of%2520GAS6%252FAXL%2520signaling%2520by%2520HIF%2520promotes%2520renal%2520metastasis%2520through%2520SRC%2520and%2520MET%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26spage%3D13373%26epage%3D13378%26doi%3D10.1073%2Fpnas.1404848111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ghosh, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Secreto, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boysen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sassoon, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shanafelt, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukhopadhyay, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kay, N. E.</span><span> </span><span class="NLM_article-title">The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">117</span><span class="NLM_x">, </span> <span class="NLM_fpage">1928</span><span class="NLM_x">–</span> <span class="NLM_lpage">1937</span><span class="refDoi"> DOI: 10.1182/blood-2010-09-305649</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1182%2Fblood-2010-09-305649" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2011&pages=1928-1937&author=A.+K.+Ghoshauthor=C.+Secretoauthor=J.+Boysenauthor=T.+Sassoonauthor=T.+D.+Shanafeltauthor=D.+Mukhopadhyayauthor=N.+E.+Kay&title=The+novel+receptor+tyrosine+kinase+Axl+is+constitutively+active+in+B-cell+chronic+lymphocytic+leukemia+and+acts+as+a+docking+site+of+nonreceptor+kinases%3A+implications+for+therapy&doi=10.1182%2Fblood-2010-09-305649"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.1182%2Fblood-2010-09-305649&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2010-09-305649%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DA.%2BK.%26aulast%3DSecreto%26aufirst%3DC.%26aulast%3DBoysen%26aufirst%3DJ.%26aulast%3DSassoon%26aufirst%3DT.%26aulast%3DShanafelt%26aufirst%3DT.%2BD.%26aulast%3DMukhopadhyay%26aufirst%3DD.%26aulast%3DKay%26aufirst%3DN.%2BE.%26atitle%3DThe%2520novel%2520receptor%2520tyrosine%2520kinase%2520Axl%2520is%2520constitutively%2520active%2520in%2520B-cell%2520chronic%2520lymphocytic%2520leukemia%2520and%2520acts%2520as%2520a%2520docking%2520site%2520of%2520nonreceptor%2520kinases%253A%2520implications%2520for%2520therapy%26jtitle%3DBlood%26date%3D2011%26volume%3D117%26spage%3D1928%26epage%3D1937%26doi%3D10.1182%2Fblood-2010-09-305649" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit17b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ben-Batalla, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultze, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wroblewski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erdmann, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heuser, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waizenegger, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riecken, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Binder, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schewe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawall, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witzke, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cubas-Cordova, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janning, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wellbrock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fehse, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krauter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ganser, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorens, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiedler, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmeliet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pantel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bokemeyer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loges, S.</span><span> </span><span class="NLM_article-title">Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">2443</span><span class="NLM_x">–</span> <span class="NLM_lpage">2452</span><span class="refDoi"> DOI: 10.1182/blood-2013-03-491431</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1182%2Fblood-2013-03-491431" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=23982172" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1Sqt7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2013&pages=2443-2452&author=I.+Ben-Batallaauthor=A.+Schultzeauthor=M.+Wroblewskiauthor=R.+Erdmannauthor=M.+Heuserauthor=J.+S.+Waizeneggerauthor=K.+Rieckenauthor=M.+Binderauthor=D.+Scheweauthor=S.+Sawallauthor=V.+Witzkeauthor=M.+Cubas-Cordovaauthor=M.+Janningauthor=J.+Wellbrockauthor=B.+Fehseauthor=C.+Hagelauthor=J.+Krauterauthor=A.+Ganserauthor=J.+B.+Lorensauthor=W.+Fiedlerauthor=P.+Carmelietauthor=K.+Pantelauthor=C.+Bokemeyerauthor=S.+Loges&title=Axl%2C+a+prognostic+and+therapeutic+target+in+acute+myeloid+leukemia+mediates+paracrine+crosstalk+of+leukemia+cells+with+bone+marrow+stroma&doi=10.1182%2Fblood-2013-03-491431"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17bR"><div class="casContent"><span class="casTitleNuber">17b</span><div class="casTitle"><span class="NLM_cas:atitle">Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma</span></div><div class="casAuthors">Ben-Batalla, Isabel; Schultze, Alexander; Wroblewski, Mark; Erdmann, Robert; Heuser, Michael; Waizenegger, Jonas S.; Riecken, Kristoffer; Binder, Mascha; Schewe, Denis; Sawall, Stefanie; Witzke, Victoria; Cubas-Cordova, Miguel; Janning, Melanie; Wellbrock, Jasmin; Fehse, Boris; Hagel, Christian; Krauter, Juergen; Ganser, Arnold; Lorens, James B.; Fiedler, Walter; Carmeliet, Peter; Pantel, Klaus; Bokemeyer, Carsten; Loges, Sonja</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2443-2452</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Acute myeloid leukemia (AML) represents a clonal disease of hematopoietic progenitors characterized by acquired heterogeneous genetic changes that alter normal mechanisms of proliferation, self-renewal, and differentiation.  Although 40% to 45% of patients younger than 65 years of age can be cured with current therapies, only 10% of older patients reach long-term survival.  Because only very few novel AML drugs were approved in the past 2 decades, there is an urgent need to identify novel targets and therapeutic strategies to treat underserved AML patients.  We report here that Axl, a member of the Tyro3, Axl, Mer receptor tyrosine kinase family, represents an independent prognostic marker and therapeutic target in AML.  AML cells induce expression and secretion of the Axl ligand growth arrest-specific gene 6 (Gas6) by bone marrow-derived stromal cells (BMDSCs).  Gas6 in turn mediates proliferation, survival, and chemoresistance of Axl-expressing AML cells.  This Gas6-Axl paracrine axis between AML cells and BMDSCs establishes a chemoprotective tumor cell niche that can be abrogated by Axl-targeting approaches.  Axl inhibition is active in FLT3-mutated and FLT3 wild-type AML, improves clin. relevant end points, and its efficacy depends on presence of Gas6 and Axl.  Axl inhibition alone or in combination with chemotherapy might represent a novel therapeutic avenue for AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCdV7UN_cvNLVg90H21EOLACvtfcHk0li5xdJREIjiCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1Sqt7nO&md5=7b2b67ec3ba0c46218e88e4ea190026c</span></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.1182%2Fblood-2013-03-491431&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2013-03-491431%26sid%3Dliteratum%253Aachs%26aulast%3DBen-Batalla%26aufirst%3DI.%26aulast%3DSchultze%26aufirst%3DA.%26aulast%3DWroblewski%26aufirst%3DM.%26aulast%3DErdmann%26aufirst%3DR.%26aulast%3DHeuser%26aufirst%3DM.%26aulast%3DWaizenegger%26aufirst%3DJ.%2BS.%26aulast%3DRiecken%26aufirst%3DK.%26aulast%3DBinder%26aufirst%3DM.%26aulast%3DSchewe%26aufirst%3DD.%26aulast%3DSawall%26aufirst%3DS.%26aulast%3DWitzke%26aufirst%3DV.%26aulast%3DCubas-Cordova%26aufirst%3DM.%26aulast%3DJanning%26aufirst%3DM.%26aulast%3DWellbrock%26aufirst%3DJ.%26aulast%3DFehse%26aufirst%3DB.%26aulast%3DHagel%26aufirst%3DC.%26aulast%3DKrauter%26aufirst%3DJ.%26aulast%3DGanser%26aufirst%3DA.%26aulast%3DLorens%26aufirst%3DJ.%2BB.%26aulast%3DFiedler%26aufirst%3DW.%26aulast%3DCarmeliet%26aufirst%3DP.%26aulast%3DPantel%26aufirst%3DK.%26aulast%3DBokemeyer%26aufirst%3DC.%26aulast%3DLoges%26aufirst%3DS.%26atitle%3DAxl%252C%2520a%2520prognostic%2520and%2520therapeutic%2520target%2520in%2520acute%2520myeloid%2520leukemia%2520mediates%2520paracrine%2520crosstalk%2520of%2520leukemia%2520cells%2520with%2520bone%2520marrow%2520stroma%26jtitle%3DBlood%26date%3D2013%26volume%3D122%26spage%3D2443%26epage%3D2452%26doi%3D10.1182%2Fblood-2013-03-491431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit17c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Park, I. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mishra, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitman, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcucci, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caligiuri, M. A.</span><span> </span><span class="NLM_article-title">Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">121</span><span class="NLM_x">, </span> <span class="NLM_fpage">2064</span><span class="NLM_x">–</span> <span class="NLM_lpage">2073</span><span class="refDoi"> DOI: 10.1182/blood-2012-07-444018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1182%2Fblood-2012-07-444018" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2013&pages=2064-2073&author=I.+K.+Parkauthor=A.+Mishraauthor=J.+Chandlerauthor=S.+P.+Whitmanauthor=G.+Marcucciauthor=M.+A.+Caligiuri&title=Inhibition+of+the+receptor+tyrosine+kinase+Axl+impedes+activation+of+the+FLT3+internal+tandem+duplication+in+human+acute+myeloid+leukemia%3A+implications+for+Axl+as+a+potential+therapeutic+target&doi=10.1182%2Fblood-2012-07-444018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17c&amp;dbid=16384&amp;doi=10.1182%2Fblood-2012-07-444018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2012-07-444018%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DI.%2BK.%26aulast%3DMishra%26aufirst%3DA.%26aulast%3DChandler%26aufirst%3DJ.%26aulast%3DWhitman%26aufirst%3DS.%2BP.%26aulast%3DMarcucci%26aufirst%3DG.%26aulast%3DCaligiuri%26aufirst%3DM.%2BA.%26atitle%3DInhibition%2520of%2520the%2520receptor%2520tyrosine%2520kinase%2520Axl%2520impedes%2520activation%2520of%2520the%2520FLT3%2520internal%2520tandem%2520duplication%2520in%2520human%2520acute%2520myeloid%2520leukemia%253A%2520implications%2520for%2520Axl%2520as%2520a%2520potential%2520therapeutic%2520target%26jtitle%3DBlood%26date%3D2013%26volume%3D121%26spage%3D2064%26epage%3D2073%26doi%3D10.1182%2Fblood-2012-07-444018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Dunne, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArt, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blayney, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalimutho, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Srivastava, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ong, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arthur, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loughrey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Redmond, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Longley, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salto-Tellez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Schaeybroeck, S.</span><span> </span><span class="NLM_article-title">AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">164</span><span class="NLM_x">–</span> <span class="NLM_lpage">175</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-1354</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1158%2F1078-0432.CCR-13-1354" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=24170546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC2cXislKltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=164-175&author=P.+D.+Dunneauthor=D.+G.+McArtauthor=J.+K.+Blayneyauthor=M.+Kalimuthoauthor=S.+Greerauthor=T.+Wangauthor=S.+Srivastavaauthor=C.+W.+Ongauthor=K.+Arthurauthor=M.+Loughreyauthor=K.+Redmondauthor=D.+B.+Longleyauthor=M.+Salto-Tellezauthor=P.+G.+Johnstonauthor=S.+Van+Schaeybroeck&title=AXL+is+a+key+regulator+of+inherent+and+chemotherapy-induced+invasion+and+predicts+a+poor+clinical+outcome+in+early-stage+colon+cancer&doi=10.1158%2F1078-0432.CCR-13-1354"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">AXL Is a Key Regulator of Inherent and Chemotherapy-Induced Invasion and Predicts a Poor Clinical Outcome in Early-Stage Colon Cancer</span></div><div class="casAuthors">Dunne, Philip D.; McArt, Darragh G.; Blayney, Jaine K.; Kalimutho, Murugan; Greer, Samanda; Wang, Tingting; Srivastava, Supriya; Ong, Chee Wee; Arthur, Ken; Loughrey, Maurice; Redmond, Keara; Longley, Daniel B.; Salto-Tellez, Manuel; Johnston, Patrick G.; Van Schaeybroeck, Sandra</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">164-175</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Despite the use of 5-fluorouracil (5-FU)-based adjuvant treatments, a large proportion of patients with high-risk stage II/III colorectal cancer will relapse.  Thus, novel therapeutic strategies are needed for early-stage colorectal cancer.  Residual micrometastatic disease from the primary tumor is a major cause of patient relapse.  Exptl. Design: To model colorectal cancer tumor cell invasion/metastasis, we have generated invasive (KRASMT/KRASWT/+chr3/p53-null) colorectal cancer cell subpopulations.  Receptor tyrosine kinase (RTK) screens were used to identify novel proteins that underpin the migratory/invasive phenotype.  Migration/invasion was assessed using the XCELLigence system.  Tumors from patients with early-stage colorectal cancer (N = 336) were examd. for AXL expression.  Results: Invasive colorectal cancer cell subpopulations showed a transition from an epithelial-to-mesenchymal like phenotype with significant increases in migration, invasion, colony-forming ability, and an attenuation of EGF receptor (EGFR)/HER2 autocrine signaling.  RTK arrays showed significant increases in AXL levels in all invasive sublines.  Importantly, 5-FU treatment resulted in significantly increased migration and invasion, and targeting AXL using pharmacol. inhibition or RNA interference (RNAi) approaches suppressed basal and 5-FU-induced migration and invasion.  Significantly, high AXL mRNA and protein expression were found to be assocd. with poor overall survival in early-stage colorectal cancer tissues.  Conclusions: We have identified AXL as a poor prognostic marker and important mediator of cell migration/invasiveness in colorectal cancer.  These findings provide support for the further investigation of AXL as a novel prognostic biomarker and therapeutic target in colorectal cancer, in particular in the adjuvant disease in which EGFR/VEGF-targeted therapies have failed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojGnw9ktEIf7Vg90H21EOLACvtfcHk0li5xdJREIjiCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXislKltA%253D%253D&md5=139c2c7a6b42c4229fb11610a4d6954b</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-1354&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-1354%26sid%3Dliteratum%253Aachs%26aulast%3DDunne%26aufirst%3DP.%2BD.%26aulast%3DMcArt%26aufirst%3DD.%2BG.%26aulast%3DBlayney%26aufirst%3DJ.%2BK.%26aulast%3DKalimutho%26aufirst%3DM.%26aulast%3DGreer%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DSrivastava%26aufirst%3DS.%26aulast%3DOng%26aufirst%3DC.%2BW.%26aulast%3DArthur%26aufirst%3DK.%26aulast%3DLoughrey%26aufirst%3DM.%26aulast%3DRedmond%26aufirst%3DK.%26aulast%3DLongley%26aufirst%3DD.%2BB.%26aulast%3DSalto-Tellez%26aufirst%3DM.%26aulast%3DJohnston%26aufirst%3DP.%2BG.%26aulast%3DVan%2BSchaeybroeck%26aufirst%3DS.%26atitle%3DAXL%2520is%2520a%2520key%2520regulator%2520of%2520inherent%2520and%2520chemotherapy-induced%2520invasion%2520and%2520predicts%2520a%2520poor%2520clinical%2520outcome%2520in%2520early-stage%2520colon%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D164%26epage%3D175%26doi%3D10.1158%2F1078-0432.CCR-13-1354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Rankin, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krieg, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Musser, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Longacre, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giaccia, A. J.</span><span> </span><span class="NLM_article-title">AXL is an essential factor and therapeutic target for metastatic ovarian cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">7570</span><span class="NLM_x">–</span> <span class="NLM_lpage">7579</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-1267</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1158%2F0008-5472.CAN-10-1267" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=7570-7579&author=E.+B.+Rankinauthor=K.+C.+Fuhauthor=T.+E.+Taylorauthor=A.+J.+Kriegauthor=M.+Musserauthor=J.+Yuanauthor=K.+Weiauthor=C.+J.+Kuoauthor=T.+A.+Longacreauthor=A.+J.+Giaccia&title=AXL+is+an+essential+factor+and+therapeutic+target+for+metastatic+ovarian+cancer&doi=10.1158%2F0008-5472.CAN-10-1267"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-1267&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-1267%26sid%3Dliteratum%253Aachs%26aulast%3DRankin%26aufirst%3DE.%2BB.%26aulast%3DFuh%26aufirst%3DK.%2BC.%26aulast%3DTaylor%26aufirst%3DT.%2BE.%26aulast%3DKrieg%26aufirst%3DA.%2BJ.%26aulast%3DMusser%26aufirst%3DM.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DWei%26aufirst%3DK.%26aulast%3DKuo%26aufirst%3DC.%2BJ.%26aulast%3DLongacre%26aufirst%3DT.%2BA.%26aulast%3DGiaccia%26aufirst%3DA.%2BJ.%26atitle%3DAXL%2520is%2520an%2520essential%2520factor%2520and%2520therapeutic%2520target%2520for%2520metastatic%2520ovarian%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D7570%26epage%3D7579%26doi%3D10.1158%2F0008-5472.CAN-10-1267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hutterer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knyazev, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abate, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reschke, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maier, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stefanova, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knyazeva, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbieri, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reindl, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muigg, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kostron, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stockhammer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span> </span><span class="NLM_article-title">Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">130</span><span class="NLM_x">–</span> <span class="NLM_lpage">138</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-07-0862</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1158%2F1078-0432.CCR-07-0862" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=18172262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BD1cXoslCn" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=130-138&author=M.+Huttererauthor=P.+Knyazevauthor=A.+Abateauthor=M.+Reschkeauthor=H.+Maierauthor=N.+Stefanovaauthor=T.+Knyazevaauthor=V.+Barbieriauthor=M.+Reindlauthor=A.+Muiggauthor=H.+Kostronauthor=G.+Stockhammerauthor=A.+Ullrich&title=Axl+and+growth+arrest-specific+gene+6+are+frequently+overexpressed+in+human+gliomas+and+predict+poor+prognosis+in+patients+with+glioblastoma+multiforme&doi=10.1158%2F1078-0432.CCR-07-0862"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20aR"><div class="casContent"><span class="casTitleNuber">20a</span><div class="casTitle"><span class="NLM_cas:atitle">Axl and Growth Arrest-Specific Gene 6 Are Frequently Overexpressed in Human Gliomas and Predict Poor Prognosis in Patients with Glioblastoma Multiforme</span></div><div class="casAuthors">Hutterer, Markus; Knyazev, Pjotr; Abate, Ariane; Reschke, Markus; Maier, Hans; Stefanova, Nadia; Knyazeva, Tatjana; Barbieri, Verena; Reindl, Markus; Muigg, Armin; Kostron, Herwig; Stockhammer, Guenther; Ullrich, Axel</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">130-138</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: The receptor tyrosine kinase Axl has recently been identified as a crit. element in the invasive properties of glioma cell lines.  However, the effect of Axl and its ligand growth arrest-specific gene 6 (Gas6) in human gliomas is still unknown.  Exptl. Design: Axl and Gas6 expression was studied in 42 fresh-frozen and 79 paraffin-embedded glioma specimens by means of reverse transcription-PCR and immunohistochem.  The prognostic value of Axl and Gas6 expression was evaluated using a population-based tissue microarray derived from a cohort of 55 glioblastoma multiforme (GBM) patients.  RESULTS: Axl and Gas6 were detectable in gliomas of malignancy grades WHO 2 to 4.  Moderate to high Axl mRNA expression was found in 61%, Axl protein in 55%, Gas6 mRNA in 81%, and Gas6 protein in 74% of GBM samples, resp.  GBM patients with high Axl expression and Axl/Gas6 coexpression showed a significantly shorter time to tumor progression and an assocn. with poorer overall survival.  Comparative immunohistochem. studies showed that Axl staining was most pronounced in glioma cells of pseudopalisades and reactive astrocytes.  Addnl., Axl/Gas6 coexpression was obsd. in glioma cells and tumor vessels.  In contrast, Axl staining was not detectable in nonneoplastic brain tissue and Gas6 was strongly expressed in neurons.  CONCLUSIONS: In human gliomas, Axl and Gas6 are frequently overexpressed in both glioma and vascular cells and predict poor prognosis in GBM patients.  Our results indicate that specific targeting of the Axl/Gas6 signaling pathway may represent a potential new approach for glioma treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-54ka16GPkrVg90H21EOLACvtfcHk0ljvjE0A2VJakw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXoslCn&md5=45d8887803613422b9e704b803ee757c</span></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-0862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-0862%26sid%3Dliteratum%253Aachs%26aulast%3DHutterer%26aufirst%3DM.%26aulast%3DKnyazev%26aufirst%3DP.%26aulast%3DAbate%26aufirst%3DA.%26aulast%3DReschke%26aufirst%3DM.%26aulast%3DMaier%26aufirst%3DH.%26aulast%3DStefanova%26aufirst%3DN.%26aulast%3DKnyazeva%26aufirst%3DT.%26aulast%3DBarbieri%26aufirst%3DV.%26aulast%3DReindl%26aufirst%3DM.%26aulast%3DMuigg%26aufirst%3DA.%26aulast%3DKostron%26aufirst%3DH.%26aulast%3DStockhammer%26aufirst%3DG.%26aulast%3DUllrich%26aufirst%3DA.%26atitle%3DAxl%2520and%2520growth%2520arrest-specific%2520gene%25206%2520are%2520frequently%2520overexpressed%2520in%2520human%2520gliomas%2520and%2520predict%2520poor%2520prognosis%2520in%2520patients%2520with%2520glioblastoma%2520multiforme%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D130%26epage%3D138%26doi%3D10.1158%2F1078-0432.CCR-07-0862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit20b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Han, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, T.</span><span> </span><span class="NLM_article-title">Gas6/Axl mediates tumor cell apoptosis, migration and invasion and predicts the clinical outcome of osteosarcoma patients</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">435</span><span class="NLM_x">, </span> <span class="NLM_fpage">493</span><span class="NLM_x">–</span> <span class="NLM_lpage">500</span><span class="refDoi"> DOI: 10.1016/j.bbrc.2013.05.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1016%2Fj.bbrc.2013.05.019" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=435&publication_year=2013&pages=493-500&author=J.+Hanauthor=R.+Tianauthor=B.+Yongauthor=C.+Luoauthor=P.+Tanauthor=J.+Shenauthor=T.+Peng&title=Gas6%2FAxl+mediates+tumor+cell+apoptosis%2C+migration+and+invasion+and+predicts+the+clinical+outcome+of+osteosarcoma+patients&doi=10.1016%2Fj.bbrc.2013.05.019"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2013.05.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2013.05.019%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DTian%26aufirst%3DR.%26aulast%3DYong%26aufirst%3DB.%26aulast%3DLuo%26aufirst%3DC.%26aulast%3DTan%26aufirst%3DP.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DPeng%26aufirst%3DT.%26atitle%3DGas6%252FAxl%2520mediates%2520tumor%2520cell%2520apoptosis%252C%2520migration%2520and%2520invasion%2520and%2520predicts%2520the%2520clinical%2520outcome%2520of%2520osteosarcoma%2520patients%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2013%26volume%3D435%26spage%3D493%26epage%3D500%26doi%3D10.1016%2Fj.bbrc.2013.05.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Yauch, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Januario, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberhard, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavet, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pham, T. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soriano, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stinson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seshagiri, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modrusan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Neill, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amler, L. C.</span><span> </span><span class="NLM_article-title">Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">8686</span><span class="NLM_x">–</span> <span class="NLM_lpage">8698</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-05-1492</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1158%2F1078-0432.CCR-05-1492" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=16361555" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlWrsb3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=8686-8698&author=R.+L.+Yauchauthor=T.+Januarioauthor=D.+A.+Eberhardauthor=G.+Cavetauthor=W.+Zhuauthor=L.+Fuauthor=T.+Q.+Phamauthor=R.+Sorianoauthor=J.+Stinsonauthor=S.+Seshagiriauthor=Z.+Modrusanauthor=C.+Y.+Linauthor=V.+O%E2%80%99Neillauthor=L.+C.+Amler&title=Epithelial+versus+mesenchymal+phenotype+determines+in+vitro+sensitivity+and+predicts+clinical+activity+of+erlotinib+in+lung+cancer+patients&doi=10.1158%2F1078-0432.CCR-05-1492"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21aR"><div class="casContent"><span class="casTitleNuber">21a</span><div class="casTitle"><span class="NLM_cas:atitle">Epithelial versus Mesenchymal Phenotype Determines In vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients</span></div><div class="casAuthors">Yauch, Robert L.; Januario, Thomas; Eberhard, David A.; Cavet, Guy; Zhu, Wenjing; Fu, Ling; Pham, Thinh Q.; Soriano, Robert; Stinson, Jeremy; Seshagiri, Somasekar; Modrusan, Zora; Lin, Chin-Yu; O'Neill, Vincent; Amler, Lukas C.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">24, Pt. 1</span>),
    <span class="NLM_cas:pages">8686-8698</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Significant improvements in the outcome of non-small cell lung carcinoma (NSCLC) have been reported in patients treated with the epidermal growth factor receptor (EGFR) inhibitor, erlotinib.  To discover biomarkers for the enrichment of patients who might benefit from treatment, a pharmacogenomic approach was used to identify gene signatures that may predict erlotinib activity using in vitro model systems.  Erlotinib sensitivity in a panel of 42 NSCLC cell lines was detd. by EGFR-mediated proliferative potential, EGFR mutations, and/or EGFR gene amplification, thus supporting an underlying biol. mechanism of receptor activation.  A strong multigene signature indicative of an epithelial to mesenchymal transition (EMT) was identified as a determinant of insensitivity to erlotinib through both supervised and unsupervised gene expression approaches.  This observation was further supported by expression anal. of classic EMT marker proteins, including E-cadherin and vimentin.  To investigate the clin. relevance of these findings, we examd. expression of the epithelial marker E-cadherin by immunohistochem. on primary tumor samples from subjects enrolled in a randomized NSCLC clin. trial in which erlotinib in combination with chemotherapy previously failed to show clin. activity.  The majority (75%) of the 87 subjects tested showed strong E-cadherin staining and exhibited a significantly longer time to progression (hazard ratio, 0.37; log rank P = 0.0028) and a nonsignificant trend toward longer survival with erlotinib plus chemotherapy treatment vs. chemotherapy alone.  These data support a potential role for EMT as a determinant of EGFR activity in NSCLC tumor cells and E-cadherin expression as a novel biomarker predicting clin. activity of the EGFR inhibitor erlotinib in NSCLC patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTIfhC1v9MRLVg90H21EOLACvtfcHk0ljvjE0A2VJakw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlWrsb3L&md5=4e7ccd618d4ff5134b5532224237e8d0</span></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-1492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-1492%26sid%3Dliteratum%253Aachs%26aulast%3DYauch%26aufirst%3DR.%2BL.%26aulast%3DJanuario%26aufirst%3DT.%26aulast%3DEberhard%26aufirst%3DD.%2BA.%26aulast%3DCavet%26aufirst%3DG.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DFu%26aufirst%3DL.%26aulast%3DPham%26aufirst%3DT.%2BQ.%26aulast%3DSoriano%26aufirst%3DR.%26aulast%3DStinson%26aufirst%3DJ.%26aulast%3DSeshagiri%26aufirst%3DS.%26aulast%3DModrusan%26aufirst%3DZ.%26aulast%3DLin%26aufirst%3DC.%2BY.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DV.%26aulast%3DAmler%26aufirst%3DL.%2BC.%26atitle%3DEpithelial%2520versus%2520mesenchymal%2520phenotype%2520determines%2520in%2520vitro%2520sensitivity%2520and%2520predicts%2520clinical%2520activity%2520of%2520erlotinib%2520in%2520lung%2520cancer%2520patients%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D8686%26epage%3D8698%26doi%3D10.1158%2F1078-0432.CCR-05-1492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit21b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kim, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rho, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. C.</span><span> </span><span class="NLM_article-title">Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation</span> <span class="citation_source-journal">Mol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1093</span><span class="NLM_x">–</span> <span class="NLM_lpage">1102</span><span class="refDoi"> DOI: 10.1016/j.molonc.2013.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1016%2Fj.molonc.2013.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=23993685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlyrtr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2013&pages=1093-1102&author=H.+R.+Kimauthor=W.+S.+Kimauthor=Y.+J.+Choiauthor=C.+M.+Choiauthor=J.+K.+Rhoauthor=J.+C.+Lee&title=Epithelial-mesenchymal+transition+leads+to+crizotinib+resistance+in+H2228+lung+cancer+cells+with+EML4-ALK+translocation&doi=10.1016%2Fj.molonc.2013.08.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21bR"><div class="casContent"><span class="casTitleNuber">21b</span><div class="casTitle"><span class="NLM_cas:atitle">Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation</span></div><div class="casAuthors">Kim, Hyeong Ryul; Kim, Woo Sung; Choi, Yun Jung; Choi, Chang Min; Rho, Jin Kyung; Lee, Jae Cheol</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1093-1102</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1574-7891</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Epithelial-mesenchymal transition (EMT) is assocd. with reduced sensitivity to many chemotherapeutic drugs, including EGFR tyrosine kinase inhibitors.  Here, we investigated if this reduced sensitivity also contributes to resistance to crizotinib, an ALK inhibitor of lung cancer that exhibits the EML4-ALK translocation.  We established a crizotinib-resistant subline (H2228/CR), which was derived from the parental H2228 cell line by long-term exposure to increasing concns. of crizotinib.  Characteristics assocd. with EMT, including morphol., EMT marker proteins, and cellular mobility, were analyzed.  Compared with H2228 cells, the growth of H2228/CR cells was independent of EML4-ALK, and H2228/CR cells showed cross-resistance to TAE-684 (a second-generation ALK inhibitor).  Phenotypic changes to the spindle-cell shape were noted in H2228/CR cells, which were accompanied by a decrease in E-cadherin and increase in vimentin and AXL.  In addn., H2228/CR cells showed increased secretion and expression of TGF-β1.  Invasion and migration capabilities were dramatically increased in H2228/CR cells.  Applying TGF-β1 treatment to parental H2228 cells for 72 h induced reversible EMT, leading to crizotinib resistance, but this was reversed by the removal of TGF-β1.  Suppression of vimentin in H2228/CR cells by siRNA treatment restored sensitivity to crizotinib.  Furthermore, these resistant cells remained highly sensitive to the Hsp90 inhibitors, similar to the parental H2228 cells.  In conclusion, we suggest EMT is possibly involved in acquired resistance to crizotinib, and that HSP90 inhibitors could be a promising option for the treatment of EMT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1f1A1JNCfobVg90H21EOLACvtfcHk0li6mat4imHX8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlyrtr7I&md5=c79e45e695141be621672bf47c663c7f</span></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=10.1016%2Fj.molonc.2013.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molonc.2013.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DH.%2BR.%26aulast%3DKim%26aufirst%3DW.%2BS.%26aulast%3DChoi%26aufirst%3DY.%2BJ.%26aulast%3DChoi%26aufirst%3DC.%2BM.%26aulast%3DRho%26aufirst%3DJ.%2BK.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26atitle%3DEpithelial-mesenchymal%2520transition%2520leads%2520to%2520crizotinib%2520resistance%2520in%2520H2228%2520lung%2520cancer%2520cells%2520with%2520EML4-ALK%2520translocation%26jtitle%3DMol.%2520Oncol.%26date%3D2013%26volume%3D7%26spage%3D1093%26epage%3D1102%26doi%3D10.1016%2Fj.molonc.2013.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Byers, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saintigny, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girard, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peyton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giri, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tumula, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilsson, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gudikote, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cardnell, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bearss, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warner, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foulks, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanner, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krett, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herbst, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenschein, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippman, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ang, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinstein, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wistuba,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coombes, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minna, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heymach, J. V.</span><span> </span><span class="NLM_article-title">An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">279</span><span class="NLM_x">–</span> <span class="NLM_lpage">290</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-1558</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1158%2F1078-0432.CCR-12-1558" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=23091115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktFGlsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=279-290&author=L.+A.+Byersauthor=L.+Diaoauthor=J.+Wangauthor=P.+Saintignyauthor=L.+Girardauthor=M.+Peytonauthor=L.+Shenauthor=Y.+Fanauthor=U.+Giriauthor=P.+K.+Tumulaauthor=M.+B.+Nilssonauthor=J.+Gudikoteauthor=H.+Tranauthor=R.+J.+Cardnellauthor=D.+J.+Bearssauthor=S.+L.+Warnerauthor=J.+M.+Foulksauthor=S.+B.+Kannerauthor=V.+Gandhiauthor=N.+Krettauthor=S.+T.+Rosenauthor=E.+S.+Kimauthor=R.+S.+Herbstauthor=G.+R.+Blumenscheinauthor=J.+J.+Leeauthor=S.+M.+Lippmanauthor=K.+K.+Angauthor=G.+B.+Millsauthor=W.+K.+Hongauthor=J.+N.+Weinsteinauthor=+Wistubaauthor=K.+R.+Coombesauthor=J.+D.+Minnaauthor=J.+V.+Heymach&title=An+epithelial-mesenchymal+transition+gene+signature+predicts+resistance+to+EGFR+and+PI3K+inhibitors+and+identifies+Axl+as+a+therapeutic+target+for+overcoming+EGFR+inhibitor+resistance&doi=10.1158%2F1078-0432.CCR-12-1558"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22aR"><div class="casContent"><span class="casTitleNuber">22a</span><div class="casTitle"><span class="NLM_cas:atitle">An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance</span></div><div class="casAuthors">Byers, Lauren Averett; Diao, Lixia; Wang, Jing; Saintigny, Pierre; Girard, Luc; Peyton, Michael; Shen, Li; Fan, Youhong; Giri, Uma; Tumula, Praveen K.; Nilsson, Monique B.; Gudikote, Jayanthi; Tran, Hai; Cardnell, Robert J. G.; Bearss, David J.; Warner, Steven L.; Foulks, Jason M.; Kanner, Steven B.; Gandhi, Varsha; Krett, Nancy; Rosen, Steven T.; Kim, Edward S.; Herbst, Roy S.; Blumenschein, George R.; Lee, J. Jack; Lippman, Scott M.; Ang, K. Kian; Mills, Gordon B.; Hong, Waun K.; Weinstein, John N.; Wistuba, Ignacio I.; Coombes, Kevin R.; Minna, John D.; Heymach, John V.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">279-290</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Epithelial-mesenchymal transition (EMT) has been assocd. with metastatic spread and EGF receptor (EGFR) inhibitor resistance.  We developed and validated a robust 76-gene EMT signature using gene expression profiles from four platforms using non-small cell lung carcinoma (NSCLC) cell lines and patients treated in the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) study.  Exptl. Design: We conducted an integrated gene expression, proteomic, and drug response anal. using cell lines and tumors from patients with NSCLC.  A 76-gene EMT signature was developed and validated using gene expression profiles from four microarray platforms of NSCLC cell lines and patients treated in the BATTLE study, and potential therapeutic targets assocd. with EMT were identified.  Results: Compared with epithelial cells, mesenchymal cells showed significantly greater resistance to EGFR and PI3K/Akt pathway inhibitors, independent of EGFR mutation status, but more sensitivity to certain chemotherapies.  Mesenchymal cells also expressed increased levels of the receptor tyrosine kinase Axl and showed a trend toward greater sensitivity to the Axl inhibitor SGI-7079, whereas the combination of SGI-7079 with erlotinib reversed erlotinib resistance in mesenchymal lines expressing Axl and in a xenograft model of mesenchymal NSCLC.  In patients with NSCLC, the EMT signature predicted 8-wk disease control in patients receiving erlotinib but not other therapies.  Conclusion: We have developed a robust EMT signature that predicts resistance to EGFR and PI3K/Akt inhibitors, highlights different patterns of drug responsiveness for epithelial and mesenchymal cells, and identifies Axl as a potential therapeutic target for overcoming EGFR inhibitor resistance assocd. with the mesenchymal phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwav-PXLuwi7Vg90H21EOLACvtfcHk0li6mat4imHX8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktFGlsg%253D%253D&md5=d02e08e505b8487a48874abdb8a553a9</span></div><a href="/servlet/linkout?suffix=cit22a&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-1558&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-1558%26sid%3Dliteratum%253Aachs%26aulast%3DByers%26aufirst%3DL.%2BA.%26aulast%3DDiao%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DSaintigny%26aufirst%3DP.%26aulast%3DGirard%26aufirst%3DL.%26aulast%3DPeyton%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DL.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DGiri%26aufirst%3DU.%26aulast%3DTumula%26aufirst%3DP.%2BK.%26aulast%3DNilsson%26aufirst%3DM.%2BB.%26aulast%3DGudikote%26aufirst%3DJ.%26aulast%3DTran%26aufirst%3DH.%26aulast%3DCardnell%26aufirst%3DR.%2BJ.%26aulast%3DBearss%26aufirst%3DD.%2BJ.%26aulast%3DWarner%26aufirst%3DS.%2BL.%26aulast%3DFoulks%26aufirst%3DJ.%2BM.%26aulast%3DKanner%26aufirst%3DS.%2BB.%26aulast%3DGandhi%26aufirst%3DV.%26aulast%3DKrett%26aufirst%3DN.%26aulast%3DRosen%26aufirst%3DS.%2BT.%26aulast%3DKim%26aufirst%3DE.%2BS.%26aulast%3DHerbst%26aufirst%3DR.%2BS.%26aulast%3DBlumenschein%26aufirst%3DG.%2BR.%26aulast%3DLee%26aufirst%3DJ.%2BJ.%26aulast%3DLippman%26aufirst%3DS.%2BM.%26aulast%3DAng%26aufirst%3DK.%2BK.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DHong%26aufirst%3DW.%2BK.%26aulast%3DWeinstein%26aufirst%3DJ.%2BN.%26aulast%3DWistuba%26aulast%3DCoombes%26aufirst%3DK.%2BR.%26aulast%3DMinna%26aufirst%3DJ.%2BD.%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26atitle%3DAn%2520epithelial-mesenchymal%2520transition%2520gene%2520signature%2520predicts%2520resistance%2520to%2520EGFR%2520and%2520PI3K%2520inhibitors%2520and%2520identifies%2520Axl%2520as%2520a%2520therapeutic%2520target%2520for%2520overcoming%2520EGFR%2520inhibitor%2520resistance%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D279%26epage%3D290%26doi%3D10.1158%2F1078-0432.CCR-12-1558" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit22b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Postel-Vinay, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span> </span><span class="NLM_article-title">AXL and acquired resistance to EGFR inhibitors</span> <span class="citation_source-journal">Nat. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">835</span><span class="NLM_x">–</span> <span class="NLM_lpage">836</span><span class="refDoi"> DOI: 10.1038/ng.2362</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1038%2Fng.2362" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=22836088" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFWmsL%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2012&pages=835-836&author=S.+Postel-Vinayauthor=A.+Ashworth&title=AXL+and+acquired+resistance+to+EGFR+inhibitors&doi=10.1038%2Fng.2362"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22bR"><div class="casContent"><span class="casTitleNuber">22b</span><div class="casTitle"><span class="NLM_cas:atitle">AXL and acquired resistance to EGFR inhibitors</span></div><div class="casAuthors">Postel-Vinay, Sophie; Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">835-836</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  A combination of in vitro and in vivo models with validation in human tumors has identified AXL activation as a new mechanism of acquired resistance to EGFR inhibitors in non-small cell lung cancer.  The identification of this mechanism, alongside the current development of specific AXL inhibitors, provides the rationale for further studies that may improve treatment for EGFR inhibitor-resistant patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoc3zpckF89Q7Vg90H21EOLACvtfcHk0li-4eVLLbqeyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFWmsL%252FP&md5=63ae162ebb7795299e4914de0e9af6de</span></div><a href="/servlet/linkout?suffix=cit22b&amp;dbid=16384&amp;doi=10.1038%2Fng.2362&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.2362%26sid%3Dliteratum%253Aachs%26aulast%3DPostel-Vinay%26aufirst%3DS.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DAXL%2520and%2520acquired%2520resistance%2520to%2520EGFR%2520inhibitors%26jtitle%3DNat.%2520Genet.%26date%3D2012%26volume%3D44%26spage%3D835%26epage%3D836%26doi%3D10.1038%2Fng.2362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit22c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Rho, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoon, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bae, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. C.</span><span> </span><span class="NLM_article-title">MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">253</span><span class="NLM_x">–</span> <span class="NLM_lpage">262</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-13-1103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1158%2F0008-5472.CAN-13-1103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=24165158" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC2cXislKjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=253-262&author=J.+K.+Rhoauthor=Y.+J.+Choiauthor=S.+Y.+Kimauthor=T.+W.+Kimauthor=E.+K.+Choiauthor=S.+J.+Yoonauthor=B.+M.+Parkauthor=E.+Parkauthor=J.+H.+Baeauthor=C.+M.+Choiauthor=J.+C.+Lee&title=MET+and+AXL+inhibitor+NPS-1034+exerts+efficacy+against+lung+cancer+cells+resistant+to+EGFR+kinase+inhibitors+because+of+MET+or+AXL+activation&doi=10.1158%2F0008-5472.CAN-13-1103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22cR"><div class="casContent"><span class="casTitleNuber">22c</span><div class="casTitle"><span class="NLM_cas:atitle">MET and AXL Inhibitor NPS-1034 Exerts Efficacy against Lung Cancer Cells Resistant to EGFR Kinase Inhibitors Because of MET or AXL Activation</span></div><div class="casAuthors">Rho, Jin Kyung; Choi, Yun Jung; Kim, Seon Ye; Kim, Tae Won; Choi, Eun Kyung; Yoon, Seon-Joo; Park, Bu Man; Park, Eunhye; Bae, Jong Hwan; Choi, Chang-Min; Lee, Jae Cheol</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">253-262</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">In non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations, acquired resistance to EGFR-tyrosine kinase inhibitors (EGFR-TK1) can occur through a generation of bypass signals such as MET or AXL activation.  In this study, we investigated the antitumor activity of NPS-1034, a newly developed drug that targets both MET and AXL, in NSCLC cells with acquired resistance to gefitinib or erlotinib (HCC827/GR and HCC827/ER, resp.).  Characterization of H820 cells and evaluation of NPS-1034 efficacy in these cells were also performed.  The resistance of HCC827/GR was mediated by MET activation, whereas AXL activation led to resistance in HCC827/ER.  The combination of gefitinib or erlotinib with NPS-1034 synergistically inhibited cell proliferation and induced cell death in both resistant cell lines.  Accordingly, suppression of Akt was noted only in the presence of treatment with both drugs.  NPS-1034 was also effective in xenograft mouse models of HCC827/GR.  Although the H820 cell line was reported previously to have T790M and MET amplification, we discovered that AXL was also activated in this cell line.  There were no antitumor effects of siRNA or inhibitors specific for EGFR or MET, whereas combined treatment with AXL siRNA or NPS-1034 and EGFR-TKIs controlled H820 cells, suggesting that AXL is the main signal responsible for resistance.  In addn., NPS-1034 inhibited cell proliferation as well as ROS1 activity in HCC78 cells with ROS1 rearrangement.  Our results establish the efficacy of NPS-1034 in NSCLC cells rendered resistant to EGFR-TKIs because of MET or AXL activation or ROS1 rearrangement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzVRl7xbUBLrVg90H21EOLACvtfcHk0li-4eVLLbqeyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXislKjtA%253D%253D&md5=35929f2dcfd5d1502ba745f367dccd27</span></div><a href="/servlet/linkout?suffix=cit22c&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-13-1103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-13-1103%26sid%3Dliteratum%253Aachs%26aulast%3DRho%26aufirst%3DJ.%2BK.%26aulast%3DChoi%26aufirst%3DY.%2BJ.%26aulast%3DKim%26aufirst%3DS.%2BY.%26aulast%3DKim%26aufirst%3DT.%2BW.%26aulast%3DChoi%26aufirst%3DE.%2BK.%26aulast%3DYoon%26aufirst%3DS.%2BJ.%26aulast%3DPark%26aufirst%3DB.%2BM.%26aulast%3DPark%26aufirst%3DE.%26aulast%3DBae%26aufirst%3DJ.%2BH.%26aulast%3DChoi%26aufirst%3DC.%2BM.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26atitle%3DMET%2520and%2520AXL%2520inhibitor%2520NPS-1034%2520exerts%2520efficacy%2520against%2520lung%2520cancer%2520cells%2520resistant%2520to%2520EGFR%2520kinase%2520inhibitors%2520because%2520of%2520MET%2520or%2520AXL%2520activation%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D253%26epage%3D262%26doi%3D10.1158%2F0008-5472.CAN-13-1103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit22d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Brand, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iida, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corrigan, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braverman, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luthar, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toulany, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gill, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimple, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wheeler, D. L.</span><span> </span><span class="NLM_article-title">AXL mediates resistance to cetuximab therapy</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">5152</span><span class="NLM_x">–</span> <span class="NLM_lpage">5164</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-14-0294</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1158%2F0008-5472.CAN-14-0294" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=5152-5164&author=T.+M.+Brandauthor=M.+Iidaauthor=A.+P.+Steinauthor=K.+L.+Corriganauthor=C.+M.+Bravermanauthor=N.+Lutharauthor=M.+Toulanyauthor=P.+S.+Gillauthor=R.+Salgiaauthor=R.+J.+Kimpleauthor=D.+L.+Wheeler&title=AXL+mediates+resistance+to+cetuximab+therapy&doi=10.1158%2F0008-5472.CAN-14-0294"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22d&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-0294&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-0294%26sid%3Dliteratum%253Aachs%26aulast%3DBrand%26aufirst%3DT.%2BM.%26aulast%3DIida%26aufirst%3DM.%26aulast%3DStein%26aufirst%3DA.%2BP.%26aulast%3DCorrigan%26aufirst%3DK.%2BL.%26aulast%3DBraverman%26aufirst%3DC.%2BM.%26aulast%3DLuthar%26aufirst%3DN.%26aulast%3DToulany%26aufirst%3DM.%26aulast%3DGill%26aufirst%3DP.%2BS.%26aulast%3DSalgia%26aufirst%3DR.%26aulast%3DKimple%26aufirst%3DR.%2BJ.%26aulast%3DWheeler%26aufirst%3DD.%2BL.%26atitle%3DAXL%2520mediates%2520resistance%2520to%2520cetuximab%2520therapy%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D5152%26epage%3D5164%26doi%3D10.1158%2F0008-5472.CAN-14-0294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit22e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Wilson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pham, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neve, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belmont, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koeppen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yauch, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashkenazi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">AXL inhibition sensitizes mesenchymal cancer cells to antimitotic drugs</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">5878</span><span class="NLM_x">–</span> <span class="NLM_lpage">5890</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-14-1009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1158%2F0008-5472.CAN-14-1009" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=5878-5890&author=C.+Wilsonauthor=X.+Yeauthor=T.+Phamauthor=E.+Linauthor=S.+Chanauthor=E.+McNamaraauthor=R.+M.+Neveauthor=L.+Belmontauthor=H.+Koeppenauthor=R.+L.+Yauchauthor=A.+Ashkenaziauthor=J.+Settleman&title=AXL+inhibition+sensitizes+mesenchymal+cancer+cells+to+antimitotic+drugs&doi=10.1158%2F0008-5472.CAN-14-1009"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22e&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-1009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-1009%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DC.%26aulast%3DYe%26aufirst%3DX.%26aulast%3DPham%26aufirst%3DT.%26aulast%3DLin%26aufirst%3DE.%26aulast%3DChan%26aufirst%3DS.%26aulast%3DMcNamara%26aufirst%3DE.%26aulast%3DNeve%26aufirst%3DR.%2BM.%26aulast%3DBelmont%26aufirst%3DL.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DYauch%26aufirst%3DR.%2BL.%26aulast%3DAshkenazi%26aufirst%3DA.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DAXL%2520inhibition%2520sensitizes%2520mesenchymal%2520cancer%2520cells%2520to%2520antimitotic%2520drugs%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D5878%26epage%3D5890%26doi%3D10.1158%2F0008-5472.CAN-14-1009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit22f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Bansal, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mishra, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiPaola, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertino, J. R.</span><span> </span><span class="NLM_article-title">Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">15321</span><span class="NLM_x">–</span> <span class="NLM_lpage">15331</span><span class="refDoi"> DOI: 10.18632/oncotarget.4148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.18632%2Foncotarget.4148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=26036314" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A280%3ADC%252BC2MfpslWgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=15321-15331&author=N.+Bansalauthor=P.+J.+Mishraauthor=M.+Steinauthor=R.+S.+DiPaolaauthor=J.+R.+Bertino&title=Axl+receptor+tyrosine+kinase+is+up-regulated+in+metformin+resistant+prostate+cancer+cells&doi=10.18632%2Foncotarget.4148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22fR"><div class="casContent"><span class="casTitleNuber">22f</span><div class="casTitle"><span class="NLM_cas:atitle">Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells</span></div><div class="casAuthors">Bansal Nitu; Stein Mark; DiPaola Robert S; Bertino Joseph R; Mishra Prasun J</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">15321-31</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Recent epidemiological studies showed that metformin, a widely used anti-diabetic drug might prevent certain cancers.  Metformin also has an anti-proliferative effect in preclinical studies of both hematologic malignancies as well as solid cancers and clinical studies testing metformin as an anti-cancer drug are in progress.  However, all cancer types do not respond to metformin with the same effectiveness or acquire resistance.  To understand the mechanism of acquired resistance and possibly its mechanism of action as an anti-proliferative agent, we developed metformin resistant LNCaP prostate cancer cells.  Metformin resistant LNCaP cells had an increased proliferation rate, increased migration and invasion ability as compared to the parental cells, and expressed markers of epithelial-mesenchymal transition (EMT).  A detailed gene expression microarray comparing the resistant cells to the wild type cells revealed that Edil2, Ereg, Axl, Anax2, CD44 and Anax3 were the top up-regulated genes and calbindin 2 and TPTE (transmembrane phosphatase with tensin homology) and IGF1R were down regulated.  We focused on Axl, a receptor tyrosine kinase that has been shown to be up regulated in several drug resistance cancers.  Here, we show that the metformin resistant cell line as well as castrate resistant cell lines that over express Axl were more resistant to metformin, as well as to taxotere compared to androgen sensitive LNCaP and CWR22 cells that do not overexpress Axl.  Forced overexpression of Axl in LNCaP cells decreased metformin and taxotere sensitivity and knockdown of Axl in resistant cells increased sensitivity to these drugs.  Inhibition of Axl activity by R428, a small molecule Axl kinase inhibitor, sensitized metformin resistant cells that overexpressed Axl to metformin.  Inhibitors of Axl may enhance tumor responses to metformin and other chemotherapy in cancers that over express Axl.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTzxVEroSz9hdj_Vg2vObihfW6udTcc2ebsPnKIdwQ1Vrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MfpslWgtQ%253D%253D&md5=6dea3f587be6fb98b50e817d3735e7ef</span></div><a href="/servlet/linkout?suffix=cit22f&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.4148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.4148%26sid%3Dliteratum%253Aachs%26aulast%3DBansal%26aufirst%3DN.%26aulast%3DMishra%26aufirst%3DP.%2BJ.%26aulast%3DStein%26aufirst%3DM.%26aulast%3DDiPaola%26aufirst%3DR.%2BS.%26aulast%3DBertino%26aufirst%3DJ.%2BR.%26atitle%3DAxl%2520receptor%2520tyrosine%2520kinase%2520is%2520up-regulated%2520in%2520metformin%2520resistant%2520prostate%2520cancer%2520cells%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D15321%26epage%3D15331%26doi%3D10.18632%2Foncotarget.4148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit22g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Meyer, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gertler, F. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lauffenburger, D. A.</span><span> </span><span class="NLM_article-title">The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells</span> <span class="citation_source-journal">Sci. Signaling</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">296</span><span class="NLM_x">–</span> <span class="NLM_lpage">302</span><span class="refDoi"> DOI: 10.1126/scisignal.2004155</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1126%2Fscisignal.2004155" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=296-302&author=A.+S.+Meyerauthor=M.+A.+Millerauthor=F.+B.+Gertlerauthor=D.+A.+Lauffenburger&title=The+receptor+AXL+diversifies+EGFR+signaling+and+limits+the+response+to+EGFR-targeted+inhibitors+in+triple-negative+breast+cancer+cells&doi=10.1126%2Fscisignal.2004155"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22g&amp;dbid=16384&amp;doi=10.1126%2Fscisignal.2004155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscisignal.2004155%26sid%3Dliteratum%253Aachs%26aulast%3DMeyer%26aufirst%3DA.%2BS.%26aulast%3DMiller%26aufirst%3DM.%2BA.%26aulast%3DGertler%26aufirst%3DF.%2BB.%26aulast%3DLauffenburger%26aufirst%3DD.%2BA.%26atitle%3DThe%2520receptor%2520AXL%2520diversifies%2520EGFR%2520signaling%2520and%2520limits%2520the%2520response%2520to%2520EGFR-targeted%2520inhibitors%2520in%2520triple-negative%2520breast%2520cancer%2520cells%26jtitle%3DSci.%2520Signaling%26date%3D2013%26volume%3D6%26spage%3D296%26epage%3D302%26doi%3D10.1126%2Fscisignal.2004155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit22h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivas, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Au, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaFramboise, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abdel-Rahman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levine, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rho, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jang, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arcila, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladanyi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moonsamy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taron, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bivona, T. G.</span><span> </span><span class="NLM_article-title">Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer</span> <span class="citation_source-journal">Nat. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">852</span><span class="NLM_x">–</span> <span class="NLM_lpage">860</span><span class="refDoi"> DOI: 10.1038/ng.2330</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22h&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1038%2Fng.2330" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22h&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=22751098" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22h&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsVWit7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2012&pages=852-860&author=Z.+Zhangauthor=J.+C.+Leeauthor=L.+Linauthor=V.+Olivasauthor=V.+Auauthor=T.+LaFramboiseauthor=M.+Abdel-Rahmanauthor=X.+Wangauthor=A.+D.+Levineauthor=J.+K.+Rhoauthor=Y.+J.+Choiauthor=C.+M.+Choiauthor=S.+W.+Kimauthor=S.+J.+Jangauthor=Y.+S.+Parkauthor=W.+S.+Kimauthor=D.+H.+Leeauthor=J.+S.+Leeauthor=V.+A.+Millerauthor=M.+Arcilaauthor=M.+Ladanyiauthor=P.+Moonsamyauthor=C.+Sawyersauthor=T.+J.+Boggonauthor=P.+C.+Maauthor=C.+Costaauthor=M.+Taronauthor=R.+Rosellauthor=B.+Halmosauthor=T.+G.+Bivona&title=Activation+of+the+AXL+kinase+causes+resistance+to+EGFR-targeted+therapy+in+lung+cancer&doi=10.1038%2Fng.2330"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22hR"><div class="casContent"><span class="casTitleNuber">22h</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer</span></div><div class="casAuthors">Zhang, Zhenfeng; Lee, Jae Cheol; Lin, Luping; Olivas, Victor; Au, Valerie; LaFramboise, Thomas; Abdel-Rahman, Mohamed; Wang, Xiaoqi; Levine, Alan D.; Rho, Jin Kyung; Choi, Yun Jung; Choi, Chang-Min; Kim, Sang-We; Jang, Se Jin; Park, Young Soo; Kim, Woo Sung; Lee, Dae Ho; Lee, Jung-Shin; Miller, Vincent A.; Arcila, Maria; Ladanyi, Marc; Moonsamy, Philicia; Sawyers, Charles; Boggon, Titus J.; Ma, Patrick C.; Costa, Carlota; Taron, Miquel; Rosell, Rafael; Halmos, Balazs; Bivona, Trever G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">852-860</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Human non-small cell lung cancers (NSCLCs) with activating mutations in EGFR frequently respond to treatment with EGFR-targeted tyrosine kinase inhibitors (TKIs), such as erlotinib, but responses are not durable, as tumors acquire resistance.  Secondary mutations in EGFR (such as T790M) or upregulation of the MET kinase are found in over 50% of resistant tumors.  Here, we report increased activation of AXL and evidence for epithelial-to-mesenchymal transition (EMT) in multiple in vitro and in vivo EGFR-mutant lung cancer models with acquired resistance to erlotinib in the absence of the EGFR p.  Thr790Met alteration or MET activation.  Genetic or pharmacol. inhibition of AXL restored sensitivity to erlotinib in these tumor models.  Increased expression of AXL and, in some cases, of its ligand GAS6 was found in EGFR-mutant lung cancers obtained from individuals with acquired resistance to TKIs.  These data identify AXL as a promising therapeutic target whose inhibition could prevent or overcome acquired resistance to EGFR TKIs in individuals with EGFR-mutant lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGothnhyjpkwaLVg90H21EOLACvtfcHk0lj8IfVV0DgQ4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsVWit7s%253D&md5=f186a5b9ad4bfdbe12f68ef93d2da254</span></div><a href="/servlet/linkout?suffix=cit22h&amp;dbid=16384&amp;doi=10.1038%2Fng.2330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.2330%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DLin%26aufirst%3DL.%26aulast%3DOlivas%26aufirst%3DV.%26aulast%3DAu%26aufirst%3DV.%26aulast%3DLaFramboise%26aufirst%3DT.%26aulast%3DAbdel-Rahman%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DLevine%26aufirst%3DA.%2BD.%26aulast%3DRho%26aufirst%3DJ.%2BK.%26aulast%3DChoi%26aufirst%3DY.%2BJ.%26aulast%3DChoi%26aufirst%3DC.%2BM.%26aulast%3DKim%26aufirst%3DS.%2BW.%26aulast%3DJang%26aufirst%3DS.%2BJ.%26aulast%3DPark%26aufirst%3DY.%2BS.%26aulast%3DKim%26aufirst%3DW.%2BS.%26aulast%3DLee%26aufirst%3DD.%2BH.%26aulast%3DLee%26aufirst%3DJ.%2BS.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DArcila%26aufirst%3DM.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DMoonsamy%26aufirst%3DP.%26aulast%3DSawyers%26aufirst%3DC.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DMa%26aufirst%3DP.%2BC.%26aulast%3DCosta%26aufirst%3DC.%26aulast%3DTaron%26aufirst%3DM.%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DHalmos%26aufirst%3DB.%26aulast%3DBivona%26aufirst%3DT.%2BG.%26atitle%3DActivation%2520of%2520the%2520AXL%2520kinase%2520causes%2520resistance%2520to%2520EGFR-targeted%2520therapy%2520in%2520lung%2520cancer%26jtitle%3DNat.%2520Genet.%26date%3D2012%26volume%3D44%26spage%3D852%26epage%3D860%26doi%3D10.1038%2Fng.2330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greshock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Annan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halsey, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sathe, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmer, T. M.</span><span> </span><span class="NLM_article-title">Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">6871</span><span class="NLM_x">–</span> <span class="NLM_lpage">6878</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-08-4490</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1158%2F0008-5472.CAN-08-4490" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=6871-6878&author=L.+Liuauthor=J.+Gregerauthor=H.+Shiauthor=Y.+Liuauthor=J.+Greshockauthor=R.+Annanauthor=W.+Halseyauthor=G.+M.+Satheauthor=A.+M.+Martinauthor=T.+M.+Gilmer&title=Novel+mechanism+of+lapatinib+resistance+in+HER2-positive+breast+tumor+cells%3A+activation+of+AXL&doi=10.1158%2F0008-5472.CAN-08-4490"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-4490&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-4490%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DGreger%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGreshock%26aufirst%3DJ.%26aulast%3DAnnan%26aufirst%3DR.%26aulast%3DHalsey%26aufirst%3DW.%26aulast%3DSathe%26aufirst%3DG.%2BM.%26aulast%3DMartin%26aufirst%3DA.%2BM.%26aulast%3DGilmer%26aufirst%3DT.%2BM.%26atitle%3DNovel%2520mechanism%2520of%2520lapatinib%2520resistance%2520in%2520HER2-positive%2520breast%2520tumor%2520cells%253A%2520activation%2520of%2520AXL%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D6871%26epage%3D6878%26doi%3D10.1158%2F0008-5472.CAN-08-4490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hart, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Boer, R. H.</span><span> </span><span class="NLM_article-title">Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer</span> <span class="citation_source-journal">OncoTargets Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">7</span><span class="refDoi"> DOI: 10.2147/OTT.S27671</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.2147%2FOTT.S27671" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=23319867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVOqtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=1-7&author=C.+D.+Hartauthor=R.+H.+De+Boer&title=Profile+of+cabozantinib+and+its+potential+in+the+treatment+of+advanced+medullary+thyroid+cancer&doi=10.2147%2FOTT.S27671"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24aR"><div class="casContent"><span class="casTitleNuber">24a</span><div class="casTitle"><span class="NLM_cas:atitle">Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer</span></div><div class="casAuthors">Hart, Christopher D.; De Boer, Richard H.</div><div class="citationInfo"><span class="NLM_cas:title">OncoTargets and Therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-7</span>CODEN:
                <span class="NLM_cas:coden">OTNHAZ</span>;
        ISSN:<span class="NLM_cas:issn">1178-6930</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Medullary thyroid cancer is an uncommon malignancy for which until recently little effective treatment existed.  It is often characterized by mutation and overexpression of the receptor tyrosine kinases RET (rearranged during transfection), VEGFR2 (vascular endothelial growth factor receptor 2) and MET (mesenchymal-epithelial transition factor), which make attractive targets for drug development.  Cabozantinib is an orally bioavailable tyrosine kinase inhibitor which blocks MET, VEGRF2 and RET, and has shown considerable activity in medullary thyroid cancer in a Phase III trial, including in heavily pretreated patients.  Its novel combination of vascular endothelial growth factor and MET inhibition is believed to address the MET escape pathway, which is thought to be the cause of nonsustained tumor responses resulting from inhibition of vascular endothelial growth factor alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcdeH_ML0s97Vg90H21EOLACvtfcHk0lj8IfVV0DgQ4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVOqtr4%253D&md5=048635660f5262d406ec13baef91bc78</span></div><a href="/servlet/linkout?suffix=cit24a&amp;dbid=16384&amp;doi=10.2147%2FOTT.S27671&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FOTT.S27671%26sid%3Dliteratum%253Aachs%26aulast%3DHart%26aufirst%3DC.%2BD.%26aulast%3DDe%2BBoer%26aufirst%3DR.%2BH.%26atitle%3DProfile%2520of%2520cabozantinib%2520and%2520its%2520potential%2520in%2520the%2520treatment%2520of%2520advanced%2520medullary%2520thyroid%2520cancer%26jtitle%3DOncoTargets%2520Ther.%26date%3D2013%26volume%3D6%26spage%3D1%26epage%3D7%26doi%3D10.2147%2FOTT.S27671" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit24b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Choueiri, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Escudier, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powles, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mainwaring, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rini, B. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donskov, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammers, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutson, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peltola, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bjarnason, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geczi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keam, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maroto, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heng, D. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidinger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantoff, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borgman-Hagey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hessel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheffold, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwab, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tannir, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Motzer, R. J.</span><span> </span><span class="NLM_article-title">Cabozantinib versus everolimus in advanced renal-cell carcinoma</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">373</span><span class="NLM_x">, </span> <span class="NLM_fpage">1814</span><span class="NLM_x">–</span> <span class="NLM_lpage">1823</span><span class="refDoi"> DOI: 10.1056/NEJMoa1510016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1056%2FNEJMoa1510016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=26406150" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC28XnvFCktLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=1814-1823&author=T.+K.+Choueiriauthor=B.+Escudierauthor=T.+Powlesauthor=P.+N.+Mainwaringauthor=B.+I.+Riniauthor=F.+Donskovauthor=H.+Hammersauthor=T.+E.+Hutsonauthor=J.+L.+Leeauthor=K.+Peltolaauthor=B.+J.+Rothauthor=G.+A.+Bjarnasonauthor=L.+Gecziauthor=B.+Keamauthor=P.+Marotoauthor=D.+Y.+Hengauthor=M.+Schmidingerauthor=P.+W.+Kantoffauthor=A.+Borgman-Hageyauthor=C.+Hesselauthor=C.+Scheffoldauthor=G.+M.+Schwabauthor=N.+M.+Tannirauthor=R.+J.+Motzer&title=Cabozantinib+versus+everolimus+in+advanced+renal-cell+carcinoma&doi=10.1056%2FNEJMoa1510016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24bR"><div class="casContent"><span class="casTitleNuber">24b</span><div class="casTitle"><span class="NLM_cas:atitle">Cabozantinib versus everolimus in advanced renal-cell carcinoma</span></div><div class="casAuthors">Choueiri, T. K.; Escudier, B.; Powles, T.; Mainwaring, P. N.; Rini, B. I.; Donskov, F.; Hammers, H.; Hutson, T. E.; Lee, J.-L.; Peltola, K.; Roth, B. J.; Bjarnason, G. A.; Geczi, L.; Keam, B.; Maroto, P.; Heng, D. Y. C.; Schmidinger, M.; Kantoff, P. W.; Borgman-Hagey, A.; Hessel, C.; Scheffold, C.; Schwab, G. M.; Tannir, N. M.; Motzer, R. J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1814-1823</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Cabozantinib is an oral, small-mol. tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR) as well as MET and AXL, each of which has been implicated in the pathobiol. of metastatic renal-cell carcinoma or in the development of resistance to antiangiogenic drugs.  This randomized, open-label, phase 3 trial evaluated the efficacy of cabozantinib, as compared with everolimus, in patients with renal-cell carcinoma that had progressed after VEGFR-targeted therapy.  We randomly assigned 658 patients to receive cabozantinib at a dose of 60 mg daily or everolimus at a dose of 10 mg daily.  The primary end point was progression- free survival.  Secondary efficacy end points were overall survival and objective response rate.  Median progression-free survival was 7.4 mo with cabozantinib and 3.8 mo with everolimus.  The rate of progression or death was 42% lower with cabozantinib than with everolimus (hazard ratio, 0.58; 95% confidence interval [CI] 0.45 to 0.75; P<0.001).  The objective response rate was 21% with cabozantinib and 5% with everolimus (P<0.001).  A planned interim anal. showed that overall survival was longer with cabozantinib than with everolimus (hazard ratio for death, 0.67; 95% CI, 0.51 to 0.89; P = 0.005) but did not cross the significance boundary for the interim anal.  Adverse events were managed with dose redns.; doses were reduced in 60% of the patients who received cabozantinib and in 25% of those who received everolimus.  Discontinuation of study treatment owing to adverse events occurred in 9% of the patients who received cabozantinib and in 10% of those who received everolimus.  Progression-free survival was longer with cabozantinib than with everolimus among patients with renal-cell carcinoma that had progressed after VEGFR-targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobvjc8n5w4zbVg90H21EOLACvtfcHk0ljD-XROUR3PSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnvFCktLY%253D&md5=09927cde8f581f4ff2060679df1ff5b8</span></div><a href="/servlet/linkout?suffix=cit24b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1510016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1510016%26sid%3Dliteratum%253Aachs%26aulast%3DChoueiri%26aufirst%3DT.%2BK.%26aulast%3DEscudier%26aufirst%3DB.%26aulast%3DPowles%26aufirst%3DT.%26aulast%3DMainwaring%26aufirst%3DP.%2BN.%26aulast%3DRini%26aufirst%3DB.%2BI.%26aulast%3DDonskov%26aufirst%3DF.%26aulast%3DHammers%26aufirst%3DH.%26aulast%3DHutson%26aufirst%3DT.%2BE.%26aulast%3DLee%26aufirst%3DJ.%2BL.%26aulast%3DPeltola%26aufirst%3DK.%26aulast%3DRoth%26aufirst%3DB.%2BJ.%26aulast%3DBjarnason%26aufirst%3DG.%2BA.%26aulast%3DGeczi%26aufirst%3DL.%26aulast%3DKeam%26aufirst%3DB.%26aulast%3DMaroto%26aufirst%3DP.%26aulast%3DHeng%26aufirst%3DD.%2BY.%26aulast%3DSchmidinger%26aufirst%3DM.%26aulast%3DKantoff%26aufirst%3DP.%2BW.%26aulast%3DBorgman-Hagey%26aufirst%3DA.%26aulast%3DHessel%26aufirst%3DC.%26aulast%3DScheffold%26aufirst%3DC.%26aulast%3DSchwab%26aufirst%3DG.%2BM.%26aulast%3DTannir%26aufirst%3DN.%2BM.%26aulast%3DMotzer%26aufirst%3DR.%2BJ.%26atitle%3DCabozantinib%2520versus%2520everolimus%2520in%2520advanced%2520renal-cell%2520carcinoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26spage%3D1814%26epage%3D1823%26doi%3D10.1056%2FNEJMoa1510016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran-Dube, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pairish, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funk, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botrous, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grodsky, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padrique, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timofeevski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span> </span><span class="NLM_article-title">Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">6342</span><span class="NLM_x">–</span> <span class="NLM_lpage">6363</span><span class="refDoi"> DOI: 10.1021/jm2007613</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2007613" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6342-6363&author=J.+J.+Cuiauthor=M.+Tran-Dubeauthor=H.+Shenauthor=M.+Nambuauthor=P.+P.+Kungauthor=M.+Pairishauthor=L.+Jiaauthor=J.+Mengauthor=L.+Funkauthor=I.+Botrousauthor=M.+McTigueauthor=N.+Grodskyauthor=K.+Ryanauthor=E.+Padriqueauthor=G.+Altonauthor=S.+Timofeevskiauthor=S.+Yamazakiauthor=Q.+H.+Liauthor=H.+L.+Zouauthor=J.+Christensenauthor=B.+Mroczkowskiauthor=S.+Benderauthor=R.+S.+Kaniaauthor=M.+P.+Edwards&title=Structure+based+drug+design+of+crizotinib+%28PF-02341066%29%2C+a+potent+and+selective+dual+inhibitor+of+mesenchymal-epithelial+transition+factor+%28c-MET%29+kinase+and+anaplastic+lymphoma+kinase+%28ALK%29&doi=10.1021%2Fjm2007613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25aR"><div class="casContent"><span class="casTitleNuber">25a</span><div class="casTitle"><span class="NLM_cas:atitle">Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Cui, J. Jean; Tran-Dube, Michelle; Shen, Hong; Nambu, Mitchell; Kung, Pei-Pei; Pairish, Mason; Jia, Lei; Meng, Jerry; Funk, Lee; Botrous, Iriny; McTigue, Michele; Grodsky, Neil; Ryan, Kevin; Padrique, Ellen; Alton, Gordon; Timofeevski, Sergei; Yamazaki, Shinji; Li, Qiuhua; Zou, Helen; Christensen, James; Mroczkowski, Barbara; Bender, Steve; Kania, Robert S.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6342-6363</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Because of the crit. roles of aberrant signaling in cancer, both c-MET and ALK receptor tyrosine kinases are attractive oncol. targets for therapeutic intervention.  The cocrystal structure of 3 (PHA-665752), bound to c-MET kinase domain, revealed a novel ATP site environment, which served as the target to guide parallel, multiattribute drug design.  A novel 2-amino-5-aryl-3-benzyloxypyridine series was created to more effectively make the key interactions achieved with 3.  In the novel series, the 2-aminopyridine core allowed a 3-benzyloxy group to reach into the same pocket as the 2,6-dichlorophenyl group of 3 via a more direct vector and thus with a better ligand efficiency (LE).  Further optimization of the lead series generated the clin. candidate crizotinib (PF-02341066), which demonstrated potent in vitro and in vivo c-MET kinase and ALK inhibition, effective tumor growth inhibition, and good pharmaceutical properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHs_cKJ-U3t7Vg90H21EOLACvtfcHk0ljD-XROUR3PSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN&md5=dbab4c1b3e7c76180dbad04be2b6a474</span></div><a href="/servlet/linkout?suffix=cit25a&amp;dbid=16384&amp;doi=10.1021%2Fjm2007613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007613%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DTran-Dube%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DNambu%26aufirst%3DM.%26aulast%3DKung%26aufirst%3DP.%2BP.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DJ.%26aulast%3DFunk%26aufirst%3DL.%26aulast%3DBotrous%26aufirst%3DI.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DGrodsky%26aufirst%3DN.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DPadrique%26aufirst%3DE.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DQ.%2BH.%26aulast%3DZou%26aufirst%3DH.%2BL.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DStructure%2520based%2520drug%2520design%2520of%2520crizotinib%2520%2528PF-02341066%2529%252C%2520a%2520potent%2520and%2520selective%2520dual%2520inhibitor%2520of%2520mesenchymal-epithelial%2520transition%2520factor%2520%2528c-MET%2529%2520kinase%2520and%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6342%26epage%3D6363%26doi%3D10.1021%2Fjm2007613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit25b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arango, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonnell, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koudriakova, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Los, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span> </span><span class="NLM_article-title">An orally available small-molecule inhibitor of c-met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">4408</span><span class="NLM_x">–</span> <span class="NLM_lpage">4417</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-06-4443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1158%2F0008-5472.CAN-06-4443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=17483355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltVyrsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=4408-4417&author=H.+Y.+Zouauthor=Q.+H.+Liauthor=J.+H.+Leeauthor=M.+E.+Arangoauthor=S.+R.+McDonnellauthor=S.+Yamazakiauthor=T.+B.+Koudriakovaauthor=G.+Altonauthor=J.+J.+Cuiauthor=P.+P.+Kungauthor=M.+D.+Nambuauthor=G.+Losauthor=S.+L.+Benderauthor=B.+Mroczkowskiauthor=J.+G.+Christensen&title=An+orally+available+small-molecule+inhibitor+of+c-met%2C+PF-2341066%2C+exhibits+cytoreductive+antitumor+efficacy+through+antiproliferative+and+antiangiogenic+mechanisms&doi=10.1158%2F0008-5472.CAN-06-4443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25bR"><div class="casContent"><span class="casTitleNuber">25b</span><div class="casTitle"><span class="NLM_cas:atitle">An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms</span></div><div class="casAuthors">Zou, Helen Y.; Li, Qiuhua; Lee, Joseph H.; Arango, Maria E.; McDonnell, Scott R.; Yamazaki, Shinji; Koudriakova, Tatiana B.; Alton, Gordon; Cui, Jingrong J.; Kung, Pei-Pei; Nambu, Mitchell D.; Los, Gerrit; Bender, Steven L.; Mroczkowski, Barbara; Christensen, James G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4408-4417</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The c-Met receptor tyrosine kinase and its ligand, hepatocyte growth factor (HGF), have been implicated in the progression of several human cancers and are attractive therapeutic targets.  PF-2341066 was identified as a potent, orally bioavailable, ATP-competitive small-mol. inhibitor of the catalytic activity of c-Met kinase.  PF-2341066 was selective for c-Met (and anaplastic lymphoma kinase) compared with a panel of >120 diverse tyrosine and serine-threonine kinases.  PF-2341066 potently inhibited c-Met phosphorylation and c-Met-dependent proliferation, migration, or invasion of human tumor cells in vitro (IC50 values, 5-20 nmol/L).  In addn., PF-2341066 potently inhibited HGF-stimulated endothelial cell survival or invasion and serum-stimulated tubulogenesis in vitro, suggesting that this agent also exhibits antiangiogenic properties.  PF-2341066 showed efficacy at well-tolerated doses, including marked cytoreductive antitumor activity, in several tumor models that expressed activated c-Met.  The antitumor efficacy of PF-2341066 was dose dependent and showed a strong correlation to inhibition of c-Met phosphorylation in vivo.  Near-maximal inhibition of c-Met activity for the full dosing interval was necessary to maximize the efficacy of PF-2341066.  Addnl. mechanism-of-action studies showed dose-dependent inhibition of c-Met-dependent signal transduction, tumor cell proliferation (Ki67), induction of apoptosis (caspase-3), and redn. of microvessel d. (CD31).  These results indicated that the antitumor activity of PF-2341066 may be mediated by direct effects on tumor cell growth or survival as well as antiangiogenic mechanisms.  Collectively, these results show the therapeutic potential of targeting c-Met with selective small-mol. inhibitors for the treatment of human cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEAWtGPOBHC7Vg90H21EOLACvtfcHk0ljstLPcyw3_Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltVyrsbg%253D&md5=798bf93e6cf8d5e9897e27485cba9002</span></div><a href="/servlet/linkout?suffix=cit25b&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-4443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-4443%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DLi%26aufirst%3DQ.%2BH.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DArango%26aufirst%3DM.%2BE.%26aulast%3DMcDonnell%26aufirst%3DS.%2BR.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DKoudriakova%26aufirst%3DT.%2BB.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DKung%26aufirst%3DP.%2BP.%26aulast%3DNambu%26aufirst%3DM.%2BD.%26aulast%3DLos%26aufirst%3DG.%26aulast%3DBender%26aufirst%3DS.%2BL.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26atitle%3DAn%2520orally%2520available%2520small-molecule%2520inhibitor%2520of%2520c-met%252C%2520PF-2341066%252C%2520exhibits%2520cytoreductive%2520antitumor%2520efficacy%2520through%2520antiproliferative%2520and%2520antiangiogenic%2520mechanisms%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D4408%26epage%3D4417%26doi%3D10.1158%2F0008-5472.CAN-06-4443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Remsing Rix, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rix, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colinge, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hantschel, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stranzl, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumgartner, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valent, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Augustin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Till, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Superti-Furga, G.</span><span> </span><span class="NLM_article-title">Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">477</span><span class="NLM_x">–</span> <span class="NLM_lpage">485</span><span class="refDoi"> DOI: 10.1038/leu.2008.334</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1038%2Fleu.2008.334" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=19039322" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivVKhu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2009&pages=477-485&author=L.+L.+Remsing+Rixauthor=U.+Rixauthor=J.+Colingeauthor=O.+Hantschelauthor=K.+L.+Bennettauthor=T.+Stranzlauthor=A.+Mullerauthor=C.+Baumgartnerauthor=P.+Valentauthor=M.+Augustinauthor=J.+H.+Tillauthor=G.+Superti-Furga&title=Global+target+profile+of+the+kinase+inhibitor+bosutinib+in+primary+chronic+myeloid+leukemia+cells&doi=10.1038%2Fleu.2008.334"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells</span></div><div class="casAuthors">Remsing Rix, L. L.; Rix, U.; Colinge, J.; Hantschel, O.; Bennett, K. L.; Stranzl, T.; Mueller, A.; Baumgartner, C.; Valent, P.; Augustin, M.; Till, J. H.; Superti-Furga, G.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">477-485</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The detailed mol. mechanism of action of second-generation BCR-ABL tyrosine kinase inhibitors, including perturbed targets and pathways, should contribute to rationalized therapy in chronic myeloid leukemia (CML) or in other affected diseases.  Here, we characterized the target profile of the dual SRC/ABL inhibitor bosutinib employing a two-tiered approach using chem. proteomics to identify natural binders in whole cell lysates of primary CML and K562 cells in parallel to in vitro kinase assays against a large recombinant kinase panel.  The combined strategy resulted in a global survey of bosutinib targets comprised of over 45 novel tyrosine and serine/threonine kinases.  We have found clear differences in the target patterns of bosutinib in primary CML cells vs. the K562 cell line.  A comparison of bosutinib with dasatinib across the whole kinase panel revealed overlapping, but distinct, inhibition profiles.  Common among those were the SRC, ABL and TEC family kinases.  Bosutinib did not inhibit KIT or platelet-derived growth factor receptor, but prominently targeted the apoptosis-linked STE20 kinases.  Although in vivo bosutinib is inactive against ABL T315I, we found this clin. important mutant to be enzymically inhibited in the mid-nanomolar range.  Finally, bosutinib is the first kinase inhibitor shown to target CAMK2G, recently implicated in myeloid leukemia cell proliferation.  Leukemia (2009) 23, 477-485; doi:10.1038/leu.2008.334; published online 27 Nov. 2008.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8u0ixFotIMLVg90H21EOLACvtfcHk0ljstLPcyw3_Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivVKhu7w%253D&md5=b0d56d468ef66ddc2a6f012d08f8c1a4</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fleu.2008.334&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2008.334%26sid%3Dliteratum%253Aachs%26aulast%3DRemsing%2BRix%26aufirst%3DL.%2BL.%26aulast%3DRix%26aufirst%3DU.%26aulast%3DColinge%26aufirst%3DJ.%26aulast%3DHantschel%26aufirst%3DO.%26aulast%3DBennett%26aufirst%3DK.%2BL.%26aulast%3DStranzl%26aufirst%3DT.%26aulast%3DMuller%26aufirst%3DA.%26aulast%3DBaumgartner%26aufirst%3DC.%26aulast%3DValent%26aufirst%3DP.%26aulast%3DAugustin%26aufirst%3DM.%26aulast%3DTill%26aufirst%3DJ.%2BH.%26aulast%3DSuperti-Furga%26aufirst%3DG.%26atitle%3DGlobal%2520target%2520profile%2520of%2520the%2520kinase%2520inhibitor%2520bosutinib%2520in%2520primary%2520chronic%2520myeloid%2520leukemia%2520cells%26jtitle%3DLeukemia%26date%3D2009%26volume%3D23%26spage%3D477%26epage%3D485%26doi%3D10.1038%2Fleu.2008.334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Blumenthal, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortazar, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sridhara, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murgo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Justice, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pazdur, R.</span><span> </span><span class="NLM_article-title">FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1108</span><span class="NLM_x">–</span> <span class="NLM_lpage">1113</span><span class="refDoi"> DOI: 10.1634/theoncologist.2012-0044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1634%2Ftheoncologist.2012-0044" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=1108-1113&author=G.+M.+Blumenthalauthor=P.+Cortazarauthor=J.+J.+Zhangauthor=S.+Tangauthor=R.+Sridharaauthor=A.+Murgoauthor=R.+Justiceauthor=R.+Pazdur&title=FDA+approval+summary%3A+sunitinib+for+the+treatment+of+progressive+well-differentiated+locally+advanced+or+metastatic+pancreatic+neuroendocrine+tumors&doi=10.1634%2Ftheoncologist.2012-0044"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.2012-0044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.2012-0044%26sid%3Dliteratum%253Aachs%26aulast%3DBlumenthal%26aufirst%3DG.%2BM.%26aulast%3DCortazar%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DJ.%2BJ.%26aulast%3DTang%26aufirst%3DS.%26aulast%3DSridhara%26aufirst%3DR.%26aulast%3DMurgo%26aufirst%3DA.%26aulast%3DJustice%26aufirst%3DR.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DFDA%2520approval%2520summary%253A%2520sunitinib%2520for%2520the%2520treatment%2520of%2520progressive%2520well-differentiated%2520locally%2520advanced%2520or%2520metastatic%2520pancreatic%2520neuroendocrine%2520tumors%26jtitle%3DOncologist%26date%3D2012%26volume%3D17%26spage%3D1108%26epage%3D1113%26doi%3D10.1634%2Ftheoncologist.2012-0044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Eder, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Appleman, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, A. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miles, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cancilla, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hitchcock-Bryan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCallum, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heath, E. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boerner, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LoRusso, P. M.</span><span> </span><span class="NLM_article-title">A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">3507</span><span class="NLM_x">–</span> <span class="NLM_lpage">3516</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-10-0574</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1158%2F1078-0432.CCR-10-0574" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=20472683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC3cXot1Wlt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=3507-3516&author=J.+P.+Ederauthor=G.+I.+Shapiroauthor=L.+J.+Applemanauthor=A.+X.+Zhuauthor=D.+Milesauthor=H.+Keerauthor=B.+Cancillaauthor=F.+Chuauthor=S.+Hitchcock-Bryanauthor=L.+Shermanauthor=S.+McCallumauthor=E.+I.+Heathauthor=S.+A.+Boernerauthor=P.+M.+LoRusso&title=A+phase+I+study+of+foretinib%2C+a+multi-targeted+inhibitor+of+c-Met+and+vascular+endothelial+growth+factor+receptor+2&doi=10.1158%2F1078-0432.CCR-10-0574"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2</span></div><div class="casAuthors">Eder, Joseph Paul; Shapiro, Geoffrey I.; Appleman, Leonard J.; Zhu, Andrew X.; Miles, Dale; Keer, Harold; Cancilla, Belinda; Chu, Felix; Hitchcock-Bryan, Suzanne; Sherman, Laurie; McCallum, Stewart; Heath, Elisabeth I.; Boerner, Scott A.; Lo Russo, Patricia M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3507-3516</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Foretinib is an oral multikinase inhibitor targeting Met, RON, Axl, and vascular endothelial growth factor receptor.  We conducted a phase I, first-time-in-human, clin. trial using escalating doses of oral foretinib.  The primary objectives are to identify a max. tolerated dose and det. the safety profile of foretinib.  Secondary objectives included evaluation of plasma pharmacokinetics, long-term safety after repeated administration, preliminary antitumor activity, and pharmacodynamic activity.  Exptl. Design: Patients had histol. confirmed metastatic or unresectable solid tumors for which no std. measures exist.  All patients received foretinib orally for 5 consecutive days every 14 days.  Dose escalation followed a conventional "3+3" design.  RESULTS: Forty patients were treated in eight dose cohorts.  The max. tolerated dose was defined as 3.6 mg/kg, with a max. administered dose of 4.5 mg/kg.  Dose-limiting toxicities included grade 3 elevations in aspartate aminotransferase and lipase.  Addnl. non-dose-limiting adverse events included hypertension, fatigue, diarrhea, vomiting, proteinuria, and hematuria.  Responses were obsd. in two patients with papillary renal cell cancer and one patient with medullary thyroid cancer.  Stable disease was identified in 22 patients.  Foretinib pharmacokinetics increased linearly with dose.  Pharmacodynamic evaluation indicated inhibition of MET phosphorylation and decreased proliferation in select tumor biopsies at submaximal doses.  CONCLUSIONS: The recommended dose of foretinib was detd. to be 240 mg, given on the first 5 days of a 14-day cycle.  This dose and schedule were identified as having acceptable safety and pharmacokinetics, and will be the dose used in subsequent phase II trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1LAL1xiRe-rVg90H21EOLACvtfcHk0ljstLPcyw3_Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXot1Wlt74%253D&md5=d37b24383a08fdde5f78ed40b077963b</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-0574&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-0574%26sid%3Dliteratum%253Aachs%26aulast%3DEder%26aufirst%3DJ.%2BP.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DAppleman%26aufirst%3DL.%2BJ.%26aulast%3DZhu%26aufirst%3DA.%2BX.%26aulast%3DMiles%26aufirst%3DD.%26aulast%3DKeer%26aufirst%3DH.%26aulast%3DCancilla%26aufirst%3DB.%26aulast%3DChu%26aufirst%3DF.%26aulast%3DHitchcock-Bryan%26aufirst%3DS.%26aulast%3DSherman%26aufirst%3DL.%26aulast%3DMcCallum%26aufirst%3DS.%26aulast%3DHeath%26aufirst%3DE.%2BI.%26aulast%3DBoerner%26aufirst%3DS.%2BA.%26aulast%3DLoRusso%26aufirst%3DP.%2BM.%26atitle%3DA%2520phase%2520I%2520study%2520of%2520foretinib%252C%2520a%2520multi-targeted%2520inhibitor%2520of%2520c-Met%2520and%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%25202%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2010%26volume%3D16%26spage%3D3507%26epage%3D3516%26doi%3D10.1158%2F1078-0432.CCR-10-0574" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Yan, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peek, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ajamie, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchanan, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graff, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heidler, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hui, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huss, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konicek, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manro, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shih, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stout, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uhlik, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Um, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walgren, R. A.</span><span> </span><span class="NLM_article-title">LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">833</span><span class="NLM_x">–</span> <span class="NLM_lpage">844</span><span class="refDoi"> DOI: 10.1007/s10637-012-9912-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1007%2Fs10637-012-9912-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=23275061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOksLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=833-844&author=S.+B.+Yanauthor=V.+L.+Peekauthor=R.+Ajamieauthor=S.+G.+Buchananauthor=J.+R.+Graffauthor=S.+A.+Heidlerauthor=Y.+H.+Huiauthor=K.+L.+Hussauthor=B.+W.+Konicekauthor=J.+R.+Manroauthor=C.+Shihauthor=J.+A.+Stewartauthor=T.+R.+Stewartauthor=S.+L.+Stoutauthor=M.+T.+Uhlikauthor=S.+L.+Umauthor=Y.+Wangauthor=W.+Wuauthor=L.+Yanauthor=W.+J.+Yangauthor=B.+Zhongauthor=R.+A.+Walgren&title=LY2801653+is+an+orally+bioavailable+multi-kinase+inhibitor+with+potent+activity+against+MET%2C+MST1R%2C+and+other+oncoproteins%2C+and+displays+anti-tumor+activities+in+mouse+xenograft+models&doi=10.1007%2Fs10637-012-9912-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models</span></div><div class="casAuthors">Yan, S. Betty; Peek, Victoria L.; Ajamie, Rose; Buchanan, Sean G.; Graff, Jeremy R.; Heidler, Steven A.; Hui, Yu-Hua; Huss, Karen L.; Konicek, Bruce W.; Manro, Jason R.; Shih, Chuan; Stewart, Julie A.; Stewart, Trent R.; Stout, Stephanie L.; Uhlik, Mark T.; Um, Suzane L.; Wang, Yong; Wu, Wenjuan; Yan, Lei; Yang, Wei J.; Zhong, Boyu; Walgren, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">833-844</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The HGF/MET signaling pathway regulates a wide variety of normal cellular functions that can be subverted to support neoplasia, including cell proliferation, survival, apoptosis, scattering and motility, invasion, and angiogenesis.  MET over-expression (with or without gene amplification), aberrant autocrine or paracrine ligand prodn., and missense MET mutations are mechanisms that lead to activation of the MET pathway in tumors and are assocd. with poor prognostic outcome.  We report here preclin. development of a potent, orally bioavailable, small-mol. inhibitor LY2801653 targeting MET kinase.  LY2801653 is a type-II ATP competitive, slow-off inhibitor of MET tyrosine kinase with a dissocn. const. (Ki) of 2 nM, a pharmacodynamic residence time (Koff) of 0.00132 min-1 and t1/2 of 525 min.  LY2801653 demonstrated in vitro effects on MET pathway-dependent cell scattering and cell proliferation; in vivo anti-tumor effects in MET amplified (MKN45), MET autocrine (U-87MG, and KP4) and MET over-expressed (H441) xenograft models; and in vivo vessel normalization effects.  LY2801653 also maintained potency against 13 MET variants, each bearing a single-point mutation.  In subsequent nonclin. characterization, LY2801653 was found to have potent activity against several other receptor tyrosine oncokinases including MST1R, FLT3, AXL, MERTK, TEK, ROS1, DDR1/2 and against the serine/threonine kinases MKNK1/2.  The potential value of MET and other inhibited targets within a no. of malignancies (such as colon, bile ducts, and lung) is discussed.  LY2801653 is currently in phase 1 clin. testing in patients with advanced cancer (trial I3O-MC-JSBA, NCT01285037).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo04limPWxrHLVg90H21EOLACvtfcHk0ljVfaMzzX3nDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOksLzE&md5=9d80bcdb04ebec24e2516dcf26821ad3</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1007%2Fs10637-012-9912-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-012-9912-9%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DS.%2BB.%26aulast%3DPeek%26aufirst%3DV.%2BL.%26aulast%3DAjamie%26aufirst%3DR.%26aulast%3DBuchanan%26aufirst%3DS.%2BG.%26aulast%3DGraff%26aufirst%3DJ.%2BR.%26aulast%3DHeidler%26aufirst%3DS.%2BA.%26aulast%3DHui%26aufirst%3DY.%2BH.%26aulast%3DHuss%26aufirst%3DK.%2BL.%26aulast%3DKonicek%26aufirst%3DB.%2BW.%26aulast%3DManro%26aufirst%3DJ.%2BR.%26aulast%3DShih%26aufirst%3DC.%26aulast%3DStewart%26aufirst%3DJ.%2BA.%26aulast%3DStewart%26aufirst%3DT.%2BR.%26aulast%3DStout%26aufirst%3DS.%2BL.%26aulast%3DUhlik%26aufirst%3DM.%2BT.%26aulast%3DUm%26aufirst%3DS.%2BL.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DYan%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DW.%2BJ.%26aulast%3DZhong%26aufirst%3DB.%26aulast%3DWalgren%26aufirst%3DR.%2BA.%26atitle%3DLY2801653%2520is%2520an%2520orally%2520bioavailable%2520multi-kinase%2520inhibitor%2520with%2520potent%2520activity%2520against%2520MET%252C%2520MST1R%252C%2520and%2520other%2520oncoproteins%252C%2520and%2520displays%2520anti-tumor%2520activities%2520in%2520mouse%2520xenograft%2520models%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2013%26volume%3D31%26spage%3D833%26epage%3D844%26doi%3D10.1007%2Fs10637-012-9912-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Mori, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaneko, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueno, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saito, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondoh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimada, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuromitsu, S.</span><span> </span><span class="NLM_article-title">ASP2215, a novel FLT3/AXL inhibitor: preclinical evaluation in acute myeloid leukemia (AML)</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">7070</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=7070&author=M.+Moriauthor=N.+Kanekoauthor=Y.+Uenoauthor=R.+Tanakaauthor=K.+Choauthor=R.+Saitoauthor=Y.+Kondohauthor=I.+Shimadaauthor=S.+Kuromitsu&title=ASP2215%2C+a+novel+FLT3%2FAXL+inhibitor%3A+preclinical+evaluation+in+acute+myeloid+leukemia+%28AML%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMori%26aufirst%3DM.%26aulast%3DKaneko%26aufirst%3DN.%26aulast%3DUeno%26aufirst%3DY.%26aulast%3DTanaka%26aufirst%3DR.%26aulast%3DCho%26aufirst%3DK.%26aulast%3DSaito%26aufirst%3DR.%26aulast%3DKondoh%26aufirst%3DY.%26aulast%3DShimada%26aufirst%3DI.%26aulast%3DKuromitsu%26aufirst%3DS.%26atitle%3DASP2215%252C%2520a%2520novel%2520FLT3%252FAXL%2520inhibitor%253A%2520preclinical%2520evaluation%2520in%2520acute%2520myeloid%2520leukemia%2520%2528AML%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D32%26spage%3D7070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Burbridge, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bossard, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saunier, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fejes, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruno, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonce, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferry, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Da Violante, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouzom, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cattan, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacquet-Bescond, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comoglio, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boutin, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortuno, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierre, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cruzalegui, F. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Depil, S.</span><span> </span><span class="NLM_article-title">S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1749</span><span class="NLM_x">–</span> <span class="NLM_lpage">1762</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1158%2F1535-7163.MCT-13-0075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=23804704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtl2lur7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=1749-1762&author=M.+F.+Burbridgeauthor=C.+J.+Bossardauthor=C.+Saunierauthor=I.+Fejesauthor=A.+Brunoauthor=S.+Leonceauthor=G.+Ferryauthor=G.+Da+Violanteauthor=F.+Bouzomauthor=V.+Cattanauthor=A.+Jacquet-Bescondauthor=P.+M.+Comoglioauthor=B.+P.+Lockhartauthor=J.+A.+Boutinauthor=A.+Cordiauthor=J.+C.+Ortunoauthor=A.+Pierreauthor=J.+A.+Hickmanauthor=F.+H.+Cruzaleguiauthor=S.+Depil&title=S49076+is+a+novel+kinase+inhibitor+of+MET%2C+AXL%2C+and+FGFR+with+strong+preclinical+activity+alone+and+in+association+with+bevacizumab&doi=10.1158%2F1535-7163.MCT-13-0075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab</span></div><div class="casAuthors">Burbridge, Mike F.; Bossard, Celine J.; Saunier, Carine; Fejes, Imre; Bruno, Alain; Leonce, Stephane; Ferry, Gilles; Da Violante, Georges; Bouzom, Francois; Cattan, Valerie; Jacquet-Bescond, Anne; Comoglio, Paolo M.; Lockhart, Brian P.; Boutin, Jean A.; Cordi, Alex; Ortuno, Jean-Claude; Pierre, Alain; Hickman, John A.; Cruzalegui, Francisco H.; Depil, Stephane</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1749-1762</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Aberrant activity of the receptor tyrosine kinases MET, AXL, and FGFR1/2/3 has been assocd. with tumor progression in a wide variety of human malignancies, notably in instances of primary or acquired resistance to existing or emerging anticancer therapies.  This study describes the preclin. characterization of S49076, a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3.  S49076 potently blocked cellular phosphorylation of MET, AXL, and FGFRs and inhibited downstream signaling in vitro and in vivo.  In cell models, S49076 inhibited the proliferation of MET- and FGFR2-dependent gastric cancer cells, blocked MET-driven migration of lung carcinoma cells, and inhibited colony formation of hepatocarcinoma cells expressing FGFR1/2 and AXL.  In tumor xenograft models, a good pharmacokinetic/pharmacodynamic relationship for MET and FGFR2 inhibition following oral administration of S49076 was established and correlated well with impact on tumor growth.  MET, AXL, and the FGFRs have all been implicated in resistance to VEGF/VEGFR inhibitors such as bevacizumab.  Accordingly, combination of S49076 with bevacizumab in colon carcinoma xenograft models led to near total inhibition of tumor growth.  Moreover, S49076 alone caused tumor growth arrest in bevacizumab-resistant tumors.  On the basis of these preclin. studies showing a favorable and novel pharmacol. profile of S49076, a phase I study is currently underway in patients with advanced solid tumors.  Mol Cancer Ther; 12(9); 1749-62. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodE4VwyiV-HrVg90H21EOLACvtfcHk0ljVfaMzzX3nDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtl2lur7O&md5=a53009f7a7b0601cf45598ca5b8775c2</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0075%26sid%3Dliteratum%253Aachs%26aulast%3DBurbridge%26aufirst%3DM.%2BF.%26aulast%3DBossard%26aufirst%3DC.%2BJ.%26aulast%3DSaunier%26aufirst%3DC.%26aulast%3DFejes%26aufirst%3DI.%26aulast%3DBruno%26aufirst%3DA.%26aulast%3DLeonce%26aufirst%3DS.%26aulast%3DFerry%26aufirst%3DG.%26aulast%3DDa%2BViolante%26aufirst%3DG.%26aulast%3DBouzom%26aufirst%3DF.%26aulast%3DCattan%26aufirst%3DV.%26aulast%3DJacquet-Bescond%26aufirst%3DA.%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26aulast%3DLockhart%26aufirst%3DB.%2BP.%26aulast%3DBoutin%26aufirst%3DJ.%2BA.%26aulast%3DCordi%26aufirst%3DA.%26aulast%3DOrtuno%26aufirst%3DJ.%2BC.%26aulast%3DPierre%26aufirst%3DA.%26aulast%3DHickman%26aufirst%3DJ.%2BA.%26aulast%3DCruzalegui%26aufirst%3DF.%2BH.%26aulast%3DDepil%26aufirst%3DS.%26atitle%3DS49076%2520is%2520a%2520novel%2520kinase%2520inhibitor%2520of%2520MET%252C%2520AXL%252C%2520and%2520FGFR%2520with%2520strong%2520preclinical%2520activity%2520alone%2520and%2520in%2520association%2520with%2520bevacizumab%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26spage%3D1749%26epage%3D1762%26doi%3D10.1158%2F1535-7163.MCT-13-0075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Schroeder, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">An, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, Z. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornelius, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gullo-Brown, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henley, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeyaseelan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manne, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oppenheimer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sack, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stefanski, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokarski, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trainor, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wautlet, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fargnoli, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borzilleri, R. M.</span><span> </span><span class="NLM_article-title">Discovery of <i>N</i>-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1251</span><span class="NLM_x">–</span> <span class="NLM_lpage">1254</span><span class="refDoi"> DOI: 10.1021/jm801586s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801586s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhvVCnsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1251-1254&author=G.+M.+Schroederauthor=Y.+Anauthor=Z.+W.+Caiauthor=X.+T.+Chenauthor=C.+Clarkauthor=L.+A.+Corneliusauthor=J.+Daiauthor=J.+Gullo-Brownauthor=A.+Guptaauthor=B.+Henleyauthor=J.+T.+Huntauthor=R.+Jeyaseelanauthor=A.+Kamathauthor=K.+Kimauthor=J.+Lippyauthor=L.+J.+Lombardoauthor=V.+Manneauthor=S.+Oppenheimerauthor=J.+S.+Sackauthor=R.+J.+Schmidtauthor=G.+Shenauthor=K.+Stefanskiauthor=J.+S.+Tokarskiauthor=G.+L.+Trainorauthor=B.+S.+Wautletauthor=D.+Weiauthor=D.+K.+Williamsauthor=Y.+Zhangauthor=Y.+Zhangauthor=J.+Fargnoliauthor=R.+M.+Borzilleri&title=Discovery+of+N-%284-%282-amino-3-chloropyridin-4-yloxy%29-3-fluorophenyl%29-4-ethoxy-1-%284-fluorophenyl%29-2-oxo-1%2C2-dihydropyridine-3-carboxamide+%28BMS-777607%29%2C+a+selective+and+orally+efficacious+inhibitor+of+the+Met+kinase+superfamily&doi=10.1021%2Fjm801586s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a Selective and Orally Efficacious Inhibitor of the Met Kinase Superfamily</span></div><div class="casAuthors">Schroeder, Gretchen M.; An, Yongmi; Cai, Zhen-Wei; Chen, Xiao-Tao; Clark, Cheryl; Cornelius, Lyndon A. M.; Dai, Jun; Gullo-Brown, Johnni; Gupta, Ashok; Henley, Benjamin; Hunt, John T.; Jeyaseelan, Robert; Kamath, Amrita; Kim, Kyoung; Lippy, Jonathan; Lombardo, Louis J.; Manne, Veeraswamy; Oppenheimer, Simone; Sack, John S.; Schmidt, Robert J.; Shen, Guoxiang; Stefanski, Kevin; Tokarski, John S.; Trainor, George L.; Wautlet, Barri S.; Wei, Donna; Williams, David K.; Zhang, Yingru; Zhang, Yueping; Fargnoli, Joseph; Borzilleri, Robert M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1251-1254</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Substituted N-(4-(2-aminopyridin-4-yloxy)-3-fluoro-phenyl)-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamides were identified as potent and selective Met kinase inhibitors.  Substitution of the pyridine 3-position gave improved enzyme potency, while substitution of the pyridone 4-position led to improved aq. soly. and kinase selectivity.  Analog 10 demonstrated complete tumor stasis in a Met-dependent GTL-16 human gastric carcinoma xenograft model following oral administration.  Because of its excellent in vivo efficacy and favorable pharmacokinetic and preclin. safety profiles, 10 has been advanced into phase I clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAHEvJXf0Fq7Vg90H21EOLACvtfcHk0licT0EDh-rI0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhvVCnsLc%253D&md5=784623be820fcc8b931200ced3a476df</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm801586s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801586s%26sid%3Dliteratum%253Aachs%26aulast%3DSchroeder%26aufirst%3DG.%2BM.%26aulast%3DAn%26aufirst%3DY.%26aulast%3DCai%26aufirst%3DZ.%2BW.%26aulast%3DChen%26aufirst%3DX.%2BT.%26aulast%3DClark%26aufirst%3DC.%26aulast%3DCornelius%26aufirst%3DL.%2BA.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DGullo-Brown%26aufirst%3DJ.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DHenley%26aufirst%3DB.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DJeyaseelan%26aufirst%3DR.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DKim%26aufirst%3DK.%26aulast%3DLippy%26aufirst%3DJ.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DManne%26aufirst%3DV.%26aulast%3DOppenheimer%26aufirst%3DS.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DSchmidt%26aufirst%3DR.%2BJ.%26aulast%3DShen%26aufirst%3DG.%26aulast%3DStefanski%26aufirst%3DK.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DTrainor%26aufirst%3DG.%2BL.%26aulast%3DWautlet%26aufirst%3DB.%2BS.%26aulast%3DWei%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DD.%2BK.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DFargnoli%26aufirst%3DJ.%26aulast%3DBorzilleri%26aufirst%3DR.%2BM.%26atitle%3DDiscovery%2520of%2520N-%25284-%25282-amino-3-chloropyridin-4-yloxy%2529-3-fluorophenyl%2529-4-ethoxy-1-%25284-fluorophenyl%2529-2-oxo-1%252C2-dihydropyridine-3-carboxamide%2520%2528BMS-777607%2529%252C%2520a%2520selective%2520and%2520orally%2520efficacious%2520inhibitor%2520of%2520the%2520Met%2520kinase%2520superfamily%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1251%26epage%3D1254%26doi%3D10.1021%2Fjm801586s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Bonfils, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaulieu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fournel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ste-Croix, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besterman, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maroun, C. R.</span><span> </span><span class="NLM_article-title">The combination of MGCD265, a MET/VEGFR inhibitor in clinical development, and erlotinib potently inhibits tumor growth by altering multiple pathways including glycolysis</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">1790</span><span class="refDoi"> DOI: 10.1158/1538-7445.AM2012-1790</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1158%2F1538-7445.AM2012-1790" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=1790&author=C.+Bonfilsauthor=N.+Beaulieuauthor=M.+Fournelauthor=H.+Ste-Croixauthor=J.+M.+Bestermanauthor=C.+R.+Maroun&title=The+combination+of+MGCD265%2C+a+MET%2FVEGFR+inhibitor+in+clinical+development%2C+and+erlotinib+potently+inhibits+tumor+growth+by+altering+multiple+pathways+including+glycolysis&doi=10.1158%2F1538-7445.AM2012-1790"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2012-1790&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2012-1790%26sid%3Dliteratum%253Aachs%26aulast%3DBonfils%26aufirst%3DC.%26aulast%3DBeaulieu%26aufirst%3DN.%26aulast%3DFournel%26aufirst%3DM.%26aulast%3DSte-Croix%26aufirst%3DH.%26aulast%3DBesterman%26aufirst%3DJ.%2BM.%26aulast%3DMaroun%26aufirst%3DC.%2BR.%26atitle%3DThe%2520combination%2520of%2520MGCD265%252C%2520a%2520MET%252FVEGFR%2520inhibitor%2520in%2520clinical%2520development%252C%2520and%2520erlotinib%2520potently%2520inhibits%2520tumor%2520growth%2520by%2520altering%2520multiple%2520pathways%2520including%2520glycolysis%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D1790%26doi%3D10.1158%2F1538-7445.AM2012-1790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Rho, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoon, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bae, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. C.</span><span> </span><span class="NLM_article-title">MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">253</span><span class="NLM_x">–</span> <span class="NLM_lpage">262</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-13-1103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1158%2F0008-5472.CAN-13-1103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=24165158" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC2cXislKjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=253-262&author=J.+K.+Rhoauthor=Y.+J.+Choiauthor=S.+Y.+Kimauthor=T.+W.+Kimauthor=E.+K.+Choiauthor=S.+J.+Yoonauthor=B.+M.+Parkauthor=E.+Parkauthor=J.+H.+Baeauthor=C.+M.+Choiauthor=J.+C.+Lee&title=MET+and+AXL+inhibitor+NPS-1034+exerts+efficacy+against+lung+cancer+cells+resistant+to+EGFR+kinase+inhibitors+because+of+MET+or+AXL+activation&doi=10.1158%2F0008-5472.CAN-13-1103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">MET and AXL Inhibitor NPS-1034 Exerts Efficacy against Lung Cancer Cells Resistant to EGFR Kinase Inhibitors Because of MET or AXL Activation</span></div><div class="casAuthors">Rho, Jin Kyung; Choi, Yun Jung; Kim, Seon Ye; Kim, Tae Won; Choi, Eun Kyung; Yoon, Seon-Joo; Park, Bu Man; Park, Eunhye; Bae, Jong Hwan; Choi, Chang-Min; Lee, Jae Cheol</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">253-262</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">In non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations, acquired resistance to EGFR-tyrosine kinase inhibitors (EGFR-TK1) can occur through a generation of bypass signals such as MET or AXL activation.  In this study, we investigated the antitumor activity of NPS-1034, a newly developed drug that targets both MET and AXL, in NSCLC cells with acquired resistance to gefitinib or erlotinib (HCC827/GR and HCC827/ER, resp.).  Characterization of H820 cells and evaluation of NPS-1034 efficacy in these cells were also performed.  The resistance of HCC827/GR was mediated by MET activation, whereas AXL activation led to resistance in HCC827/ER.  The combination of gefitinib or erlotinib with NPS-1034 synergistically inhibited cell proliferation and induced cell death in both resistant cell lines.  Accordingly, suppression of Akt was noted only in the presence of treatment with both drugs.  NPS-1034 was also effective in xenograft mouse models of HCC827/GR.  Although the H820 cell line was reported previously to have T790M and MET amplification, we discovered that AXL was also activated in this cell line.  There were no antitumor effects of siRNA or inhibitors specific for EGFR or MET, whereas combined treatment with AXL siRNA or NPS-1034 and EGFR-TKIs controlled H820 cells, suggesting that AXL is the main signal responsible for resistance.  In addn., NPS-1034 inhibited cell proliferation as well as ROS1 activity in HCC78 cells with ROS1 rearrangement.  Our results establish the efficacy of NPS-1034 in NSCLC cells rendered resistant to EGFR-TKIs because of MET or AXL activation or ROS1 rearrangement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzVRl7xbUBLrVg90H21EOLACvtfcHk0lha9Vk21n0Gsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXislKjtA%253D%253D&md5=35929f2dcfd5d1502ba745f367dccd27</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-13-1103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-13-1103%26sid%3Dliteratum%253Aachs%26aulast%3DRho%26aufirst%3DJ.%2BK.%26aulast%3DChoi%26aufirst%3DY.%2BJ.%26aulast%3DKim%26aufirst%3DS.%2BY.%26aulast%3DKim%26aufirst%3DT.%2BW.%26aulast%3DChoi%26aufirst%3DE.%2BK.%26aulast%3DYoon%26aufirst%3DS.%2BJ.%26aulast%3DPark%26aufirst%3DB.%2BM.%26aulast%3DPark%26aufirst%3DE.%26aulast%3DBae%26aufirst%3DJ.%2BH.%26aulast%3DChoi%26aufirst%3DC.%2BM.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26atitle%3DMET%2520and%2520AXL%2520inhibitor%2520NPS-1034%2520exerts%2520efficacy%2520against%2520lung%2520cancer%2520cells%2520resistant%2520to%2520EGFR%2520kinase%2520inhibitors%2520because%2520of%2520MET%2520or%2520AXL%2520activation%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D253%26epage%3D262%26doi%3D10.1158%2F0008-5472.CAN-13-1103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Holland, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franci, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torneros, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heckrodt, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Apatira, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chua, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandt, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pine, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goff, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Payan, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hitoshi, Y.</span><span> </span><span class="NLM_article-title">R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">1544</span><span class="NLM_x">–</span> <span class="NLM_lpage">1554</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-09-2997</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1158%2F0008-5472.CAN-09-2997" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=1544-1554&author=S.+J.+Hollandauthor=A.+Panauthor=C.+Franciauthor=Y.+Huauthor=B.+Changauthor=W.+Liauthor=M.+Duanauthor=A.+Tornerosauthor=J.+Yuauthor=T.+J.+Heckrodtauthor=J.+Zhangauthor=P.+Dingauthor=A.+Apatiraauthor=J.+Chuaauthor=R.+Brandtauthor=P.+Pineauthor=D.+Goffauthor=R.+Singhauthor=D.+G.+Payanauthor=Y.+Hitoshi&title=R428%2C+a+selective+small+molecule+inhibitor+of+Axl+kinase%2C+blocks+tumor+spread+and+prolongs+survival+in+models+of+metastatic+breast+cancer&doi=10.1158%2F0008-5472.CAN-09-2997"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-2997&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-2997%26sid%3Dliteratum%253Aachs%26aulast%3DHolland%26aufirst%3DS.%2BJ.%26aulast%3DPan%26aufirst%3DA.%26aulast%3DFranci%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DChang%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DDuan%26aufirst%3DM.%26aulast%3DTorneros%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DHeckrodt%26aufirst%3DT.%2BJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DP.%26aulast%3DApatira%26aufirst%3DA.%26aulast%3DChua%26aufirst%3DJ.%26aulast%3DBrandt%26aufirst%3DR.%26aulast%3DPine%26aufirst%3DP.%26aulast%3DGoff%26aufirst%3DD.%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DPayan%26aufirst%3DD.%2BG.%26aulast%3DHitoshi%26aufirst%3DY.%26atitle%3DR428%252C%2520a%2520selective%2520small%2520molecule%2520inhibitor%2520of%2520Axl%2520kinase%252C%2520blocks%2520tumor%2520spread%2520and%2520prolongs%2520survival%2520in%2520models%2520of%2520metastatic%2520breast%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D1544%26epage%3D1554%26doi%3D10.1158%2F0008-5472.CAN-09-2997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Mollard, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warner, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Call, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wade, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bearss, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verma, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vankayalapati, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bearss, D. J.</span><span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of a series of novel AXL kinase inhibitors</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">907</span><span class="NLM_x">–</span> <span class="NLM_lpage">912</span><span class="refDoi"> DOI: 10.1021/ml200198x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200198x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=907-912&author=A.+Mollardauthor=S.+L.+Warnerauthor=L.+T.+Callauthor=M.+L.+Wadeauthor=J.+J.+Bearssauthor=A.+Vermaauthor=S.+Sharmaauthor=H.+Vankayalapatiauthor=D.+J.+Bearss&title=Design%2C+synthesis+and+biological+evaluation+of+a+series+of+novel+AXL+kinase+inhibitors&doi=10.1021%2Fml200198x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fml200198x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200198x%26sid%3Dliteratum%253Aachs%26aulast%3DMollard%26aufirst%3DA.%26aulast%3DWarner%26aufirst%3DS.%2BL.%26aulast%3DCall%26aufirst%3DL.%2BT.%26aulast%3DWade%26aufirst%3DM.%2BL.%26aulast%3DBearss%26aufirst%3DJ.%2BJ.%26aulast%3DVerma%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DVankayalapati%26aufirst%3DH.%26aulast%3DBearss%26aufirst%3DD.%2BJ.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520a%2520series%2520of%2520novel%2520AXL%2520kinase%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D907%26epage%3D912%26doi%3D10.1021%2Fml200198x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Feneyrolles, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spenlinhauer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guiet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fauvel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dayde-Cazals, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warnault, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheve, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasri, A.</span><span> </span><span class="NLM_article-title">Axl kinase as a key target for oncology: focus on small molecule inhibitors</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">2141</span><span class="NLM_x">–</span> <span class="NLM_lpage">2148</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-1083</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1158%2F1535-7163.MCT-13-1083" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=25139999" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVOitLrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=2141-2148&author=C.+Feneyrollesauthor=A.+Spenlinhauerauthor=L.+Guietauthor=B.+Fauvelauthor=B.+Dayde-Cazalsauthor=P.+Warnaultauthor=G.+Cheveauthor=A.+Yasri&title=Axl+kinase+as+a+key+target+for+oncology%3A+focus+on+small+molecule+inhibitors&doi=10.1158%2F1535-7163.MCT-13-1083"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Axl Kinase as a Key Target for Oncology: Focus on Small Molecule Inhibitors</span></div><div class="casAuthors">Feneyrolles, Clemence; Spenlinhauer, Aurelia; Guiet, Lea; Fauvel, Benedicte; Dayde-Cazals, Benedicte; Warnault, Pierre; Cheve, Gwenael; Yasri, Aziz</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2141-2148</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Receptor tyrosine kinases (RTK) are transmembrane receptors that regulate signal transduction in cells.  As a member of the TAM (Tyro-3, Axl, Mer) RTK subfamily, Axl regulates key processes such as cell growth, migration, aggregation, and apoptosis through several pathways.  Its overexpression/overactivation has been underlined in several conditions, esp. cancers, and in both chemotherapy and targeted therapy sensitivity loss.  In this review, we propose to highlight the therapeutic implication of Axl, starting with the pathways it regulates, validating its interest as a therapeutic target, and defining the tools available to develop strategies for its inhibition.  We esp. focus on small mol. inhibitors, their structure, inhibition profile, and development stages.  Mol Cancer Ther; 13(9); 2141-8. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRn5-b7gNJkLVg90H21EOLACvtfcHk0lha9Vk21n0Gsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVOitLrO&md5=6c569ae44113e6cae2f59e8ba462a787</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-1083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-1083%26sid%3Dliteratum%253Aachs%26aulast%3DFeneyrolles%26aufirst%3DC.%26aulast%3DSpenlinhauer%26aufirst%3DA.%26aulast%3DGuiet%26aufirst%3DL.%26aulast%3DFauvel%26aufirst%3DB.%26aulast%3DDayde-Cazals%26aufirst%3DB.%26aulast%3DWarnault%26aufirst%3DP.%26aulast%3DCheve%26aufirst%3DG.%26aulast%3DYasri%26aufirst%3DA.%26atitle%3DAxl%2520kinase%2520as%2520a%2520key%2520target%2520for%2520oncology%253A%2520focus%2520on%2520small%2520molecule%2520inhibitors%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D2141%26epage%3D2148%26doi%3D10.1158%2F1535-7163.MCT-13-1083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Wise, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrews, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, L. J.</span><span> </span><span class="NLM_article-title">In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1983</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">559</span><span class="NLM_x">–</span> <span class="NLM_lpage">564</span><span class="refDoi"> DOI: 10.1128/AAC.23.4.559</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1128%2FAAC.23.4.559" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1983&pages=559-564&author=R.+Wiseauthor=J.+M.+Andrewsauthor=L.+J.+Edwards&title=In+vitro+activity+of+Bay+09867%2C+a+new+quinoline+derivative%2C+compared+with+those+of+other+antimicrobial+agents&doi=10.1128%2FAAC.23.4.559"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38a&amp;dbid=16384&amp;doi=10.1128%2FAAC.23.4.559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.23.4.559%26sid%3Dliteratum%253Aachs%26aulast%3DWise%26aufirst%3DR.%26aulast%3DAndrews%26aufirst%3DJ.%2BM.%26aulast%3DEdwards%26aufirst%3DL.%2BJ.%26atitle%3DIn%2520vitro%2520activity%2520of%2520Bay%252009867%252C%2520a%2520new%2520quinoline%2520derivative%252C%2520compared%2520with%2520those%2520of%2520other%2520antimicrobial%2520agents%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1983%26volume%3D23%26spage%3D559%26epage%3D564%26doi%3D10.1128%2FAAC.23.4.559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit38b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Chin, N. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neu, H. C.</span><span> </span><span class="NLM_article-title">Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1984</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">319</span><span class="NLM_x">–</span> <span class="NLM_lpage">326</span><span class="refDoi"> DOI: 10.1128/AAC.25.3.319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1128%2FAAC.25.3.319" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1984&pages=319-326&author=N.+X.+Chinauthor=H.+C.+Neu&title=Ciprofloxacin%2C+a+quinolone+carboxylic+acid+compound+active+against+aerobic+and+anaerobic+bacteria&doi=10.1128%2FAAC.25.3.319"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38b&amp;dbid=16384&amp;doi=10.1128%2FAAC.25.3.319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.25.3.319%26sid%3Dliteratum%253Aachs%26aulast%3DChin%26aufirst%3DN.%2BX.%26aulast%3DNeu%26aufirst%3DH.%2BC.%26atitle%3DCiprofloxacin%252C%2520a%2520quinolone%2520carboxylic%2520acid%2520compound%2520active%2520against%2520aerobic%2520and%2520anaerobic%2520bacteria%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1984%26volume%3D25%26spage%3D319%26epage%3D326%26doi%3D10.1128%2FAAC.25.3.319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit38c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Pan, X. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehtar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, L. M.</span><span> </span><span class="NLM_article-title">Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in streptococcus pneumonia</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">2321</span><span class="NLM_x">–</span> <span class="NLM_lpage">2326</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1996&pages=2321-2326&author=X.+S.+Panauthor=J.+Amblerauthor=S.+Mehtarauthor=L.+M.+Fisher&title=Involvement+of+topoisomerase+IV+and+DNA+gyrase+as+ciprofloxacin+targets+in+streptococcus+pneumonia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DX.%2BS.%26aulast%3DAmbler%26aufirst%3DJ.%26aulast%3DMehtar%26aufirst%3DS.%26aulast%3DFisher%26aufirst%3DL.%2BM.%26atitle%3DInvolvement%2520of%2520topoisomerase%2520IV%2520and%2520DNA%2520gyrase%2520as%2520ciprofloxacin%2520targets%2520in%2520streptococcus%2520pneumonia%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1996%26volume%3D40%26spage%3D2321%26epage%3D2326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Fu, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lafredo, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foleno, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isaacson, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tobia, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenthale, M. E.</span><span> </span><span class="NLM_article-title">In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">860</span><span class="NLM_x">–</span> <span class="NLM_lpage">866</span><span class="refDoi"> DOI: 10.1128/AAC.36.4.860</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1128%2FAAC.36.4.860" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1992&pages=860-866&author=K.+P.+Fuauthor=S.+C.+Lafredoauthor=B.+Folenoauthor=D.+M.+Isaacsonauthor=J.+F.+Barrettauthor=A.+J.+Tobiaauthor=M.+E.+Rosenthale&title=In+vitro+and+in+vivo+antibacterial+activities+of+levofloxacin+%28l-ofloxacin%29%2C+an+optically+active+ofloxacin&doi=10.1128%2FAAC.36.4.860"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39a&amp;dbid=16384&amp;doi=10.1128%2FAAC.36.4.860&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.36.4.860%26sid%3Dliteratum%253Aachs%26aulast%3DFu%26aufirst%3DK.%2BP.%26aulast%3DLafredo%26aufirst%3DS.%2BC.%26aulast%3DFoleno%26aufirst%3DB.%26aulast%3DIsaacson%26aufirst%3DD.%2BM.%26aulast%3DBarrett%26aufirst%3DJ.%2BF.%26aulast%3DTobia%26aufirst%3DA.%2BJ.%26aulast%3DRosenthale%26aufirst%3DM.%2BE.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520antibacterial%2520activities%2520of%2520levofloxacin%2520%2528l-ofloxacin%2529%252C%2520an%2520optically%2520active%2520ofloxacin%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1992%26volume%3D36%26spage%3D860%26epage%3D866%26doi%3D10.1128%2FAAC.36.4.860" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit39b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Davis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bryson, H. M.</span><span> </span><span class="NLM_article-title">Levofloxacin. a review of its antibacterial activity, pharmacokinetics and therapeutic efficacy</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">677</span><span class="NLM_x">–</span> <span class="NLM_lpage">700</span><span class="refDoi"> DOI: 10.2165/00003495-199447040-00008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.2165%2F00003495-199447040-00008" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=1994&pages=677-700&author=R.+Davisauthor=H.+M.+Bryson&title=Levofloxacin.+a+review+of+its+antibacterial+activity%2C+pharmacokinetics+and+therapeutic+efficacy&doi=10.2165%2F00003495-199447040-00008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39b&amp;dbid=16384&amp;doi=10.2165%2F00003495-199447040-00008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-199447040-00008%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DR.%26aulast%3DBryson%26aufirst%3DH.%2BM.%26atitle%3DLevofloxacin.%2520a%2520review%2520of%2520its%2520antibacterial%2520activity%252C%2520pharmacokinetics%2520and%2520therapeutic%2520efficacy%26jtitle%3DDrugs%26date%3D1994%26volume%3D47%26spage%3D677%26epage%3D700%26doi%3D10.2165%2F00003495-199447040-00008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit39c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Bucaneve, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Micozzi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menichetti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martino, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dionisi, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinelli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allione, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Antonio, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nosari, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cilloni, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zuffa, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantaffa, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Specchia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amadori, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbiano, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deliliers, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lauria, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foa, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Del Favero, A.</span><span> </span><span class="NLM_article-title">Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">353</span><span class="NLM_x">, </span> <span class="NLM_fpage">977</span><span class="NLM_x">–</span> <span class="NLM_lpage">987</span><span class="refDoi"> DOI: 10.1056/NEJMoa044097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1056%2FNEJMoa044097" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=16148283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpvVOis7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2005&pages=977-987&author=G.+Bucaneveauthor=A.+Micozziauthor=F.+Menichettiauthor=P.+Martinoauthor=M.+S.+Dionisiauthor=G.+Martinelliauthor=B.+Allioneauthor=D.+D%E2%80%99Antonioauthor=M.+Buelliauthor=A.+M.+Nosariauthor=D.+Cilloniauthor=E.+Zuffaauthor=R.+Cantaffaauthor=G.+Specchiaauthor=S.+Amadoriauthor=F.+Fabbianoauthor=G.+L.+Deliliersauthor=F.+Lauriaauthor=R.+Foaauthor=A.+Del+Favero&title=Levofloxacin+to+prevent+bacterial+infection+in+patients+with+cancer+and+neutropenia&doi=10.1056%2FNEJMoa044097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39cR"><div class="casContent"><span class="casTitleNuber">39c</span><div class="casTitle"><span class="NLM_cas:atitle">Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia</span></div><div class="casAuthors">Bucaneve, Giampaolo; Micozzi, Alessandra; Menichetti, Francesco; Martino, Pietro; Dionisi, M. Stella; Martinelli, Giovanni; Allione, Bernardino; D'Antonio, Domenico; Buelli, Maurizio; Nosari, A. Maria; Cilloni, Daniela; Zuffa, Eliana; Cantaffa, Renato; Specchia, Giorgina; Amadori, Sergio; Fabbiano, Francesco; Deliliers, Giorgio Lambertenghi; Lauria, Francesco; Foa, Robin; Del Favero, Albano</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">977-987</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: The prophylactic use of fluoroquinolones in patients with cancer and neutropenia is controversial and is not a recommended intervention.  METHODS: We randomly assigned 760 consecutive adult patients with cancer in whom chemotherapy-induced neutropenia (<1000 neutrophils per cubic millimeter) was expected to occur for more than seven days to receive either oral levofloxacin (500 mg daily) or placebo from the start of chemotherapy until the resoln. of neutropenia.  Patients were stratified according to their underlying disease (acute leukemia vs. solid tumor or lymphoma).  RESULTS: An intention-to-treat anal. showed that fever was present for the duration of neutropenia in 65 % of patients who received levofloxacin prophylaxis, as compared with 85 % of those receiving placebo (243 of 375 vs. 308 of 363; relative risk, 0.76; abs. difference in risk, -20 %; 95 % confidence interval, -26 to -14 %; P = 0.001).  The levofloxacin group had a lower rate of microbiol. documented infections (abs. difference in risk, -17 %; 95 % confidence interval, -24 to -10 %; P < 0.001), bacteremias (difference in risk, -16 %; 95 % confidence interval, -22 to -9 %; P < 0.001), and single-agent gram-neg. bacteremias (difference in risk, -7 %; 95 % confidence interval, -10 to -2 %; P < 0.01) than did the placebo group.  Mortality and tolerability were similar in the two groups.  The effects of prophylaxis were also similar between patients with acute leukemia and those with solid tumors or lymphoma.  CONCLUSIONS: Prophylactic treatment with levofloxacin is an effective and well-tolerated way of preventing febrile episodes and other relevant infection-related outcomes in patients with cancer and profound and protracted neutropenia.  The long-term effect of this intervention on microbial resistance in the community is not known.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqb1q0PotP99LVg90H21EOLACvtfcHk0lipUsvpNemzPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpvVOis7k%253D&md5=0f5820d78f7928ed6c0267fbeb2b6e1c</span></div><a href="/servlet/linkout?suffix=cit39c&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa044097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa044097%26sid%3Dliteratum%253Aachs%26aulast%3DBucaneve%26aufirst%3DG.%26aulast%3DMicozzi%26aufirst%3DA.%26aulast%3DMenichetti%26aufirst%3DF.%26aulast%3DMartino%26aufirst%3DP.%26aulast%3DDionisi%26aufirst%3DM.%2BS.%26aulast%3DMartinelli%26aufirst%3DG.%26aulast%3DAllione%26aufirst%3DB.%26aulast%3DD%25E2%2580%2599Antonio%26aufirst%3DD.%26aulast%3DBuelli%26aufirst%3DM.%26aulast%3DNosari%26aufirst%3DA.%2BM.%26aulast%3DCilloni%26aufirst%3DD.%26aulast%3DZuffa%26aufirst%3DE.%26aulast%3DCantaffa%26aufirst%3DR.%26aulast%3DSpecchia%26aufirst%3DG.%26aulast%3DAmadori%26aufirst%3DS.%26aulast%3DFabbiano%26aufirst%3DF.%26aulast%3DDeliliers%26aufirst%3DG.%2BL.%26aulast%3DLauria%26aufirst%3DF.%26aulast%3DFoa%26aufirst%3DR.%26aulast%3DDel%2BFavero%26aufirst%3DA.%26atitle%3DLevofloxacin%2520to%2520prevent%2520bacterial%2520infection%2520in%2520patients%2520with%2520cancer%2520and%2520neutropenia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D353%26spage%3D977%26epage%3D987%26doi%3D10.1056%2FNEJMoa044097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Littke, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, G. C.</span><span> </span><span class="NLM_article-title">Versatile catalysts for the Suzuki cross-coupling of arylboronic acids with aryl and vinyl halides and triflates under mild conditions</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">4020</span><span class="NLM_x">–</span> <span class="NLM_lpage">4028</span><span class="refDoi"> DOI: 10.1021/ja0002058</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja0002058" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BD3cXisVKktb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2000&pages=4020-4028&author=A.+F.+Littkeauthor=C.+Y.+Daiauthor=G.+C.+Fu&title=Versatile+catalysts+for+the+Suzuki+cross-coupling+of+arylboronic+acids+with+aryl+and+vinyl+halides+and+triflates+under+mild+conditions&doi=10.1021%2Fja0002058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40aR"><div class="casContent"><span class="casTitleNuber">40a</span><div class="casTitle"><span class="NLM_cas:atitle">Versatile Catalysts for the Suzuki Cross-Coupling of Arylboronic Acids with Aryl and Vinyl Halides and Triflates under Mild Conditions</span></div><div class="casAuthors">Littke, Adam F.; Dai, Chaoyang; Fu, Gregory C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4020-4028</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Through the use of Pd2(dba)3/P(t-Bu)3 as a catalyst, a wide range of aryl and vinyl chlorides, bromides, and iodides undergo Suzuki cross-coupling with arylboronic acids in very good yield, typically at room temp.  In the presence of Pd(OAc)2 and PCy3, a diverse array of aryl and vinyl triflates react cleanly at room temp. with arylboronic acids.  The catalyst systems Pd2(dba)3/(Me3C)3P and Pd(OAc)2/PCy3 cover a broad spectrum of commonly encountered substrates for Suzuki couplings.  Selective cross-coupling of an aryl chloride in the presence of an aryl triflate was performed in the presence of Pd2(dba)3/P(t-Bu)3 while selective coupling of an aryl triflate in the presence of an aryl chloride was performed in the presence of Pd(OAc)2/PCy3.  Both Suzuki cross-coupling catalyst systems are effective at low loadings [as low as 0.005 mol% Pd2(dba)3/0.01 mol% P(Bu-t)3], even with aryl chloride substrates [0.05 - 3 mol% Pd2(dba)3/0.12 - 6 mol% P(Bu-t)3].  Preliminary mechanistic work indicates that a palladium monophosphine complex is the active catalyst in the cross-coupling of aryl halides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRwuDVqwRT-bVg90H21EOLACvtfcHk0lifdh9gYnItTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXisVKktb4%253D&md5=1bd3a8daa7a9f110479a7d12520cc5fb</span></div><a href="/servlet/linkout?suffix=cit40a&amp;dbid=16384&amp;doi=10.1021%2Fja0002058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja0002058%26sid%3Dliteratum%253Aachs%26aulast%3DLittke%26aufirst%3DA.%2BF.%26aulast%3DDai%26aufirst%3DC.%2BY.%26aulast%3DFu%26aufirst%3DG.%2BC.%26atitle%3DVersatile%2520catalysts%2520for%2520the%2520Suzuki%2520cross-coupling%2520of%2520arylboronic%2520acids%2520with%2520aryl%2520and%2520vinyl%2520halides%2520and%2520triflates%2520under%2520mild%2520conditions%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2000%26volume%3D122%26spage%3D4020%26epage%3D4028%26doi%3D10.1021%2Fja0002058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit40b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kotha, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lahiri, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kashinath, D.</span><span> </span><span class="NLM_article-title">Recent applications of the Suzuki-Miyaura cross-coupling reaction in organic synthesis</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">9633</span><span class="NLM_x">–</span> <span class="NLM_lpage">9695</span><span class="refDoi"> DOI: 10.1016/S0040-4020(02)01188-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1016%2FS0040-4020%2802%2901188-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BD38XovVSmtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2002&pages=9633-9695&author=S.+Kothaauthor=K.+Lahiriauthor=D.+Kashinath&title=Recent+applications+of+the+Suzuki-Miyaura+cross-coupling+reaction+in+organic+synthesis&doi=10.1016%2FS0040-4020%2802%2901188-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40bR"><div class="casContent"><span class="casTitleNuber">40b</span><div class="casTitle"><span class="NLM_cas:atitle">Recent applications of the Suzuki-Miyaura cross-coupling reaction in organic synthesis</span></div><div class="casAuthors">Kotha, Sambasivarao; Lahiri, Kakali; Kashinath, Dhurke</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">9633-9695</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review including prepn. of boronic acids and their derivs.; catalyst development; reactions under green conditions; prepn. of biphenyls and related systems; dendrimer prepn.; prepn. of unusual amino acids and peptides; cross-coupling of sp3, sp2, and sp hybridized compds.; prepn. of natural and unnatural products; solid-supported synthesis; formation of C-N, C-O, and C-S bonds; prepn. of diaryl ketones via carbonylative cross-coupling; and rhodium- and nickel-catalyzed reactions of arylboronic acids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqifcXmma-5_bVg90H21EOLACvtfcHk0lifdh9gYnItTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XovVSmtbg%253D&md5=e0060b7e3391257704c2ee55d07c2660</span></div><a href="/servlet/linkout?suffix=cit40b&amp;dbid=16384&amp;doi=10.1016%2FS0040-4020%2802%2901188-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4020%252802%252901188-2%26sid%3Dliteratum%253Aachs%26aulast%3DKotha%26aufirst%3DS.%26aulast%3DLahiri%26aufirst%3DK.%26aulast%3DKashinath%26aufirst%3DD.%26atitle%3DRecent%2520applications%2520of%2520the%2520Suzuki-Miyaura%2520cross-coupling%2520reaction%2520in%2520organic%2520synthesis%26jtitle%3DTetrahedron%26date%3D2002%26volume%3D58%26spage%3D9633%26epage%3D9695%26doi%3D10.1016%2FS0040-4020%2802%2901188-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Rodems, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamman, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heidary, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Makings, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stack, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollok, B. A.</span><span> </span><span class="NLM_article-title">A FRET-based assay platform for ultra-high density drug screening of protein kinases and phosphatases</span> <span class="citation_source-journal">Assay Drug Dev. Technol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">9</span><span class="NLM_x">–</span> <span class="NLM_lpage">19</span><span class="refDoi"> DOI: 10.1089/154065802761001266</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1089%2F154065802761001266" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=9-19&author=S.+M.+Rodemsauthor=B.+D.+Hammanauthor=C.+Linauthor=J.+Zhaoauthor=S.+Shahauthor=D.+Heidaryauthor=L.+Makingsauthor=J.+H.+Stackauthor=B.+A.+Pollok&title=A+FRET-based+assay+platform+for+ultra-high+density+drug+screening+of+protein+kinases+and+phosphatases&doi=10.1089%2F154065802761001266"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1089%2F154065802761001266&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252F154065802761001266%26sid%3Dliteratum%253Aachs%26aulast%3DRodems%26aufirst%3DS.%2BM.%26aulast%3DHamman%26aufirst%3DB.%2BD.%26aulast%3DLin%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DShah%26aufirst%3DS.%26aulast%3DHeidary%26aufirst%3DD.%26aulast%3DMakings%26aufirst%3DL.%26aulast%3DStack%26aufirst%3DJ.%2BH.%26aulast%3DPollok%26aufirst%3DB.%2BA.%26atitle%3DA%2520FRET-based%2520assay%2520platform%2520for%2520ultra-high%2520density%2520drug%2520screening%2520of%2520protein%2520kinases%2520and%2520phosphatases%26jtitle%3DAssay%2520Drug%2520Dev.%2520Technol.%26date%3D2002%26volume%3D1%26spage%3D9%26epage%3D19%26doi%3D10.1089%2F154065802761001266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Fabian, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biggs, W. H.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azimioara, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benedetti, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerlach, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grotzfeld, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lelias, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span> </span><span class="NLM_article-title">A small molecule-kinase interaction map for clinical kinase inhibitors</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">329</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span><span class="refDoi"> DOI: 10.1038/nbt1068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1038%2Fnbt1068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=15711537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=329-336&author=M.+A.+Fabianauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=C.+E.+Atteridgeauthor=M.+D.+Azimioaraauthor=M.+G.+Benedettiauthor=T.+A.+Carterauthor=P.+Ciceriauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=M.+Galvinauthor=J.+L.+Gerlachauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=M.+A.+Inskoauthor=A.+G.+Laiauthor=J.+M.+Leliasauthor=S.+A.+Mehtaauthor=Z.+V.+Milanovauthor=A.+M.+Velascoauthor=L.+M.+Wodickaauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=A+small+molecule-kinase+interaction+map+for+clinical+kinase+inhibitors&doi=10.1038%2Fnbt1068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42aR"><div class="casContent"><span class="casTitleNuber">42a</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule-kinase interaction map for clinical kinase inhibitors</span></div><div class="casAuthors">Fabian, Miles A.; Biggs, William H.; Treiber, Daniel K.; Atteridge, Corey E.; Azimioara, Mihai D.; Benedetti, Michael G.; Carter, Todd A.; Ciceri, Pietro; Edeen, Philip T.; Floyd, Mark; Ford, Julia M.; Galvin, Margaret; Gerlach, Jay L.; Grotzfeld, Robert M.; Herrgard, Sanna; Insko, Darren E.; Insko, Michael A.; Lai, Andiliy G.; Lelias, Jean-Michel; Mehta, Shamal A.; Milanov, Zdravko V.; Velasco, Anne Marie; Wodicka, Lisa M.; Patel, Hitesh K.; Zarrinkar, Patrick P.; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors show great promise as a new class of therapeutics.  Here the authors describe an efficient way to det. kinase inhibitor specificity by measuring binding of small mols. to the ATP site of kinases.  The authors have profiled 20 kinase inhibitors, including 16 that are approved drugs or in clin. development, against a panel of 119 protein kinases.  The authors find that specificity varies widely and is not strongly correlated with chem. structure or the identity of the intended target.  Many novel interactions were identified, including tight binding of the p38 inhibitor BIRB-796 to an imatinib-resistant variant of the ABL kinase, and binding of imatinib to the SRC-family kinase LCK.  The authors also show that mutations in the epidermal growth factor receptor (EGFR) found in gefitinib-responsive patients do not affect the binding affinity of gefitinib or erlotinib.  Our results represent a systematic small mol.-protein interaction map for clin. compds. across a large no. of related proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA0vNmMOXrnrVg90H21EOLACvtfcHk0lifdh9gYnItTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D&md5=6aedd5ceb8f77cd26ee50425dcec7bdf</span></div><a href="/servlet/linkout?suffix=cit42a&amp;dbid=16384&amp;doi=10.1038%2Fnbt1068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1068%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DAzimioara%26aufirst%3DM.%2BD.%26aulast%3DBenedetti%26aufirst%3DM.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGalvin%26aufirst%3DM.%26aulast%3DGerlach%26aufirst%3DJ.%2BL.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DInsko%26aufirst%3DM.%2BA.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DLelias%26aufirst%3DJ.%2BM.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DA%2520small%2520molecule-kinase%2520interaction%2520map%2520for%2520clinical%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D329%26epage%3D336%26doi%3D10.1038%2Fnbt1068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit42b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Karaman, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallant, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faraoni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span> </span><span class="NLM_article-title">A quantitative analysis of kinase inhibitor selectivity</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">132</span><span class="refDoi"> DOI: 10.1038/nbt1358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1038%2Fnbt1358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=18183025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=127-132&author=M.+W.+Karamanauthor=S.+Herrgardauthor=D.+K.+Treiberauthor=P.+Gallantauthor=C.+E.+Atteridgeauthor=B.+T.+Campbellauthor=K.+W.+Chanauthor=P.+Ciceriauthor=M.+I.+Davisauthor=P.+T.+Edeenauthor=R.+Faraoniauthor=M.+Floydauthor=J.+P.+Huntauthor=D.+J.+Lockhartauthor=Z.+V.+Milanovauthor=M.+J.+Morrisonauthor=G.+Pallaresauthor=H.+K.+Patelauthor=S.+Pritchardauthor=L.+M.+Wodickaauthor=P.+P.+Zarrinkar&title=A+quantitative+analysis+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt1358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42bR"><div class="casContent"><span class="casTitleNuber">42b</span><div class="casTitle"><span class="NLM_cas:atitle">A quantitative analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-132</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets.  The biol. consequences of multikinase activity are poorly defined, and an important step toward understanding the relationship between selectivity, efficacy and safety is the exploration of how inhibitors interact with the human kinome.  The authors present interaction maps for 38 kinase inhibitors across a panel of 317 kinases representing >50% of the predicted human protein kinome.  The data constitute the most comprehensive study of kinase inhibitor selectivity to date and reveal a wide diversity of interaction patterns.  To enable a global anal. of the results, the authors introduce the concept of a selectivity score as a general tool to quantify and differentiate the obsd. interaction patterns.  The authors further investigate the impact of panel size and find that small assay panels do not provide a robust measure of selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiArJSq2_lPrVg90H21EOLACvtfcHk0ljDqpcZu5vVTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D&md5=346265d412853ced636ad4128ed8a76f</span></div><a href="/servlet/linkout?suffix=cit42b&amp;dbid=16384&amp;doi=10.1038%2Fnbt1358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1358%26sid%3Dliteratum%253Aachs%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DChan%26aufirst%3DK.%2BW.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DMorrison%26aufirst%3DM.%2BJ.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DA%2520quantitative%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D127%26epage%3D132%26doi%3D10.1038%2Fnbt1358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Valencia, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ormazabal, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zandueta, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luis-Ravelo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anton, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pajares, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agorreta, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montuenga, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez-Canarias, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leitinger, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lecanda, F.</span><span> </span><span class="NLM_article-title">Inhibition of collagen receptor discoidin domain receptor-1 (DDR1) reduces cell survival, homing, and colonization in lung cancer bone metastasis</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">969</span><span class="NLM_x">–</span> <span class="NLM_lpage">980</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-1686</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1158%2F1078-0432.CCR-11-1686" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=22223527" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC38XisVGgs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=969-980&author=K.+Valenciaauthor=C.+Ormazabalauthor=C.+Zanduetaauthor=D.+Luis-Raveloauthor=I.+Antonauthor=M.+J.+Pajaresauthor=J.+Agorretaauthor=L.+M.+Montuengaauthor=S.+Martinez-Canariasauthor=B.+Leitingerauthor=F.+Lecanda&title=Inhibition+of+collagen+receptor+discoidin+domain+receptor-1+%28DDR1%29+reduces+cell+survival%2C+homing%2C+and+colonization+in+lung+cancer+bone+metastasis&doi=10.1158%2F1078-0432.CCR-11-1686"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43aR"><div class="casContent"><span class="casTitleNuber">43a</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Collagen Receptor Discoidin Domain Receptor-1 (DDR1) Reduces Cell Survival, Homing, and Colonization in Lung Cancer Bone Metastasis</span></div><div class="casAuthors">Valencia, Karmele; Ormazabal, Cristina; Zandueta, Carolina; Luis-Ravelo, Diego; Anton, Iker; Pajares, Maria J.; Agorreta, Jackeline; Montuenga, Luis M.; Martinez-Canarias, Susana; Leitinger, Birgit; Lecanda, Fernando</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">969-980</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: We investigated the role of the collagen-binding receptor discoidin domain receptor-1 (DDR1) in the initiation and development of bone metastasis.  Exptl. Design: We conducted immunohistochem. analyses in a cohort of 83 lung cancer specimens and examd. phosphorylation status in a panel of human lung cancer cell lines.  Adhesion, chemotaxis, invasiveness, metalloproteolytic, osteoclastogenic, and apoptotic assays were conducted in DDR1-silenced cells.  In vivo, metastatic osseous homing and colonization were assessed in a murine model of metastasis.  RESULTS: DDR1 was expressed in a panel of human lung cancer cell lines, and high DDR1 levels in human lung tumors were assocd. with poor survival.  Knockdown (shDDR1) cells displayed unaltered growth kinetics in vitro and in vivo.  In contrast, shDDR1 cells showed reduced invasiveness in collagen matrixes and increased apoptosis in basal conditions and induced apoptosis in vitro.  More importantly, conditioned media of DDR1-knockdown cells decreased osteoclastogenic activity in vitro.  Consequently, in a model of tumor metastasis to bone, lack of DDR1 showed decreased metastatic activity assocd. with reduced tumor burden and osteolytic lesions.  These effects were consistent with a substantial redn. in the no. of cells reaching the bone compartment.  Moreover, intratibial injection of shDDR1 cells significantly decreased bone tumor burden, suggesting impaired colonization ability that was highly dependent on the bone microenvironment.  CONCLUSIONS: Disruption of DDR1 hampers tumor cell survival, leading to impaired early tumor-bone engagement during skeletal homing.  Furthermore, inhibition of DDR1 crucially alters bone colonization.  We suggest that DDR1 represents a novel therapeutic target involved in bone metastasis.  Clin Cancer Res; 18(4); 969-80.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRyWFLZ7ytcbVg90H21EOLACvtfcHk0ljDqpcZu5vVTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XisVGgs7s%253D&md5=34984329a0773cfff78cc244b0ea9a51</span></div><a href="/servlet/linkout?suffix=cit43a&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-1686&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-1686%26sid%3Dliteratum%253Aachs%26aulast%3DValencia%26aufirst%3DK.%26aulast%3DOrmazabal%26aufirst%3DC.%26aulast%3DZandueta%26aufirst%3DC.%26aulast%3DLuis-Ravelo%26aufirst%3DD.%26aulast%3DAnton%26aufirst%3DI.%26aulast%3DPajares%26aufirst%3DM.%2BJ.%26aulast%3DAgorreta%26aufirst%3DJ.%26aulast%3DMontuenga%26aufirst%3DL.%2BM.%26aulast%3DMartinez-Canarias%26aufirst%3DS.%26aulast%3DLeitinger%26aufirst%3DB.%26aulast%3DLecanda%26aufirst%3DF.%26atitle%3DInhibition%2520of%2520collagen%2520receptor%2520discoidin%2520domain%2520receptor-1%2520%2528DDR1%2529%2520reduces%2520cell%2520survival%252C%2520homing%252C%2520and%2520colonization%2520in%2520lung%2520cancer%2520bone%2520metastasis%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D969%26epage%3D980%26doi%3D10.1158%2F1078-0432.CCR-11-1686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit43b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Meshinchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Appelbaum, F. R.</span><span> </span><span class="NLM_article-title">Structural and functional alterations of FLT3 in acute myeloid leukemia</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">4263</span><span class="NLM_x">–</span> <span class="NLM_lpage">4269</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-08-1123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1158%2F1078-0432.CCR-08-1123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=19549778" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnvFajsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=4263-4269&author=S.+Meshinchiauthor=F.+R.+Appelbaum&title=Structural+and+functional+alterations+of+FLT3+in+acute+myeloid+leukemia&doi=10.1158%2F1078-0432.CCR-08-1123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43bR"><div class="casContent"><span class="casTitleNuber">43b</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Functional Alterations of FLT3 in Acute Myeloid Leukemia</span></div><div class="casAuthors">Meshinchi, Soheil; Appelbaum, Frederick R.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4263-4269</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Hematopoiesis is highly regulated through cytokine-induced stimulation of multiple signal transduction pathways in order to mediate appropriate differentiation and proliferation of specific progenitor populations.  Ligand-induced stimulation of the FMS-like tyrosine kinase 3 (FLT3) leads to activation of multiple downstream effector pathways resulting in differentiation and proliferation of specific progenitor cell populations.  Genomic alterations of the FLT3 gene, including FLT3 internal tandem duplication (FLT3/ITD) and FLT3 activation loop mutation (FLT3/ALM) lead to autonomous receptor activation, dysregulation of FLT3 signal transduction pathways, contribute to myeloid pathogenesis, and have been linked to response to therapy and clin. outcome.  Exploring the mechanisms by which these FLT3 alterations lead to dysregulated proliferation should provide a better understanding of the mol. pathogenesis of acute myeloid leukemia (AML) and may provide insights into potential therapeutic interventions.  FLT3 inhibitors are under evaluation for their efficacy in AML patients with FLT3 mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAErdWLDL077Vg90H21EOLACvtfcHk0liASFHVAzYhDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnvFajsb4%253D&md5=ddde20ad844268c1baf2df563604f40f</span></div><a href="/servlet/linkout?suffix=cit43b&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-1123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-1123%26sid%3Dliteratum%253Aachs%26aulast%3DMeshinchi%26aufirst%3DS.%26aulast%3DAppelbaum%26aufirst%3DF.%2BR.%26atitle%3DStructural%2520and%2520functional%2520alterations%2520of%2520FLT3%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D4263%26epage%3D4269%26doi%3D10.1158%2F1078-0432.CCR-08-1123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit43cc"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Belkina, N. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hao, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karasuyama, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, S.</span><span> </span><span class="NLM_article-title">LOK is a major ERM kinase in resting lymphocytes and regulates cytoskeletal rearrangement through ERM phosphorylation</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">4707</span><span class="NLM_x">–</span> <span class="NLM_lpage">4712</span><span class="refDoi"> DOI: 10.1073/pnas.0805963106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43cc&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1073%2Fpnas.0805963106" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=4707-4712&author=N.+V.+Belkinaauthor=Y.+Liuauthor=J.+J.+Haoauthor=H.+Karasuyamaauthor=S.+Shaw&title=LOK+is+a+major+ERM+kinase+in+resting+lymphocytes+and+regulates+cytoskeletal+rearrangement+through+ERM+phosphorylation&doi=10.1073%2Fpnas.0805963106"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43cc&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0805963106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0805963106%26sid%3Dliteratum%253Aachs%26aulast%3DBelkina%26aufirst%3DN.%2BV.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DHao%26aufirst%3DJ.%2BJ.%26aulast%3DKarasuyama%26aufirst%3DH.%26aulast%3DShaw%26aufirst%3DS.%26atitle%3DLOK%2520is%2520a%2520major%2520ERM%2520kinase%2520in%2520resting%2520lymphocytes%2520and%2520regulates%2520cytoskeletal%2520rearrangement%2520through%2520ERM%2520phosphorylation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2009%26volume%3D106%26spage%3D4707%26epage%3D4712%26doi%3D10.1073%2Fpnas.0805963106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit43c"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Mehta, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarthy, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thilak, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robson, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neal, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, H. Y.</span><span> </span><span class="NLM_article-title">MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1381</span><span class="NLM_x">–</span> <span class="NLM_lpage">1389</span><span class="refDoi"> DOI: 10.1038/sj.onc.1206154</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1038%2Fsj.onc.1206154" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2003&pages=1381-1389&author=P.+B.+Mehtaauthor=B.+L.+Jenkinsauthor=L.+McCarthyauthor=L.+Thilakauthor=C.+N.+Robsonauthor=D.+E.+Nealauthor=H.+Y.+Leung&title=MEK5+overexpression+is+associated+with+metastatic+prostate+cancer%2C+and+stimulates+proliferation%2C+MMP-9+expression+and+invasion&doi=10.1038%2Fsj.onc.1206154"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43c&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1206154&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1206154%26sid%3Dliteratum%253Aachs%26aulast%3DMehta%26aufirst%3DP.%2BB.%26aulast%3DJenkins%26aufirst%3DB.%2BL.%26aulast%3DMcCarthy%26aufirst%3DL.%26aulast%3DThilak%26aufirst%3DL.%26aulast%3DRobson%26aufirst%3DC.%2BN.%26aulast%3DNeal%26aufirst%3DD.%2BE.%26aulast%3DLeung%26aufirst%3DH.%2BY.%26atitle%3DMEK5%2520overexpression%2520is%2520associated%2520with%2520metastatic%2520prostate%2520cancer%252C%2520and%2520stimulates%2520proliferation%252C%2520MMP-9%2520expression%2520and%2520invasion%26jtitle%3DOncogene%26date%3D2003%26volume%3D22%26spage%3D1381%26epage%3D1389%26doi%3D10.1038%2Fsj.onc.1206154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit43d"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zejnullahu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsudomi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hyland, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gale, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappuzzo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mok, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantley, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">316</span><span class="NLM_x">, </span> <span class="NLM_fpage">1039</span><span class="NLM_x">–</span> <span class="NLM_lpage">1043</span><span class="refDoi"> DOI: 10.1126/science.1141478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1126%2Fscience.1141478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=17463250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltlOjt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=2007&pages=1039-1043&author=J.+A.+Engelmanauthor=K.+Zejnullahuauthor=T.+Mitsudomiauthor=Y.+C.+Songauthor=C.+Hylandauthor=J.+O.+Parkauthor=N.+Lindemanauthor=C.+M.+Galeauthor=X.+J.+Zhaoauthor=J.+Christensenauthor=T.+Kosakaauthor=A.+J.+Holmesauthor=A.+M.+Rogersauthor=F.+Cappuzzoauthor=T.+Mokauthor=C.+Leeauthor=B.+E.+Johnsonauthor=L.+C.+Cantleyauthor=P.+A.+Janne&title=MET+amplification+leads+to+gefitinib+resistance+in+lung+cancer+by+activating+ERBB3+signaling&doi=10.1126%2Fscience.1141478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43dR"><div class="casContent"><span class="casTitleNuber">43e</span><div class="casTitle"><span class="NLM_cas:atitle">MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling</span></div><div class="casAuthors">Engelman, Jeffrey A.; Zejnullahu, Kreshnik; Mitsudomi, Tetsuya; Song, Youngchul; Hyland, Courtney; Park, Joon Oh; Lindeman, Neal; Gale, Christopher-Michael; Zhao, Xiaojun; Christensen, James; Kosaka, Takayuki; Holmes, Alison J.; Rogers, Andrew M.; Cappuzzo, Federico; Mok, Tony; Lee, Charles; Johnson, Bruce E.; Cantley, Lewis C.; Jaenne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">316</span>
        (<span class="NLM_cas:issue">5827</span>),
    <span class="NLM_cas:pages">1039-1043</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR) kinase inhibitors gefitinib and erlotinib are effective treatments for lung cancers with EGFR activating mutations, but these tumors invariably develop drug resistance.  Here, we describe a gefitinib-sensitive lung cancer cell line that developed resistance to gefitinib as a result of focal amplification of the MET proto-oncogene. inhibition of MET signaling in these cells restored their sensitivity to gefitinib.  MET amplification was detected in 4 of 18 (22%) lung cancer specimens that had developed resistance to gefitinib or erlotinib.  We find that amplification of MET causes gefitinib resistance by driving ERBB3 (HER3)-dependent activation of PI3K, a pathway thought to be specific to EGFR/ERBB family receptors.  Thus, we propose that MET amplification may promote drug resistance in other ERBB-driven cancers as well.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr430gbvBeIoLVg90H21EOLACvtfcHk0liASFHVAzYhDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltlOjt7g%253D&md5=3da9383b4acb965f57529b095f8f4686</span></div><a href="/servlet/linkout?suffix=cit43d&amp;dbid=16384&amp;doi=10.1126%2Fscience.1141478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1141478%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DZejnullahu%26aufirst%3DK.%26aulast%3DMitsudomi%26aufirst%3DT.%26aulast%3DSong%26aufirst%3DY.%2BC.%26aulast%3DHyland%26aufirst%3DC.%26aulast%3DPark%26aufirst%3DJ.%2BO.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DGale%26aufirst%3DC.%2BM.%26aulast%3DZhao%26aufirst%3DX.%2BJ.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DKosaka%26aufirst%3DT.%26aulast%3DHolmes%26aufirst%3DA.%2BJ.%26aulast%3DRogers%26aufirst%3DA.%2BM.%26aulast%3DCappuzzo%26aufirst%3DF.%26aulast%3DMok%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DMET%2520amplification%2520leads%2520to%2520gefitinib%2520resistance%2520in%2520lung%2520cancer%2520by%2520activating%2520ERBB3%2520signaling%26jtitle%3DScience%26date%3D2007%26volume%3D316%26spage%3D1039%26epage%3D1043%26doi%3D10.1126%2Fscience.1141478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit43e"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Wadhwa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nag, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jindal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kushwaha, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahapatra, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarkar, C.</span><span> </span><span class="NLM_article-title">Expression of the neurotrophin receptors Trk A and Trk B in adult human astrocytoma and glioblastoma</span> <span class="citation_source-journal">J. Biosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">181</span><span class="NLM_x">–</span> <span class="NLM_lpage">188</span><span class="refDoi"> DOI: 10.1007/BF02706217</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1007%2FBF02706217" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=12711810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BD3sXislWitb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2003&pages=181-188&author=S.+Wadhwaauthor=T.+C.+Nagauthor=A.+Jindalauthor=R.+Kushwahaauthor=A.+K.+Mahapatraauthor=C.+Sarkar&title=Expression+of+the+neurotrophin+receptors+Trk+A+and+Trk+B+in+adult+human+astrocytoma+and+glioblastoma&doi=10.1007%2FBF02706217"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43eR"><div class="casContent"><span class="casTitleNuber">43f</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of the neurotrophin receptors Trk A and Trk B in adult human astrocytoma and glioblastoma</span></div><div class="casAuthors">Wadhwa, Shashi; Nag, Tapas C.; Jindal, Anupam; Kushwaha, Rahul; Mahapatra, Ashok K.; Sarkar, Chitra</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biosciences (Bangalore, India)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">181-188</span>CODEN:
                <span class="NLM_cas:coden">JOBSDN</span>;
        ISSN:<span class="NLM_cas:issn">0250-5991</span>.
    
            (<span class="NLM_cas:orgname">Indian Academy of Sciences</span>)
        </div><div class="casAbstract">Neurotrophins and their receptors of the Trk family play a crit. role in proliferation, differentiation and survival of the developing neurons.  There are reports on their expression in neoplasms too, namely, the primitive neuroectodermal tumors of childhood, and in adult astrocytic gliomas.  The involvement of Trk receptors in tumor pathogenesis, if any, is not known.  With this end in view, the present study has examd. 10 tumor biopsy samples (identified as astrocytoma, pilocytic astrocytoma and glioblastoma) and peritumoral brain tissue of adult patients, for the presence of Trk A and Trk B receptors, by immunohistochem.  The nature of the tumor samples was also confirmed by their immunoreactivity (IR) to glial fibrillary acidic protein.  In the peritumoral brain tissue, only neurons showed IR for Trk A and Trk B.  On the contrary, in the tumor sections, the IR to both receptors was localized in the vast majority of glia and capillary endothelium.  There was an obvious pattern of IR in these gliomas: high levels of IR were present in the low-grade (type I and II) astrocytoma; whereas in the advanced malignant forms (WHO grade IV giant cell glioblastoma and glioblastoma multiforme) the IR was very weak.  These findings suggest that Trk A and Trk B are involved in tumor pathogenesis, esp. in the early stage, and may respond to signals that elicit glial proliferation, and thus contribute to progression towards malignancy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriBJYe5VdXG7Vg90H21EOLACvtfcHk0liASFHVAzYhDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXislWitb8%253D&md5=d5a14151772b6fa49dad99749273af5f</span></div><a href="/servlet/linkout?suffix=cit43e&amp;dbid=16384&amp;doi=10.1007%2FBF02706217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF02706217%26sid%3Dliteratum%253Aachs%26aulast%3DWadhwa%26aufirst%3DS.%26aulast%3DNag%26aufirst%3DT.%2BC.%26aulast%3DJindal%26aufirst%3DA.%26aulast%3DKushwaha%26aufirst%3DR.%26aulast%3DMahapatra%26aufirst%3DA.%2BK.%26aulast%3DSarkar%26aufirst%3DC.%26atitle%3DExpression%2520of%2520the%2520neurotrophin%2520receptors%2520Trk%2520A%2520and%2520Trk%2520B%2520in%2520adult%2520human%2520astrocytoma%2520and%2520glioblastoma%26jtitle%3DJ.%2520Biosci.%26date%3D2003%26volume%3D28%26spage%3D181%26epage%3D188%26doi%3D10.1007%2FBF02706217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Y.</span><span> </span><span class="NLM_article-title">Axl as a downstream effector of TGF-beta1 via PI3K/Akt-PAK1 signaling pathway promotes tumor invasion and chemoresistance in breast carcinoma</span> <span class="citation_source-journal">Tumor Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">1115</span><span class="NLM_x">–</span> <span class="NLM_lpage">1127</span><span class="refDoi"> DOI: 10.1007/s13277-014-2677-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1007%2Fs13277-014-2677-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=25327287" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVent7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2015&pages=1115-1127&author=Y.+Liauthor=L.+Jiaauthor=C.+Liuauthor=Y.+Gongauthor=D.+Renauthor=N.+Wangauthor=X.+Zhangauthor=Y.+Zhao&title=Axl+as+a+downstream+effector+of+TGF-beta1+via+PI3K%2FAkt-PAK1+signaling+pathway+promotes+tumor+invasion+and+chemoresistance+in+breast+carcinoma&doi=10.1007%2Fs13277-014-2677-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Axl as a downstream effector of TGF-β1 via PI3K/Akt-PAK1 signaling pathway promotes tumor invasion and chemoresistance in breast carcinoma</span></div><div class="casAuthors">Li, Yanyan; Jia, Li; Liu, Chen; Gong, Yanxin; Ren, Dongliang; Wang, Ning; Zhang, Xu; Zhao, Yongfu</div><div class="citationInfo"><span class="NLM_cas:title">Tumor Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1115-1127</span>CODEN:
                <span class="NLM_cas:coden">TUMBEA</span>;
        ISSN:<span class="NLM_cas:issn">1010-4283</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The invasion and chemoresistance are crucial causes of morbidity and death for cancer patients.  Axl is closely assocd. with malignant phenotype of breast tumor cells, including invasiveness and metastasis.  Both breast cancer cell line and tissue displayed increased expression of Axl, esp. in highly metastatic breast cancer.  On the contrary, exptl. inhibition of Axl or transforming growth factor beta 1 (TGF-β1) by RNAi assay could suppress cell invasion ability and chemoresistance.  Moreover, the up-regulation of Axl was induced by TGF-β1, further activated phosphatidylinositol 3-kinase (PI3K)/Akt and PAK1 translocation, and resulted in greater cell motility, invasion, and chemoresistance in vitro and in vivo.  After the detection and statistics in human breast cancer specimens, we found that the Axl expression was closely correlated with TGF-β1 level, tumor differentiation, lymph node metastasis, and clin. stage (p < 0.01).  Our findings support the possibility that Axl is a significant regulator of invasion and chemosensitivity, and it means by targeting Axl or its related signaling pathways, we can reduce the invasion and chemosensitivity of breast tumor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG6SCNfxukf7Vg90H21EOLACvtfcHk0lhvo-aOUSwdnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVent7fF&md5=beb693147ee2a38c3113e98bf2beb0bc</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1007%2Fs13277-014-2677-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13277-014-2677-3%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DGong%26aufirst%3DY.%26aulast%3DRen%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DY.%26atitle%3DAxl%2520as%2520a%2520downstream%2520effector%2520of%2520TGF-beta1%2520via%2520PI3K%252FAkt-PAK1%2520signaling%2520pathway%2520promotes%2520tumor%2520invasion%2520and%2520chemoresistance%2520in%2520breast%2520carcinoma%26jtitle%3DTumor%2520Biol.%26date%3D2015%26volume%3D36%26spage%3D1115%26epage%3D1127%26doi%3D10.1007%2Fs13277-014-2677-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Sinha, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boysen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Secreto, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warner, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bearss, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesnick, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shanafelt, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kay, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, A. K.</span><span> </span><span class="NLM_article-title">Targeted Axl inhibition primes chronic lymphocytic leukemia B cells to apoptosis and shows synergistic/additive effects in combination with BTK inhibitors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">2115</span><span class="NLM_x">–</span> <span class="NLM_lpage">2126</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-1892</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1158%2F1078-0432.CCR-14-1892" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=25673699" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnvFaqs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=2115-2126&author=S.+Sinhaauthor=J.+Boysenauthor=M.+Nelsonauthor=C.+Secretoauthor=S.+L.+Warnerauthor=D.+J.+Bearssauthor=C.+Lesnickauthor=T.+D.+Shanafeltauthor=N.+E.+Kayauthor=A.+K.+Ghosh&title=Targeted+Axl+inhibition+primes+chronic+lymphocytic+leukemia+B+cells+to+apoptosis+and+shows+synergistic%2Fadditive+effects+in+combination+with+BTK+inhibitors&doi=10.1158%2F1078-0432.CCR-14-1892"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors</span></div><div class="casAuthors">Sinha, Sutapa; Boysen, Justin; Nelson, Michael; Secreto, Charla; Warner, Steven L.; Bearss, David J.; Lesnick, Connie; Shanafelt, Tait D.; Kay, Neil E.; Ghosh, Asish K.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2115-2126</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: B-cell chronic lymphocytic leukemia (CLL) is an incurable disease despite aggressive therapeutic approaches.  We previously found that Axl receptor tyrosine kinase (RTK) plays a crit. role in CLL B-cell survival.  Here, we explored the possibility of using a high-affinity Axl inhibitor as a single agent or in combination with Bruton's tyrosine kinase (BTK) inhibitors for future clin. trial to treat patients with CLL.  Exptl. Design: Expression/activation status of other members of the TAM (e.g., Tyro3, Axl, and MER) family of RTKs in CLL B cells was evaluated.  Cells were treated with a high-affinity orally bioavailable Axl inhibitor TP-0903 with or without the presence of CLL bone marrow stromal cells (BMSCs).  Inhibitory effects of TP-0903 on the Axl signaling pathway were also evaluated in CLL B cells.  Finally, cells were exposed to TP-0903 in combination with BTK inhibitors to det. any synergistic/additive effects of the combination.  Results: CLL B cells overexpress Tyro3, but not MER.  Of interest, Tyro3 remains as constitutively phosphorylated and forms a complex with Axl in CLL B cells.  TP-0903 induces massive apoptosis in CLL B cells with LD50 values of nanomolar ranges.  Importantly, CLL BMSCs could not protect the leukemic B cells from TP-0903-induced apoptosis.  A marked redn. of the antiapoptotic proteins Mcl-1, Bcl-2, and XIAP and upregulation of the proapoptotic protein BIM in CLL B cells was detected as a result of Axl inhibition.  Finally, combination of TP-0903 with BTK inhibitors augments CLL B-cell apoptosis.  Conclusions: Administration of TP-0903 either as a single agent or in combination with BTK inhibitors may be effective in treating patients with CLL.  Clin Cancer Res; 21(9); 2115-26. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmCcdSntQPu7Vg90H21EOLACvtfcHk0lhvo-aOUSwdnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnvFaqs7o%253D&md5=2d7554e400d1d5e4bee347f43dea2762</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-1892&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-1892%26sid%3Dliteratum%253Aachs%26aulast%3DSinha%26aufirst%3DS.%26aulast%3DBoysen%26aufirst%3DJ.%26aulast%3DNelson%26aufirst%3DM.%26aulast%3DSecreto%26aufirst%3DC.%26aulast%3DWarner%26aufirst%3DS.%2BL.%26aulast%3DBearss%26aufirst%3DD.%2BJ.%26aulast%3DLesnick%26aufirst%3DC.%26aulast%3DShanafelt%26aufirst%3DT.%2BD.%26aulast%3DKay%26aufirst%3DN.%2BE.%26aulast%3DGhosh%26aufirst%3DA.%2BK.%26atitle%3DTargeted%2520Axl%2520inhibition%2520primes%2520chronic%2520lymphocytic%2520leukemia%2520B%2520cells%2520to%2520apoptosis%2520and%2520shows%2520synergistic%252Fadditive%2520effects%2520in%2520combination%2520with%2520BTK%2520inhibitors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D2115%26epage%3D2126%26doi%3D10.1158%2F1078-0432.CCR-14-1892" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Rodriguez, L. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, X. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guan, J. L.</span><span> </span><span class="NLM_article-title">Wound-healing assay</span> <span class="citation_source-journal">Methods Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">294</span><span class="NLM_x">, </span> <span class="NLM_fpage">23</span><span class="NLM_x">–</span> <span class="NLM_lpage">29</span><span class="refDoi"> DOI: 10.1385/1-59259-860-9:023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1385%2F1-59259-860-9%3A023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=15576902" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A280%3ADC%252BD2cngsVaksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=294&publication_year=2005&pages=23-29&author=L.+G.+Rodriguezauthor=X.+Y.+Wuauthor=J.+L.+Guan&title=Wound-healing+assay&doi=10.1385%2F1-59259-860-9%3A023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Wound-healing assay</span></div><div class="casAuthors">Rodriguez Luis G; Wu Xiaoyang; Guan Jun-Lin</div><div class="citationInfo"><span class="NLM_cas:title">Methods in molecular biology (Clifton, N.J.)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">294</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">23-9</span>
        ISSN:<span class="NLM_cas:issn">1064-3745</span>.
    </div><div class="casAbstract">The wound-healing assay is simple, inexpensive, and one of the earliest developed methods to study directional cell migration in vitro.  This method mimics cell migration during wound healing in vivo.  The basic steps involve creating a "wound" in a cell monolayer, capturing the images at the beginning and at regular intervals during cell migration to close the wound, and comparing the images to quantify the migration rate of the cells.  It is particularly suitable for studies on the effects of cell-matrix and cell-cell interactions on cell migration.  A variation of this method that tracks the migration of individual cells in the leading edge of the wound is also described in this chapter.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQl9QyTalxlY0odMGTatQ7LfW6udTcc2eZAAkmDHRIM57ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2cngsVaksA%253D%253D&md5=6e48b14b34d8f3e673795ba74c95a647</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1385%2F1-59259-860-9%3A023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1385%252F1-59259-860-9%253A023%26sid%3Dliteratum%253Aachs%26aulast%3DRodriguez%26aufirst%3DL.%2BG.%26aulast%3DWu%26aufirst%3DX.%2BY.%26aulast%3DGuan%26aufirst%3DJ.%2BL.%26atitle%3DWound-healing%2520assay%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2005%26volume%3D294%26spage%3D23%26epage%3D29%26doi%3D10.1385%2F1-59259-860-9%3A023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Marshall, J.</span><span> </span><span class="NLM_article-title">Transwell  invasion assays</span> <span class="citation_source-journal">Methods Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">769</span><span class="NLM_x">, </span> <span class="NLM_fpage">97</span><span class="NLM_x">–</span> <span class="NLM_lpage">110</span><span class="refDoi"> DOI: 10.1007/978-1-61779-207-6_8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1007%2F978-1-61779-207-6_8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=21748672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvValtL3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=769&publication_year=2011&pages=97-110&author=J.+Marshall&title=Transwell++invasion+assays&doi=10.1007%2F978-1-61779-207-6_8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Transwell invasion assays</span></div><div class="casAuthors">Marshall, John</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">769</span>
        (<span class="NLM_cas:issue">Cell Migration</span>),
    <span class="NLM_cas:pages">97-110</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1064-3745</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The need to identify inhibitors of cancer invasion has driven the development of quant. in vitro invasion assays.  The most common assays used are based on the original Boyden assay system.  Today com. available plastic inserts for multi-well plates, which possess a cell-permeable membrane, as typified by Transwell Permeable Supports, permit accurate repeatable invasion assays.  When placed in the well of a multi-well tissue culture plate these inserts create a two-chamber system sepd. by the cell-permeable membrane.  To create an invasion assay the pores in the membrane are blocked with a gel composed of extracellular matrix that is meant to mimic the typical matrixes that tumor cells encounter during the invasion process in vivo.  By placing the cells on one side of the gel and a chemoattractant on the other side of the gel, invasion is detd. by counting those cells that have traversed the cell-permeable membrane having invaded towards the higher concn. of chemoattractant.  In this chapter, in addn. to protocols for performing Transwell invasion assays, there is consideration of the limitations of current assay designs with regard to available matrixes and the absence of tumor microenvironment cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7zbRBB-kc5LVg90H21EOLACvtfcHk0ljTVm7rejVihQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvValtL3F&md5=0e1a7a2315e8891770ad14540bd8e9b5</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1007%2F978-1-61779-207-6_8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-61779-207-6_8%26sid%3Dliteratum%253Aachs%26aulast%3DMarshall%26aufirst%3DJ.%26atitle%3DTranswell%2520%2520invasion%2520assays%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2011%26volume%3D769%26spage%3D97%26epage%3D110%26doi%3D10.1007%2F978-1-61779-207-6_8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Chen, H. C.</span><span> </span><span class="NLM_article-title">Boyden chamber assay</span> <span class="citation_source-journal">Methods Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">294</span><span class="NLM_x">, </span> <span class="NLM_fpage">15</span><span class="NLM_x">–</span> <span class="NLM_lpage">22</span><span class="refDoi"> DOI: 10.1385/1-59259-860-9:015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1385%2F1-59259-860-9%3A015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=15576901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A280%3ADC%252BD2cngsVaksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=294&publication_year=2005&pages=15-22&author=H.+C.+Chen&title=Boyden+chamber+assay&doi=10.1385%2F1-59259-860-9%3A015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Boyden chamber assay</span></div><div class="casAuthors">Chen Hong-Chen</div><div class="citationInfo"><span class="NLM_cas:title">Methods in molecular biology (Clifton, N.J.)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">294</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">15-22</span>
        ISSN:<span class="NLM_cas:issn">1064-3745</span>.
    </div><div class="casAbstract">The Boyden chamber assay, originally introduced by Boyden for the analysis of leukocyte chemotaxis, is based on a chamber of two medium-filled compartments separated by a microporous membrane.  In general, cells are placed in the upper compartment and are allowed to migrate through the pores of the membrane into the lower compartment, in which chemotactic agents are present.  After an appropriate incubation time, the membrane between the two compartments is fixed and stained, and the number of cells that have migrated to the lower side of the membrane is determined.  Therefore, the Boyden chamber-based cell migration assay has also been called filter membrane migration assay, trans-well migration assay, or chemotaxis assay.  A number of different Boyden chamber devices are available commercially.  The method described in this chapter is intended specifically for measuring the migration of Madin-Darby canine kidney cells using a 48-well chamber from Neuro Probe, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQl9QyTalxlY5w7prLlxLOzfW6udTcc2eYI5fsPHXD327ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2cngsVaksw%253D%253D&md5=bc388c5231733596bc778c560437a3de</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1385%2F1-59259-860-9%3A015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1385%252F1-59259-860-9%253A015%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DH.%2BC.%26atitle%3DBoyden%2520chamber%2520assay%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2005%26volume%3D294%26spage%3D15%26epage%3D22%26doi%3D10.1385%2F1-59259-860-9%3A015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1a','cit1b'],'ref2':['cit2a','cit2b','cit2c','cit2d'],'ref3':['cit3a','cit3b'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6a','cit6b','cit6c'],'ref7':['cit7a','cit7b','cit7c','cit7d','cit7e'],'ref8':['cit8a','cit8b','cit8c','cit8d','cit8e'],'ref9':['cit9a','cit9b','cit9c','cit9d','cit9e'],'ref10':['cit10a','cit10b','cit10c'],'ref11':['cit11a','cit11b'],'ref12':['cit12a','cit12b','cit12c'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15a','cit15b'],'ref16':['cit16a','cit16b'],'ref17':['cit17a','cit17b','cit17c'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20a','cit20b'],'ref21':['cit21a','cit21b'],'ref22':['cit22a','cit22b','cit22c','cit22d','cit22e','cit22f','cit22g','cit22h'],'ref23':['cit23'],'ref24':['cit24a','cit24b'],'ref25':['cit25a','cit25b'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38a','cit38b','cit38c'],'ref39':['cit39a','cit39b','cit39c'],'ref40':['cit40a','cit40b'],'ref41':['cit41'],'ref42':['cit42a','cit42b'],'ref43':['cit43a','cit43b','cit43cc','cit43c','cit43d','cit43e'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 24 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Hefeng Zhang, Xia Peng, Yang Dai, Jingwei Shao, Yinchun Ji, Yiming Sun, Bo Liu, Xu Cheng, Jing Ai, <span class="NLM_string-name hlFld-ContribAuthor">Wenhu Duan</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Pyrimidinedione Derivative as a Potent and Orally Bioavailable Axl Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (7)
                                     , 3956-3975. <a href="https://doi.org/10.1021/acs.jmedchem.0c02093" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02093</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c02093%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252BPyrimidinedione%252BDerivative%252Bas%252Ba%252BPotent%252Band%252BOrally%252BBioavailable%252BAxl%252BInhibitor%26aulast%3DZhang%26aufirst%3DHefeng%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D03122020%26date%3D18032021%26volume%3D64%26issue%3D7%26spage%3D3956%26epage%3D3975" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jisheng Liu, Yuting Wang, Chen Chen, Zhengchao Tu, Sihua Zhu, Fengtao Zhou, Hongfei Si, Canhui Zheng, Zhang Zhang, <span class="NLM_string-name hlFld-ContribAuthor">Qian Cai</span>. </span><span class="cited-content_cbyCitation_article-title">Identification and Development of 1,4-Diaryl-1,2,3-triazolo-Based Ureas as Novel FLT3 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (8)
                                     , 1567-1572. <a href="https://doi.org/10.1021/acsmedchemlett.0c00216" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00216</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00216&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00216%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DIdentification%252Band%252BDevelopment%252Bof%252B1%25252C4-Diaryl-1%25252C2%25252C3-triazolo-Based%252BUreas%252Bas%252BNovel%252BFLT3%252BInhibitors%26aulast%3DLiu%26aufirst%3DJisheng%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D27042020%26date%3D27072020%26date%3D30072020%26date%3D27072020%26volume%3D11%26issue%3D8%26spage%3D1567%26epage%3D1572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Qinfang Chen, Yihao Pan, Tingting Yue, Weiran Yang, Hua Liu, <span class="NLM_string-name hlFld-ContribAuthor">Jing Zheng</span>. </span><span class="cited-content_cbyCitation_article-title">[4 + 2]-Annulation of Prop-2-ynylsulfonium Salts and Isatoic Anhydrides: Access to 3-Methylthio-4-quinolones. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2020,</strong> <em>22 </em>
                                    (15)
                                     , 6096-6100. <a href="https://doi.org/10.1021/acs.orglett.0c02173" title="DOI URL">https://doi.org/10.1021/acs.orglett.0c02173</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.0c02173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.0c02173%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3D%25255B4%252B%25252B%252B2%25255D-Annulation%252Bof%252BProp-2-ynylsulfonium%252BSalts%252Band%252BIsatoic%252BAnhydrides%25253A%252BAccess%252Bto%252B3-Methylthio-4-quinolones%26aulast%3DChen%26aufirst%3DQinfang%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D30062020%26date%3D17072020%26volume%3D22%26issue%3D15%26spage%3D6096%26epage%3D6100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xiaoyun Lu, Tao Zhang, Su-Jie Zhu, Qiuju Xun, Lingjiang Tong, Xianglong Hu, Yan Li, Shingpan Chan, Yi Su, Yiming Sun, Yi Chen, Jian Ding, Cai-Hong Yun, Hua Xie, <span class="NLM_string-name hlFld-ContribAuthor">Ke Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of JND3229 as a New EGFRC797S Mutant Inhibitor with In Vivo Monodrug Efficacy. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>9 </em>
                                    (11)
                                     , 1123-1127. <a href="https://doi.org/10.1021/acsmedchemlett.8b00373" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.8b00373</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.8b00373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.8b00373%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BJND3229%252Bas%252Ba%252BNew%252BEGFRC797S%252BMutant%252BInhibitor%252Bwith%252BIn%252BVivo%252BMonodrug%252BEfficacy%26aulast%3DLu%26aufirst%3DXiaoyun%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D15082018%26date%3D08102018%26date%3D10102018%26date%3D08102018%26volume%3D9%26issue%3D11%26spage%3D1123%26epage%3D1127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Qiuju Xun, Zhang Zhang, Jinfeng Luo, Linjiang Tong, Minhao Huang, Zhen Wang, Jian Zou, Yingqiang Liu, Yong Xu, Hua Xie, Zheng-Chao Tu, Xiaoyun Lu, <span class="NLM_string-name hlFld-ContribAuthor">Ke Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Structure–Activity Relationship Study of 2-Oxo-3,4-dihydropyrimido[4,5-d]pyrimidines as New Colony Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (6)
                                     , 2353-2371. <a href="https://doi.org/10.1021/acs.jmedchem.7b01612" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01612</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01612%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BStructure%2525E2%252580%252593Activity%252BRelationship%252BStudy%252Bof%252B2-Oxo-3%25252C4-dihydropyrimido%25255B4%25252C5-d%25255Dpyrimidines%252Bas%252BNew%252BColony%252BStimulating%252BFactor%252B1%252BReceptor%252B%252528CSF1R%252529%252BKinase%252BInhibitors%26aulast%3DXun%26aufirst%3DQiuju%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D01112017%26date%3D13032018%26date%3D02032018%26volume%3D61%26issue%3D6%26spage%3D2353%26epage%3D2371" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dandan  Xu</span>, <span class="hlFld-ContribAuthor ">Deqiao  Sun</span>, <span class="hlFld-ContribAuthor ">Wei  Wang</span>, <span class="hlFld-ContribAuthor ">Xia  Peng</span>, <span class="hlFld-ContribAuthor ">Zhengsheng  Zhan</span>, <span class="hlFld-ContribAuthor ">Yinchun  Ji</span>, <span class="hlFld-ContribAuthor ">Yanyan  Shen</span>, <span class="hlFld-ContribAuthor ">Meiyu  Geng</span>, <span class="hlFld-ContribAuthor ">Jing  Ai</span>, <span class="hlFld-ContribAuthor ">Wenhu  Duan</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of pyrrolo[2,3-d]pyrimidine derivatives as potent Axl inhibitors: Design, synthesis and biological evaluation. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>220 </em>, 113497. <a href="https://doi.org/10.1016/j.ejmech.2021.113497" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113497</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113497&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113497%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bpyrrolo%25255B2%25252C3-d%25255Dpyrimidine%252Bderivatives%252Bas%252Bpotent%252BAxl%252Binhibitors%25253A%252BDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%26aulast%3DXu%26aufirst%3DDandan%26date%3D2021%26volume%3D220%26spage%3D113497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sarinya  Palakhachane</span>, <span class="hlFld-ContribAuthor ">Yuwaporn  Ketkaew</span>, <span class="hlFld-ContribAuthor ">Natthaya  Chuaypen</span>, <span class="hlFld-ContribAuthor ">Jitnapa  Sirirak</span>, <span class="hlFld-ContribAuthor ">Jutatip  Boonsombat</span>, <span class="hlFld-ContribAuthor ">Somsak  Ruchirawat</span>, <span class="hlFld-ContribAuthor ">Pisit  Tangkijvanich</span>, <span class="hlFld-ContribAuthor ">Apichart  Suksamrarn</span>, <span class="hlFld-ContribAuthor ">Panupun  Limpachayaporn</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of sorafenib analogues incorporating a 1,2,3-triazole ring and cytotoxicity towards hepatocellular carcinoma cell lines. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>112 </em>, 104831. <a href="https://doi.org/10.1016/j.bioorg.2021.104831" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.104831</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.104831&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.104831%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DSynthesis%252Bof%252Bsorafenib%252Banalogues%252Bincorporating%252Ba%252B1%25252C2%25252C3-triazole%252Bring%252Band%252Bcytotoxicity%252Btowards%252Bhepatocellular%252Bcarcinoma%252Bcell%252Blines%26aulast%3DPalakhachane%26aufirst%3DSarinya%26date%3D2021%26volume%3D112%26spage%3D104831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jie  He</span>, <span class="hlFld-ContribAuthor ">Zhihui  Zhou</span>, <span class="hlFld-ContribAuthor ">Xin  Sun</span>, <span class="hlFld-ContribAuthor ">Zunhua  Yang</span>, <span class="hlFld-ContribAuthor ">Pengwu  Zheng</span>, <span class="hlFld-ContribAuthor ">Shan  Xu</span>, <span class="hlFld-ContribAuthor ">Wufu  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">The new opportunities in medicinal chemistry of fourth-generation EGFR inhibitors to overcome C797S mutation. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>210 </em>, 112995. <a href="https://doi.org/10.1016/j.ejmech.2020.112995" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112995</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112995&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112995%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThe%252Bnew%252Bopportunities%252Bin%252Bmedicinal%252Bchemistry%252Bof%252Bfourth-generation%252BEGFR%252Binhibitors%252Bto%252Bovercome%252BC797S%252Bmutation%26aulast%3DHe%26aufirst%3DJie%26date%3D2021%26volume%3D210%26spage%3D112995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rossella  Di Stasi</span>, <span class="hlFld-ContribAuthor ">Lucia  De Rosa</span>, <span class="hlFld-ContribAuthor ">Luca D.  D’Andrea</span>. </span><span class="cited-content_cbyCitation_article-title">Therapeutic aspects of the Axl/Gas6 molecular system. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2020,</strong> <em>25 </em>
                                    (12)
                                     , 2130-2148. <a href="https://doi.org/10.1016/j.drudis.2020.09.022" title="DOI URL">https://doi.org/10.1016/j.drudis.2020.09.022</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2020.09.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2020.09.022%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DTherapeutic%252Baspects%252Bof%252Bthe%252BAxl%25252FGas6%252Bmolecular%252Bsystem%26aulast%3DDi%2BStasi%26aufirst%3DRossella%26date%3D2020%26volume%3D25%26issue%3D12%26spage%3D2130%26epage%3D2148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jing  Zhou</span>, <span class="hlFld-ContribAuthor ">Zhengtong  Mao</span>, <span class="hlFld-ContribAuthor ">Haokun  Pan</span>, <span class="hlFld-ContribAuthor ">Xingxian  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Pd-Catalyzed highly selective and direct
              ortho
              C–H arylation of pyrrolo[2,3-
              d
              ]pyrimidine derivatives. </span><span class="cited-content_cbyCitation_journal-name">Organic Chemistry Frontiers</span><span> <strong>2020,</strong> <em>7 </em>
                                    (2)
                                     , 324-328. <a href="https://doi.org/10.1039/C9QO01312A" title="DOI URL">https://doi.org/10.1039/C9QO01312A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9QO01312A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9QO01312A%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Chemistry%2520Frontiers%26atitle%3DPd-Catalyzed%252Bhighly%252Bselective%252Band%252Bdirect%252Bortho%252BC%2525E2%252580%252593H%252Barylation%252Bof%252Bpyrrolo%25255B2%25252C3-%252Bd%252B%25255Dpyrimidine%252Bderivatives%26aulast%3DZhou%26aufirst%3DJing%26date%3D2020%26date%3D2020%26volume%3D7%26issue%3D2%26spage%3D324%26epage%3D328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiaqian  Xu</span>, <span class="hlFld-ContribAuthor ">Xiaoqian  Li</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>, <span class="hlFld-ContribAuthor ">Zhengqiu  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Applications of Activity‐Based Protein Profiling (ABPP) and Bioimaging in Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name">Chemistry – An Asian Journal</span><span> <strong>2020,</strong> <em>15 </em>
                                    (1)
                                     , 34-41. <a href="https://doi.org/10.1002/asia.201901500" title="DOI URL">https://doi.org/10.1002/asia.201901500</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/asia.201901500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fasia.201901500%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%25E2%2580%2593%2520An%2520Asian%2520Journal%26atitle%3DApplications%252Bof%252BActivity%2525E2%252580%252590Based%252BProtein%252BProfiling%252B%252528ABPP%252529%252Band%252BBioimaging%252Bin%252BDrug%252BDiscovery%26aulast%3DXu%26aufirst%3DJiaqian%26date%3D2020%26date%3D2019%26volume%3D15%26issue%3D1%26spage%3D34%26epage%3D41" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Congjun  Xu</span>, <span class="hlFld-ContribAuthor ">Yufei  Han</span>, <span class="hlFld-ContribAuthor ">Sicong  Xu</span>, <span class="hlFld-ContribAuthor ">Ruxin  Wang</span>, <span class="hlFld-ContribAuthor ">Ming  Yue</span>, <span class="hlFld-ContribAuthor ">Yu  Tian</span>, <span class="hlFld-ContribAuthor ">Xiaofan  Li</span>, <span class="hlFld-ContribAuthor ">Yanfang  Zhao</span>, <span class="hlFld-ContribAuthor ">Ping  Gong</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of new Axl kinase inhibitors containing 1,3,4-oxadiazole acetamide moiety as novel linker. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>186 </em>, 111867. <a href="https://doi.org/10.1016/j.ejmech.2019.111867" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111867</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111867&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111867%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnew%252BAxl%252Bkinase%252Binhibitors%252Bcontaining%252B1%25252C3%25252C4-oxadiazole%252Bacetamide%252Bmoiety%252Bas%252Bnovel%252Blinker%26aulast%3DXu%26aufirst%3DCongjun%26date%3D2020%26volume%3D186%26spage%3D111867" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Roger  Clark</span>, <span class="hlFld-ContribAuthor ">Laura  Usselmann</span>, <span class="hlFld-ContribAuthor ">Martin R.  Brown</span>, <span class="hlFld-ContribAuthor ">Anne U.  Goeppert</span>, <span class="hlFld-ContribAuthor ">Adam  Corrigan</span>. </span><span class="cited-content_cbyCitation_article-title">A flexible high content imaging assay for profiling macrophage efferocytosis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Immunological Methods</span><span> <strong>2019,</strong> <em>473 </em>, 112636. <a href="https://doi.org/10.1016/j.jim.2019.112636" title="DOI URL">https://doi.org/10.1016/j.jim.2019.112636</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jim.2019.112636&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jim.2019.112636%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Immunological%2520Methods%26atitle%3DA%252Bflexible%252Bhigh%252Bcontent%252Bimaging%252Bassay%252Bfor%252Bprofiling%252Bmacrophage%252Befferocytosis%26aulast%3DClark%26aufirst%3DRoger%26date%3D2019%26volume%3D473%26spage%3D112636" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhi-Gang  Sun</span>, <span class="hlFld-ContribAuthor ">Jian-Hua  Liu</span>, <span class="hlFld-ContribAuthor ">Jin-Mai  Zhang</span>, <span class="hlFld-ContribAuthor ">Yong  Qian</span>. </span><span class="cited-content_cbyCitation_article-title">Research Progress of Axl Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Current Topics in Medicinal Chemistry</span><span> <strong>2019,</strong> <em>19 </em>
                                    (15)
                                     , 1338-1349. <a href="https://doi.org/10.2174/1568026619666190620155613" title="DOI URL">https://doi.org/10.2174/1568026619666190620155613</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1568026619666190620155613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1568026619666190620155613%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Topics%2520in%2520Medicinal%2520Chemistry%26atitle%3DResearch%252BProgress%252Bof%252BAxl%252BInhibitors%26aulast%3DSun%26aufirst%3DZhi-Gang%26date%3D2019%26volume%3D19%26issue%3D15%26spage%3D1338%26epage%3D1349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tianwei  Liu</span>, <span class="hlFld-ContribAuthor ">Jianghua  He</span>, <span class="hlFld-ContribAuthor ">Yuetao  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Regioselective 1,2-hydroboration of N-heteroarenes using a potassium-based catalyst. </span><span class="cited-content_cbyCitation_journal-name">Organic Chemistry Frontiers</span><span> <strong>2019,</strong> <em>6 </em>
                                    (15)
                                     , 2749-2755. <a href="https://doi.org/10.1039/C9QO00497A" title="DOI URL">https://doi.org/10.1039/C9QO00497A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9QO00497A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9QO00497A%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Chemistry%2520Frontiers%26atitle%3DRegioselective%252B1%25252C2-hydroboration%252Bof%252BN-heteroarenes%252Busing%252Ba%252Bpotassium-based%252Bcatalyst%26aulast%3DLiu%26aufirst%3DTianwei%26date%3D2019%26date%3D2019%26volume%3D6%26issue%3D15%26spage%3D2749%26epage%3D2755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jing  Xu</span>, <span class="hlFld-ContribAuthor ">Wenbo  Huang</span>, <span class="hlFld-ContribAuthor ">Rongxian  Bai</span>, <span class="hlFld-ContribAuthor ">Yves  Queneau</span>, <span class="hlFld-ContribAuthor ">François  Jérôme</span>, <span class="hlFld-ContribAuthor ">Yanlong  Gu</span>. </span><span class="cited-content_cbyCitation_article-title">Utilization of bio-based glycolaldehyde aqueous solution in organic synthesis: application to the synthesis of 2,3-dihydrofurans. </span><span class="cited-content_cbyCitation_journal-name">Green Chemistry</span><span> <strong>2019,</strong> <em>21 </em>
                                    (8)
                                     , 2061-2069. <a href="https://doi.org/10.1039/C8GC04000A" title="DOI URL">https://doi.org/10.1039/C8GC04000A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8GC04000A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8GC04000A%26sid%3Dliteratum%253Aachs%26jtitle%3DGreen%2520Chemistry%26atitle%3DUtilization%252Bof%252Bbio-based%252Bglycolaldehyde%252Baqueous%252Bsolution%252Bin%252Borganic%252Bsynthesis%25253A%252Bapplication%252Bto%252Bthe%252Bsynthesis%252Bof%252B2%25252C3-dihydrofurans%26aulast%3DXu%26aufirst%3DJing%26date%3D2019%26date%3D2019%26volume%3D21%26issue%3D8%26spage%3D2061%26epage%3D2069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Li  Tan</span>, <span class="hlFld-ContribAuthor ">Zhang  Zhang</span>, <span class="hlFld-ContribAuthor ">Donglin  Gao</span>, <span class="hlFld-ContribAuthor ">Shingpan  Chan</span>, <span class="hlFld-ContribAuthor ">Jinfeng  Luo</span>, <span class="hlFld-ContribAuthor ">Zheng-Chao  Tu</span>, <span class="hlFld-ContribAuthor ">Zhi-Min  Zhang</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>, <span class="hlFld-ContribAuthor ">Xiaomei  Ren</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>. </span><span class="cited-content_cbyCitation_article-title">Quinolone antibiotic derivatives as new selective Axl kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>166 </em>, 318-327. <a href="https://doi.org/10.1016/j.ejmech.2019.01.065" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.01.065</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.01.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.01.065%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DQuinolone%252Bantibiotic%252Bderivatives%252Bas%252Bnew%252Bselective%252BAxl%252Bkinase%252Binhibitors%26aulast%3DTan%26aufirst%3DLi%26date%3D2019%26volume%3D166%26spage%3D318%26epage%3D327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">On-Yu  Kang</span>, <span class="hlFld-ContribAuthor ">Seong Jun  Park</span>, <span class="hlFld-ContribAuthor ">Hyojung  Ahn</span>, <span class="hlFld-ContribAuthor ">Kyung Chae  Jeong</span>, <span class="hlFld-ContribAuthor ">Hwan Jung  Lim</span>. </span><span class="cited-content_cbyCitation_article-title">Structural assignment of the enol–keto tautomers of one-pot synthesized 4-hydroxyquinolines/4-quinolones. </span><span class="cited-content_cbyCitation_journal-name">Organic Chemistry Frontiers</span><span> <strong>2019,</strong> <em>6 </em>
                                    (2)
                                     , 183-189. <a href="https://doi.org/10.1039/C8QO00884A" title="DOI URL">https://doi.org/10.1039/C8QO00884A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8QO00884A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8QO00884A%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Chemistry%2520Frontiers%26atitle%3DStructural%252Bassignment%252Bof%252Bthe%252Benol%2525E2%252580%252593keto%252Btautomers%252Bof%252Bone-pot%252Bsynthesized%252B4-hydroxyquinolines%25252F4-quinolones%26aulast%3DKang%26aufirst%3DOn-Yu%26date%3D2019%26date%3D2019%26volume%3D6%26issue%3D2%26spage%3D183%26epage%3D189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Binbin  Zheng</span>, <span class="hlFld-ContribAuthor ">Haijun  Guo</span>, <span class="hlFld-ContribAuthor ">Nan  Ma</span>, <span class="hlFld-ContribAuthor ">Yun  Ni</span>, <span class="hlFld-ContribAuthor ">Jiaqian  Xu</span>, <span class="hlFld-ContribAuthor ">Lin  Li</span>, <span class="hlFld-ContribAuthor ">Piliang  Hao</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>, <span class="hlFld-ContribAuthor ">Zhengqiu  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Cell- and Tissue-Based Proteome Profiling and Bioimaging with Probes Derived from a Potent AXL Kinase Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Chemistry - An Asian Journal</span><span> <strong>2018,</strong> <em>13 </em>
                                    (18)
                                     , 2601-2605. <a href="https://doi.org/10.1002/asia.201800605" title="DOI URL">https://doi.org/10.1002/asia.201800605</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/asia.201800605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fasia.201800605%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520-%2520An%2520Asian%2520Journal%26atitle%3DCell-%252Band%252BTissue-Based%252BProteome%252BProfiling%252Band%252BBioimaging%252Bwith%252BProbes%252BDerived%252Bfrom%252Ba%252BPotent%252BAXL%252BKinase%252BInhibitor%26aulast%3DZheng%26aufirst%3DBinbin%26date%3D2018%26date%3D2018%26volume%3D13%26issue%3D18%26spage%3D2601%26epage%3D2605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xin-Sheng  Xiao</span>, <span class="hlFld-ContribAuthor ">Guo-Kai  Jia</span>, <span class="hlFld-ContribAuthor ">Wen-Yi  Li</span>, <span class="hlFld-ContribAuthor ">Xiu-Wen  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Crystal structure of (Z)-N-(4-nitrophenyl)-3-phenyl-3-(phenylamino)acrylamide, C21H17N3O3. </span><span class="cited-content_cbyCitation_journal-name">Zeitschrift für Kristallographie - New Crystal Structures</span><span> <strong>2018,</strong> <em>233 </em>
                                    (4)
                                     , 699-700. <a href="https://doi.org/10.1515/ncrs-2018-0026" title="DOI URL">https://doi.org/10.1515/ncrs-2018-0026</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1515/ncrs-2018-0026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1515%2Fncrs-2018-0026%26sid%3Dliteratum%253Aachs%26jtitle%3DZeitschrift%2520f%25C3%25BCr%2520Kristallographie%2520-%2520New%2520Crystal%2520Structures%26atitle%3DCrystal%252Bstructure%252Bof%252B%252528Z%252529-N-%2525284-nitrophenyl%252529-3-phenyl-3-%252528phenylamino%252529acrylamide%25252C%252BC21H17N3O3%26aulast%3DXiao%26aufirst%3DXin-Sheng%26date%3D2018%26volume%3D233%26issue%3D4%26spage%3D699%26epage%3D700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaochen  Ji</span>, <span class="hlFld-ContribAuthor ">Dongdong  Li</span>, <span class="hlFld-ContribAuthor ">Zhongzhen  Wang</span>, <span class="hlFld-ContribAuthor ">Muyun  Tan</span>, <span class="hlFld-ContribAuthor ">Huawen  Huang</span>, <span class="hlFld-ContribAuthor ">Guo-Jun  Deng</span>. </span><span class="cited-content_cbyCitation_article-title">Visible Light-Induced Aerobic Oxidation of Indoles: One-Pot Formation of 4-Quinolones at Room Temperature. </span><span class="cited-content_cbyCitation_journal-name">Asian Journal of Organic Chemistry</span><span> <strong>2018,</strong> <em>7 </em>
                                    (4)
                                     , 711-714. <a href="https://doi.org/10.1002/ajoc.201800036" title="DOI URL">https://doi.org/10.1002/ajoc.201800036</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ajoc.201800036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fajoc.201800036%26sid%3Dliteratum%253Aachs%26jtitle%3DAsian%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DVisible%252BLight-Induced%252BAerobic%252BOxidation%252Bof%252BIndoles%25253A%252BOne-Pot%252BFormation%252Bof%252B4-Quinolones%252Bat%252BRoom%252BTemperature%26aulast%3DJi%26aufirst%3DXiaochen%26date%3D2018%26date%3D2018%26volume%3D7%26issue%3D4%26spage%3D711%26epage%3D714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ketan S.  Gajiwala</span>, <span class="hlFld-ContribAuthor ">Neil  Grodsky</span>, <span class="hlFld-ContribAuthor ">Ben  Bolaños</span>, <span class="hlFld-ContribAuthor ">Junli  Feng</span>, <span class="hlFld-ContribAuthor ">RoseAnn  Ferre</span>, <span class="hlFld-ContribAuthor ">Sergei  Timofeevski</span>, <span class="hlFld-ContribAuthor ">Meirong  Xu</span>, <span class="hlFld-ContribAuthor ">Brion W.  Murray</span>, <span class="hlFld-ContribAuthor ">Ted W.  Johnson</span>, <span class="hlFld-ContribAuthor ">Al  Stewart</span>. </span><span class="cited-content_cbyCitation_article-title">The Axl kinase domain in complex with a macrocyclic inhibitor offers first structural insights into an active TAM receptor kinase. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biological Chemistry</span><span> <strong>2017,</strong> <em>292 </em>
                                    (38)
                                     , 15705-15716. <a href="https://doi.org/10.1074/jbc.M116.771485" title="DOI URL">https://doi.org/10.1074/jbc.M116.771485</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1074/jbc.M116.771485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1074%2Fjbc.M116.771485%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biological%2520Chemistry%26atitle%3DThe%252BAxl%252Bkinase%252Bdomain%252Bin%252Bcomplex%252Bwith%252Ba%252Bmacrocyclic%252Binhibitor%252Boffers%252Bfirst%252Bstructural%252Binsights%252Binto%252Ban%252Bactive%252BTAM%252Breceptor%252Bkinase%26aulast%3DGajiwala%26aufirst%3DKetan%2BS.%26date%3D2017%26volume%3D292%26issue%3D38%26spage%3D15705%26epage%3D15716" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jane  Antony</span>, <span class="hlFld-ContribAuthor ">Ruby Yun-Ju  Huang</span>. </span><span class="cited-content_cbyCitation_article-title">AXL-Driven EMT State as a Targetable Conduit in Cancer. </span><span class="cited-content_cbyCitation_journal-name">Cancer Research</span><span> <strong>2017,</strong> <em>77 </em>
                                    (14)
                                     , 3725-3732. <a href="https://doi.org/10.1158/0008-5472.CAN-17-0392" title="DOI URL">https://doi.org/10.1158/0008-5472.CAN-17-0392</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/0008-5472.CAN-17-0392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F0008-5472.CAN-17-0392%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Research%26atitle%3DAXL-Driven%252BEMT%252BState%252Bas%252Ba%252BTargetable%252BConduit%252Bin%252BCancer%26aulast%3DAntony%26aufirst%3DJane%26date%3D2017%26date%3D2017%26volume%3D77%26issue%3D14%26spage%3D3725%26epage%3D3732" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Akinari  Sumita</span>, <span class="hlFld-ContribAuthor ">Yuko  Otani</span>, <span class="hlFld-ContribAuthor ">Tomohiko  Ohwada</span>. </span><span class="cited-content_cbyCitation_article-title">Chemoselective generation of acyl phosphates, acylium ion equivalents, from carboxylic acids and an organophosphate ester in the presence of a Brønsted acid. </span><span class="cited-content_cbyCitation_journal-name">Chemical Communications</span><span> <strong>2017,</strong> <em>53 </em>
                                    (9)
                                     , 1482-1485. <a href="https://doi.org/10.1039/C6CC09618B" title="DOI URL">https://doi.org/10.1039/C6CC09618B</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C6CC09618B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC6CC09618B%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Communications%26atitle%3DChemoselective%252Bgeneration%252Bof%252Bacyl%252Bphosphates%25252C%252Bacylium%252Bion%252Bequivalents%25252C%252Bfrom%252Bcarboxylic%252Bacids%252Band%252Ban%252Borganophosphate%252Bester%252Bin%252Bthe%252Bpresence%252Bof%252Ba%252BBr%2525C3%2525B8nsted%252Bacid%26aulast%3DSumita%26aufirst%3DAkinari%26date%3D2017%26date%3D2017%26volume%3D53%26issue%3D9%26spage%3D1482%26epage%3D1485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/medium/jm-2016-00608n_0014.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/large/jm-2016-00608n_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00608&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/medium/jm-2016-00608n_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/large/jm-2016-00608n_0002.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of reported selective and nonselective Axl inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/large/jm-2016-00608n_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00608&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/medium/jm-2016-00608n_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/large/jm-2016-00608n_0003.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Design strategy of the potential new selective Axl inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/large/jm-2016-00608n_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00608&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/medium/jm-2016-00608n_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/large/jm-2016-00608n_0008.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>9</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/large/jm-2016-00608n_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00608&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) ethyl diisopropylamine (DIPEA), 1-methyl-2-pyrrolidinone (NMP), microwave, 200 °C, 1.0 h, 30–85%; (b) iodine, KOH, <i>N,N</i>-dimethylformamide (DMF), 0 °C, 4.0 h, 75–80%; (c) SEMCl, NaOH, DMF, room temperature (rt), overnight, 70–78%; (d) Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, toluene, 90 °C, overnight, 65–75%; (e) NiCl<sub>2</sub>·6H<sub>2</sub>O, NaBH<sub>4</sub>, tetrahydrofuran (THF), MeOH, rt, 2.0 h, 60–72%; (f) 2-(7-aza-1<i>H</i>-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU), DIPEA, DMF, rt, overnight, 68–85%; (g) trifluoroacetic acid (F<sub>3</sub>CCOOH), dichloromethane (DCM), rt, overnight, 85–90%; (h) NaOH, THF–H<sub>2</sub>O, rt, overnight, 80–90%.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/medium/jm-2016-00608n_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/large/jm-2016-00608n_0009.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Intermediates <b>29</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/large/jm-2016-00608n_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00608&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) triphosgene, pyridine, acetonitrile (MeCN), 0–55 °C, 2.0 h, 82–94%; (j) R<sub>2</sub>I, DIPEA, DMF, 40 °C, overnight, 75–82%; (k) <b>22</b>, NaH, DMF, 120 °C, overnight, 70–85%; (l) diethyl 2-acetylmalonate or diethyl 2-(ethoxymethylene)malonate, <i>p</i>-toluenesulfonic acid, H<sub>2</sub>O, pentane, reflux, overnight, 75–90%; (m) diphenyl oxide, 200 °C, 2.0 h, or polyphosphoric acid (PPA), 100 °C, overnight, 75–90%; (n) MeI, K<sub>2</sub>CO<sub>3</sub>, DMF, 50 °C, overnight, 78–88%; (o) NaOH, THF–H<sub>2</sub>O, reflux, overnight, 84–93%.</p></p></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/medium/jm-2016-00608n_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/large/jm-2016-00608n_0004.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Inhibitors <b>9i</b>, <b>9im</b>, and <b>7</b> suppress the Axl signaling pathway in MDA-MB-231 breast cancer cells. (A) Compound <b>7</b> inhibits activation of Axl and downstream signaling in MDA-MB-231 cells after 6-h treatments. (B) Compound <b>9i</b> inhibits phosphorylation of Axl and downstream signaling in MDA-MB-231 cells after 6-h treatments. (C) Compound <b>9im</b> inhibits phosphorylation of Axl and downstream signaling in MDA-MB-231 cells after 6-h treatments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/large/jm-2016-00608n_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00608&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/medium/jm-2016-00608n_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/large/jm-2016-00608n_0005.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Compound <b>9im</b> blocks TGF-β1-induced EMT process in MDA-MB-231 breast cancer cells. (A) Compound <b>9im</b> reverses TGF-β1-induced expression level changes of E-cadherin (an epithelial marker) and N-cadherin (a meschenchymal marker) EMT markers in MDA-MB-231 cells, as determined by optical and immunofluorescence microscopy. (B) Compound <b>9im</b> reverses TGF-β1-induced changes of the EMT markers expression in MDA-MB-231 cells as determined by Western blot analysis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/large/jm-2016-00608n_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00608&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/medium/jm-2016-00608n_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/large/jm-2016-00608n_0006.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Compound <b>9im</b> suppresses migration and invasion of MDA-MB-231 cells. (A) Effect of <b>9im</b> on the wound healing induced by TGF-β1 in MDA-MB-231 cells. (B) Compound <b>9im</b> suppresses migration and invasion induced by TGF-β1 (10 ng/mL) of MDA-MB-231 cells. (C–E) Quantitative analysis of wound healing (C), migration (D), and invasion (E). The results are presented as the mean ± standard deviation, *<i>P</i> < 0.05 (compared with TGF-β1 treatment).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/large/jm-2016-00608n_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00608&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/medium/jm-2016-00608n_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/large/jm-2016-00608n_0007.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Compound <b>9im</b> reduces hepatic metastasis of 4T1 murine breast cancer cells. (A) H&E staining showed that <b>9im</b> decreased the size and number of the metastatic colons in liver (×100). Arrow indicates the tumor metastasis (B) Quantity analysis of the micrometastases in panel A. (C) Photos of the isolated tumor tissues after administration of <b>9im</b> for 21 continuous days. The results are presented as the mean ± standard deviation, *<i>P</i> < 0.05 (compare with untreated group).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.6b00608/20160722/images/large/jm-2016-00608n_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00608&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i82">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82155" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82155" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 48 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">O’Bryan, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frye, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cogswell, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neubauer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitch, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prokop, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Espinosa, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Beau, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Earp, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, E. T.</span><span> </span><span class="NLM_article-title">Axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">5016</span><span class="NLM_x">–</span> <span class="NLM_lpage">5031</span><span class="refDoi"> DOI: 10.1128/MCB.11.10.5016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1128%2FMCB.11.10.5016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1656220" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADyaK38XlvVGrsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1991&pages=5016-5031&author=J.+P.+O%E2%80%99Bryanauthor=R.+A.+Fryeauthor=P.+C.+Cogswellauthor=A.+Neubauerauthor=B.+Kitchauthor=C.+Prokopauthor=R.+Espinosaauthor=M.+M.+Le+Beauauthor=H.+S.+Earpauthor=E.+T.+Liu&title=Axl%2C+a+transforming+gene+isolated+from+primary+human+myeloid+leukemia+cells%2C+encodes+a+novel+receptor+tyrosine+kinase&doi=10.1128%2FMCB.11.10.5016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">axl, A transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase</span></div><div class="casAuthors">O'Bryan, John P.; Frye, Roy A.; Cogswell, Patricia C.; Neubauer, Andreas; Kitch, Barry; Prokop, Carol; Espinosa, Rafael, III; Le Beau, Michelle M.; Earp, H. Shelton; Liu, Edison T.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5016-31</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    </div><div class="casAbstract">A sensitive transfection-tumorigenicity assay was used to isolate a novel transforming gene from the DNA of 2 patients with chronic myelogenous leukemia.  Sequence anal. indicates that the product of this gene, axl, is a receptor tyrosine kinase.  Overexpression of axl cDNA in NIH 3T3 cells induces neoplastic transformation with the concomitant appearance of a 140-kDa axl tyrosine-phosphorylated protein.  Expression of axl cDNA in the baculovirus system results in the expression of the appropriate recombinant protein that is tyrosine kinase.  The juxtaposition of fibronectin type III and immunoglobulinlike repeats in the extracellular domain, as well as distinct amino acid sequences in the kinase domain, indicate that the axl protein represents a novel subclass of receptor tyrosine kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCIaouGK3RfrVg90H21EOLACvtfcHk0lgICLYZm6O8QA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XlvVGrsLs%253D&md5=f244ff83822fdb98c22a35f918723d3a</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1128%2FMCB.11.10.5016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.11.10.5016%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Bryan%26aufirst%3DJ.%2BP.%26aulast%3DFrye%26aufirst%3DR.%2BA.%26aulast%3DCogswell%26aufirst%3DP.%2BC.%26aulast%3DNeubauer%26aufirst%3DA.%26aulast%3DKitch%26aufirst%3DB.%26aulast%3DProkop%26aufirst%3DC.%26aulast%3DEspinosa%26aufirst%3DR.%26aulast%3DLe%2BBeau%26aufirst%3DM.%2BM.%26aulast%3DEarp%26aufirst%3DH.%2BS.%26aulast%3DLiu%26aufirst%3DE.%2BT.%26atitle%3DAxl%252C%2520a%2520transforming%2520gene%2520isolated%2520from%2520primary%2520human%2520myeloid%2520leukemia%2520cells%252C%2520encodes%2520a%2520novel%2520receptor%2520tyrosine%2520kinase%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1991%26volume%3D11%26spage%3D5016%26epage%3D5031%26doi%3D10.1128%2FMCB.11.10.5016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Myers, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunton, V. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unciti-Broceta, A.</span><span> </span><span class="NLM_article-title">Axl inhibitors in cancer: a medicinal chemistry perspective</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">3593</span><span class="NLM_x">–</span> <span class="NLM_lpage">3608</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01273</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01273" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVWnsbnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=3593-3608&author=S.+H.+Myersauthor=V.+G.+Bruntonauthor=A.+Unciti-Broceta&title=Axl+inhibitors+in+cancer%3A+a+medicinal+chemistry+perspective&doi=10.1021%2Facs.jmedchem.5b01273"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective</span></div><div class="casAuthors">Myers, Samuel H.; Brunton, Valerie G.; Unciti-Broceta, Asier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3593-3608</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dysregulation of the AXL receptor tyrosine kinase has been assocd. with many types of cancer.  It has not been until recently, however, that targeting AXL has come under the spotlight because of ever accumulating evidence of its strong correlation with poor prognosis and drug resistance.  The entry of the first AXL-branded inhibitor in clin. trials in 2013 marked an important milestone for the clin. validation of AXL as an anticancer target.  Nevertheless, to weigh the current contribution and potential future impact of AXL inhibition in the clinic, it is fundamental to recognize that several kinase inhibitors approved or in clin. development have AXL as either a prominent secondary or even the primary target.  Through this review, the chem. and biol. properties of the main inhibitors targeting AXL (either intentionally or unintentionally) will be discussed, along with the prospects and challenges to translate AXL inhibitors into a bona fide therapeutic option.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7-ZTTNRD9LLVg90H21EOLACvtfcHk0liS2ICm6I9hUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVWnsbnI&md5=4643d9d9950251a14c3991c306c4cec0</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01273%26sid%3Dliteratum%253Aachs%26aulast%3DMyers%26aufirst%3DS.%2BH.%26aulast%3DBrunton%26aufirst%3DV.%2BG.%26aulast%3DUnciti-Broceta%26aufirst%3DA.%26atitle%3DAxl%2520inhibitors%2520in%2520cancer%253A%2520a%2520medicinal%2520chemistry%2520perspective%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D3593%26epage%3D3608%26doi%3D10.1021%2Facs.jmedchem.5b01273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Varnum, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartley, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridell, Y. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trail, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clogston, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toso, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yanagihara, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sylber, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merewether, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tseng, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Escobar, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamane, H. K.</span><span> </span><span class="NLM_article-title">Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">373</span><span class="NLM_x">, </span> <span class="NLM_fpage">623</span><span class="NLM_x">–</span> <span class="NLM_lpage">626</span><span class="refDoi"> DOI: 10.1038/373623a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1038%2F373623a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=7854420" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADyaK2MXjsl2mtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=1995&pages=623-626&author=B.+C.+Varnumauthor=C.+Youngauthor=G.+Elliottauthor=A.+Garciaauthor=T.+D.+Bartleyauthor=Y.+W.+Fridellauthor=R.+W.+Huntauthor=G.+Trailauthor=C.+Clogstonauthor=R.+J.+Tosoauthor=D.+Yanagiharaauthor=L.+Bennettauthor=M.+Sylberauthor=L.+A.+Merewetherauthor=A.+Tsengauthor=E.+Escobarauthor=E.+T.+Liuauthor=H.+K.+Yamane&title=Axl+receptor+tyrosine+kinase+stimulated+by+the+vitamin+K-dependent+protein+encoded+by+growth-arrest-specific+gene+6&doi=10.1038%2F373623a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Ax1 receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6</span></div><div class="casAuthors">Varnum, Brian C.; Young, Cynthia; Elliott, Gary; Garcia, Andy; Bartley, Timothy D.; Fridell, Yih-Woei; Hunt, Robert W.; Trail, Geraldine; Clogston, Chris; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">6515</span>),
    <span class="NLM_cas:pages">623-6</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">The Axl receptor tyrosine kinase was identified as a protein encoded by a transforming gene from primary human myeloid leukemia cells by DNA-mediated transformation of NIH 3T3 cells.  Ax1 is the founding member of a family of related receptors that includes Eyk, encoded by a chicken proto-oncogene originally described as a retroviral transforming gene, and c-Mer, encoded by a human proto-oncogene expressed in neoplastic B- and T-cell lines.  The transforming activity of Axl demonstrates that the receptor can drive cellular proliferation.  The function of Ax1 in non-transformed cells and tissues is unknown, but may involve the stimulation of cell proliferation in response to an appropriate signal, namely a ligand that activates the receptor.  We report here the purifn. of an Ax1 stimulatory factor, and its identification as the product of growth-arrest-specific gene 6.  This is, to our knowledge, the first description of a ligand for the Ax1 family of receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-4cxnEY4sPbVg90H21EOLACvtfcHk0liS2ICm6I9hUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXjsl2mtr4%253D&md5=0d8ecf55926f43384ca646ffa3692529</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1038%2F373623a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F373623a0%26sid%3Dliteratum%253Aachs%26aulast%3DVarnum%26aufirst%3DB.%2BC.%26aulast%3DYoung%26aufirst%3DC.%26aulast%3DElliott%26aufirst%3DG.%26aulast%3DGarcia%26aufirst%3DA.%26aulast%3DBartley%26aufirst%3DT.%2BD.%26aulast%3DFridell%26aufirst%3DY.%2BW.%26aulast%3DHunt%26aufirst%3DR.%2BW.%26aulast%3DTrail%26aufirst%3DG.%26aulast%3DClogston%26aufirst%3DC.%26aulast%3DToso%26aufirst%3DR.%2BJ.%26aulast%3DYanagihara%26aufirst%3DD.%26aulast%3DBennett%26aufirst%3DL.%26aulast%3DSylber%26aufirst%3DM.%26aulast%3DMerewether%26aufirst%3DL.%2BA.%26aulast%3DTseng%26aufirst%3DA.%26aulast%3DEscobar%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DE.%2BT.%26aulast%3DYamane%26aufirst%3DH.%2BK.%26atitle%3DAxl%2520receptor%2520tyrosine%2520kinase%2520stimulated%2520by%2520the%2520vitamin%2520K-dependent%2520protein%2520encoded%2520by%2520growth-arrest-specific%2520gene%25206%26jtitle%3DNature%26date%3D1995%26volume%3D373%26spage%3D623%26epage%3D626%26doi%3D10.1038%2F373623a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Nagata, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakano, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arita, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zong, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanafusa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mizuno, K.</span><span> </span><span class="NLM_article-title">Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">271</span><span class="NLM_x">, </span> <span class="NLM_fpage">30022</span><span class="NLM_x">–</span> <span class="NLM_lpage">30027</span><span class="refDoi"> DOI: 10.1074/jbc.271.47.30022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1074%2Fjbc.271.47.30022" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=271&publication_year=1996&pages=30022-30027&author=K.+Nagataauthor=K.+Ohashiauthor=T.+Nakanoauthor=H.+Aritaauthor=C.+Zongauthor=H.+Hanafusaauthor=K.+Mizuno&title=Identification+of+the+product+of+growth+arrest-specific+gene+6+as+a+common+ligand+for+Axl%2C+Sky%2C+and+Mer+receptor+tyrosine+kinases&doi=10.1074%2Fjbc.271.47.30022"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1074%2Fjbc.271.47.30022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.271.47.30022%26sid%3Dliteratum%253Aachs%26aulast%3DNagata%26aufirst%3DK.%26aulast%3DOhashi%26aufirst%3DK.%26aulast%3DNakano%26aufirst%3DT.%26aulast%3DArita%26aufirst%3DH.%26aulast%3DZong%26aufirst%3DC.%26aulast%3DHanafusa%26aufirst%3DH.%26aulast%3DMizuno%26aufirst%3DK.%26atitle%3DIdentification%2520of%2520the%2520product%2520of%2520growth%2520arrest-specific%2520gene%25206%2520as%2520a%2520common%2520ligand%2520for%2520Axl%252C%2520Sky%252C%2520and%2520Mer%2520receptor%2520tyrosine%2520kinases%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1996%26volume%3D271%26spage%3D30022%26epage%3D30027%26doi%3D10.1074%2Fjbc.271.47.30022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Hafizi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahlback, B.</span><span> </span><span class="NLM_article-title">Gas6 and protein S. Vitamin K-dependent ligands for the Axl receptor tyrosine kinase subfamily</span> <span class="citation_source-journal">FEBS J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">273</span><span class="NLM_x">, </span> <span class="NLM_fpage">5231</span><span class="NLM_x">–</span> <span class="NLM_lpage">5244</span><span class="refDoi"> DOI: 10.1111/j.1742-4658.2006.05529.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1111%2Fj.1742-4658.2006.05529.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=2006&pages=5231-5244&author=S.+Hafiziauthor=B.+Dahlback&title=Gas6+and+protein+S.+Vitamin+K-dependent+ligands+for+the+Axl+receptor+tyrosine+kinase+subfamily&doi=10.1111%2Fj.1742-4658.2006.05529.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2c&amp;dbid=16384&amp;doi=10.1111%2Fj.1742-4658.2006.05529.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1742-4658.2006.05529.x%26sid%3Dliteratum%253Aachs%26aulast%3DHafizi%26aufirst%3DS.%26aulast%3DDahlback%26aufirst%3DB.%26atitle%3DGas6%2520and%2520protein%2520S.%2520Vitamin%2520K-dependent%2520ligands%2520for%2520the%2520Axl%2520receptor%2520tyrosine%2520kinase%2520subfamily%26jtitle%3DFEBS%2520J.%26date%3D2006%26volume%3D273%26spage%3D5231%26epage%3D5244%26doi%3D10.1111%2Fj.1742-4658.2006.05529.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Stitt, T. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conn, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goret, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruno, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radzliejewski, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattsson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gies, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masiakowski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tobkes, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiStefano, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basilico, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldfarb, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemke, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glass, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yancopoulos, G. D.</span><span> </span><span class="NLM_article-title">The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x">, </span> <span class="NLM_fpage">661</span><span class="NLM_x">–</span> <span class="NLM_lpage">670</span><span class="refDoi"> DOI: 10.1016/0092-8674(95)90520-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1016%2F0092-8674%2895%2990520-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=7867073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADyaK2MXktV2it74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=1995&pages=661-670&author=T.+N.+Stittauthor=G.+Connauthor=M.+Goretauthor=C.+Laiauthor=J.+Brunoauthor=C.+Radzliejewskiauthor=K.+Mattssonauthor=J.+Fisherauthor=D.+R.+Giesauthor=P.+F.+Jonesauthor=P.+Masiakowskiauthor=T.+E.+Ryanauthor=N.+J.+Tobkesauthor=D.+H.+Chenauthor=P.+S.+DiStefanoauthor=G.+L.+Longauthor=C.+Basilicoauthor=M.+P.+Goldfarbauthor=G.+Lemkeauthor=D.+J.+Glassauthor=G.+D.+Yancopoulos&title=The+anticoagulation+factor+protein+S+and+its+relative%2C+Gas6%2C+are+ligands+for+the+Tyro+3%2FAxl+family+of+receptor+tyrosine+kinases&doi=10.1016%2F0092-8674%2895%2990520-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2dR"><div class="casContent"><span class="casTitleNuber">2d</span><div class="casTitle"><span class="NLM_cas:atitle">The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases</span></div><div class="casAuthors">Stitt, Trevor N.; Conn, Greg; Gore, Martin; Lai, Cary; Bruno, Joanne; Radziejewski, Czeslaw; Mattsson, Karen; Fisher, John; Gies, David R.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">661-70</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The authors report the identification of ligands for Tyro 3 (alternatively called Sky, rse, brt, or tif) and Axl (alternatively, Ark or UFO), members of a previously orphan family of receptor-like tyrosine kinases.  These ligands correspond to protein S, a protease regulator that is a potent anticoagulant, and Gas6, a protein related to protein S but lacking any known function.  The results are reminiscent of recent findings that the procoagulant thrombin, a protease that drives clot formation by cleaving fibrinogen to form fibrin, also binds and activates intracellular signaling via a G protein-coupled cell surface receptor.  Proteases and protease regulators that also activate specific cell surface receptors may serve to integrate coagulation with assocd. cellular responses required for tissue repair and growth, as well as to coordinate protease cascades and assocd. cellular responses in other systems, such as those involved in growth and remodeling of the nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0Kc6zOMgNobVg90H21EOLACvtfcHk0lgpeES2IfQ03Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXktV2it74%253D&md5=a12eece9ec055c4ee7927d97a9789fdb</span></div><a href="/servlet/linkout?suffix=cit2d&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2895%2990520-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252895%252990520-0%26sid%3Dliteratum%253Aachs%26aulast%3DStitt%26aufirst%3DT.%2BN.%26aulast%3DConn%26aufirst%3DG.%26aulast%3DGoret%26aufirst%3DM.%26aulast%3DLai%26aufirst%3DC.%26aulast%3DBruno%26aufirst%3DJ.%26aulast%3DRadzliejewski%26aufirst%3DC.%26aulast%3DMattsson%26aufirst%3DK.%26aulast%3DFisher%26aufirst%3DJ.%26aulast%3DGies%26aufirst%3DD.%2BR.%26aulast%3DJones%26aufirst%3DP.%2BF.%26aulast%3DMasiakowski%26aufirst%3DP.%26aulast%3DRyan%26aufirst%3DT.%2BE.%26aulast%3DTobkes%26aufirst%3DN.%2BJ.%26aulast%3DChen%26aufirst%3DD.%2BH.%26aulast%3DDiStefano%26aufirst%3DP.%2BS.%26aulast%3DLong%26aufirst%3DG.%2BL.%26aulast%3DBasilico%26aufirst%3DC.%26aulast%3DGoldfarb%26aufirst%3DM.%2BP.%26aulast%3DLemke%26aufirst%3DG.%26aulast%3DGlass%26aufirst%3DD.%2BJ.%26aulast%3DYancopoulos%26aufirst%3DG.%2BD.%26atitle%3DThe%2520anticoagulation%2520factor%2520protein%2520S%2520and%2520its%2520relative%252C%2520Gas6%252C%2520are%2520ligands%2520for%2520the%2520Tyro%25203%252FAxl%2520family%2520of%2520receptor%2520tyrosine%2520kinases%26jtitle%3DCell%26date%3D1995%26volume%3D80%26spage%3D661%26epage%3D670%26doi%3D10.1016%2F0092-8674%2895%2990520-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Axelrod, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pienta, K. J.</span><span> </span><span class="NLM_article-title">Axl as a mediator of cellular growth and survival</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">8818</span><span class="NLM_x">–</span> <span class="NLM_lpage">8852</span><span class="refDoi"> DOI: 10.18632/oncotarget.2422</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.18632%2Foncotarget.2422" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=8818-8852&author=H.+Axelrodauthor=K.+J.+Pienta&title=Axl+as+a+mediator+of+cellular+growth+and+survival&doi=10.18632%2Foncotarget.2422"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.2422&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.2422%26sid%3Dliteratum%253Aachs%26aulast%3DAxelrod%26aufirst%3DH.%26aulast%3DPienta%26aufirst%3DK.%2BJ.%26atitle%3DAxl%2520as%2520a%2520mediator%2520of%2520cellular%2520growth%2520and%2520survival%26jtitle%3DOncotarget%26date%3D2014%26volume%3D5%26spage%3D8818%26epage%3D8852%26doi%3D10.18632%2Foncotarget.2422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit3b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Lee, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hung, M. C.</span><span> </span><span class="NLM_article-title">Axl-Gas6 interaction counteracts E1A-mediated cell growth suppression and proapoptotic activity</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">8075</span><span class="NLM_x">–</span> <span class="NLM_lpage">8082</span><span class="refDoi"> DOI: 10.1128/MCB.19.12.8075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1128%2FMCB.19.12.8075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10567533" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADyaK1MXns1ygtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=1999&pages=8075-8082&author=W.+P.+Leeauthor=Y.+Liaoauthor=D.+Robinsonauthor=H.+J.+Kungauthor=E.+T.+Liuauthor=M.+C.+Hung&title=Axl-Gas6+interaction+counteracts+E1A-mediated+cell+growth+suppression+and+proapoptotic+activity&doi=10.1128%2FMCB.19.12.8075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3bR"><div class="casContent"><span class="casTitleNuber">3b</span><div class="casTitle"><span class="NLM_cas:atitle">Axl-Gas6 interaction counteracts E1A-mediated cell growth suppression and proapoptotic activity</span></div><div class="casAuthors">Lee, Wei-Ping; Liao, Yong; Robinson, Dan; Kung, Hsing-Jien; Liu, Edison T.; Hung, Mien-Chie</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">8075-8082</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The adenovirus type 5 early region 1A gene (E1A) has previously been known as an immortalization oncogene because E1A is required for transforming oncogenes, such as ras and E1B, to transform cells in primary cultures.  However, E1A has also been shown to downregulate the overexpression of the Her-2/neu oncogene, resulting in suppression of transformation and tumorigenesis induced by that oncogene.  In addn., E1A is able to promote apoptosis induced by anticancer drugs, irradn., and serum deprivation.  Many tyrosine kinases, such as the epidermal growth factor receptor, Her-2/Neu, Src, and Axl, are known to play a role in oncogenic signals in transformed cells.  To study the mechanism underlying the E1A-mediated tumor-suppressing function, we exploited a modified tyrosine kinase profile assay to identify potential tyrosine kinases regulated by E1A.  Reverse transcription (RT)-PCR products were synthesized with two degenerate primers derived from the conserved motifs of various tyrosine kinases.  A tyrosine kinase downregulated by E1A was identified by analyzing the AluI-digested RT-PCR products.  We isolated the DNA fragment of interest and found that E1A neg. regulated the expression of the transforming receptor tyrosine kinase Axl at the transcriptional level.  To study whether downregulation of the Axl receptor is involved in E1A-mediated growth suppression, we transfected axl cDNA into E1A-expressing cells (i.p.1-E1A) to establish cells that overexpressed Axl.  The Axl ligand Gas6 triggered a greater mitogenic effect in these i.p.1-E1A-Axl cells than in i.p.1-E1A control cells and protected the Axl-expressing cells from serum deprivation-induced apoptosis.  These results indicate that downregulation of the Axl receptor by E1A is involved in E1A-mediated growth suppression and E1A-induced apoptosis and thereby contributes to E1A's antitumor activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5bTvkTBbsorVg90H21EOLACvtfcHk0lgpeES2IfQ03Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXns1ygtrs%253D&md5=abce95b0399479189340f34a279fd6fc</span></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=10.1128%2FMCB.19.12.8075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.19.12.8075%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DLiao%26aufirst%3DY.%26aulast%3DRobinson%26aufirst%3DD.%26aulast%3DKung%26aufirst%3DH.%2BJ.%26aulast%3DLiu%26aufirst%3DE.%2BT.%26aulast%3DHung%26aufirst%3DM.%2BC.%26atitle%3DAxl-Gas6%2520interaction%2520counteracts%2520E1A-mediated%2520cell%2520growth%2520suppression%2520and%2520proapoptotic%2520activity%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1999%26volume%3D19%26spage%3D8075%26epage%3D8082%26doi%3D10.1128%2FMCB.19.12.8075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Valverde, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obin, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, A.</span><span> </span><span class="NLM_article-title">Role of Gas6/Axl signaling in lens epithelial cell proliferation and survival</span> <span class="citation_source-journal">Exp. Eye Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">78</span><span class="NLM_x">, </span> <span class="NLM_fpage">27</span><span class="NLM_x">–</span> <span class="NLM_lpage">37</span><span class="refDoi"> DOI: 10.1016/j.exer.2003.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1016%2Fj.exer.2003.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=14667825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BD3sXps1erur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2004&pages=27-37&author=P.+Valverdeauthor=M.+S.+Obinauthor=A.+Taylor&title=Role+of+Gas6%2FAxl+signaling+in+lens+epithelial+cell+proliferation+and+survival&doi=10.1016%2Fj.exer.2003.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Role of Gas6/Axl signaling in lens epithelial cell proliferation and survival</span></div><div class="casAuthors">Valverde, P.; Obin, M. S.; Taylor, A.</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Eye Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-37</span>CODEN:
                <span class="NLM_cas:coden">EXERA6</span>;
        ISSN:<span class="NLM_cas:issn">0014-4835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Axl is a receptor tyrosine kinase that is activated by Gas6, a growth factor that belongs to the vitamin K-dependent protein family.  Although Gas6 binding to Axl has been shown to transmit mitogenic and/or anti-apoptotic signals to a variety of cell types, the role of the Axl-Gas6 system in normal and pathol. lens biol. is not known.  We demonstrate for the first time that Axl protein is expressed in normal rat and bovine lens and that its ligand, Gas6, is present in bovine aq. humor.  In addn., we have detected tyrosine-phosphorylated Axl in normal rat and bovine lens epithelial tissues.  We further show that human recombinant Gas6 is able to act as a growth factor in cultured human lens epithelial cells by activating Axl and then the AKT signaling pathway.  Gas6 mediates a survival and anti-apoptotic response in cultured human lens epithelial cells subjected to serum-starvation (48-72 h), or treated with transforming growth factor β1 (5 ng ml-1, 48 h) or tumor necrosis factor α (100 ng ml-1, 48 h), as demonstrated by increased no. of viable cells, and decreased DNA condensation or caspase-3 activity.  In contrast, Gas6 is not able to block apoptosis induced by staurosporin (1 μm, 5-24 h) in human lens epithelial cells.  Taken together, these data suggest that the Gas6/Axl signaling plays an important role in the control of lens epithelial cell growth and survival and hence in the maintenance of lens homeostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrp-fUwE5As2bVg90H21EOLACvtfcHk0lgpeES2IfQ03Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXps1erur0%253D&md5=5ee0b3ecd6319729b765e5a1fe178218</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.exer.2003.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.exer.2003.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DValverde%26aufirst%3DP.%26aulast%3DObin%26aufirst%3DM.%2BS.%26aulast%3DTaylor%26aufirst%3DA.%26atitle%3DRole%2520of%2520Gas6%252FAxl%2520signaling%2520in%2520lens%2520epithelial%2520cell%2520proliferation%2520and%2520survival%26jtitle%3DExp.%2520Eye%2520Res.%26date%3D2004%26volume%3D78%26spage%3D27%26epage%3D37%26doi%3D10.1016%2Fj.exer.2003.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Bauer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zagórska, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jurkin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasmin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Köffel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gesslbauer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemke, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strobl, H.</span><span> </span><span class="NLM_article-title">Identification of Axl as a downstream effector of TGF-β1 during Langerhans cell differentiation and epidermal homeostasis</span> <span class="citation_source-journal">J. Exp. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">209</span><span class="NLM_x">, </span> <span class="NLM_fpage">2033</span><span class="NLM_x">–</span> <span class="NLM_lpage">2047</span><span class="refDoi"> DOI: 10.1084/jem.20120493</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1084%2Fjem.20120493" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=209&publication_year=2012&pages=2033-2047&author=T.+Bauerauthor=A.+Zag%C3%B3rskaauthor=J.+Jurkinauthor=N.+Yasminauthor=R.+K%C3%B6ffelauthor=S.+Richterauthor=B.+Gesslbauerauthor=G.+Lemkeauthor=H.+Strobl&title=Identification+of+Axl+as+a+downstream+effector+of+TGF-%CE%B21+during+Langerhans+cell+differentiation+and+epidermal+homeostasis&doi=10.1084%2Fjem.20120493"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1084%2Fjem.20120493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20120493%26sid%3Dliteratum%253Aachs%26aulast%3DBauer%26aufirst%3DT.%26aulast%3DZag%25C3%25B3rska%26aufirst%3DA.%26aulast%3DJurkin%26aufirst%3DJ.%26aulast%3DYasmin%26aufirst%3DN.%26aulast%3DK%25C3%25B6ffel%26aufirst%3DR.%26aulast%3DRichter%26aufirst%3DS.%26aulast%3DGesslbauer%26aufirst%3DB.%26aulast%3DLemke%26aufirst%3DG.%26aulast%3DStrobl%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520Axl%2520as%2520a%2520downstream%2520effector%2520of%2520TGF-%25CE%25B21%2520during%2520Langerhans%2520cell%2520differentiation%2520and%2520epidermal%2520homeostasis%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2012%26volume%3D209%26spage%3D2033%26epage%3D2047%26doi%3D10.1084%2Fjem.20120493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Tai, K. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shieh, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiah, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, C. W.</span><span> </span><span class="NLM_article-title">Axl promotes cell invasion by inducing MMP-9 activity through activation of NF-κB and Brg-1</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">4044</span><span class="NLM_x">–</span> <span class="NLM_lpage">4055</span><span class="refDoi"> DOI: 10.1038/onc.2008.57</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1038%2Fonc.2008.57" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=4044-4055&author=K.+Y.+Taiauthor=Y.+S.+Shiehauthor=C.+S.+Leeauthor=S.+G.+Shiahauthor=C.+W.+Wu&title=Axl+promotes+cell+invasion+by+inducing+MMP-9+activity+through+activation+of+NF-%CE%BAB+and+Brg-1&doi=10.1038%2Fonc.2008.57"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1038%2Fonc.2008.57&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2008.57%26sid%3Dliteratum%253Aachs%26aulast%3DTai%26aufirst%3DK.%2BY.%26aulast%3DShieh%26aufirst%3DY.%2BS.%26aulast%3DLee%26aufirst%3DC.%2BS.%26aulast%3DShiah%26aufirst%3DS.%2BG.%26aulast%3DWu%26aufirst%3DC.%2BW.%26atitle%3DAxl%2520promotes%2520cell%2520invasion%2520by%2520inducing%2520MMP-9%2520activity%2520through%2520activation%2520of%2520NF-%25CE%25BAB%2520and%2520Brg-1%26jtitle%3DOncogene%26date%3D2008%26volume%3D27%26spage%3D4044%26epage%3D4055%26doi%3D10.1038%2Fonc.2008.57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Woo, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Min, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwon, T. K.</span><span> </span><span class="NLM_article-title">Axl is a novel target of withaferin A in the induction of apoptosis and the suppression of invasion</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">451</span><span class="NLM_x">, </span> <span class="NLM_fpage">455</span><span class="NLM_x">–</span> <span class="NLM_lpage">460</span><span class="refDoi"> DOI: 10.1016/j.bbrc.2014.08.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1016%2Fj.bbrc.2014.08.018" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=451&publication_year=2014&pages=455-460&author=S.+M.+Wooauthor=K.+J.+Minauthor=S.+Kimauthor=J.+W.+Parkauthor=D.+E.+Kimauthor=S.+H.+Kimauthor=Y.+H.+Choiauthor=T.+K.+Kwon&title=Axl+is+a+novel+target+of+withaferin+A+in+the+induction+of+apoptosis+and+the+suppression+of+invasion&doi=10.1016%2Fj.bbrc.2014.08.018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2014.08.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2014.08.018%26sid%3Dliteratum%253Aachs%26aulast%3DWoo%26aufirst%3DS.%2BM.%26aulast%3DMin%26aufirst%3DK.%2BJ.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DJ.%2BW.%26aulast%3DKim%26aufirst%3DD.%2BE.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DChoi%26aufirst%3DY.%2BH.%26aulast%3DKwon%26aufirst%3DT.%2BK.%26atitle%3DAxl%2520is%2520a%2520novel%2520target%2520of%2520withaferin%2520A%2520in%2520the%2520induction%2520of%2520apoptosis%2520and%2520the%2520suppression%2520of%2520invasion%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2014%26volume%3D451%26spage%3D455%26epage%3D460%26doi%3D10.1016%2Fj.bbrc.2014.08.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Abu-Thuraia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gauthier, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chidiac, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukui, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Screaton, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gratton, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Côté, J. F.</span><span> </span><span class="NLM_article-title">Axl phosphorylates Elmo scaffold proteins to promote Rac activation and cell invasion</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">76</span><span class="NLM_x">–</span> <span class="NLM_lpage">87</span><span class="refDoi"> DOI: 10.1128/MCB.00764-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1128%2FMCB.00764-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=25332238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslKktro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2015&pages=76-87&author=A.+Abu-Thuraiaauthor=R.+Gauthierauthor=R.+Chidiacauthor=Y.+Fukuiauthor=R.+A.+Screatonauthor=J.+P.+Grattonauthor=J.+F.+C%C3%B4t%C3%A9&title=Axl+phosphorylates+Elmo+scaffold+proteins+to+promote+Rac+activation+and+cell+invasion&doi=10.1128%2FMCB.00764-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6cR"><div class="casContent"><span class="casTitleNuber">6c</span><div class="casTitle"><span class="NLM_cas:atitle">Axl phosphorylates Elmo scaffold proteins to promote Rac activation and cell invasion</span></div><div class="casAuthors">Abu-Thuraia, Afnan; Gauthier, Rosemarie; Chidiac, Rony; Fukui, Yoshinori; Screaton, Robert A.; Gratton, Jean-Philippe; Cote, Jean-Francois</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">76-87/1-76-87/12, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">1098-5549</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The receptor tyrosine kinase Axl contributes to cell migration and invasion.  Expression of Axl correlates with metastatic progression in cancer patients, yet the specific signaling events promoting invasion downstream of Axl are poorly defined.  Herein, we report Elmo scaffolds to be direct substrates and binding partners of Axl.  Elmo proteins are established to interact with Dock family guanine nucleotide exchange factors to control Rac-mediated cytoskeletal dynamics.  Proteomics and mutagenesis studies reveal that Axl phosphorylates Elmo1/2 on a conserved carboxyl-terminal tyrosine residue.  Upon Gas6-dependent activation of Axl, endogenous Elmo2 becomes phosphorylated on Tyr-713 and enters into a phys. complex with Axl in breast cancer cells.  Interfering with Elmo2 expression prevented Gas6-induced Rac1 activation in breast cancer cells.  Similarly to blocking of Axl, Elmo2 knockdown or pharmacol. inhibition of Dock1 abolishes breast cancer cell invasion.  Interestingly, Axl or Elmo2 knockdown diminishes breast cancer cell proliferation.  Rescue of Elmo2 knockdown cells with the wild-type protein but not with Elmo2 harboring Tyr-713-Phe mutations restores cell invasion and cell proliferation.  These results define a new mechanism by which Axl promotes cell proliferation and invasion and identifies inhibition of the Elmo-Dock pathway as a potential therapeutic target to stop Axl-induced metastases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokdhdGfjbt6bVg90H21EOLACvtfcHk0lj0A7TueLOKOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslKktro%253D&md5=f89bc57cd15b039f2bb72b4eebcbc81c</span></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=10.1128%2FMCB.00764-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.00764-14%26sid%3Dliteratum%253Aachs%26aulast%3DAbu-Thuraia%26aufirst%3DA.%26aulast%3DGauthier%26aufirst%3DR.%26aulast%3DChidiac%26aufirst%3DR.%26aulast%3DFukui%26aufirst%3DY.%26aulast%3DScreaton%26aufirst%3DR.%2BA.%26aulast%3DGratton%26aufirst%3DJ.%2BP.%26aulast%3DC%25C3%25B4t%25C3%25A9%26aufirst%3DJ.%2BF.%26atitle%3DAxl%2520phosphorylates%2520Elmo%2520scaffold%2520proteins%2520to%2520promote%2520Rac%2520activation%2520and%2520cell%2520invasion%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2015%26volume%3D35%26spage%3D76%26epage%3D87%26doi%3D10.1128%2FMCB.00764-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Seitz, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camenisch, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemke, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Earp, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsushima, G. K.</span><span> </span><span class="NLM_article-title">Macrophages and dendritic cells use different Axl/Mertk/Tyro3 receptors in clearance of apoptotic cells</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">178</span><span class="NLM_x">, </span> <span class="NLM_fpage">5635</span><span class="NLM_x">–</span> <span class="NLM_lpage">5642</span><span class="refDoi"> DOI: 10.4049/jimmunol.178.9.5635</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.4049%2Fjimmunol.178.9.5635" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=178&publication_year=2007&pages=5635-5642&author=H.+M.+Seitzauthor=T.+D.+Camenischauthor=G.+Lemkeauthor=H.+S.+Earpauthor=G.+K.+Matsushima&title=Macrophages+and+dendritic+cells+use+different+Axl%2FMertk%2FTyro3+receptors+in+clearance+of+apoptotic+cells&doi=10.4049%2Fjimmunol.178.9.5635"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.178.9.5635&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.178.9.5635%26sid%3Dliteratum%253Aachs%26aulast%3DSeitz%26aufirst%3DH.%2BM.%26aulast%3DCamenisch%26aufirst%3DT.%2BD.%26aulast%3DLemke%26aufirst%3DG.%26aulast%3DEarp%26aufirst%3DH.%2BS.%26aulast%3DMatsushima%26aufirst%3DG.%2BK.%26atitle%3DMacrophages%2520and%2520dendritic%2520cells%2520use%2520different%2520Axl%252FMertk%252FTyro3%2520receptors%2520in%2520clearance%2520of%2520apoptotic%2520cells%26jtitle%3DJ.%2520Immunol.%26date%3D2007%26volume%3D178%26spage%3D5635%26epage%3D5642%26doi%3D10.4049%2Fjimmunol.178.9.5635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Rothlin, C. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zuniga, E. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oldstone, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemke, G.</span><span> </span><span class="NLM_article-title">TAM receptors are pleiotropic inhibitors of the innate immune response</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">131</span><span class="NLM_x">, </span> <span class="NLM_fpage">1124</span><span class="NLM_x">–</span> <span class="NLM_lpage">1136</span><span class="refDoi"> DOI: 10.1016/j.cell.2007.10.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1016%2Fj.cell.2007.10.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=18083102" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BD1cXksFGgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2007&pages=1124-1136&author=C.+V.+Rothlinauthor=S.+Ghoshauthor=E.+I.+Zunigaauthor=M.+B.+Oldstoneauthor=G.+Lemke&title=TAM+receptors+are+pleiotropic+inhibitors+of+the+innate+immune+response&doi=10.1016%2Fj.cell.2007.10.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">TAM receptors are pleiotropic inhibitors of the innate immune response</span></div><div class="casAuthors">Rothlin, Carla V.; Ghosh, Sourav; Zuniga, Elina I.; Oldstone, Michael B. A.; Lemke, Greg</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1124-1136</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The activation of Toll-like receptors (TLRs) in dendritic cells (DCs) triggers a rapid inflammatory response to pathogens.  However, this response must be tightly regulated because unrestrained TLR signaling generates a chronic inflammatory milieu that often leads to autoimmunity.  We have found that the TAM receptor tyrosine kinases-Tyro3, Axl, and Mer-broadly inhibit both TLR and TLR-induced cytokine-receptor cascades.  Remarkably, TAM inhibition of inflammation is transduced through an essential stimulator of inflammation-the type I interferon receptor (IFNAR)-and its assocd. transcription factor STAT1.  TLR induction of IFNAR-STAT1 signaling upregulates the TAM system, which in turn usurps the IFNAR-STAT1 cassette to induce the cytokine and TLR suppressors SOCS1 and SOCS3.  These results illuminate a self-regulating cycle of inflammation, in which the obligatory, cytokine-dependent activation of TAM signaling hijacks a proinflammatory pathway to provide an intrinsic feedback inhibitor of both TLR- and cytokine-driven immune responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWCPRBPKbiNrVg90H21EOLACvtfcHk0lj0A7TueLOKOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXksFGgug%253D%253D&md5=32511c20288ef6f92b60d9a6bc94637d</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2007.10.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2007.10.034%26sid%3Dliteratum%253Aachs%26aulast%3DRothlin%26aufirst%3DC.%2BV.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DZuniga%26aufirst%3DE.%2BI.%26aulast%3DOldstone%26aufirst%3DM.%2BB.%26aulast%3DLemke%26aufirst%3DG.%26atitle%3DTAM%2520receptors%2520are%2520pleiotropic%2520inhibitors%2520of%2520the%2520innate%2520immune%2520response%26jtitle%3DCell%26date%3D2007%26volume%3D131%26spage%3D1124%26epage%3D1136%26doi%3D10.1016%2Fj.cell.2007.10.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Lemke, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rothlin, C. V.</span><span> </span><span class="NLM_article-title">Immunobiology of the TAM receptors</span> <span class="citation_source-journal">Nat. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">327</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span><span class="refDoi"> DOI: 10.1038/nri2303</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1038%2Fnri2303" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=18421305" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltFejsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=327-336&author=G.+Lemkeauthor=C.+V.+Rothlin&title=Immunobiology+of+the+TAM+receptors&doi=10.1038%2Fnri2303"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7cR"><div class="casContent"><span class="casTitleNuber">7c</span><div class="casTitle"><span class="NLM_cas:atitle">Immunobiology of the TAM receptors</span></div><div class="casAuthors">Lemke, Greg; Rothlin, Carla V.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">327-336</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Recent studies have revealed that the TAM receptor protein tyrosine kinases - TYRO3, AXL and MER - have pivotal roles in innate immunity.  They inhibit inflammation in dendritic cells and macrophages, promote the phagocytosis of apoptotic cells and membranous organelles, and stimulate the maturation of natural killer cells.  Each of these phenomena may depend on a cooperative interaction between TAM receptor and cytokine receptor signalling systems.  Although its importance was previously unrecognized, TAM signalling promises to have an increasingly prominent role in studies of innate immune regulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpW_CJak8Sc-LVg90H21EOLACvtfcHk0ljCFc0aXfyjhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltFejsbg%253D&md5=7726fd6ab58ce205941aa74f7bcdcf32</span></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=10.1038%2Fnri2303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2303%26sid%3Dliteratum%253Aachs%26aulast%3DLemke%26aufirst%3DG.%26aulast%3DRothlin%26aufirst%3DC.%2BV.%26atitle%3DImmunobiology%2520of%2520the%2520TAM%2520receptors%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2008%26volume%3D8%26spage%3D327%26epage%3D336%26doi%3D10.1038%2Fnri2303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Rothlin, C. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemke, G.</span><span> </span><span class="NLM_article-title">TAM receptor signaling and autoimmune disease</span> <span class="citation_source-journal">Curr. Opin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">740</span><span class="NLM_x">–</span> <span class="NLM_lpage">746</span><span class="refDoi"> DOI: 10.1016/j.coi.2010.10.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1016%2Fj.coi.2010.10.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=21030229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFaqsrjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2010&pages=740-746&author=C.+V.+Rothlinauthor=G.+Lemke&title=TAM+receptor+signaling+and+autoimmune+disease&doi=10.1016%2Fj.coi.2010.10.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7dR"><div class="casContent"><span class="casTitleNuber">7d</span><div class="casTitle"><span class="NLM_cas:atitle">TAM receptor signaling and autoimmune disease</span></div><div class="casAuthors">Rothlin, Carla V.; Lemke, Greg</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">740-746</span>CODEN:
                <span class="NLM_cas:coden">COPIEL</span>;
        ISSN:<span class="NLM_cas:issn">0952-7915</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The TAM receptor tyrosine kinases Tyro3, Axl, and Mer and their ligands Gas6 and Protein S are essential for the phagocytosis of apoptotic cells and membranes in the adult immune, nervous, and reproductive systems.  Genetic studies indicate that this receptor-ligand system is central to apoptotic cell engulfment that is triggered by the eat-me' signal phosphatidylserine (PtdSer).  At the same time, TAM signaling is normally activated by Toll-like receptor (TLR) and type I interferon signaling, as part of the innate inflammatory response in dendritic cells (DCs) and macrophages, where it inhibits this response.  Deficiencies in TAM signaling result in human retinal dystrophies and may contribute to lupus and other human autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNh1G6pHA1wrVg90H21EOLACvtfcHk0ljCFc0aXfyjhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFaqsrjN&md5=78794bcaf2dcb2dcf0e00409fae2c321</span></div><a href="/servlet/linkout?suffix=cit7d&amp;dbid=16384&amp;doi=10.1016%2Fj.coi.2010.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coi.2010.10.001%26sid%3Dliteratum%253Aachs%26aulast%3DRothlin%26aufirst%3DC.%2BV.%26aulast%3DLemke%26aufirst%3DG.%26atitle%3DTAM%2520receptor%2520signaling%2520and%2520autoimmune%2520disease%26jtitle%3DCurr.%2520Opin.%2520Immunol.%26date%3D2010%26volume%3D22%26spage%3D740%26epage%3D746%26doi%3D10.1016%2Fj.coi.2010.10.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Shibata, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habiel, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coelho, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunkel, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lukacs, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogaboam, C. M.</span><span> </span><span class="NLM_article-title">Axl receptor blockade ameliorates pulmonary pathology resulting from primary viral infection and viral exacerbation of asthma</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">192</span><span class="NLM_x">, </span> <span class="NLM_fpage">3569</span><span class="NLM_x">–</span> <span class="NLM_lpage">3581</span><span class="refDoi"> DOI: 10.4049/jimmunol.1302766</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.4049%2Fjimmunol.1302766" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=2014&pages=3569-3581&author=T.+Shibataauthor=D.+M.+Habielauthor=A.+L.+Coelhoauthor=S.+L.+Kunkelauthor=N.+W.+Lukacsauthor=C.+M.+Hogaboam&title=Axl+receptor+blockade+ameliorates+pulmonary+pathology+resulting+from+primary+viral+infection+and+viral+exacerbation+of+asthma&doi=10.4049%2Fjimmunol.1302766"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7e&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1302766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1302766%26sid%3Dliteratum%253Aachs%26aulast%3DShibata%26aufirst%3DT.%26aulast%3DHabiel%26aufirst%3DD.%2BM.%26aulast%3DCoelho%26aufirst%3DA.%2BL.%26aulast%3DKunkel%26aufirst%3DS.%2BL.%26aulast%3DLukacs%26aufirst%3DN.%2BW.%26aulast%3DHogaboam%26aufirst%3DC.%2BM.%26atitle%3DAxl%2520receptor%2520blockade%2520ameliorates%2520pulmonary%2520pathology%2520resulting%2520from%2520primary%2520viral%2520infection%2520and%2520viral%2520exacerbation%2520of%2520asthma%26jtitle%3DJ.%2520Immunol.%26date%3D2014%26volume%3D192%26spage%3D3569%26epage%3D3581%26doi%3D10.4049%2Fjimmunol.1302766" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Wimmel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glitz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraus, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roeder, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuermann, M.</span><span> </span><span class="NLM_article-title">Axl receptor tyrosine kinase expression in human lung cancer cell lines correlates with cellular adhesion</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">2264</span><span class="NLM_x">–</span> <span class="NLM_lpage">2274</span><span class="refDoi"> DOI: 10.1016/S0959-8049(01)00271-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1016%2FS0959-8049%2801%2900271-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2001&pages=2264-2274&author=A.+Wimmelauthor=D.+Glitzauthor=A.+Krausauthor=J.+Roederauthor=M.+Schuermann&title=Axl+receptor+tyrosine+kinase+expression+in+human+lung+cancer+cell+lines+correlates+with+cellular+adhesion&doi=10.1016%2FS0959-8049%2801%2900271-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1016%2FS0959-8049%2801%2900271-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0959-8049%252801%252900271-4%26sid%3Dliteratum%253Aachs%26aulast%3DWimmel%26aufirst%3DA.%26aulast%3DGlitz%26aufirst%3DD.%26aulast%3DKraus%26aufirst%3DA.%26aulast%3DRoeder%26aufirst%3DJ.%26aulast%3DSchuermann%26aufirst%3DM.%26atitle%3DAxl%2520receptor%2520tyrosine%2520kinase%2520expression%2520in%2520human%2520lung%2520cancer%2520cell%2520lines%2520correlates%2520with%2520cellular%2520adhesion%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2001%26volume%3D37%26spage%3D2264%26epage%3D2274%26doi%3D10.1016%2FS0959-8049%2801%2900271-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Shinh, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kao, Y. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiah, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, Y. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, C. W.</span><span> </span><span class="NLM_article-title">Expression of Axl in lung adenocarcinoma and correlation with tumor progression</span> <span class="citation_source-journal">Neoplasia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1058</span><span class="NLM_x">–</span> <span class="NLM_lpage">1064</span><span class="refDoi"> DOI: 10.1593/neo.05640</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1593%2Fneo.05640" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=16354588" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=1058-1064&author=Y.+S.+Shinhauthor=C.+Y.+Laiauthor=Y.+R.+Kaoauthor=S.+G.+Shiahauthor=Y.+W.+Chuauthor=H.+S.+Leeauthor=C.+W.+Wu&title=Expression+of+Axl+in+lung+adenocarcinoma+and+correlation+with+tumor+progression&doi=10.1593%2Fneo.05640"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=10.1593%2Fneo.05640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1593%252Fneo.05640%26sid%3Dliteratum%253Aachs%26aulast%3DShinh%26aufirst%3DY.%2BS.%26aulast%3DLai%26aufirst%3DC.%2BY.%26aulast%3DKao%26aufirst%3DY.%2BR.%26aulast%3DShiah%26aufirst%3DS.%2BG.%26aulast%3DChu%26aufirst%3DY.%2BW.%26aulast%3DLee%26aufirst%3DH.%2BS.%26aulast%3DWu%26aufirst%3DC.%2BW.%26atitle%3DExpression%2520of%2520Axl%2520in%2520lung%2520adenocarcinoma%2520and%2520correlation%2520with%2520tumor%2520progression%26jtitle%3DNeoplasia%26date%3D2005%26volume%3D7%26spage%3D1058%26epage%3D1064%26doi%3D10.1593%2Fneo.05640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Ishikawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sonobe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakayama, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kikuchi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitamura, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imamura, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Date, H.</span><span> </span><span class="NLM_article-title">Higher expression of receptor tyrosine kinase Axl, and differential expression of its ligand, Gas6, predict poor survival in lung adenocarcinoma patients</span> <span class="citation_source-journal">Ann. Surg. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">467</span><span class="NLM_x">–</span> <span class="NLM_lpage">476</span><span class="refDoi"> DOI: 10.1245/s10434-012-2795-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1245%2Fs10434-012-2795-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=467-476&author=M.+Ishikawaauthor=M.+Sonobeauthor=E.+Nakayamaauthor=M.+Kobayashiauthor=R.+Kikuchiauthor=J.+Kitamuraauthor=N.+Imamuraauthor=H.+Date&title=Higher+expression+of+receptor+tyrosine+kinase+Axl%2C+and+differential+expression+of+its+ligand%2C+Gas6%2C+predict+poor+survival+in+lung+adenocarcinoma+patients&doi=10.1245%2Fs10434-012-2795-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8c&amp;dbid=16384&amp;doi=10.1245%2Fs10434-012-2795-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1245%252Fs10434-012-2795-3%26sid%3Dliteratum%253Aachs%26aulast%3DIshikawa%26aufirst%3DM.%26aulast%3DSonobe%26aufirst%3DM.%26aulast%3DNakayama%26aufirst%3DE.%26aulast%3DKobayashi%26aufirst%3DM.%26aulast%3DKikuchi%26aufirst%3DR.%26aulast%3DKitamura%26aufirst%3DJ.%26aulast%3DImamura%26aufirst%3DN.%26aulast%3DDate%26aufirst%3DH.%26atitle%3DHigher%2520expression%2520of%2520receptor%2520tyrosine%2520kinase%2520Axl%252C%2520and%2520differential%2520expression%2520of%2520its%2520ligand%252C%2520Gas6%252C%2520predict%2520poor%2520survival%2520in%2520lung%2520adenocarcinoma%2520patients%26jtitle%3DAnn.%2520Surg.%2520Oncol.%26date%3D2013%26volume%3D20%26spage%3D467%26epage%3D476%26doi%3D10.1245%2Fs10434-012-2795-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Linger, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sather, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Migdall-Wilson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middleton, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baron, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franklin, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merrick, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jedlicka, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeRyckere, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heasley, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, D. K.</span><span> </span><span class="NLM_article-title">Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">3420</span><span class="NLM_x">–</span> <span class="NLM_lpage">3431</span><span class="refDoi"> DOI: 10.1038/onc.2012.355</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1038%2Fonc.2012.355" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2013&pages=3420-3431&author=R.+M.+Lingerauthor=R.+A.+Cohenauthor=C.+T.+Cummingsauthor=S.+Satherauthor=J.+Migdall-Wilsonauthor=D.+H.+Middletonauthor=X.+Luauthor=A.+E.+Baronauthor=W.+A.+Franklinauthor=D.+T.+Merrickauthor=P.+Jedlickaauthor=D.+DeRyckereauthor=L.+E.+Heasleyauthor=D.+K.+Graham&title=Mer+or+Axl+receptor+tyrosine+kinase+inhibition+promotes+apoptosis%2C+blocks+growth+and+enhances+chemosensitivity+of+human+non-small+cell+lung+cancer&doi=10.1038%2Fonc.2012.355"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8d&amp;dbid=16384&amp;doi=10.1038%2Fonc.2012.355&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2012.355%26sid%3Dliteratum%253Aachs%26aulast%3DLinger%26aufirst%3DR.%2BM.%26aulast%3DCohen%26aufirst%3DR.%2BA.%26aulast%3DCummings%26aufirst%3DC.%2BT.%26aulast%3DSather%26aufirst%3DS.%26aulast%3DMigdall-Wilson%26aufirst%3DJ.%26aulast%3DMiddleton%26aufirst%3DD.%2BH.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DBaron%26aufirst%3DA.%2BE.%26aulast%3DFranklin%26aufirst%3DW.%2BA.%26aulast%3DMerrick%26aufirst%3DD.%2BT.%26aulast%3DJedlicka%26aufirst%3DP.%26aulast%3DDeRyckere%26aufirst%3DD.%26aulast%3DHeasley%26aufirst%3DL.%2BE.%26aulast%3DGraham%26aufirst%3DD.%2BK.%26atitle%3DMer%2520or%2520Axl%2520receptor%2520tyrosine%2520kinase%2520inhibition%2520promotes%2520apoptosis%252C%2520blocks%2520growth%2520and%2520enhances%2520chemosensitivity%2520of%2520human%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DOncogene%26date%3D2013%26volume%3D32%26spage%3D3420%26epage%3D3431%26doi%3D10.1038%2Fonc.2012.355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Bivona, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okimoto, R.</span><span> </span><span class="NLM_article-title">AXL receptor tyrosine kinase as a therapeutic target in NSCLC</span> <span class="citation_source-journal">Lung Cancer: Targets Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">27</span><span class="NLM_x">–</span> <span class="NLM_lpage">34</span><span class="refDoi"> DOI: 10.2147/LCTT.S60438</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.2147%2FLCTT.S60438" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC28XosVCrsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=27-34&author=T.+Bivonaauthor=R.+Okimoto&title=AXL+receptor+tyrosine+kinase+as+a+therapeutic+target+in+NSCLC&doi=10.2147%2FLCTT.S60438"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8eR"><div class="casContent"><span class="casTitleNuber">8e</span><div class="casTitle"><span class="NLM_cas:atitle">AXL receptor tyrosine kinase as a therapeutic target in NSCLC</span></div><div class="casAuthors">Okimoto, Ross A.; Bivona, Trever G.</div><div class="citationInfo"><span class="NLM_cas:title">Lung Cancer: Targets and Therapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">27-34</span>CODEN:
                <span class="NLM_cas:coden">LCTTBI</span>;
        ISSN:<span class="NLM_cas:issn">1179-2728</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">The AXL receptor tyrosine kinase and its ligand, Gas6, regulate key processes in lung cancer growth, metastasis, and epithelial-mesenchymal transition-assocd. drug resistance.  Gas6 and AXL expression have been correlated with poor prognosis and advanced clin. stage in patients with lung cancer, and targeting the Gas6/AXL pathway demonstrates antitumor activity, decreases cellular invasion, and restores sensitivity in de novo and acquired drug resistance models.  These findings implicate AXL as a promising therapeutic target in lung cancer.  In this review, we explore the role of AXL in lung cancer progression, from tumor development to disseminated disease, and highlight the current clin. landscape of anti-AXL therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAZYZvs1l4vrVg90H21EOLACvtfcHk0liud5c_F9-Wxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XosVCrsLs%253D&md5=23e221a3549d60126db8d2a9bd035932</span></div><a href="/servlet/linkout?suffix=cit8e&amp;dbid=16384&amp;doi=10.2147%2FLCTT.S60438&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FLCTT.S60438%26sid%3Dliteratum%253Aachs%26aulast%3DBivona%26aufirst%3DT.%26aulast%3DOkimoto%26aufirst%3DR.%26atitle%3DAXL%2520receptor%2520tyrosine%2520kinase%2520as%2520a%2520therapeutic%2520target%2520in%2520NSCLC%26jtitle%3DLung%2520Cancer%253A%2520Targets%2520Ther.%26date%3D2015%26volume%3D6%26spage%3D27%26epage%3D34%26doi%3D10.2147%2FLCTT.S60438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Berclaz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altermatt, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rohrbach, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kieffer, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dreher, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andres, A. C.</span><span> </span><span class="NLM_article-title">Estrogen dependent expression of the receptor tyrosine kinase axl in normal and malignant human breast</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">819</span><span class="NLM_x">–</span> <span class="NLM_lpage">824</span><span class="refDoi"> DOI: 10.1023/A:1011126330233</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1023%2FA%3A1011126330233" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=11484958" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A280%3ADC%252BD38%252FislSrtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2001&pages=819-824&author=G.+Berclazauthor=H.+J.+Altermattauthor=V.+Rohrbachauthor=I.+Kiefferauthor=E.+Dreherauthor=A.+C.+Andres&title=Estrogen+dependent+expression+of+the+receptor+tyrosine+kinase+axl+in+normal+and+malignant+human+breast&doi=10.1023%2FA%3A1011126330233"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9aR"><div class="casContent"><span class="casTitleNuber">9a</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogen dependent expression of the receptor tyrosine kinase axl in normal and malignant human breast</span></div><div class="casAuthors">Berclaz G; Altermatt H J; Rohrbach V; Kieffer I; Dreher E; Andres A C</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology / ESMO</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">819-24</span>
        ISSN:<span class="NLM_cas:issn">0923-7534</span>.
    </div><div class="casAbstract">BACKGROUND:  Axl, a member of a family of receptor tyrosine kinases characterized by an extracellular domain resembling cell adhesion molecules and an intracellular conserved tyrosine kinase domain has been reported to induce cell proliferation and transformation.  In mice, axl is expressed in the normal mammary gland and over-expressed in aggressive mammary tumors.  PATIENTS AND METHODS:  We have investigated the expression of axl immunohistochemically in 23 normal human breast samples and in 111 consecutive breast carcinomas.  Expression of axl was correlated with tumour characteristics (lymph node involvement, stage, grade) and immunohistochemical expression of ER, PR, Ki-67 and c-erbB-2.  RESULTS:  In normal tissue, axl localizes to the membrane of breast epithelial cells.  Axl protein shows membrane associated staining in high correlation (P = 0.004) with the expression of the estrogen receptor (ER).  Axl expression was found in a subset of breast carcinomas and was also correlated with high significance (P < 0.0001) with the presence of ER.  CONCLUSION:  Our results suggest that axl may serve as a mediator of estrogen stimulation preventing the completion of the breast epithelial life cycle and that estrogen induced axl expression may give a survival signal to cancerous cells, preventing them from dying through apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS4jH3dLUflJ91QT_1O5WBYfW6udTcc2eYZQ6FwFJ0D5rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38%252FislSrtw%253D%253D&md5=36a9041a5d19646e01b47ea4886e182e</span></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.1023%2FA%3A1011126330233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1011126330233%26sid%3Dliteratum%253Aachs%26aulast%3DBerclaz%26aufirst%3DG.%26aulast%3DAltermatt%26aufirst%3DH.%2BJ.%26aulast%3DRohrbach%26aufirst%3DV.%26aulast%3DKieffer%26aufirst%3DI.%26aulast%3DDreher%26aufirst%3DE.%26aulast%3DAndres%26aufirst%3DA.%2BC.%26atitle%3DEstrogen%2520dependent%2520expression%2520of%2520the%2520receptor%2520tyrosine%2520kinase%2520axl%2520in%2520normal%2520and%2520malignant%2520human%2520breast%26jtitle%3DAnn.%2520Oncol.%26date%3D2001%26volume%3D12%26spage%3D819%26epage%3D824%26doi%3D10.1023%2FA%3A1011126330233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Zhang, Y. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knyazev, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheburkin, Y. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knyazev, Y. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orfi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabadkai, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daub, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span> </span><span class="NLM_article-title">AXL is a potential target for therapeutic intervention in breast cancer progression</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">1905</span><span class="NLM_x">–</span> <span class="NLM_lpage">1915</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-2661</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1158%2F0008-5472.CAN-07-2661" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=1905-1915&author=Y.+X.+Zhangauthor=P.+G.+Knyazevauthor=Y.+V.+Cheburkinauthor=K.+Sharmaauthor=Y.+P.+Knyazevauthor=L.+Orfiauthor=I.+Szabadkaiauthor=H.+Daubauthor=G.+Keriauthor=A.+Ullrich&title=AXL+is+a+potential+target+for+therapeutic+intervention+in+breast+cancer+progression&doi=10.1158%2F0008-5472.CAN-07-2661"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-2661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-2661%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%2BX.%26aulast%3DKnyazev%26aufirst%3DP.%2BG.%26aulast%3DCheburkin%26aufirst%3DY.%2BV.%26aulast%3DSharma%26aufirst%3DK.%26aulast%3DKnyazev%26aufirst%3DY.%2BP.%26aulast%3DOrfi%26aufirst%3DL.%26aulast%3DSzabadkai%26aufirst%3DI.%26aulast%3DDaub%26aufirst%3DH.%26aulast%3DKeri%26aufirst%3DG.%26aulast%3DUllrich%26aufirst%3DA.%26atitle%3DAXL%2520is%2520a%2520potential%2520target%2520for%2520therapeutic%2520intervention%2520in%2520breast%2520cancer%2520progression%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D1905%26epage%3D1915%26doi%3D10.1158%2F0008-5472.CAN-07-2661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Gjerdrum, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiron, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoiby, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stefansson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haugen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandal, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collett, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCormack, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gjertsen, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Micklem, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akslen, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glackin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorens, J. B.</span><span> </span><span class="NLM_article-title">Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">1124</span><span class="NLM_x">–</span> <span class="NLM_lpage">1129</span><span class="refDoi"> DOI: 10.1073/pnas.0909333107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1073%2Fpnas.0909333107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=20080645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFyku7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=1124-1129&author=C.+Gjerdrumauthor=C.+Tironauthor=T.+Hoibyauthor=I.+Stefanssonauthor=H.+Haugenauthor=T.+Sandalauthor=K.+Collettauthor=S.+Liauthor=E.+McCormackauthor=B.+T.+Gjertsenauthor=D.+R.+Micklemauthor=L.+A.+Akslenauthor=C.+Glackinauthor=J.+B.+Lorens&title=Axl+is+an+essential+epithelial-to-mesenchymal+transition-induced+regulator+of+breast+cancer+metastasis+and+patient+survival&doi=10.1073%2Fpnas.0909333107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9cR"><div class="casContent"><span class="casTitleNuber">9c</span><div class="casTitle"><span class="NLM_cas:atitle">Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival</span></div><div class="casAuthors">Gjerdrum, Christine; Tiron, Crina; Hoeiby, Torill; Stefansson, Ingunn; Haugen, Hallvard; Sandal, Tone; Collett, Karin; Li, Shan; McCormack, Emmet; Gjertsen, Bjoern Tore; Micklem, David R.; Akslen, Lars A.; Glackin, Carlotta; Lorens, James B.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1124-1129, S1124/1-S1124/11</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Metastasis underlies the majority of cancer-related deaths.  Thus, furthering our understanding of the mol. mechanisms that enable tumor cell dissemination is a vital health issue.  Epithelial-to-mesenchymal transitions (EMTs) endow carcinoma cells with enhanced migratory and survival attributes that facilitate malignant progression.  Characterization of EMT effectors is likely to yield new insights into metastasis and novel avenues for treatment.  We show that the presence of the receptor tyrosine kinase Axl in primary breast cancers independently predicts strongly reduced overall patient survival, and that matched patient metastatic lesions show enhanced Axl expression.  We demonstrate that Axl is strongly induced by EMT in immortalized mammary epithelial cells that establishes an autocrine signaling loop with its ligand, Gas6.  Epiallelic RNA interference anal. in metastatic breast cancer cells delineated a distinct threshold of Axl expression for mesenchymal-like in vitro cell invasiveness and formation of tumors in foreign and tissue-engineered micro-environments in vivo.  Importantly, in two different optical imaging-based exptl. breast cancer models, Axl knockdown completely prevented the spread of highly metastatic breast carcinoma cells from the mammary gland to lymph nodes and several major organs and increased overall survival.  These findings suggest that Axl represents a downstream effector of the tumor cell EMT that is required for breast cancer metastasis.  Thus, the detection and targeted treatment of Axl-expressing tumors represents an important new therapeutic strategy for breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPiST_cnXhqrVg90H21EOLACvtfcHk0lgYUpptmNdUCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFyku7s%253D&md5=dbd7113028010a800e22ff1f206b9337</span></div><a href="/servlet/linkout?suffix=cit9c&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0909333107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0909333107%26sid%3Dliteratum%253Aachs%26aulast%3DGjerdrum%26aufirst%3DC.%26aulast%3DTiron%26aufirst%3DC.%26aulast%3DHoiby%26aufirst%3DT.%26aulast%3DStefansson%26aufirst%3DI.%26aulast%3DHaugen%26aufirst%3DH.%26aulast%3DSandal%26aufirst%3DT.%26aulast%3DCollett%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DMcCormack%26aufirst%3DE.%26aulast%3DGjertsen%26aufirst%3DB.%2BT.%26aulast%3DMicklem%26aufirst%3DD.%2BR.%26aulast%3DAkslen%26aufirst%3DL.%2BA.%26aulast%3DGlackin%26aufirst%3DC.%26aulast%3DLorens%26aufirst%3DJ.%2BB.%26atitle%3DAxl%2520is%2520an%2520essential%2520epithelial-to-mesenchymal%2520transition-induced%2520regulator%2520of%2520breast%2520cancer%2520metastasis%2520and%2520patient%2520survival%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26spage%3D1124%26epage%3D1129%26doi%3D10.1073%2Fpnas.0909333107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Asiedu, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beauchamp-Perez, F. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingle, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behrens, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radisky, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knutson, K. L.</span><span> </span><span class="NLM_article-title">AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">1316</span><span class="NLM_x">–</span> <span class="NLM_lpage">1324</span><span class="refDoi"> DOI: 10.1038/onc.2013.57</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1038%2Fonc.2013.57" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=23474758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjslKlsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2014&pages=1316-1324&author=M.+K.+Asieduauthor=F.+D.+Beauchamp-Perezauthor=J.+N.+Ingleauthor=M.+D.+Behrensauthor=D.+C.+Radiskyauthor=K.+L.+Knutson&title=AXL+induces+epithelial-to-mesenchymal+transition+and+regulates+the+function+of+breast+cancer+stem+cells&doi=10.1038%2Fonc.2013.57"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9dR"><div class="casContent"><span class="casTitleNuber">9d</span><div class="casTitle"><span class="NLM_cas:atitle">AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells</span></div><div class="casAuthors">Asiedu, M. K.; Beauchamp-Perez, F. D.; Ingle, J. N.; Behrens, M. D.; Radisky, D. C.; Knutson, K. L.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1316-1324</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Despite significant progress in the treatment of breast cancer, particularly through the use of targeted therapy, relapse and chemoresistance remain a major hindrance to the fight to minimize the burden of the disease.  It is becoming increasingly clear that a rare subpopulation of cells known as cancer stem cells (CSC), able to be generated through epithelial-to-mesenchymal transition (EMT) and capable of tumor initiation and self-renewal, contributes to treatment resistance and metastases.  This means that a more effective therapy should target both the chemoresistant CSCs and the proliferating epithelial cells that give rise to them to reverse EMT and to attenuate their conversion to CSCs.  Here, we demonstrate a novel function of AXL in acting upstream to induce EMT in normal and immortalized human mammary epithelial cells in an apparent pos. feedback loop mechanism and regulate breast CSC (BCSC) self-renewal and chemoresistance.  Downregulation of AXL using MP470 (Amuvatinib) reversed EMT in mesenchymal normal human mammary epithelial cells and murine BCSCs attenuating self-renewal and restored chemosensitivity of the BCSCs.  AXL expression was also found to be assocd. with the expression of stem cell genes, regulation of metastases genes, increased tumorigenicity and was important for BCSC invasion and migration.  Inactivation of AXL also led to the downregulation of nuclear factor-κB pathway and reduced tumor formation in vivo.  Taken together, our data suggest that targeted therapy against AXL, in combination with systemic therapies, has the potential to improve response to anticancer therapies and to reduce breast cancer recurrence and metastases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqR3FaG5OgnVrVg90H21EOLACvtfcHk0lgYUpptmNdUCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjslKlsb0%253D&md5=a30463cda3288fbc2c92d712f7ef43a8</span></div><a href="/servlet/linkout?suffix=cit9d&amp;dbid=16384&amp;doi=10.1038%2Fonc.2013.57&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2013.57%26sid%3Dliteratum%253Aachs%26aulast%3DAsiedu%26aufirst%3DM.%2BK.%26aulast%3DBeauchamp-Perez%26aufirst%3DF.%2BD.%26aulast%3DIngle%26aufirst%3DJ.%2BN.%26aulast%3DBehrens%26aufirst%3DM.%2BD.%26aulast%3DRadisky%26aufirst%3DD.%2BC.%26aulast%3DKnutson%26aufirst%3DK.%2BL.%26atitle%3DAXL%2520induces%2520epithelial-to-mesenchymal%2520transition%2520and%2520regulates%2520the%2520function%2520of%2520breast%2520cancer%2520stem%2520cells%26jtitle%3DOncogene%26date%3D2014%26volume%3D33%26spage%3D1316%26epage%3D1324%26doi%3D10.1038%2Fonc.2013.57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">D’Alfonso, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hannah, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, S. J.</span><span> </span><span class="NLM_article-title">Axl receptor tyrosine kinase expression in breast cancer</span> <span class="citation_source-journal">J. Clin. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">690</span><span class="NLM_x">–</span> <span class="NLM_lpage">696</span><span class="refDoi"> DOI: 10.1136/jclinpath-2013-202161</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1136%2Fjclinpath-2013-202161" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=24904064" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslOqu77E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2014&pages=690-696&author=T.+M.+D%E2%80%99Alfonsoauthor=J.+Hannahauthor=Z.+M.+Chenauthor=Y.+F.+Liuauthor=P.+B.+Zhouauthor=S.+J.+Shin&title=Axl+receptor+tyrosine+kinase+expression+in+breast+cancer&doi=10.1136%2Fjclinpath-2013-202161"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9eR"><div class="casContent"><span class="casTitleNuber">9e</span><div class="casTitle"><span class="NLM_cas:atitle">Axl receptor tyrosine kinase expression in breast cancer</span></div><div class="casAuthors">D'Alfonso, Timothy M.; Hannah, Jeffrey; Chen, Zhengming; Liu, Yifang; Zhou, Pengbo; Shin, Sandra J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pathology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">690-696</span>CODEN:
                <span class="NLM_cas:coden">JCPAAK</span>;
        ISSN:<span class="NLM_cas:issn">0021-9746</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Aims Triple-neg. breast cancer comprises a clin. aggressive group of invasive carcinomas.  We examd. a published gene expression screen of a panel of breast cancer cell lines to identify a potential triple-neg. breast cancer-specific gene signature, and attempted to verify our findings by performing immunohistochem. anal. on tissue microarrays contg. a large cohort of invasive breast carcinomas.  Methods The microarray dataset for a panel of human breast cancer cell lines was interrogated for triple-neg. breast cancer-specific genes.  Membranous immunohistochem. expression of the protein product of the AXL gene was assessed semiquant. in 569 invasive breast carcinomas grouped according to mol. subgroup by immunohistochem.  Results AXL was significantly upregulated in triple-neg./basal B cell lines compared with luminal or basal A cell lines.  No significant difference was obsd. in the level of immunohistochem. expression of Axl protein between triple-neg. breast cancers and other mol. subgroups (p=0.257).  Axl expression was significantly assocd. with lymphovascular invasion (LVI) in all subgroups combined (p=0.033), and within the luminal A (p=0.002) and triple-neg. breast cancer subgroups (p=0.026).  Conclusions Despite preferential upregulation of AXL in triple-neg./basal B cell lines, anal. of Axl protein expression in a large series of patients' breast tumors revealed no assocn. between Axl expression and triple-neg. breast cancer or other subtype.  The assocn. of Axl expression with LVI supports previous work that implicates Axl as a promoter of invasiveness in breast cancer cell lines.  Further studies are necessary to explore whether Axl expression of individual breast cancer tumors can be clin. useful.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprcgtaivOWrLVg90H21EOLACvtfcHk0lgYUpptmNdUCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslOqu77E&md5=f856dcd153719c4f00c0d660d8bd85a4</span></div><a href="/servlet/linkout?suffix=cit9e&amp;dbid=16384&amp;doi=10.1136%2Fjclinpath-2013-202161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fjclinpath-2013-202161%26sid%3Dliteratum%253Aachs%26aulast%3DD%25E2%2580%2599Alfonso%26aufirst%3DT.%2BM.%26aulast%3DHannah%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DZ.%2BM.%26aulast%3DLiu%26aufirst%3DY.%2BF.%26aulast%3DZhou%26aufirst%3DP.%2BB.%26aulast%3DShin%26aufirst%3DS.%2BJ.%26atitle%3DAxl%2520receptor%2520tyrosine%2520kinase%2520expression%2520in%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Pathol.%26date%3D2014%26volume%3D67%26spage%3D690%26epage%3D696%26doi%3D10.1136%2Fjclinpath-2013-202161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Xu, M. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poon, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zender, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowe, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luk, J. M.</span><span> </span><span class="NLM_article-title">AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">1229</span><span class="NLM_x">–</span> <span class="NLM_lpage">1240</span><span class="refDoi"> DOI: 10.1038/onc.2010.504</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1038%2Fonc.2010.504" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=21076472" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVWmurjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2011&pages=1229-1240&author=M.+Z.+Xuauthor=S.+W.+Chanauthor=A.+M.+Liuauthor=K.+F.+Wongauthor=S.+T.+Fanauthor=J.+Chenauthor=R.+T.+Poonauthor=L.+Zenderauthor=S.+W.+Loweauthor=W.+Hongauthor=J.+M.+Luk&title=AXL+receptor+kinase+is+a+mediator+of+YAP-dependent+oncogenic+functions+in+hepatocellular+carcinoma&doi=10.1038%2Fonc.2010.504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10a</span><div class="casTitle"><span class="NLM_cas:atitle">AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma</span></div><div class="casAuthors">Xu, M. Z.; Chan, S. W.; Liu, A. M.; Wong, K. F.; Fan, S. T.; Chen, J.; Poon, R. T.; Zender, L.; Lowe, S. W.; Hong, W.; Luk, J. M.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1229-1240</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Yes-assocd. protein (YAP) is a downstream effector of the Hippo signaling pathway, which controls organ expansion and tissue development.  We have recently defined the tumorigenic potential and clin. significance of the YAP1 oncogene in human hepatocellular carcinoma (HCC).  The present study aims to define the tumorigenic properties of YAP in HCC and elucidate the related downstream signaling mechanism.  In a gain-of-function study, we demonstrated that ectopic increased expression of YAP in the immortalized non-tumorigenic hepatocyte cell line MIHA confers tumorigenic and metastatic potentials, as evidenced by (1) enhanced aptitudes in cell viability, anchorage-independent growth, migration and invasion; (2) tumor formation in a xenograft mouse model; and (3) induction of HCC biomarker α-fetoprotein and activation of mitogen-activated protein kinase.  Furthermore, we have identified AXL, a receptor tyrosine kinase, as a key downstream target that drives YAP-dependent oncogenic functions.  RNAi-mediated knockdown of AXL expression decreased the ability of YAP-expressing MIHA cells and of the primary HCC cell line to proliferate and invade.  These results indicate that AXL is a mediator of YAP-dependent oncogenic activities and implicates it as a potential therapeutic target for HCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhMeq35gO5yrVg90H21EOLACvtfcHk0ljV2-K1iy6qxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVWmurjJ&md5=7d49124ddec8fafc084a336e55ecb80b</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1038%2Fonc.2010.504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2010.504%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DM.%2BZ.%26aulast%3DChan%26aufirst%3DS.%2BW.%26aulast%3DLiu%26aufirst%3DA.%2BM.%26aulast%3DWong%26aufirst%3DK.%2BF.%26aulast%3DFan%26aufirst%3DS.%2BT.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DPoon%26aufirst%3DR.%2BT.%26aulast%3DZender%26aufirst%3DL.%26aulast%3DLowe%26aufirst%3DS.%2BW.%26aulast%3DHong%26aufirst%3DW.%26aulast%3DLuk%26aufirst%3DJ.%2BM.%26atitle%3DAXL%2520receptor%2520kinase%2520is%2520a%2520mediator%2520of%2520YAP-dependent%2520oncogenic%2520functions%2520in%2520hepatocellular%2520carcinoma%26jtitle%3DOncogene%26date%3D2011%26volume%3D30%26spage%3D1229%26epage%3D1240%26doi%3D10.1038%2Fonc.2010.504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Lee, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeng, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, R. H.</span><span> </span><span class="NLM_article-title">Gas6/Axl pathway promotes tumor invasion through the transcriptional activation of Slug in hepatocellular carcinoma</span> <span class="citation_source-journal">Carcinogenesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">769</span><span class="NLM_x">–</span> <span class="NLM_lpage">775</span><span class="refDoi"> DOI: 10.1093/carcin/bgt372</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1093%2Fcarcin%2Fbgt372" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2014&pages=769-775&author=H.+J.+Leeauthor=Y.+M.+Jengauthor=Y.+L.+Chenauthor=L.+Chungauthor=R.+H.+Yuan&title=Gas6%2FAxl+pathway+promotes+tumor+invasion+through+the+transcriptional+activation+of+Slug+in+hepatocellular+carcinoma&doi=10.1093%2Fcarcin%2Fbgt372"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1093%2Fcarcin%2Fbgt372&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcarcin%252Fbgt372%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DH.%2BJ.%26aulast%3DJeng%26aufirst%3DY.%2BM.%26aulast%3DChen%26aufirst%3DY.%2BL.%26aulast%3DChung%26aufirst%3DL.%26aulast%3DYuan%26aufirst%3DR.%2BH.%26atitle%3DGas6%252FAxl%2520pathway%2520promotes%2520tumor%2520invasion%2520through%2520the%2520transcriptional%2520activation%2520of%2520Slug%2520in%2520hepatocellular%2520carcinoma%26jtitle%3DCarcinogenesis%26date%3D2014%26volume%3D35%26spage%3D769%26epage%3D775%26doi%3D10.1093%2Fcarcin%2Fbgt372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Reichl, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dengler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Zijl, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huber, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuhrlinger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reichel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sieghart, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peck-Radosavljevic, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grubinger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mikulits, W.</span><span> </span><span class="NLM_article-title">Axl activates autocrine transforming growth factor-beta signaling in hepatocellular carcinoma</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">930</span><span class="NLM_x">–</span> <span class="NLM_lpage">941</span><span class="refDoi"> DOI: 10.1002/hep.27492</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1002%2Fhep.27492" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=25251599" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtFejtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2015&pages=930-941&author=P.+Reichlauthor=M.+Denglerauthor=F.+van+Zijlauthor=H.+Huberauthor=G.+Fuhrlingerauthor=C.+Reichelauthor=W.+Sieghartauthor=M.+Peck-Radosavljevicauthor=M.+Grubingerauthor=W.+Mikulits&title=Axl+activates+autocrine+transforming+growth+factor-beta+signaling+in+hepatocellular+carcinoma&doi=10.1002%2Fhep.27492"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10cR"><div class="casContent"><span class="casTitleNuber">10c</span><div class="casTitle"><span class="NLM_cas:atitle">Axl activates autocrine transforming growth factor-β signaling in hepatocellular carcinoma</span></div><div class="casAuthors">Reichl, Patrick; Dengler, Mirko; van Zijl, Franziska; Huber, Heidemarie; Fuehrlinger, Gerhard; Reichel, Christian; Sieghart, Wolfgang; Peck-Radosavljevic, Markus; Grubinger, Markus; Mikulits, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">930-941</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">In hepatocellular carcinoma (HCC), intrahepatic metastasis frequently correlates with epithelial to mesenchymal transition (EMT) of malignant hepatocytes.  Several mechanisms have been identified to be essentially involved in hepatocellular EMT, among them transforming growth factor (TGF)-β signaling.  Here we show the up-regulation and activation of the receptor tyrosine kinase Axl in EMT-transformed hepatoma cells.  Knockdown of Axl expression resulted in abrogation of invasive and transendothelial migratory abilities of mesenchymal HCC cells in vitro and Axl overexpression-induced metastatic colonization of epithelial hepatoma cells in vivo.  Importantly, Axl knockdown severely impaired resistance to TGF-β-mediated growth inhibition.  Anal. of the Axl interactome revealed binding of Axl to 14-3-3ζ, which is essentially required for Axl-mediated cell invasion, transendothelial migration, and resistance against TGF-β.  Axl/14-3-3ζ signaling caused phosphorylation of Smad3 linker region (Smad3L) at Ser213, resulting in the up-regulation of tumor-progressive TGF-β target genes such as PAI1, MMP9, and Snail as well as augmented TGF-β1 secretion in mesenchymal HCC cells.  Accordingly, high Axl expression in HCC patient samples correlated with elevated vessel invasion of HCC cells, higher risk of tumor recurrence after liver transplantation, strong phosphorylation of Smad3L, and lower survival.  In addn., elevated expression of both Axl and 14-3-3ζ showed strongly reduced survival of HCC patients.  Conclusion: Our data suggest that Axl/14-3-3ζ signaling is central for TGF-β-mediated HCC progression and a promising target for HCC therapy. (Hepatol. 2015;61:930-941).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYINc0VpFLaLVg90H21EOLACvtfcHk0ljV2-K1iy6qxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtFejtbo%253D&md5=9a7978862c05e63ad91bea57520c6c89</span></div><a href="/servlet/linkout?suffix=cit10c&amp;dbid=16384&amp;doi=10.1002%2Fhep.27492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.27492%26sid%3Dliteratum%253Aachs%26aulast%3DReichl%26aufirst%3DP.%26aulast%3DDengler%26aufirst%3DM.%26aulast%3Dvan%2BZijl%26aufirst%3DF.%26aulast%3DHuber%26aufirst%3DH.%26aulast%3DFuhrlinger%26aufirst%3DG.%26aulast%3DReichel%26aufirst%3DC.%26aulast%3DSieghart%26aufirst%3DW.%26aulast%3DPeck-Radosavljevic%26aufirst%3DM.%26aulast%3DGrubinger%26aufirst%3DM.%26aulast%3DMikulits%26aufirst%3DW.%26atitle%3DAxl%2520activates%2520autocrine%2520transforming%2520growth%2520factor-beta%2520signaling%2520in%2520hepatocellular%2520carcinoma%26jtitle%3DHepatology%26date%3D2015%26volume%3D61%26spage%3D930%26epage%3D941%26doi%3D10.1002%2Fhep.27492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Koorstra, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karikari, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldmann, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bisht, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rojas, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Offerhaus, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alvarez, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maitra, A.</span><span> </span><span class="NLM_article-title">The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target</span> <span class="citation_source-journal">Cancer Biol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">618</span><span class="NLM_x">–</span> <span class="NLM_lpage">626</span><span class="refDoi"> DOI: 10.4161/cbt.8.7.7923</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.4161%2Fcbt.8.7.7923" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=19252414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotFSjsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=618-626&author=J.+B.+Koorstraauthor=C.+A.+Karikariauthor=G.+Feldmannauthor=S.+Bishtauthor=P.+L.+Rojasauthor=G.+J.+Offerhausauthor=H.+Alvarezauthor=A.+Maitra&title=The+Axl+receptor+tyrosine+kinase+confers+an+adverse+prognostic+influence+in+pancreatic+cancer+and+represents+a+new+therapeutic+target&doi=10.4161%2Fcbt.8.7.7923"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11aR"><div class="casContent"><span class="casTitleNuber">11a</span><div class="casTitle"><span class="NLM_cas:atitle">The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target</span></div><div class="casAuthors">Koorstra, Jan-Bart M.; Karikari, Collins A.; Feldmann, Georg; Bisht, Savita; Rojas, Pamela Leal; Offerhaus, G. Johan A.; Alvarez, Hector; Maitra, Anirban</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">618-626</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1538-4047</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">Background: Pancreatic cancer is a near uniformly lethal disease and a better understanding of the mol. basis of this malignancy may lead to improved therapeutics.  The Axl receptor tyrosine kinase is implicated in cellular transformation and tumor progression, although its role in pancreatic cancer has not been previously documented.  Results: Axl labeling was present in 54 of 99 (55%), and was absent in 45 of 99 (45%) cases, resp.  Axl expression in pancreatic cancer was significantly assocd. with lymph node metastases (p < 0.01), and a shorter median survival (12 vs. 18 mo, p < 0.01), than in tumors with neg. labeling.  Stable knockdown of Axl resulted in significant redn. in cell viability (p < 0.001), anchorage independent growth (p = 0.0031), as well as attenuation of migratory (p < 0.001) and invasive properties (p < 0.005), compared to vector-transfected cells.  Profound inhibition of p42/p44 MAP kinase and PI-3kinase/Akt effector pathways was obsd. in MIAPaCa-2 cells with loss of Axl function.  The redn. in invasion and migration upon Axl knockdown was mirrored by a decrease in the amts. of activated (GTP-bound) GTPase proteins Rho and Rac, significant downregulation in transcript levels of the epithelial mesenchymal transition (EMT)-assocd. transcription factors slug, snail and twist, and significant decrease in matrix metalloproteinase MMP-9 mRNA levels.  Materials: The immunohistochem. expression of Axl protein was assessed in a panel of 99 archival pancreatic cancers.  Endogenous Axl expression was stably downregulated by lentiviral short hairpin shRNA directed against AXL mRNA in MIAPaCa-2 cells, and the effects on cell viability, anchorage independent growth, invasion, migration and intracellular effector pathways was assessed, by comparing to lentiviral vector-transfected cells.  Conclusion: Expression of Axl tyrosine kinase in pancreatic cancers confers an adverse prognostic influence, and represents a new therapeutic target in this malignancy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHVcT_EyeJ5LVg90H21EOLACvtfcHk0ljV2-K1iy6qxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotFSjsLo%253D&md5=36b9836411f2b315629eb951b8765a72</span></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.4161%2Fcbt.8.7.7923&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.8.7.7923%26sid%3Dliteratum%253Aachs%26aulast%3DKoorstra%26aufirst%3DJ.%2BB.%26aulast%3DKarikari%26aufirst%3DC.%2BA.%26aulast%3DFeldmann%26aufirst%3DG.%26aulast%3DBisht%26aufirst%3DS.%26aulast%3DRojas%26aufirst%3DP.%2BL.%26aulast%3DOfferhaus%26aufirst%3DG.%2BJ.%26aulast%3DAlvarez%26aufirst%3DH.%26aulast%3DMaitra%26aufirst%3DA.%26atitle%3DThe%2520Axl%2520receptor%2520tyrosine%2520kinase%2520confers%2520an%2520adverse%2520prognostic%2520influence%2520in%2520pancreatic%2520cancer%2520and%2520represents%2520a%2520new%2520therapeutic%2520target%26jtitle%3DCancer%2520Biol.%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D618%26epage%3D626%26doi%3D10.4161%2Fcbt.8.7.7923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Leconet, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larbouret, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chardes, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neiveyans, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Busson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarlier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radosevic-Robin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pugniere, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernex, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penault-Llorca, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasquet, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelegrin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, B.</span><span> </span><span class="NLM_article-title">Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">5405</span><span class="NLM_x">–</span> <span class="NLM_lpage">5414</span><span class="refDoi"> DOI: 10.1038/onc.2013.487</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1038%2Fonc.2013.487" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2014&pages=5405-5414&author=W.+Leconetauthor=C.+Larbouretauthor=T.+Chardesauthor=G.+Thomasauthor=M.+Neiveyansauthor=M.+Bussonauthor=M.+Jarlierauthor=N.+Radosevic-Robinauthor=M.+Pugniereauthor=F.+Bernexauthor=F.+Penault-Llorcaauthor=J.+M.+Pasquetauthor=A.+Pelegrinauthor=B.+Robert&title=Preclinical+validation+of+AXL+receptor+as+a+target+for+antibody-based+pancreatic+cancer+immunotherapy&doi=10.1038%2Fonc.2013.487"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1038%2Fonc.2013.487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2013.487%26sid%3Dliteratum%253Aachs%26aulast%3DLeconet%26aufirst%3DW.%26aulast%3DLarbouret%26aufirst%3DC.%26aulast%3DChardes%26aufirst%3DT.%26aulast%3DThomas%26aufirst%3DG.%26aulast%3DNeiveyans%26aufirst%3DM.%26aulast%3DBusson%26aufirst%3DM.%26aulast%3DJarlier%26aufirst%3DM.%26aulast%3DRadosevic-Robin%26aufirst%3DN.%26aulast%3DPugniere%26aufirst%3DM.%26aulast%3DBernex%26aufirst%3DF.%26aulast%3DPenault-Llorca%26aufirst%3DF.%26aulast%3DPasquet%26aufirst%3DJ.%2BM.%26aulast%3DPelegrin%26aufirst%3DA.%26aulast%3DRobert%26aufirst%3DB.%26atitle%3DPreclinical%2520validation%2520of%2520AXL%2520receptor%2520as%2520a%2520target%2520for%2520antibody-based%2520pancreatic%2520cancer%2520immunotherapy%26jtitle%3DOncogene%26date%3D2014%26volume%3D33%26spage%3D5405%26epage%3D5414%26doi%3D10.1038%2Fonc.2013.487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Green, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikram, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vyas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proby, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghali, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leigh, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Toole, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storey, A.</span><span> </span><span class="NLM_article-title">Overexpression of the Axl tyrosine kinase receptor in cutaneous SCC-derived cell lines and tumours</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">1446</span><span class="NLM_x">–</span> <span class="NLM_lpage">1451</span><span class="refDoi"> DOI: 10.1038/sj.bjc.6603135</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1038%2Fsj.bjc.6603135" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=16641895" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BD28XksFKnurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2006&pages=1446-1451&author=J.+Greenauthor=M.+Ikramauthor=J.+Vyasauthor=N.+Patelauthor=C.+M.+Probyauthor=L.+Ghaliauthor=I.+M.+Leighauthor=E.+A.+O%E2%80%99Tooleauthor=A.+Storey&title=Overexpression+of+the+Axl+tyrosine+kinase+receptor+in+cutaneous+SCC-derived+cell+lines+and+tumours&doi=10.1038%2Fsj.bjc.6603135"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12aR"><div class="casContent"><span class="casTitleNuber">12a</span><div class="casTitle"><span class="NLM_cas:atitle">Overexpression of the Axl tyrosine kinase receptor in cutaneous SCC-derived cell lines and tumours</span></div><div class="casAuthors">Green, J.; Ikram, M.; Vyas, J.; Patel, N.; Proby, C. M.; Ghali, L.; Leigh, I. M.; O'Toole, E. A.; Storey, A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1446-1451</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The mol. mechanisms that underlie the development of squamous cell skin cancers (SSC) are poorly understood.  We have used oligonucleotide microarrays to compare the differences in cellular gene expression between a series of keratinocyte cell that mimic disease progression with the aim of identifying genes that may potentially contribute towards squamous cell carcinoma (SCC) progression in vivo, and in particular to identify markers that may serve as potential therapeutic targets for SCC treatment.  Gene expression differences were corroborated by polymerase chain reaction and Western blotting.  We identified Axl, a receptor tyrosine kinase with transforming potential that has also been shown to have a role in cell survival, adhesion and chemotaxis, was upregulated in vitro in SCC-derived cells compared to premalignant cells.  Extending the investigation to tumor biopsies showed that the Axl protein was overexpressed in vivo in a series of SCCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbYT3STDhQT7Vg90H21EOLACvtfcHk0lg6ryHVfO375g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XksFKnurc%253D&md5=c74bb75e82fee91be3fb8afcd22fa223</span></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6603135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6603135%26sid%3Dliteratum%253Aachs%26aulast%3DGreen%26aufirst%3DJ.%26aulast%3DIkram%26aufirst%3DM.%26aulast%3DVyas%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DN.%26aulast%3DProby%26aufirst%3DC.%2BM.%26aulast%3DGhali%26aufirst%3DL.%26aulast%3DLeigh%26aufirst%3DI.%2BM.%26aulast%3DO%25E2%2580%2599Toole%26aufirst%3DE.%2BA.%26aulast%3DStorey%26aufirst%3DA.%26atitle%3DOverexpression%2520of%2520the%2520Axl%2520tyrosine%2520kinase%2520receptor%2520in%2520cutaneous%2520SCC-derived%2520cell%2520lines%2520and%2520tumours%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2006%26volume%3D94%26spage%3D1446%26epage%3D1451%26doi%3D10.1038%2Fsj.bjc.6603135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit12b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Papadakis, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cichon, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vyas, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghali, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerio, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Toole, E. A.</span><span> </span><span class="NLM_article-title">Axl promotes cutaneous squamous cell carcinoma survival through negative regulation of pro-apoptotic Bcl-2 family members</span> <span class="citation_source-journal">J. Invest. Dermatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">131</span><span class="NLM_x">, </span> <span class="NLM_fpage">509</span><span class="NLM_x">–</span> <span class="NLM_lpage">517</span><span class="refDoi"> DOI: 10.1038/jid.2010.326</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1038%2Fjid.2010.326" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2011&pages=509-517&author=E.+S.+Papadakisauthor=M.+A.+Cichonauthor=J.+J.+Vyasauthor=N.+Patelauthor=L.+Ghaliauthor=R.+Cerioauthor=A.+Storeyauthor=E.+A.+O%E2%80%99Toole&title=Axl+promotes+cutaneous+squamous+cell+carcinoma+survival+through+negative+regulation+of+pro-apoptotic+Bcl-2+family+members&doi=10.1038%2Fjid.2010.326"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1038%2Fjid.2010.326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fjid.2010.326%26sid%3Dliteratum%253Aachs%26aulast%3DPapadakis%26aufirst%3DE.%2BS.%26aulast%3DCichon%26aufirst%3DM.%2BA.%26aulast%3DVyas%26aufirst%3DJ.%2BJ.%26aulast%3DPatel%26aufirst%3DN.%26aulast%3DGhali%26aufirst%3DL.%26aulast%3DCerio%26aufirst%3DR.%26aulast%3DStorey%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Toole%26aufirst%3DE.%2BA.%26atitle%3DAxl%2520promotes%2520cutaneous%2520squamous%2520cell%2520carcinoma%2520survival%2520through%2520negative%2520regulation%2520of%2520pro-apoptotic%2520Bcl-2%2520family%2520members%26jtitle%3DJ.%2520Invest.%2520Dermatol.%26date%3D2011%26volume%3D131%26spage%3D509%26epage%3D517%26doi%3D10.1038%2Fjid.2010.326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit12c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Lee, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yen, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiang, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiah, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shieh, Y. S.</span><span> </span><span class="NLM_article-title">Axl is a prognostic marker in oral squamous cell carcinoma</span> <span class="citation_source-journal">Ann. Surg. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">500</span><span class="NLM_x">–</span> <span class="NLM_lpage">508</span><span class="refDoi"> DOI: 10.1245/s10434-011-1985-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1245%2Fs10434-011-1985-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=500-508&author=C.+H.+Leeauthor=C.+Y.+Yenauthor=S.+Y.+Liuauthor=C.+K.+Chenauthor=C.+F.+Chiangauthor=S.+G.+Shiahauthor=P.+H.+Chenauthor=Y.+S.+Shieh&title=Axl+is+a+prognostic+marker+in+oral+squamous+cell+carcinoma&doi=10.1245%2Fs10434-011-1985-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12c&amp;dbid=16384&amp;doi=10.1245%2Fs10434-011-1985-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1245%252Fs10434-011-1985-8%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DC.%2BH.%26aulast%3DYen%26aufirst%3DC.%2BY.%26aulast%3DLiu%26aufirst%3DS.%2BY.%26aulast%3DChen%26aufirst%3DC.%2BK.%26aulast%3DChiang%26aufirst%3DC.%2BF.%26aulast%3DShiah%26aufirst%3DS.%2BG.%26aulast%3DChen%26aufirst%3DP.%2BH.%26aulast%3DShieh%26aufirst%3DY.%2BS.%26atitle%3DAxl%2520is%2520a%2520prognostic%2520marker%2520in%2520oral%2520squamous%2520cell%2520carcinoma%26jtitle%3DAnn.%2520Surg.%2520Oncol.%26date%3D2012%26volume%3D19%26spage%3D500%26epage%3D508%26doi%3D10.1245%2Fs10434-011-1985-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Sainaghi, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castello, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergamasco, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellosta, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avanzi, G. C.</span><span> </span><span class="NLM_article-title">Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor</span> <span class="citation_source-journal">J. Cell. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">204</span><span class="NLM_x">, </span> <span class="NLM_fpage">36</span><span class="NLM_x">–</span> <span class="NLM_lpage">44</span><span class="refDoi"> DOI: 10.1002/jcp.20265</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1002%2Fjcp.20265" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=15605394" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkvF2qsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=204&publication_year=2005&pages=36-44&author=P.+P.+Sainaghiauthor=L.+Castelloauthor=L.+Bergamascoauthor=M.+Gallettiauthor=P.+Bellostaauthor=G.+C.+Avanzi&title=Gas6+induces+proliferation+in+prostate+carcinoma+cell+lines+expressing+the+Axl+receptor&doi=10.1002%2Fjcp.20265"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor</span></div><div class="casAuthors">Sainaghi, Pier Paolo; Castello, Luigi; Bergamasco, Luca; Galletti, Margherita; Bellosta, Paola; Avanzi, Gian Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">204</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">36-44</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Axl is a Tyr kinase receptor and although it is expressed in malignancy such as leukemia, colon cancer, melanoma, endometrial, prostate and thyroid cancers, its role was not completely elucidated yet and appears to be complex.  The ligand of Axl, Gas6, is a 75 KDa multimodular protein with an N-terminal γ-carboxy-glutamic acid that is essential for binding.  Gas6 has a mitogenic effect on several normal cell lines.  The receptor Axl is expressed in primary prostate carcinoma and in prostate cancer cell lines as such as PC-3 and DU 145.  We demonstrated a mitogenic activity detd. by Gas6/Axl interaction in these undifferentiated metastatic human prostatic cancer cell lines.  This effect is proportional to Axl expression, not due to inhibition of apoptosis, and induces AKT and MAPK phosphorylation.  However, only MEK phosphorylation seems to be essential for growth signaling.  Our results suggest that Axl overexpression and activation by Gas6 could be involved in progression of prostate neoplastic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgNkOPWaojibVg90H21EOLACvtfcHk0ljFf9XC15OMRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkvF2qsr0%253D&md5=21e2ec8a6dab885ea9dcfed641c71f9c</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1002%2Fjcp.20265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.20265%26sid%3Dliteratum%253Aachs%26aulast%3DSainaghi%26aufirst%3DP.%2BP.%26aulast%3DCastello%26aufirst%3DL.%26aulast%3DBergamasco%26aufirst%3DL.%26aulast%3DGalletti%26aufirst%3DM.%26aulast%3DBellosta%26aufirst%3DP.%26aulast%3DAvanzi%26aufirst%3DG.%2BC.%26atitle%3DGas6%2520induces%2520proliferation%2520in%2520prostate%2520carcinoma%2520cell%2520lines%2520expressing%2520the%2520Axl%2520receptor%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2005%26volume%3D204%26spage%3D36%26epage%3D44%26doi%3D10.1002%2Fjcp.20265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Mahadevan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooke, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riley, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swart, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simons, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Della Croce, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wisner, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iorio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakalya, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garewal, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagle, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bearss, D.</span><span> </span><span class="NLM_article-title">A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">3909</span><span class="NLM_x">–</span> <span class="NLM_lpage">3919</span><span class="refDoi"> DOI: 10.1038/sj.onc.1210173</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1038%2Fsj.onc.1210173" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=3909-3919&author=D.+Mahadevanauthor=L.+Cookeauthor=C.+Rileyauthor=R.+Swartauthor=B.+Simonsauthor=K.+Della+Croceauthor=L.+Wisnerauthor=M.+Iorioauthor=K.+Shakalyaauthor=H.+Garewalauthor=R.+Nagleauthor=D.+Bearss&title=A+novel+tyrosine+kinase+switch+is+a+mechanism+of+imatinib+resistance+in+gastrointestinal+stromal+tumors&doi=10.1038%2Fsj.onc.1210173"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210173%26sid%3Dliteratum%253Aachs%26aulast%3DMahadevan%26aufirst%3DD.%26aulast%3DCooke%26aufirst%3DL.%26aulast%3DRiley%26aufirst%3DC.%26aulast%3DSwart%26aufirst%3DR.%26aulast%3DSimons%26aufirst%3DB.%26aulast%3DDella%2BCroce%26aufirst%3DK.%26aulast%3DWisner%26aufirst%3DL.%26aulast%3DIorio%26aufirst%3DM.%26aulast%3DShakalya%26aufirst%3DK.%26aulast%3DGarewal%26aufirst%3DH.%26aulast%3DNagle%26aufirst%3DR.%26aulast%3DBearss%26aufirst%3DD.%26atitle%3DA%2520novel%2520tyrosine%2520kinase%2520switch%2520is%2520a%2520mechanism%2520of%2520imatinib%2520resistance%2520in%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D3909%26epage%3D3919%26doi%3D10.1038%2Fsj.onc.1210173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Sensi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castellano, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicolini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alciato, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tragni, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Santis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bersani, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avanzi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomassetti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canevari, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anichini, A.</span><span> </span><span class="NLM_article-title">Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase</span> <span class="citation_source-journal">J. Invest. Dermatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">131</span><span class="NLM_x">, </span> <span class="NLM_fpage">2448</span><span class="NLM_x">–</span> <span class="NLM_lpage">2457</span><span class="refDoi"> DOI: 10.1038/jid.2011.218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1038%2Fjid.2011.218" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2011&pages=2448-2457&author=M.+Sensiauthor=M.+Cataniauthor=G.+Castellanoauthor=G.+Nicoliniauthor=F.+Alciatoauthor=G.+Tragniauthor=G.+De+Santisauthor=I.+Bersaniauthor=G.+Avanziauthor=A.+Tomassettiauthor=S.+Canevariauthor=A.+Anichini&title=Human+cutaneous+melanomas+lacking+MITF+and+melanocyte+differentiation+antigens+express+a+functional+Axl+receptor+kinase&doi=10.1038%2Fjid.2011.218"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.1038%2Fjid.2011.218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fjid.2011.218%26sid%3Dliteratum%253Aachs%26aulast%3DSensi%26aufirst%3DM.%26aulast%3DCatani%26aufirst%3DM.%26aulast%3DCastellano%26aufirst%3DG.%26aulast%3DNicolini%26aufirst%3DG.%26aulast%3DAlciato%26aufirst%3DF.%26aulast%3DTragni%26aufirst%3DG.%26aulast%3DDe%2BSantis%26aufirst%3DG.%26aulast%3DBersani%26aufirst%3DI.%26aulast%3DAvanzi%26aufirst%3DG.%26aulast%3DTomassetti%26aufirst%3DA.%26aulast%3DCanevari%26aufirst%3DS.%26aulast%3DAnichini%26aufirst%3DA.%26atitle%3DHuman%2520cutaneous%2520melanomas%2520lacking%2520MITF%2520and%2520melanocyte%2520differentiation%2520antigens%2520express%2520a%2520functional%2520Axl%2520receptor%2520kinase%26jtitle%3DJ.%2520Invest.%2520Dermatol.%26date%3D2011%26volume%3D131%26spage%3D2448%26epage%3D2457%26doi%3D10.1038%2Fjid.2011.218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit15b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Muller, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krijgsman, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsoi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hugo, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Possik, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornelissen-Steijger, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foppen, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kemper, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goding, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDermott, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blank, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haanen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graeber, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peeper, D. S.</span><span> </span><span class="NLM_article-title">Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma</span> <span class="citation_source-journal">Nat. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">5712</span><span class="refDoi"> DOI: 10.1038/ncomms6712</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1038%2Fncomms6712" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=25502142" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A280%3ADC%252BC2MvgtV2ksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=5712&author=J.+Mullerauthor=O.+Krijgsmanauthor=J.+Tsoiauthor=L.+Robertauthor=W.+Hugoauthor=C.+Songauthor=X.+Kongauthor=P.+A.+Possikauthor=P.+D.+Cornelissen-Steijgerauthor=M.+H.+Foppenauthor=K.+Kemperauthor=C.+R.+Godingauthor=U.+McDermottauthor=C.+Blankauthor=J.+Haanenauthor=T.+G.+Graeberauthor=A.+Ribasauthor=R.+S.+Loauthor=D.+S.+Peeper&title=Low+MITF%2FAXL+ratio+predicts+early+resistance+to+multiple+targeted+drugs+in+melanoma&doi=10.1038%2Fncomms6712"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15bR"><div class="casContent"><span class="casTitleNuber">15b</span><div class="casTitle"><span class="NLM_cas:atitle">Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma</span></div><div class="casAuthors">Muller Judith; Krijgsman Oscar; Possik Patricia A; Cornelissen-Steijger Paulien D M; Kemper Kristel; Peeper Daniel S; Tsoi Jennifer; Robert Lidia; Hugo Willy; Song Chunying; Kong Xiangju; Geukes Foppen Marnix H; Blank Christian; Haanen John; Goding Colin R; McDermott Ultan; Graeber Thomas G; Ribas Antoni; Lo Roger S</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">5712</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Increased expression of the Microphthalmia-associated transcription factor (MITF) contributes to melanoma progression and resistance to BRAF pathway inhibition.  Here we show that the lack of MITF is associated with more severe resistance to a range of inhibitors, while its presence is required for robust drug responses.  Both in primary and acquired resistance, MITF levels inversely correlate with the expression of several activated receptor tyrosine kinases, most frequently AXL.  The MITF-low/AXL-high/drug-resistance phenotype is common among mutant BRAF and NRAS melanoma cell lines.  The dichotomous behaviour of MITF in drug response is corroborated in vemurafenib-resistant biopsies, including MITF-high and -low clones in a relapsed patient.  Furthermore, drug cocktails containing AXL inhibitor enhance melanoma cell elimination by BRAF or ERK inhibition.  Our results demonstrate that a low MITF/AXL ratio predicts early resistance to multiple targeted drugs, and warrant clinical validation of AXL inhibitors to combat resistance of BRAF and NRAS mutant MITF-low melanomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRBPp9KggQbmfh3YQQtAhNufW6udTcc2ebPYer7CaUQGbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MvgtV2ksw%253D%253D&md5=2617d6a0337c130696f3858827b1015c</span></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=10.1038%2Fncomms6712&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms6712%26sid%3Dliteratum%253Aachs%26aulast%3DMuller%26aufirst%3DJ.%26aulast%3DKrijgsman%26aufirst%3DO.%26aulast%3DTsoi%26aufirst%3DJ.%26aulast%3DRobert%26aufirst%3DL.%26aulast%3DHugo%26aufirst%3DW.%26aulast%3DSong%26aufirst%3DC.%26aulast%3DKong%26aufirst%3DX.%26aulast%3DPossik%26aufirst%3DP.%2BA.%26aulast%3DCornelissen-Steijger%26aufirst%3DP.%2BD.%26aulast%3DFoppen%26aufirst%3DM.%2BH.%26aulast%3DKemper%26aufirst%3DK.%26aulast%3DGoding%26aufirst%3DC.%2BR.%26aulast%3DMcDermott%26aufirst%3DU.%26aulast%3DBlank%26aufirst%3DC.%26aulast%3DHaanen%26aufirst%3DJ.%26aulast%3DGraeber%26aufirst%3DT.%2BG.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DLo%26aufirst%3DR.%2BS.%26aulast%3DPeeper%26aufirst%3DD.%2BS.%26atitle%3DLow%2520MITF%252FAXL%2520ratio%2520predicts%2520early%2520resistance%2520to%2520multiple%2520targeted%2520drugs%2520in%2520melanoma%26jtitle%3DNat.%2520Commun.%26date%3D2014%26volume%3D5%26spage%3D5712%26doi%3D10.1038%2Fncomms6712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Yu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yen, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krasnoperov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bove, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buscarini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parekh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gill, I. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tretiakova, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinn, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gill, P. S.</span><span> </span><span class="NLM_article-title">Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">616</span><span class="NLM_x">–</span> <span class="NLM_lpage">625</span><span class="refDoi"> DOI: 10.1038/bjc.2015.237</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1038%2Fbjc.2015.237" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=26180925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1WrtbrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2015&pages=616-625&author=H.+Yuauthor=R.+Liuauthor=B.+Maauthor=X.+Liauthor=H.+Y.+Yenauthor=Y.+Zhouauthor=V.+Krasnoperovauthor=Z.+Xiaauthor=X.+Zhangauthor=A.+M.+Boveauthor=M.+Buscariniauthor=D.+Parekhauthor=I.+S.+Gillauthor=Q.+Liaoauthor=M.+Tretiakovaauthor=D.+Quinnauthor=J.+Zhaoauthor=P.+S.+Gill&title=Axl+receptor+tyrosine+kinase+is+a+potential+therapeutic+target+in+renal+cell+carcinoma&doi=10.1038%2Fbjc.2015.237"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16aR"><div class="casContent"><span class="casTitleNuber">16a</span><div class="casTitle"><span class="NLM_cas:atitle">Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma</span></div><div class="casAuthors">Yu, H.; Liu, R.; Ma, B.; Li, X.; Yen, H.-Y.; Zhou, Y.; Krasnoperov, V.; Xia, Z.; Zhang, X.; Bove, A. M.; Buscarini, M.; Parekh, D.; Gill, I. S.; Liao, Q.; Tretiakova, M.; Quinn, D.; Zhao, J.; Gill, P. S.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">616-625</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: Axl plays multiple roles in tumorigenesis in several cancers.  Here we evaluated the expression and biol. function of Axl in renal cell carcinoma (RCC).  Methods: Axl expression was analyzed in a tissue microarray of 174 RCC samples by immunostaining and a panel of 11 normal tumor pairs of human RCC tissues by western blot, as well as in RCC cell lines by both western blot and quant. PCR.  The effects of Axl knockdown in RCC cells on cell growth and signalling were investigated.  The efficacy of a humanized Axl targeting monoclonal antibody hMAb173 was tested in histoculture and tumor xenograft.  Results: We have detd. by immunohistochem. (IHC) that Axl is expressed in 59% of RCC array samples with moderate to high in 20% but not expressed in normal kidney tissue.  Western blot anal. of 11 pairs of tumor and adjacent normal tissue show high Axl expression in 73% of the tumors but not normal tissue.  Axl is also expressed in RCC cell lines in which Axl knockdown reduces cell viability and PI3K/Akt signalling.  The Axl antibody hMAb173 significantly induced RCC cell apoptosis in histoculture and inhibited the growth of RCC tumor in vivo by 78%.  The hMAb173-treated tumors also had significantly reduced Axl protein levels, inhibited PI3K signalling, decreased proliferation, and induced apoptosis.  Conclusions: Axl is highly expressed in RCC and crit. for RCC cell survival.  Targeting Axl is a potential approach for RCC treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwKf4yyaQhWrVg90H21EOLACvtfcHk0liw5XknhLRq4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1WrtbrO&md5=3f916c7beaa150038cbc5ed35594be29</span></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2015.237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2015.237%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DMa%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DYen%26aufirst%3DH.%2BY.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DKrasnoperov%26aufirst%3DV.%26aulast%3DXia%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DBove%26aufirst%3DA.%2BM.%26aulast%3DBuscarini%26aufirst%3DM.%26aulast%3DParekh%26aufirst%3DD.%26aulast%3DGill%26aufirst%3DI.%2BS.%26aulast%3DLiao%26aufirst%3DQ.%26aulast%3DTretiakova%26aufirst%3DM.%26aulast%3DQuinn%26aufirst%3DD.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DGill%26aufirst%3DP.%2BS.%26atitle%3DAxl%2520receptor%2520tyrosine%2520kinase%2520is%2520a%2520potential%2520therapeutic%2520target%2520in%2520renal%2520cell%2520carcinoma%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2015%26volume%3D113%26spage%3D616%26epage%3D625%26doi%3D10.1038%2Fbjc.2015.237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit16b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Rankin, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castellini, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viswanathan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finger, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diep, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaGory, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kariolis, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindgren, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Axelson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miao, Y. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krieg, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giaccia, A. J.</span><span> </span><span class="NLM_article-title">Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">13373</span><span class="NLM_x">–</span> <span class="NLM_lpage">13378</span><span class="refDoi"> DOI: 10.1073/pnas.1404848111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1073%2Fpnas.1404848111" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=13373-13378&author=E.+B.+Rankinauthor=K.+C.+Fuhauthor=L.+Castelliniauthor=K.+Viswanathanauthor=E.+C.+Fingerauthor=A.+N.+Diepauthor=E.+L.+LaGoryauthor=M.+S.+Kariolisauthor=A.+Chanauthor=D.+Lindgrenauthor=H.+Axelsonauthor=Y.+R.+Miaoauthor=A.+J.+Kriegauthor=A.+J.+Giaccia&title=Direct+regulation+of+GAS6%2FAXL+signaling+by+HIF+promotes+renal+metastasis+through+SRC+and+MET&doi=10.1073%2Fpnas.1404848111"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1404848111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1404848111%26sid%3Dliteratum%253Aachs%26aulast%3DRankin%26aufirst%3DE.%2BB.%26aulast%3DFuh%26aufirst%3DK.%2BC.%26aulast%3DCastellini%26aufirst%3DL.%26aulast%3DViswanathan%26aufirst%3DK.%26aulast%3DFinger%26aufirst%3DE.%2BC.%26aulast%3DDiep%26aufirst%3DA.%2BN.%26aulast%3DLaGory%26aufirst%3DE.%2BL.%26aulast%3DKariolis%26aufirst%3DM.%2BS.%26aulast%3DChan%26aufirst%3DA.%26aulast%3DLindgren%26aufirst%3DD.%26aulast%3DAxelson%26aufirst%3DH.%26aulast%3DMiao%26aufirst%3DY.%2BR.%26aulast%3DKrieg%26aufirst%3DA.%2BJ.%26aulast%3DGiaccia%26aufirst%3DA.%2BJ.%26atitle%3DDirect%2520regulation%2520of%2520GAS6%252FAXL%2520signaling%2520by%2520HIF%2520promotes%2520renal%2520metastasis%2520through%2520SRC%2520and%2520MET%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26spage%3D13373%26epage%3D13378%26doi%3D10.1073%2Fpnas.1404848111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ghosh, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Secreto, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boysen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sassoon, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shanafelt, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukhopadhyay, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kay, N. E.</span><span> </span><span class="NLM_article-title">The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">117</span><span class="NLM_x">, </span> <span class="NLM_fpage">1928</span><span class="NLM_x">–</span> <span class="NLM_lpage">1937</span><span class="refDoi"> DOI: 10.1182/blood-2010-09-305649</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1182%2Fblood-2010-09-305649" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2011&pages=1928-1937&author=A.+K.+Ghoshauthor=C.+Secretoauthor=J.+Boysenauthor=T.+Sassoonauthor=T.+D.+Shanafeltauthor=D.+Mukhopadhyayauthor=N.+E.+Kay&title=The+novel+receptor+tyrosine+kinase+Axl+is+constitutively+active+in+B-cell+chronic+lymphocytic+leukemia+and+acts+as+a+docking+site+of+nonreceptor+kinases%3A+implications+for+therapy&doi=10.1182%2Fblood-2010-09-305649"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.1182%2Fblood-2010-09-305649&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2010-09-305649%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DA.%2BK.%26aulast%3DSecreto%26aufirst%3DC.%26aulast%3DBoysen%26aufirst%3DJ.%26aulast%3DSassoon%26aufirst%3DT.%26aulast%3DShanafelt%26aufirst%3DT.%2BD.%26aulast%3DMukhopadhyay%26aufirst%3DD.%26aulast%3DKay%26aufirst%3DN.%2BE.%26atitle%3DThe%2520novel%2520receptor%2520tyrosine%2520kinase%2520Axl%2520is%2520constitutively%2520active%2520in%2520B-cell%2520chronic%2520lymphocytic%2520leukemia%2520and%2520acts%2520as%2520a%2520docking%2520site%2520of%2520nonreceptor%2520kinases%253A%2520implications%2520for%2520therapy%26jtitle%3DBlood%26date%3D2011%26volume%3D117%26spage%3D1928%26epage%3D1937%26doi%3D10.1182%2Fblood-2010-09-305649" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit17b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ben-Batalla, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultze, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wroblewski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erdmann, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heuser, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waizenegger, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riecken, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Binder, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schewe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawall, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witzke, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cubas-Cordova, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janning, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wellbrock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fehse, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krauter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ganser, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorens, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiedler, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmeliet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pantel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bokemeyer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loges, S.</span><span> </span><span class="NLM_article-title">Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">2443</span><span class="NLM_x">–</span> <span class="NLM_lpage">2452</span><span class="refDoi"> DOI: 10.1182/blood-2013-03-491431</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1182%2Fblood-2013-03-491431" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=23982172" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1Sqt7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2013&pages=2443-2452&author=I.+Ben-Batallaauthor=A.+Schultzeauthor=M.+Wroblewskiauthor=R.+Erdmannauthor=M.+Heuserauthor=J.+S.+Waizeneggerauthor=K.+Rieckenauthor=M.+Binderauthor=D.+Scheweauthor=S.+Sawallauthor=V.+Witzkeauthor=M.+Cubas-Cordovaauthor=M.+Janningauthor=J.+Wellbrockauthor=B.+Fehseauthor=C.+Hagelauthor=J.+Krauterauthor=A.+Ganserauthor=J.+B.+Lorensauthor=W.+Fiedlerauthor=P.+Carmelietauthor=K.+Pantelauthor=C.+Bokemeyerauthor=S.+Loges&title=Axl%2C+a+prognostic+and+therapeutic+target+in+acute+myeloid+leukemia+mediates+paracrine+crosstalk+of+leukemia+cells+with+bone+marrow+stroma&doi=10.1182%2Fblood-2013-03-491431"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17bR"><div class="casContent"><span class="casTitleNuber">17b</span><div class="casTitle"><span class="NLM_cas:atitle">Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma</span></div><div class="casAuthors">Ben-Batalla, Isabel; Schultze, Alexander; Wroblewski, Mark; Erdmann, Robert; Heuser, Michael; Waizenegger, Jonas S.; Riecken, Kristoffer; Binder, Mascha; Schewe, Denis; Sawall, Stefanie; Witzke, Victoria; Cubas-Cordova, Miguel; Janning, Melanie; Wellbrock, Jasmin; Fehse, Boris; Hagel, Christian; Krauter, Juergen; Ganser, Arnold; Lorens, James B.; Fiedler, Walter; Carmeliet, Peter; Pantel, Klaus; Bokemeyer, Carsten; Loges, Sonja</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2443-2452</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Acute myeloid leukemia (AML) represents a clonal disease of hematopoietic progenitors characterized by acquired heterogeneous genetic changes that alter normal mechanisms of proliferation, self-renewal, and differentiation.  Although 40% to 45% of patients younger than 65 years of age can be cured with current therapies, only 10% of older patients reach long-term survival.  Because only very few novel AML drugs were approved in the past 2 decades, there is an urgent need to identify novel targets and therapeutic strategies to treat underserved AML patients.  We report here that Axl, a member of the Tyro3, Axl, Mer receptor tyrosine kinase family, represents an independent prognostic marker and therapeutic target in AML.  AML cells induce expression and secretion of the Axl ligand growth arrest-specific gene 6 (Gas6) by bone marrow-derived stromal cells (BMDSCs).  Gas6 in turn mediates proliferation, survival, and chemoresistance of Axl-expressing AML cells.  This Gas6-Axl paracrine axis between AML cells and BMDSCs establishes a chemoprotective tumor cell niche that can be abrogated by Axl-targeting approaches.  Axl inhibition is active in FLT3-mutated and FLT3 wild-type AML, improves clin. relevant end points, and its efficacy depends on presence of Gas6 and Axl.  Axl inhibition alone or in combination with chemotherapy might represent a novel therapeutic avenue for AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCdV7UN_cvNLVg90H21EOLACvtfcHk0liw5XknhLRq4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1Sqt7nO&md5=7b2b67ec3ba0c46218e88e4ea190026c</span></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.1182%2Fblood-2013-03-491431&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2013-03-491431%26sid%3Dliteratum%253Aachs%26aulast%3DBen-Batalla%26aufirst%3DI.%26aulast%3DSchultze%26aufirst%3DA.%26aulast%3DWroblewski%26aufirst%3DM.%26aulast%3DErdmann%26aufirst%3DR.%26aulast%3DHeuser%26aufirst%3DM.%26aulast%3DWaizenegger%26aufirst%3DJ.%2BS.%26aulast%3DRiecken%26aufirst%3DK.%26aulast%3DBinder%26aufirst%3DM.%26aulast%3DSchewe%26aufirst%3DD.%26aulast%3DSawall%26aufirst%3DS.%26aulast%3DWitzke%26aufirst%3DV.%26aulast%3DCubas-Cordova%26aufirst%3DM.%26aulast%3DJanning%26aufirst%3DM.%26aulast%3DWellbrock%26aufirst%3DJ.%26aulast%3DFehse%26aufirst%3DB.%26aulast%3DHagel%26aufirst%3DC.%26aulast%3DKrauter%26aufirst%3DJ.%26aulast%3DGanser%26aufirst%3DA.%26aulast%3DLorens%26aufirst%3DJ.%2BB.%26aulast%3DFiedler%26aufirst%3DW.%26aulast%3DCarmeliet%26aufirst%3DP.%26aulast%3DPantel%26aufirst%3DK.%26aulast%3DBokemeyer%26aufirst%3DC.%26aulast%3DLoges%26aufirst%3DS.%26atitle%3DAxl%252C%2520a%2520prognostic%2520and%2520therapeutic%2520target%2520in%2520acute%2520myeloid%2520leukemia%2520mediates%2520paracrine%2520crosstalk%2520of%2520leukemia%2520cells%2520with%2520bone%2520marrow%2520stroma%26jtitle%3DBlood%26date%3D2013%26volume%3D122%26spage%3D2443%26epage%3D2452%26doi%3D10.1182%2Fblood-2013-03-491431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit17c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Park, I. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mishra, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitman, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcucci, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caligiuri, M. A.</span><span> </span><span class="NLM_article-title">Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">121</span><span class="NLM_x">, </span> <span class="NLM_fpage">2064</span><span class="NLM_x">–</span> <span class="NLM_lpage">2073</span><span class="refDoi"> DOI: 10.1182/blood-2012-07-444018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1182%2Fblood-2012-07-444018" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2013&pages=2064-2073&author=I.+K.+Parkauthor=A.+Mishraauthor=J.+Chandlerauthor=S.+P.+Whitmanauthor=G.+Marcucciauthor=M.+A.+Caligiuri&title=Inhibition+of+the+receptor+tyrosine+kinase+Axl+impedes+activation+of+the+FLT3+internal+tandem+duplication+in+human+acute+myeloid+leukemia%3A+implications+for+Axl+as+a+potential+therapeutic+target&doi=10.1182%2Fblood-2012-07-444018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17c&amp;dbid=16384&amp;doi=10.1182%2Fblood-2012-07-444018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2012-07-444018%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DI.%2BK.%26aulast%3DMishra%26aufirst%3DA.%26aulast%3DChandler%26aufirst%3DJ.%26aulast%3DWhitman%26aufirst%3DS.%2BP.%26aulast%3DMarcucci%26aufirst%3DG.%26aulast%3DCaligiuri%26aufirst%3DM.%2BA.%26atitle%3DInhibition%2520of%2520the%2520receptor%2520tyrosine%2520kinase%2520Axl%2520impedes%2520activation%2520of%2520the%2520FLT3%2520internal%2520tandem%2520duplication%2520in%2520human%2520acute%2520myeloid%2520leukemia%253A%2520implications%2520for%2520Axl%2520as%2520a%2520potential%2520therapeutic%2520target%26jtitle%3DBlood%26date%3D2013%26volume%3D121%26spage%3D2064%26epage%3D2073%26doi%3D10.1182%2Fblood-2012-07-444018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Dunne, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArt, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blayney, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalimutho, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Srivastava, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ong, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arthur, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loughrey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Redmond, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Longley, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salto-Tellez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Schaeybroeck, S.</span><span> </span><span class="NLM_article-title">AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">164</span><span class="NLM_x">–</span> <span class="NLM_lpage">175</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-1354</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1158%2F1078-0432.CCR-13-1354" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=24170546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC2cXislKltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=164-175&author=P.+D.+Dunneauthor=D.+G.+McArtauthor=J.+K.+Blayneyauthor=M.+Kalimuthoauthor=S.+Greerauthor=T.+Wangauthor=S.+Srivastavaauthor=C.+W.+Ongauthor=K.+Arthurauthor=M.+Loughreyauthor=K.+Redmondauthor=D.+B.+Longleyauthor=M.+Salto-Tellezauthor=P.+G.+Johnstonauthor=S.+Van+Schaeybroeck&title=AXL+is+a+key+regulator+of+inherent+and+chemotherapy-induced+invasion+and+predicts+a+poor+clinical+outcome+in+early-stage+colon+cancer&doi=10.1158%2F1078-0432.CCR-13-1354"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">AXL Is a Key Regulator of Inherent and Chemotherapy-Induced Invasion and Predicts a Poor Clinical Outcome in Early-Stage Colon Cancer</span></div><div class="casAuthors">Dunne, Philip D.; McArt, Darragh G.; Blayney, Jaine K.; Kalimutho, Murugan; Greer, Samanda; Wang, Tingting; Srivastava, Supriya; Ong, Chee Wee; Arthur, Ken; Loughrey, Maurice; Redmond, Keara; Longley, Daniel B.; Salto-Tellez, Manuel; Johnston, Patrick G.; Van Schaeybroeck, Sandra</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">164-175</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Despite the use of 5-fluorouracil (5-FU)-based adjuvant treatments, a large proportion of patients with high-risk stage II/III colorectal cancer will relapse.  Thus, novel therapeutic strategies are needed for early-stage colorectal cancer.  Residual micrometastatic disease from the primary tumor is a major cause of patient relapse.  Exptl. Design: To model colorectal cancer tumor cell invasion/metastasis, we have generated invasive (KRASMT/KRASWT/+chr3/p53-null) colorectal cancer cell subpopulations.  Receptor tyrosine kinase (RTK) screens were used to identify novel proteins that underpin the migratory/invasive phenotype.  Migration/invasion was assessed using the XCELLigence system.  Tumors from patients with early-stage colorectal cancer (N = 336) were examd. for AXL expression.  Results: Invasive colorectal cancer cell subpopulations showed a transition from an epithelial-to-mesenchymal like phenotype with significant increases in migration, invasion, colony-forming ability, and an attenuation of EGF receptor (EGFR)/HER2 autocrine signaling.  RTK arrays showed significant increases in AXL levels in all invasive sublines.  Importantly, 5-FU treatment resulted in significantly increased migration and invasion, and targeting AXL using pharmacol. inhibition or RNA interference (RNAi) approaches suppressed basal and 5-FU-induced migration and invasion.  Significantly, high AXL mRNA and protein expression were found to be assocd. with poor overall survival in early-stage colorectal cancer tissues.  Conclusions: We have identified AXL as a poor prognostic marker and important mediator of cell migration/invasiveness in colorectal cancer.  These findings provide support for the further investigation of AXL as a novel prognostic biomarker and therapeutic target in colorectal cancer, in particular in the adjuvant disease in which EGFR/VEGF-targeted therapies have failed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojGnw9ktEIf7Vg90H21EOLACvtfcHk0li4BueCt7HWgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXislKltA%253D%253D&md5=139c2c7a6b42c4229fb11610a4d6954b</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-1354&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-1354%26sid%3Dliteratum%253Aachs%26aulast%3DDunne%26aufirst%3DP.%2BD.%26aulast%3DMcArt%26aufirst%3DD.%2BG.%26aulast%3DBlayney%26aufirst%3DJ.%2BK.%26aulast%3DKalimutho%26aufirst%3DM.%26aulast%3DGreer%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DSrivastava%26aufirst%3DS.%26aulast%3DOng%26aufirst%3DC.%2BW.%26aulast%3DArthur%26aufirst%3DK.%26aulast%3DLoughrey%26aufirst%3DM.%26aulast%3DRedmond%26aufirst%3DK.%26aulast%3DLongley%26aufirst%3DD.%2BB.%26aulast%3DSalto-Tellez%26aufirst%3DM.%26aulast%3DJohnston%26aufirst%3DP.%2BG.%26aulast%3DVan%2BSchaeybroeck%26aufirst%3DS.%26atitle%3DAXL%2520is%2520a%2520key%2520regulator%2520of%2520inherent%2520and%2520chemotherapy-induced%2520invasion%2520and%2520predicts%2520a%2520poor%2520clinical%2520outcome%2520in%2520early-stage%2520colon%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D164%26epage%3D175%26doi%3D10.1158%2F1078-0432.CCR-13-1354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Rankin, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krieg, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Musser, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Longacre, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giaccia, A. J.</span><span> </span><span class="NLM_article-title">AXL is an essential factor and therapeutic target for metastatic ovarian cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">7570</span><span class="NLM_x">–</span> <span class="NLM_lpage">7579</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-1267</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1158%2F0008-5472.CAN-10-1267" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=7570-7579&author=E.+B.+Rankinauthor=K.+C.+Fuhauthor=T.+E.+Taylorauthor=A.+J.+Kriegauthor=M.+Musserauthor=J.+Yuanauthor=K.+Weiauthor=C.+J.+Kuoauthor=T.+A.+Longacreauthor=A.+J.+Giaccia&title=AXL+is+an+essential+factor+and+therapeutic+target+for+metastatic+ovarian+cancer&doi=10.1158%2F0008-5472.CAN-10-1267"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-1267&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-1267%26sid%3Dliteratum%253Aachs%26aulast%3DRankin%26aufirst%3DE.%2BB.%26aulast%3DFuh%26aufirst%3DK.%2BC.%26aulast%3DTaylor%26aufirst%3DT.%2BE.%26aulast%3DKrieg%26aufirst%3DA.%2BJ.%26aulast%3DMusser%26aufirst%3DM.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DWei%26aufirst%3DK.%26aulast%3DKuo%26aufirst%3DC.%2BJ.%26aulast%3DLongacre%26aufirst%3DT.%2BA.%26aulast%3DGiaccia%26aufirst%3DA.%2BJ.%26atitle%3DAXL%2520is%2520an%2520essential%2520factor%2520and%2520therapeutic%2520target%2520for%2520metastatic%2520ovarian%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D7570%26epage%3D7579%26doi%3D10.1158%2F0008-5472.CAN-10-1267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hutterer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knyazev, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abate, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reschke, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maier, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stefanova, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knyazeva, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbieri, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reindl, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muigg, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kostron, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stockhammer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span> </span><span class="NLM_article-title">Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">130</span><span class="NLM_x">–</span> <span class="NLM_lpage">138</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-07-0862</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1158%2F1078-0432.CCR-07-0862" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=18172262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BD1cXoslCn" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=130-138&author=M.+Huttererauthor=P.+Knyazevauthor=A.+Abateauthor=M.+Reschkeauthor=H.+Maierauthor=N.+Stefanovaauthor=T.+Knyazevaauthor=V.+Barbieriauthor=M.+Reindlauthor=A.+Muiggauthor=H.+Kostronauthor=G.+Stockhammerauthor=A.+Ullrich&title=Axl+and+growth+arrest-specific+gene+6+are+frequently+overexpressed+in+human+gliomas+and+predict+poor+prognosis+in+patients+with+glioblastoma+multiforme&doi=10.1158%2F1078-0432.CCR-07-0862"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20aR"><div class="casContent"><span class="casTitleNuber">20a</span><div class="casTitle"><span class="NLM_cas:atitle">Axl and Growth Arrest-Specific Gene 6 Are Frequently Overexpressed in Human Gliomas and Predict Poor Prognosis in Patients with Glioblastoma Multiforme</span></div><div class="casAuthors">Hutterer, Markus; Knyazev, Pjotr; Abate, Ariane; Reschke, Markus; Maier, Hans; Stefanova, Nadia; Knyazeva, Tatjana; Barbieri, Verena; Reindl, Markus; Muigg, Armin; Kostron, Herwig; Stockhammer, Guenther; Ullrich, Axel</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">130-138</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: The receptor tyrosine kinase Axl has recently been identified as a crit. element in the invasive properties of glioma cell lines.  However, the effect of Axl and its ligand growth arrest-specific gene 6 (Gas6) in human gliomas is still unknown.  Exptl. Design: Axl and Gas6 expression was studied in 42 fresh-frozen and 79 paraffin-embedded glioma specimens by means of reverse transcription-PCR and immunohistochem.  The prognostic value of Axl and Gas6 expression was evaluated using a population-based tissue microarray derived from a cohort of 55 glioblastoma multiforme (GBM) patients.  RESULTS: Axl and Gas6 were detectable in gliomas of malignancy grades WHO 2 to 4.  Moderate to high Axl mRNA expression was found in 61%, Axl protein in 55%, Gas6 mRNA in 81%, and Gas6 protein in 74% of GBM samples, resp.  GBM patients with high Axl expression and Axl/Gas6 coexpression showed a significantly shorter time to tumor progression and an assocn. with poorer overall survival.  Comparative immunohistochem. studies showed that Axl staining was most pronounced in glioma cells of pseudopalisades and reactive astrocytes.  Addnl., Axl/Gas6 coexpression was obsd. in glioma cells and tumor vessels.  In contrast, Axl staining was not detectable in nonneoplastic brain tissue and Gas6 was strongly expressed in neurons.  CONCLUSIONS: In human gliomas, Axl and Gas6 are frequently overexpressed in both glioma and vascular cells and predict poor prognosis in GBM patients.  Our results indicate that specific targeting of the Axl/Gas6 signaling pathway may represent a potential new approach for glioma treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-54ka16GPkrVg90H21EOLACvtfcHk0li4BueCt7HWgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXoslCn&md5=45d8887803613422b9e704b803ee757c</span></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-0862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-0862%26sid%3Dliteratum%253Aachs%26aulast%3DHutterer%26aufirst%3DM.%26aulast%3DKnyazev%26aufirst%3DP.%26aulast%3DAbate%26aufirst%3DA.%26aulast%3DReschke%26aufirst%3DM.%26aulast%3DMaier%26aufirst%3DH.%26aulast%3DStefanova%26aufirst%3DN.%26aulast%3DKnyazeva%26aufirst%3DT.%26aulast%3DBarbieri%26aufirst%3DV.%26aulast%3DReindl%26aufirst%3DM.%26aulast%3DMuigg%26aufirst%3DA.%26aulast%3DKostron%26aufirst%3DH.%26aulast%3DStockhammer%26aufirst%3DG.%26aulast%3DUllrich%26aufirst%3DA.%26atitle%3DAxl%2520and%2520growth%2520arrest-specific%2520gene%25206%2520are%2520frequently%2520overexpressed%2520in%2520human%2520gliomas%2520and%2520predict%2520poor%2520prognosis%2520in%2520patients%2520with%2520glioblastoma%2520multiforme%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D130%26epage%3D138%26doi%3D10.1158%2F1078-0432.CCR-07-0862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit20b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Han, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, T.</span><span> </span><span class="NLM_article-title">Gas6/Axl mediates tumor cell apoptosis, migration and invasion and predicts the clinical outcome of osteosarcoma patients</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">435</span><span class="NLM_x">, </span> <span class="NLM_fpage">493</span><span class="NLM_x">–</span> <span class="NLM_lpage">500</span><span class="refDoi"> DOI: 10.1016/j.bbrc.2013.05.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1016%2Fj.bbrc.2013.05.019" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=435&publication_year=2013&pages=493-500&author=J.+Hanauthor=R.+Tianauthor=B.+Yongauthor=C.+Luoauthor=P.+Tanauthor=J.+Shenauthor=T.+Peng&title=Gas6%2FAxl+mediates+tumor+cell+apoptosis%2C+migration+and+invasion+and+predicts+the+clinical+outcome+of+osteosarcoma+patients&doi=10.1016%2Fj.bbrc.2013.05.019"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2013.05.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2013.05.019%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DTian%26aufirst%3DR.%26aulast%3DYong%26aufirst%3DB.%26aulast%3DLuo%26aufirst%3DC.%26aulast%3DTan%26aufirst%3DP.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DPeng%26aufirst%3DT.%26atitle%3DGas6%252FAxl%2520mediates%2520tumor%2520cell%2520apoptosis%252C%2520migration%2520and%2520invasion%2520and%2520predicts%2520the%2520clinical%2520outcome%2520of%2520osteosarcoma%2520patients%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2013%26volume%3D435%26spage%3D493%26epage%3D500%26doi%3D10.1016%2Fj.bbrc.2013.05.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Yauch, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Januario, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberhard, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavet, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pham, T. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soriano, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stinson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seshagiri, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modrusan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Neill, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amler, L. C.</span><span> </span><span class="NLM_article-title">Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">8686</span><span class="NLM_x">–</span> <span class="NLM_lpage">8698</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-05-1492</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1158%2F1078-0432.CCR-05-1492" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=16361555" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlWrsb3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=8686-8698&author=R.+L.+Yauchauthor=T.+Januarioauthor=D.+A.+Eberhardauthor=G.+Cavetauthor=W.+Zhuauthor=L.+Fuauthor=T.+Q.+Phamauthor=R.+Sorianoauthor=J.+Stinsonauthor=S.+Seshagiriauthor=Z.+Modrusanauthor=C.+Y.+Linauthor=V.+O%E2%80%99Neillauthor=L.+C.+Amler&title=Epithelial+versus+mesenchymal+phenotype+determines+in+vitro+sensitivity+and+predicts+clinical+activity+of+erlotinib+in+lung+cancer+patients&doi=10.1158%2F1078-0432.CCR-05-1492"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21aR"><div class="casContent"><span class="casTitleNuber">21a</span><div class="casTitle"><span class="NLM_cas:atitle">Epithelial versus Mesenchymal Phenotype Determines In vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients</span></div><div class="casAuthors">Yauch, Robert L.; Januario, Thomas; Eberhard, David A.; Cavet, Guy; Zhu, Wenjing; Fu, Ling; Pham, Thinh Q.; Soriano, Robert; Stinson, Jeremy; Seshagiri, Somasekar; Modrusan, Zora; Lin, Chin-Yu; O'Neill, Vincent; Amler, Lukas C.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">24, Pt. 1</span>),
    <span class="NLM_cas:pages">8686-8698</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Significant improvements in the outcome of non-small cell lung carcinoma (NSCLC) have been reported in patients treated with the epidermal growth factor receptor (EGFR) inhibitor, erlotinib.  To discover biomarkers for the enrichment of patients who might benefit from treatment, a pharmacogenomic approach was used to identify gene signatures that may predict erlotinib activity using in vitro model systems.  Erlotinib sensitivity in a panel of 42 NSCLC cell lines was detd. by EGFR-mediated proliferative potential, EGFR mutations, and/or EGFR gene amplification, thus supporting an underlying biol. mechanism of receptor activation.  A strong multigene signature indicative of an epithelial to mesenchymal transition (EMT) was identified as a determinant of insensitivity to erlotinib through both supervised and unsupervised gene expression approaches.  This observation was further supported by expression anal. of classic EMT marker proteins, including E-cadherin and vimentin.  To investigate the clin. relevance of these findings, we examd. expression of the epithelial marker E-cadherin by immunohistochem. on primary tumor samples from subjects enrolled in a randomized NSCLC clin. trial in which erlotinib in combination with chemotherapy previously failed to show clin. activity.  The majority (75%) of the 87 subjects tested showed strong E-cadherin staining and exhibited a significantly longer time to progression (hazard ratio, 0.37; log rank P = 0.0028) and a nonsignificant trend toward longer survival with erlotinib plus chemotherapy treatment vs. chemotherapy alone.  These data support a potential role for EMT as a determinant of EGFR activity in NSCLC tumor cells and E-cadherin expression as a novel biomarker predicting clin. activity of the EGFR inhibitor erlotinib in NSCLC patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTIfhC1v9MRLVg90H21EOLACvtfcHk0lhSZ0awk5ok1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlWrsb3L&md5=4e7ccd618d4ff5134b5532224237e8d0</span></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-1492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-1492%26sid%3Dliteratum%253Aachs%26aulast%3DYauch%26aufirst%3DR.%2BL.%26aulast%3DJanuario%26aufirst%3DT.%26aulast%3DEberhard%26aufirst%3DD.%2BA.%26aulast%3DCavet%26aufirst%3DG.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DFu%26aufirst%3DL.%26aulast%3DPham%26aufirst%3DT.%2BQ.%26aulast%3DSoriano%26aufirst%3DR.%26aulast%3DStinson%26aufirst%3DJ.%26aulast%3DSeshagiri%26aufirst%3DS.%26aulast%3DModrusan%26aufirst%3DZ.%26aulast%3DLin%26aufirst%3DC.%2BY.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DV.%26aulast%3DAmler%26aufirst%3DL.%2BC.%26atitle%3DEpithelial%2520versus%2520mesenchymal%2520phenotype%2520determines%2520in%2520vitro%2520sensitivity%2520and%2520predicts%2520clinical%2520activity%2520of%2520erlotinib%2520in%2520lung%2520cancer%2520patients%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D8686%26epage%3D8698%26doi%3D10.1158%2F1078-0432.CCR-05-1492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit21b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kim, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rho, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. C.</span><span> </span><span class="NLM_article-title">Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation</span> <span class="citation_source-journal">Mol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1093</span><span class="NLM_x">–</span> <span class="NLM_lpage">1102</span><span class="refDoi"> DOI: 10.1016/j.molonc.2013.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1016%2Fj.molonc.2013.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=23993685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlyrtr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2013&pages=1093-1102&author=H.+R.+Kimauthor=W.+S.+Kimauthor=Y.+J.+Choiauthor=C.+M.+Choiauthor=J.+K.+Rhoauthor=J.+C.+Lee&title=Epithelial-mesenchymal+transition+leads+to+crizotinib+resistance+in+H2228+lung+cancer+cells+with+EML4-ALK+translocation&doi=10.1016%2Fj.molonc.2013.08.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21bR"><div class="casContent"><span class="casTitleNuber">21b</span><div class="casTitle"><span class="NLM_cas:atitle">Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation</span></div><div class="casAuthors">Kim, Hyeong Ryul; Kim, Woo Sung; Choi, Yun Jung; Choi, Chang Min; Rho, Jin Kyung; Lee, Jae Cheol</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1093-1102</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1574-7891</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Epithelial-mesenchymal transition (EMT) is assocd. with reduced sensitivity to many chemotherapeutic drugs, including EGFR tyrosine kinase inhibitors.  Here, we investigated if this reduced sensitivity also contributes to resistance to crizotinib, an ALK inhibitor of lung cancer that exhibits the EML4-ALK translocation.  We established a crizotinib-resistant subline (H2228/CR), which was derived from the parental H2228 cell line by long-term exposure to increasing concns. of crizotinib.  Characteristics assocd. with EMT, including morphol., EMT marker proteins, and cellular mobility, were analyzed.  Compared with H2228 cells, the growth of H2228/CR cells was independent of EML4-ALK, and H2228/CR cells showed cross-resistance to TAE-684 (a second-generation ALK inhibitor).  Phenotypic changes to the spindle-cell shape were noted in H2228/CR cells, which were accompanied by a decrease in E-cadherin and increase in vimentin and AXL.  In addn., H2228/CR cells showed increased secretion and expression of TGF-β1.  Invasion and migration capabilities were dramatically increased in H2228/CR cells.  Applying TGF-β1 treatment to parental H2228 cells for 72 h induced reversible EMT, leading to crizotinib resistance, but this was reversed by the removal of TGF-β1.  Suppression of vimentin in H2228/CR cells by siRNA treatment restored sensitivity to crizotinib.  Furthermore, these resistant cells remained highly sensitive to the Hsp90 inhibitors, similar to the parental H2228 cells.  In conclusion, we suggest EMT is possibly involved in acquired resistance to crizotinib, and that HSP90 inhibitors could be a promising option for the treatment of EMT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1f1A1JNCfobVg90H21EOLACvtfcHk0lhSZ0awk5ok1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlyrtr7I&md5=c79e45e695141be621672bf47c663c7f</span></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=10.1016%2Fj.molonc.2013.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molonc.2013.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DH.%2BR.%26aulast%3DKim%26aufirst%3DW.%2BS.%26aulast%3DChoi%26aufirst%3DY.%2BJ.%26aulast%3DChoi%26aufirst%3DC.%2BM.%26aulast%3DRho%26aufirst%3DJ.%2BK.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26atitle%3DEpithelial-mesenchymal%2520transition%2520leads%2520to%2520crizotinib%2520resistance%2520in%2520H2228%2520lung%2520cancer%2520cells%2520with%2520EML4-ALK%2520translocation%26jtitle%3DMol.%2520Oncol.%26date%3D2013%26volume%3D7%26spage%3D1093%26epage%3D1102%26doi%3D10.1016%2Fj.molonc.2013.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Byers, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saintigny, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girard, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peyton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giri, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tumula, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilsson, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gudikote, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cardnell, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bearss, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warner, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foulks, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanner, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krett, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herbst, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenschein, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippman, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ang, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinstein, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wistuba,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coombes, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minna, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heymach, J. V.</span><span> </span><span class="NLM_article-title">An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">279</span><span class="NLM_x">–</span> <span class="NLM_lpage">290</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-1558</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1158%2F1078-0432.CCR-12-1558" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=23091115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktFGlsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=279-290&author=L.+A.+Byersauthor=L.+Diaoauthor=J.+Wangauthor=P.+Saintignyauthor=L.+Girardauthor=M.+Peytonauthor=L.+Shenauthor=Y.+Fanauthor=U.+Giriauthor=P.+K.+Tumulaauthor=M.+B.+Nilssonauthor=J.+Gudikoteauthor=H.+Tranauthor=R.+J.+Cardnellauthor=D.+J.+Bearssauthor=S.+L.+Warnerauthor=J.+M.+Foulksauthor=S.+B.+Kannerauthor=V.+Gandhiauthor=N.+Krettauthor=S.+T.+Rosenauthor=E.+S.+Kimauthor=R.+S.+Herbstauthor=G.+R.+Blumenscheinauthor=J.+J.+Leeauthor=S.+M.+Lippmanauthor=K.+K.+Angauthor=G.+B.+Millsauthor=W.+K.+Hongauthor=J.+N.+Weinsteinauthor=+Wistubaauthor=K.+R.+Coombesauthor=J.+D.+Minnaauthor=J.+V.+Heymach&title=An+epithelial-mesenchymal+transition+gene+signature+predicts+resistance+to+EGFR+and+PI3K+inhibitors+and+identifies+Axl+as+a+therapeutic+target+for+overcoming+EGFR+inhibitor+resistance&doi=10.1158%2F1078-0432.CCR-12-1558"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22aR"><div class="casContent"><span class="casTitleNuber">22a</span><div class="casTitle"><span class="NLM_cas:atitle">An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance</span></div><div class="casAuthors">Byers, Lauren Averett; Diao, Lixia; Wang, Jing; Saintigny, Pierre; Girard, Luc; Peyton, Michael; Shen, Li; Fan, Youhong; Giri, Uma; Tumula, Praveen K.; Nilsson, Monique B.; Gudikote, Jayanthi; Tran, Hai; Cardnell, Robert J. G.; Bearss, David J.; Warner, Steven L.; Foulks, Jason M.; Kanner, Steven B.; Gandhi, Varsha; Krett, Nancy; Rosen, Steven T.; Kim, Edward S.; Herbst, Roy S.; Blumenschein, George R.; Lee, J. Jack; Lippman, Scott M.; Ang, K. Kian; Mills, Gordon B.; Hong, Waun K.; Weinstein, John N.; Wistuba, Ignacio I.; Coombes, Kevin R.; Minna, John D.; Heymach, John V.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">279-290</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Epithelial-mesenchymal transition (EMT) has been assocd. with metastatic spread and EGF receptor (EGFR) inhibitor resistance.  We developed and validated a robust 76-gene EMT signature using gene expression profiles from four platforms using non-small cell lung carcinoma (NSCLC) cell lines and patients treated in the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) study.  Exptl. Design: We conducted an integrated gene expression, proteomic, and drug response anal. using cell lines and tumors from patients with NSCLC.  A 76-gene EMT signature was developed and validated using gene expression profiles from four microarray platforms of NSCLC cell lines and patients treated in the BATTLE study, and potential therapeutic targets assocd. with EMT were identified.  Results: Compared with epithelial cells, mesenchymal cells showed significantly greater resistance to EGFR and PI3K/Akt pathway inhibitors, independent of EGFR mutation status, but more sensitivity to certain chemotherapies.  Mesenchymal cells also expressed increased levels of the receptor tyrosine kinase Axl and showed a trend toward greater sensitivity to the Axl inhibitor SGI-7079, whereas the combination of SGI-7079 with erlotinib reversed erlotinib resistance in mesenchymal lines expressing Axl and in a xenograft model of mesenchymal NSCLC.  In patients with NSCLC, the EMT signature predicted 8-wk disease control in patients receiving erlotinib but not other therapies.  Conclusion: We have developed a robust EMT signature that predicts resistance to EGFR and PI3K/Akt inhibitors, highlights different patterns of drug responsiveness for epithelial and mesenchymal cells, and identifies Axl as a potential therapeutic target for overcoming EGFR inhibitor resistance assocd. with the mesenchymal phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwav-PXLuwi7Vg90H21EOLACvtfcHk0lj-K5VWGUCZbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktFGlsg%253D%253D&md5=d02e08e505b8487a48874abdb8a553a9</span></div><a href="/servlet/linkout?suffix=cit22a&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-1558&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-1558%26sid%3Dliteratum%253Aachs%26aulast%3DByers%26aufirst%3DL.%2BA.%26aulast%3DDiao%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DSaintigny%26aufirst%3DP.%26aulast%3DGirard%26aufirst%3DL.%26aulast%3DPeyton%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DL.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DGiri%26aufirst%3DU.%26aulast%3DTumula%26aufirst%3DP.%2BK.%26aulast%3DNilsson%26aufirst%3DM.%2BB.%26aulast%3DGudikote%26aufirst%3DJ.%26aulast%3DTran%26aufirst%3DH.%26aulast%3DCardnell%26aufirst%3DR.%2BJ.%26aulast%3DBearss%26aufirst%3DD.%2BJ.%26aulast%3DWarner%26aufirst%3DS.%2BL.%26aulast%3DFoulks%26aufirst%3DJ.%2BM.%26aulast%3DKanner%26aufirst%3DS.%2BB.%26aulast%3DGandhi%26aufirst%3DV.%26aulast%3DKrett%26aufirst%3DN.%26aulast%3DRosen%26aufirst%3DS.%2BT.%26aulast%3DKim%26aufirst%3DE.%2BS.%26aulast%3DHerbst%26aufirst%3DR.%2BS.%26aulast%3DBlumenschein%26aufirst%3DG.%2BR.%26aulast%3DLee%26aufirst%3DJ.%2BJ.%26aulast%3DLippman%26aufirst%3DS.%2BM.%26aulast%3DAng%26aufirst%3DK.%2BK.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DHong%26aufirst%3DW.%2BK.%26aulast%3DWeinstein%26aufirst%3DJ.%2BN.%26aulast%3DWistuba%26aulast%3DCoombes%26aufirst%3DK.%2BR.%26aulast%3DMinna%26aufirst%3DJ.%2BD.%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26atitle%3DAn%2520epithelial-mesenchymal%2520transition%2520gene%2520signature%2520predicts%2520resistance%2520to%2520EGFR%2520and%2520PI3K%2520inhibitors%2520and%2520identifies%2520Axl%2520as%2520a%2520therapeutic%2520target%2520for%2520overcoming%2520EGFR%2520inhibitor%2520resistance%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D279%26epage%3D290%26doi%3D10.1158%2F1078-0432.CCR-12-1558" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit22b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Postel-Vinay, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span> </span><span class="NLM_article-title">AXL and acquired resistance to EGFR inhibitors</span> <span class="citation_source-journal">Nat. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">835</span><span class="NLM_x">–</span> <span class="NLM_lpage">836</span><span class="refDoi"> DOI: 10.1038/ng.2362</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1038%2Fng.2362" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=22836088" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFWmsL%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2012&pages=835-836&author=S.+Postel-Vinayauthor=A.+Ashworth&title=AXL+and+acquired+resistance+to+EGFR+inhibitors&doi=10.1038%2Fng.2362"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22bR"><div class="casContent"><span class="casTitleNuber">22b</span><div class="casTitle"><span class="NLM_cas:atitle">AXL and acquired resistance to EGFR inhibitors</span></div><div class="casAuthors">Postel-Vinay, Sophie; Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">835-836</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  A combination of in vitro and in vivo models with validation in human tumors has identified AXL activation as a new mechanism of acquired resistance to EGFR inhibitors in non-small cell lung cancer.  The identification of this mechanism, alongside the current development of specific AXL inhibitors, provides the rationale for further studies that may improve treatment for EGFR inhibitor-resistant patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoc3zpckF89Q7Vg90H21EOLACvtfcHk0lj-K5VWGUCZbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFWmsL%252FP&md5=63ae162ebb7795299e4914de0e9af6de</span></div><a href="/servlet/linkout?suffix=cit22b&amp;dbid=16384&amp;doi=10.1038%2Fng.2362&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.2362%26sid%3Dliteratum%253Aachs%26aulast%3DPostel-Vinay%26aufirst%3DS.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DAXL%2520and%2520acquired%2520resistance%2520to%2520EGFR%2520inhibitors%26jtitle%3DNat.%2520Genet.%26date%3D2012%26volume%3D44%26spage%3D835%26epage%3D836%26doi%3D10.1038%2Fng.2362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit22c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Rho, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoon, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bae, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. C.</span><span> </span><span class="NLM_article-title">MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">253</span><span class="NLM_x">–</span> <span class="NLM_lpage">262</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-13-1103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1158%2F0008-5472.CAN-13-1103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=24165158" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC2cXislKjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=253-262&author=J.+K.+Rhoauthor=Y.+J.+Choiauthor=S.+Y.+Kimauthor=T.+W.+Kimauthor=E.+K.+Choiauthor=S.+J.+Yoonauthor=B.+M.+Parkauthor=E.+Parkauthor=J.+H.+Baeauthor=C.+M.+Choiauthor=J.+C.+Lee&title=MET+and+AXL+inhibitor+NPS-1034+exerts+efficacy+against+lung+cancer+cells+resistant+to+EGFR+kinase+inhibitors+because+of+MET+or+AXL+activation&doi=10.1158%2F0008-5472.CAN-13-1103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22cR"><div class="casContent"><span class="casTitleNuber">22c</span><div class="casTitle"><span class="NLM_cas:atitle">MET and AXL Inhibitor NPS-1034 Exerts Efficacy against Lung Cancer Cells Resistant to EGFR Kinase Inhibitors Because of MET or AXL Activation</span></div><div class="casAuthors">Rho, Jin Kyung; Choi, Yun Jung; Kim, Seon Ye; Kim, Tae Won; Choi, Eun Kyung; Yoon, Seon-Joo; Park, Bu Man; Park, Eunhye; Bae, Jong Hwan; Choi, Chang-Min; Lee, Jae Cheol</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">253-262</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">In non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations, acquired resistance to EGFR-tyrosine kinase inhibitors (EGFR-TK1) can occur through a generation of bypass signals such as MET or AXL activation.  In this study, we investigated the antitumor activity of NPS-1034, a newly developed drug that targets both MET and AXL, in NSCLC cells with acquired resistance to gefitinib or erlotinib (HCC827/GR and HCC827/ER, resp.).  Characterization of H820 cells and evaluation of NPS-1034 efficacy in these cells were also performed.  The resistance of HCC827/GR was mediated by MET activation, whereas AXL activation led to resistance in HCC827/ER.  The combination of gefitinib or erlotinib with NPS-1034 synergistically inhibited cell proliferation and induced cell death in both resistant cell lines.  Accordingly, suppression of Akt was noted only in the presence of treatment with both drugs.  NPS-1034 was also effective in xenograft mouse models of HCC827/GR.  Although the H820 cell line was reported previously to have T790M and MET amplification, we discovered that AXL was also activated in this cell line.  There were no antitumor effects of siRNA or inhibitors specific for EGFR or MET, whereas combined treatment with AXL siRNA or NPS-1034 and EGFR-TKIs controlled H820 cells, suggesting that AXL is the main signal responsible for resistance.  In addn., NPS-1034 inhibited cell proliferation as well as ROS1 activity in HCC78 cells with ROS1 rearrangement.  Our results establish the efficacy of NPS-1034 in NSCLC cells rendered resistant to EGFR-TKIs because of MET or AXL activation or ROS1 rearrangement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzVRl7xbUBLrVg90H21EOLACvtfcHk0lj-K5VWGUCZbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXislKjtA%253D%253D&md5=35929f2dcfd5d1502ba745f367dccd27</span></div><a href="/servlet/linkout?suffix=cit22c&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-13-1103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-13-1103%26sid%3Dliteratum%253Aachs%26aulast%3DRho%26aufirst%3DJ.%2BK.%26aulast%3DChoi%26aufirst%3DY.%2BJ.%26aulast%3DKim%26aufirst%3DS.%2BY.%26aulast%3DKim%26aufirst%3DT.%2BW.%26aulast%3DChoi%26aufirst%3DE.%2BK.%26aulast%3DYoon%26aufirst%3DS.%2BJ.%26aulast%3DPark%26aufirst%3DB.%2BM.%26aulast%3DPark%26aufirst%3DE.%26aulast%3DBae%26aufirst%3DJ.%2BH.%26aulast%3DChoi%26aufirst%3DC.%2BM.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26atitle%3DMET%2520and%2520AXL%2520inhibitor%2520NPS-1034%2520exerts%2520efficacy%2520against%2520lung%2520cancer%2520cells%2520resistant%2520to%2520EGFR%2520kinase%2520inhibitors%2520because%2520of%2520MET%2520or%2520AXL%2520activation%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D253%26epage%3D262%26doi%3D10.1158%2F0008-5472.CAN-13-1103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit22d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Brand, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iida, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corrigan, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braverman, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luthar, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toulany, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gill, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimple, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wheeler, D. L.</span><span> </span><span class="NLM_article-title">AXL mediates resistance to cetuximab therapy</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">5152</span><span class="NLM_x">–</span> <span class="NLM_lpage">5164</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-14-0294</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1158%2F0008-5472.CAN-14-0294" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=5152-5164&author=T.+M.+Brandauthor=M.+Iidaauthor=A.+P.+Steinauthor=K.+L.+Corriganauthor=C.+M.+Bravermanauthor=N.+Lutharauthor=M.+Toulanyauthor=P.+S.+Gillauthor=R.+Salgiaauthor=R.+J.+Kimpleauthor=D.+L.+Wheeler&title=AXL+mediates+resistance+to+cetuximab+therapy&doi=10.1158%2F0008-5472.CAN-14-0294"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22d&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-0294&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-0294%26sid%3Dliteratum%253Aachs%26aulast%3DBrand%26aufirst%3DT.%2BM.%26aulast%3DIida%26aufirst%3DM.%26aulast%3DStein%26aufirst%3DA.%2BP.%26aulast%3DCorrigan%26aufirst%3DK.%2BL.%26aulast%3DBraverman%26aufirst%3DC.%2BM.%26aulast%3DLuthar%26aufirst%3DN.%26aulast%3DToulany%26aufirst%3DM.%26aulast%3DGill%26aufirst%3DP.%2BS.%26aulast%3DSalgia%26aufirst%3DR.%26aulast%3DKimple%26aufirst%3DR.%2BJ.%26aulast%3DWheeler%26aufirst%3DD.%2BL.%26atitle%3DAXL%2520mediates%2520resistance%2520to%2520cetuximab%2520therapy%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D5152%26epage%3D5164%26doi%3D10.1158%2F0008-5472.CAN-14-0294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit22e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Wilson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pham, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neve, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belmont, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koeppen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yauch, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashkenazi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">AXL inhibition sensitizes mesenchymal cancer cells to antimitotic drugs</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">5878</span><span class="NLM_x">–</span> <span class="NLM_lpage">5890</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-14-1009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1158%2F0008-5472.CAN-14-1009" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=5878-5890&author=C.+Wilsonauthor=X.+Yeauthor=T.+Phamauthor=E.+Linauthor=S.+Chanauthor=E.+McNamaraauthor=R.+M.+Neveauthor=L.+Belmontauthor=H.+Koeppenauthor=R.+L.+Yauchauthor=A.+Ashkenaziauthor=J.+Settleman&title=AXL+inhibition+sensitizes+mesenchymal+cancer+cells+to+antimitotic+drugs&doi=10.1158%2F0008-5472.CAN-14-1009"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22e&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-1009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-1009%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DC.%26aulast%3DYe%26aufirst%3DX.%26aulast%3DPham%26aufirst%3DT.%26aulast%3DLin%26aufirst%3DE.%26aulast%3DChan%26aufirst%3DS.%26aulast%3DMcNamara%26aufirst%3DE.%26aulast%3DNeve%26aufirst%3DR.%2BM.%26aulast%3DBelmont%26aufirst%3DL.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DYauch%26aufirst%3DR.%2BL.%26aulast%3DAshkenazi%26aufirst%3DA.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DAXL%2520inhibition%2520sensitizes%2520mesenchymal%2520cancer%2520cells%2520to%2520antimitotic%2520drugs%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D5878%26epage%3D5890%26doi%3D10.1158%2F0008-5472.CAN-14-1009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit22f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Bansal, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mishra, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiPaola, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertino, J. R.</span><span> </span><span class="NLM_article-title">Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">15321</span><span class="NLM_x">–</span> <span class="NLM_lpage">15331</span><span class="refDoi"> DOI: 10.18632/oncotarget.4148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.18632%2Foncotarget.4148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=26036314" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A280%3ADC%252BC2MfpslWgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=15321-15331&author=N.+Bansalauthor=P.+J.+Mishraauthor=M.+Steinauthor=R.+S.+DiPaolaauthor=J.+R.+Bertino&title=Axl+receptor+tyrosine+kinase+is+up-regulated+in+metformin+resistant+prostate+cancer+cells&doi=10.18632%2Foncotarget.4148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22fR"><div class="casContent"><span class="casTitleNuber">22f</span><div class="casTitle"><span class="NLM_cas:atitle">Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells</span></div><div class="casAuthors">Bansal Nitu; Stein Mark; DiPaola Robert S; Bertino Joseph R; Mishra Prasun J</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">15321-31</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Recent epidemiological studies showed that metformin, a widely used anti-diabetic drug might prevent certain cancers.  Metformin also has an anti-proliferative effect in preclinical studies of both hematologic malignancies as well as solid cancers and clinical studies testing metformin as an anti-cancer drug are in progress.  However, all cancer types do not respond to metformin with the same effectiveness or acquire resistance.  To understand the mechanism of acquired resistance and possibly its mechanism of action as an anti-proliferative agent, we developed metformin resistant LNCaP prostate cancer cells.  Metformin resistant LNCaP cells had an increased proliferation rate, increased migration and invasion ability as compared to the parental cells, and expressed markers of epithelial-mesenchymal transition (EMT).  A detailed gene expression microarray comparing the resistant cells to the wild type cells revealed that Edil2, Ereg, Axl, Anax2, CD44 and Anax3 were the top up-regulated genes and calbindin 2 and TPTE (transmembrane phosphatase with tensin homology) and IGF1R were down regulated.  We focused on Axl, a receptor tyrosine kinase that has been shown to be up regulated in several drug resistance cancers.  Here, we show that the metformin resistant cell line as well as castrate resistant cell lines that over express Axl were more resistant to metformin, as well as to taxotere compared to androgen sensitive LNCaP and CWR22 cells that do not overexpress Axl.  Forced overexpression of Axl in LNCaP cells decreased metformin and taxotere sensitivity and knockdown of Axl in resistant cells increased sensitivity to these drugs.  Inhibition of Axl activity by R428, a small molecule Axl kinase inhibitor, sensitized metformin resistant cells that overexpressed Axl to metformin.  Inhibitors of Axl may enhance tumor responses to metformin and other chemotherapy in cancers that over express Axl.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTzxVEroSz9hdj_Vg2vObihfW6udTcc2eZOkSlpKktCOrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MfpslWgtQ%253D%253D&md5=6dea3f587be6fb98b50e817d3735e7ef</span></div><a href="/servlet/linkout?suffix=cit22f&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.4148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.4148%26sid%3Dliteratum%253Aachs%26aulast%3DBansal%26aufirst%3DN.%26aulast%3DMishra%26aufirst%3DP.%2BJ.%26aulast%3DStein%26aufirst%3DM.%26aulast%3DDiPaola%26aufirst%3DR.%2BS.%26aulast%3DBertino%26aufirst%3DJ.%2BR.%26atitle%3DAxl%2520receptor%2520tyrosine%2520kinase%2520is%2520up-regulated%2520in%2520metformin%2520resistant%2520prostate%2520cancer%2520cells%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D15321%26epage%3D15331%26doi%3D10.18632%2Foncotarget.4148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit22g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Meyer, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gertler, F. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lauffenburger, D. A.</span><span> </span><span class="NLM_article-title">The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells</span> <span class="citation_source-journal">Sci. Signaling</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">296</span><span class="NLM_x">–</span> <span class="NLM_lpage">302</span><span class="refDoi"> DOI: 10.1126/scisignal.2004155</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1126%2Fscisignal.2004155" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=296-302&author=A.+S.+Meyerauthor=M.+A.+Millerauthor=F.+B.+Gertlerauthor=D.+A.+Lauffenburger&title=The+receptor+AXL+diversifies+EGFR+signaling+and+limits+the+response+to+EGFR-targeted+inhibitors+in+triple-negative+breast+cancer+cells&doi=10.1126%2Fscisignal.2004155"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22g&amp;dbid=16384&amp;doi=10.1126%2Fscisignal.2004155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscisignal.2004155%26sid%3Dliteratum%253Aachs%26aulast%3DMeyer%26aufirst%3DA.%2BS.%26aulast%3DMiller%26aufirst%3DM.%2BA.%26aulast%3DGertler%26aufirst%3DF.%2BB.%26aulast%3DLauffenburger%26aufirst%3DD.%2BA.%26atitle%3DThe%2520receptor%2520AXL%2520diversifies%2520EGFR%2520signaling%2520and%2520limits%2520the%2520response%2520to%2520EGFR-targeted%2520inhibitors%2520in%2520triple-negative%2520breast%2520cancer%2520cells%26jtitle%3DSci.%2520Signaling%26date%3D2013%26volume%3D6%26spage%3D296%26epage%3D302%26doi%3D10.1126%2Fscisignal.2004155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit22h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivas, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Au, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaFramboise, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abdel-Rahman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levine, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rho, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jang, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arcila, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladanyi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moonsamy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taron, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bivona, T. G.</span><span> </span><span class="NLM_article-title">Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer</span> <span class="citation_source-journal">Nat. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">852</span><span class="NLM_x">–</span> <span class="NLM_lpage">860</span><span class="refDoi"> DOI: 10.1038/ng.2330</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22h&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1038%2Fng.2330" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22h&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=22751098" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22h&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsVWit7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2012&pages=852-860&author=Z.+Zhangauthor=J.+C.+Leeauthor=L.+Linauthor=V.+Olivasauthor=V.+Auauthor=T.+LaFramboiseauthor=M.+Abdel-Rahmanauthor=X.+Wangauthor=A.+D.+Levineauthor=J.+K.+Rhoauthor=Y.+J.+Choiauthor=C.+M.+Choiauthor=S.+W.+Kimauthor=S.+J.+Jangauthor=Y.+S.+Parkauthor=W.+S.+Kimauthor=D.+H.+Leeauthor=J.+S.+Leeauthor=V.+A.+Millerauthor=M.+Arcilaauthor=M.+Ladanyiauthor=P.+Moonsamyauthor=C.+Sawyersauthor=T.+J.+Boggonauthor=P.+C.+Maauthor=C.+Costaauthor=M.+Taronauthor=R.+Rosellauthor=B.+Halmosauthor=T.+G.+Bivona&title=Activation+of+the+AXL+kinase+causes+resistance+to+EGFR-targeted+therapy+in+lung+cancer&doi=10.1038%2Fng.2330"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22hR"><div class="casContent"><span class="casTitleNuber">22h</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer</span></div><div class="casAuthors">Zhang, Zhenfeng; Lee, Jae Cheol; Lin, Luping; Olivas, Victor; Au, Valerie; LaFramboise, Thomas; Abdel-Rahman, Mohamed; Wang, Xiaoqi; Levine, Alan D.; Rho, Jin Kyung; Choi, Yun Jung; Choi, Chang-Min; Kim, Sang-We; Jang, Se Jin; Park, Young Soo; Kim, Woo Sung; Lee, Dae Ho; Lee, Jung-Shin; Miller, Vincent A.; Arcila, Maria; Ladanyi, Marc; Moonsamy, Philicia; Sawyers, Charles; Boggon, Titus J.; Ma, Patrick C.; Costa, Carlota; Taron, Miquel; Rosell, Rafael; Halmos, Balazs; Bivona, Trever G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">852-860</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Human non-small cell lung cancers (NSCLCs) with activating mutations in EGFR frequently respond to treatment with EGFR-targeted tyrosine kinase inhibitors (TKIs), such as erlotinib, but responses are not durable, as tumors acquire resistance.  Secondary mutations in EGFR (such as T790M) or upregulation of the MET kinase are found in over 50% of resistant tumors.  Here, we report increased activation of AXL and evidence for epithelial-to-mesenchymal transition (EMT) in multiple in vitro and in vivo EGFR-mutant lung cancer models with acquired resistance to erlotinib in the absence of the EGFR p.  Thr790Met alteration or MET activation.  Genetic or pharmacol. inhibition of AXL restored sensitivity to erlotinib in these tumor models.  Increased expression of AXL and, in some cases, of its ligand GAS6 was found in EGFR-mutant lung cancers obtained from individuals with acquired resistance to TKIs.  These data identify AXL as a promising therapeutic target whose inhibition could prevent or overcome acquired resistance to EGFR TKIs in individuals with EGFR-mutant lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGothnhyjpkwaLVg90H21EOLACvtfcHk0liQkUKbMTVYzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsVWit7s%253D&md5=f186a5b9ad4bfdbe12f68ef93d2da254</span></div><a href="/servlet/linkout?suffix=cit22h&amp;dbid=16384&amp;doi=10.1038%2Fng.2330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.2330%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DLin%26aufirst%3DL.%26aulast%3DOlivas%26aufirst%3DV.%26aulast%3DAu%26aufirst%3DV.%26aulast%3DLaFramboise%26aufirst%3DT.%26aulast%3DAbdel-Rahman%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DLevine%26aufirst%3DA.%2BD.%26aulast%3DRho%26aufirst%3DJ.%2BK.%26aulast%3DChoi%26aufirst%3DY.%2BJ.%26aulast%3DChoi%26aufirst%3DC.%2BM.%26aulast%3DKim%26aufirst%3DS.%2BW.%26aulast%3DJang%26aufirst%3DS.%2BJ.%26aulast%3DPark%26aufirst%3DY.%2BS.%26aulast%3DKim%26aufirst%3DW.%2BS.%26aulast%3DLee%26aufirst%3DD.%2BH.%26aulast%3DLee%26aufirst%3DJ.%2BS.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DArcila%26aufirst%3DM.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DMoonsamy%26aufirst%3DP.%26aulast%3DSawyers%26aufirst%3DC.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DMa%26aufirst%3DP.%2BC.%26aulast%3DCosta%26aufirst%3DC.%26aulast%3DTaron%26aufirst%3DM.%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DHalmos%26aufirst%3DB.%26aulast%3DBivona%26aufirst%3DT.%2BG.%26atitle%3DActivation%2520of%2520the%2520AXL%2520kinase%2520causes%2520resistance%2520to%2520EGFR-targeted%2520therapy%2520in%2520lung%2520cancer%26jtitle%3DNat.%2520Genet.%26date%3D2012%26volume%3D44%26spage%3D852%26epage%3D860%26doi%3D10.1038%2Fng.2330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greshock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Annan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halsey, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sathe, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmer, T. M.</span><span> </span><span class="NLM_article-title">Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">6871</span><span class="NLM_x">–</span> <span class="NLM_lpage">6878</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-08-4490</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1158%2F0008-5472.CAN-08-4490" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=6871-6878&author=L.+Liuauthor=J.+Gregerauthor=H.+Shiauthor=Y.+Liuauthor=J.+Greshockauthor=R.+Annanauthor=W.+Halseyauthor=G.+M.+Satheauthor=A.+M.+Martinauthor=T.+M.+Gilmer&title=Novel+mechanism+of+lapatinib+resistance+in+HER2-positive+breast+tumor+cells%3A+activation+of+AXL&doi=10.1158%2F0008-5472.CAN-08-4490"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-4490&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-4490%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DGreger%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGreshock%26aufirst%3DJ.%26aulast%3DAnnan%26aufirst%3DR.%26aulast%3DHalsey%26aufirst%3DW.%26aulast%3DSathe%26aufirst%3DG.%2BM.%26aulast%3DMartin%26aufirst%3DA.%2BM.%26aulast%3DGilmer%26aufirst%3DT.%2BM.%26atitle%3DNovel%2520mechanism%2520of%2520lapatinib%2520resistance%2520in%2520HER2-positive%2520breast%2520tumor%2520cells%253A%2520activation%2520of%2520AXL%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D6871%26epage%3D6878%26doi%3D10.1158%2F0008-5472.CAN-08-4490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hart, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Boer, R. H.</span><span> </span><span class="NLM_article-title">Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer</span> <span class="citation_source-journal">OncoTargets Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">7</span><span class="refDoi"> DOI: 10.2147/OTT.S27671</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.2147%2FOTT.S27671" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=23319867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVOqtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=1-7&author=C.+D.+Hartauthor=R.+H.+De+Boer&title=Profile+of+cabozantinib+and+its+potential+in+the+treatment+of+advanced+medullary+thyroid+cancer&doi=10.2147%2FOTT.S27671"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24aR"><div class="casContent"><span class="casTitleNuber">24a</span><div class="casTitle"><span class="NLM_cas:atitle">Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer</span></div><div class="casAuthors">Hart, Christopher D.; De Boer, Richard H.</div><div class="citationInfo"><span class="NLM_cas:title">OncoTargets and Therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-7</span>CODEN:
                <span class="NLM_cas:coden">OTNHAZ</span>;
        ISSN:<span class="NLM_cas:issn">1178-6930</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Medullary thyroid cancer is an uncommon malignancy for which until recently little effective treatment existed.  It is often characterized by mutation and overexpression of the receptor tyrosine kinases RET (rearranged during transfection), VEGFR2 (vascular endothelial growth factor receptor 2) and MET (mesenchymal-epithelial transition factor), which make attractive targets for drug development.  Cabozantinib is an orally bioavailable tyrosine kinase inhibitor which blocks MET, VEGRF2 and RET, and has shown considerable activity in medullary thyroid cancer in a Phase III trial, including in heavily pretreated patients.  Its novel combination of vascular endothelial growth factor and MET inhibition is believed to address the MET escape pathway, which is thought to be the cause of nonsustained tumor responses resulting from inhibition of vascular endothelial growth factor alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcdeH_ML0s97Vg90H21EOLACvtfcHk0lh52diWdKSFWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVOqtr4%253D&md5=048635660f5262d406ec13baef91bc78</span></div><a href="/servlet/linkout?suffix=cit24a&amp;dbid=16384&amp;doi=10.2147%2FOTT.S27671&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FOTT.S27671%26sid%3Dliteratum%253Aachs%26aulast%3DHart%26aufirst%3DC.%2BD.%26aulast%3DDe%2BBoer%26aufirst%3DR.%2BH.%26atitle%3DProfile%2520of%2520cabozantinib%2520and%2520its%2520potential%2520in%2520the%2520treatment%2520of%2520advanced%2520medullary%2520thyroid%2520cancer%26jtitle%3DOncoTargets%2520Ther.%26date%3D2013%26volume%3D6%26spage%3D1%26epage%3D7%26doi%3D10.2147%2FOTT.S27671" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit24b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Choueiri, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Escudier, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powles, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mainwaring, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rini, B. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donskov, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammers, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutson, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peltola, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bjarnason, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geczi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keam, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maroto, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heng, D. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidinger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantoff, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borgman-Hagey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hessel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheffold, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwab, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tannir, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Motzer, R. J.</span><span> </span><span class="NLM_article-title">Cabozantinib versus everolimus in advanced renal-cell carcinoma</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">373</span><span class="NLM_x">, </span> <span class="NLM_fpage">1814</span><span class="NLM_x">–</span> <span class="NLM_lpage">1823</span><span class="refDoi"> DOI: 10.1056/NEJMoa1510016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1056%2FNEJMoa1510016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=26406150" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC28XnvFCktLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=1814-1823&author=T.+K.+Choueiriauthor=B.+Escudierauthor=T.+Powlesauthor=P.+N.+Mainwaringauthor=B.+I.+Riniauthor=F.+Donskovauthor=H.+Hammersauthor=T.+E.+Hutsonauthor=J.+L.+Leeauthor=K.+Peltolaauthor=B.+J.+Rothauthor=G.+A.+Bjarnasonauthor=L.+Gecziauthor=B.+Keamauthor=P.+Marotoauthor=D.+Y.+Hengauthor=M.+Schmidingerauthor=P.+W.+Kantoffauthor=A.+Borgman-Hageyauthor=C.+Hesselauthor=C.+Scheffoldauthor=G.+M.+Schwabauthor=N.+M.+Tannirauthor=R.+J.+Motzer&title=Cabozantinib+versus+everolimus+in+advanced+renal-cell+carcinoma&doi=10.1056%2FNEJMoa1510016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24bR"><div class="casContent"><span class="casTitleNuber">24b</span><div class="casTitle"><span class="NLM_cas:atitle">Cabozantinib versus everolimus in advanced renal-cell carcinoma</span></div><div class="casAuthors">Choueiri, T. K.; Escudier, B.; Powles, T.; Mainwaring, P. N.; Rini, B. I.; Donskov, F.; Hammers, H.; Hutson, T. E.; Lee, J.-L.; Peltola, K.; Roth, B. J.; Bjarnason, G. A.; Geczi, L.; Keam, B.; Maroto, P.; Heng, D. Y. C.; Schmidinger, M.; Kantoff, P. W.; Borgman-Hagey, A.; Hessel, C.; Scheffold, C.; Schwab, G. M.; Tannir, N. M.; Motzer, R. J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1814-1823</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Cabozantinib is an oral, small-mol. tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR) as well as MET and AXL, each of which has been implicated in the pathobiol. of metastatic renal-cell carcinoma or in the development of resistance to antiangiogenic drugs.  This randomized, open-label, phase 3 trial evaluated the efficacy of cabozantinib, as compared with everolimus, in patients with renal-cell carcinoma that had progressed after VEGFR-targeted therapy.  We randomly assigned 658 patients to receive cabozantinib at a dose of 60 mg daily or everolimus at a dose of 10 mg daily.  The primary end point was progression- free survival.  Secondary efficacy end points were overall survival and objective response rate.  Median progression-free survival was 7.4 mo with cabozantinib and 3.8 mo with everolimus.  The rate of progression or death was 42% lower with cabozantinib than with everolimus (hazard ratio, 0.58; 95% confidence interval [CI] 0.45 to 0.75; P<0.001).  The objective response rate was 21% with cabozantinib and 5% with everolimus (P<0.001).  A planned interim anal. showed that overall survival was longer with cabozantinib than with everolimus (hazard ratio for death, 0.67; 95% CI, 0.51 to 0.89; P = 0.005) but did not cross the significance boundary for the interim anal.  Adverse events were managed with dose redns.; doses were reduced in 60% of the patients who received cabozantinib and in 25% of those who received everolimus.  Discontinuation of study treatment owing to adverse events occurred in 9% of the patients who received cabozantinib and in 10% of those who received everolimus.  Progression-free survival was longer with cabozantinib than with everolimus among patients with renal-cell carcinoma that had progressed after VEGFR-targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobvjc8n5w4zbVg90H21EOLACvtfcHk0lh52diWdKSFWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnvFCktLY%253D&md5=09927cde8f581f4ff2060679df1ff5b8</span></div><a href="/servlet/linkout?suffix=cit24b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1510016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1510016%26sid%3Dliteratum%253Aachs%26aulast%3DChoueiri%26aufirst%3DT.%2BK.%26aulast%3DEscudier%26aufirst%3DB.%26aulast%3DPowles%26aufirst%3DT.%26aulast%3DMainwaring%26aufirst%3DP.%2BN.%26aulast%3DRini%26aufirst%3DB.%2BI.%26aulast%3DDonskov%26aufirst%3DF.%26aulast%3DHammers%26aufirst%3DH.%26aulast%3DHutson%26aufirst%3DT.%2BE.%26aulast%3DLee%26aufirst%3DJ.%2BL.%26aulast%3DPeltola%26aufirst%3DK.%26aulast%3DRoth%26aufirst%3DB.%2BJ.%26aulast%3DBjarnason%26aufirst%3DG.%2BA.%26aulast%3DGeczi%26aufirst%3DL.%26aulast%3DKeam%26aufirst%3DB.%26aulast%3DMaroto%26aufirst%3DP.%26aulast%3DHeng%26aufirst%3DD.%2BY.%26aulast%3DSchmidinger%26aufirst%3DM.%26aulast%3DKantoff%26aufirst%3DP.%2BW.%26aulast%3DBorgman-Hagey%26aufirst%3DA.%26aulast%3DHessel%26aufirst%3DC.%26aulast%3DScheffold%26aufirst%3DC.%26aulast%3DSchwab%26aufirst%3DG.%2BM.%26aulast%3DTannir%26aufirst%3DN.%2BM.%26aulast%3DMotzer%26aufirst%3DR.%2BJ.%26atitle%3DCabozantinib%2520versus%2520everolimus%2520in%2520advanced%2520renal-cell%2520carcinoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26spage%3D1814%26epage%3D1823%26doi%3D10.1056%2FNEJMoa1510016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran-Dube, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pairish, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funk, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botrous, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grodsky, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padrique, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timofeevski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span> </span><span class="NLM_article-title">Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">6342</span><span class="NLM_x">–</span> <span class="NLM_lpage">6363</span><span class="refDoi"> DOI: 10.1021/jm2007613</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2007613" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6342-6363&author=J.+J.+Cuiauthor=M.+Tran-Dubeauthor=H.+Shenauthor=M.+Nambuauthor=P.+P.+Kungauthor=M.+Pairishauthor=L.+Jiaauthor=J.+Mengauthor=L.+Funkauthor=I.+Botrousauthor=M.+McTigueauthor=N.+Grodskyauthor=K.+Ryanauthor=E.+Padriqueauthor=G.+Altonauthor=S.+Timofeevskiauthor=S.+Yamazakiauthor=Q.+H.+Liauthor=H.+L.+Zouauthor=J.+Christensenauthor=B.+Mroczkowskiauthor=S.+Benderauthor=R.+S.+Kaniaauthor=M.+P.+Edwards&title=Structure+based+drug+design+of+crizotinib+%28PF-02341066%29%2C+a+potent+and+selective+dual+inhibitor+of+mesenchymal-epithelial+transition+factor+%28c-MET%29+kinase+and+anaplastic+lymphoma+kinase+%28ALK%29&doi=10.1021%2Fjm2007613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25aR"><div class="casContent"><span class="casTitleNuber">25a</span><div class="casTitle"><span class="NLM_cas:atitle">Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Cui, J. Jean; Tran-Dube, Michelle; Shen, Hong; Nambu, Mitchell; Kung, Pei-Pei; Pairish, Mason; Jia, Lei; Meng, Jerry; Funk, Lee; Botrous, Iriny; McTigue, Michele; Grodsky, Neil; Ryan, Kevin; Padrique, Ellen; Alton, Gordon; Timofeevski, Sergei; Yamazaki, Shinji; Li, Qiuhua; Zou, Helen; Christensen, James; Mroczkowski, Barbara; Bender, Steve; Kania, Robert S.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6342-6363</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Because of the crit. roles of aberrant signaling in cancer, both c-MET and ALK receptor tyrosine kinases are attractive oncol. targets for therapeutic intervention.  The cocrystal structure of 3 (PHA-665752), bound to c-MET kinase domain, revealed a novel ATP site environment, which served as the target to guide parallel, multiattribute drug design.  A novel 2-amino-5-aryl-3-benzyloxypyridine series was created to more effectively make the key interactions achieved with 3.  In the novel series, the 2-aminopyridine core allowed a 3-benzyloxy group to reach into the same pocket as the 2,6-dichlorophenyl group of 3 via a more direct vector and thus with a better ligand efficiency (LE).  Further optimization of the lead series generated the clin. candidate crizotinib (PF-02341066), which demonstrated potent in vitro and in vivo c-MET kinase and ALK inhibition, effective tumor growth inhibition, and good pharmaceutical properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHs_cKJ-U3t7Vg90H21EOLACvtfcHk0lj36x68o_ODEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN&md5=dbab4c1b3e7c76180dbad04be2b6a474</span></div><a href="/servlet/linkout?suffix=cit25a&amp;dbid=16384&amp;doi=10.1021%2Fjm2007613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007613%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DTran-Dube%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DNambu%26aufirst%3DM.%26aulast%3DKung%26aufirst%3DP.%2BP.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DJ.%26aulast%3DFunk%26aufirst%3DL.%26aulast%3DBotrous%26aufirst%3DI.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DGrodsky%26aufirst%3DN.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DPadrique%26aufirst%3DE.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DQ.%2BH.%26aulast%3DZou%26aufirst%3DH.%2BL.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DStructure%2520based%2520drug%2520design%2520of%2520crizotinib%2520%2528PF-02341066%2529%252C%2520a%2520potent%2520and%2520selective%2520dual%2520inhibitor%2520of%2520mesenchymal-epithelial%2520transition%2520factor%2520%2528c-MET%2529%2520kinase%2520and%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6342%26epage%3D6363%26doi%3D10.1021%2Fjm2007613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit25b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arango, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonnell, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koudriakova, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Los, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span> </span><span class="NLM_article-title">An orally available small-molecule inhibitor of c-met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">4408</span><span class="NLM_x">–</span> <span class="NLM_lpage">4417</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-06-4443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1158%2F0008-5472.CAN-06-4443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=17483355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltVyrsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=4408-4417&author=H.+Y.+Zouauthor=Q.+H.+Liauthor=J.+H.+Leeauthor=M.+E.+Arangoauthor=S.+R.+McDonnellauthor=S.+Yamazakiauthor=T.+B.+Koudriakovaauthor=G.+Altonauthor=J.+J.+Cuiauthor=P.+P.+Kungauthor=M.+D.+Nambuauthor=G.+Losauthor=S.+L.+Benderauthor=B.+Mroczkowskiauthor=J.+G.+Christensen&title=An+orally+available+small-molecule+inhibitor+of+c-met%2C+PF-2341066%2C+exhibits+cytoreductive+antitumor+efficacy+through+antiproliferative+and+antiangiogenic+mechanisms&doi=10.1158%2F0008-5472.CAN-06-4443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25bR"><div class="casContent"><span class="casTitleNuber">25b</span><div class="casTitle"><span class="NLM_cas:atitle">An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms</span></div><div class="casAuthors">Zou, Helen Y.; Li, Qiuhua; Lee, Joseph H.; Arango, Maria E.; McDonnell, Scott R.; Yamazaki, Shinji; Koudriakova, Tatiana B.; Alton, Gordon; Cui, Jingrong J.; Kung, Pei-Pei; Nambu, Mitchell D.; Los, Gerrit; Bender, Steven L.; Mroczkowski, Barbara; Christensen, James G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4408-4417</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The c-Met receptor tyrosine kinase and its ligand, hepatocyte growth factor (HGF), have been implicated in the progression of several human cancers and are attractive therapeutic targets.  PF-2341066 was identified as a potent, orally bioavailable, ATP-competitive small-mol. inhibitor of the catalytic activity of c-Met kinase.  PF-2341066 was selective for c-Met (and anaplastic lymphoma kinase) compared with a panel of >120 diverse tyrosine and serine-threonine kinases.  PF-2341066 potently inhibited c-Met phosphorylation and c-Met-dependent proliferation, migration, or invasion of human tumor cells in vitro (IC50 values, 5-20 nmol/L).  In addn., PF-2341066 potently inhibited HGF-stimulated endothelial cell survival or invasion and serum-stimulated tubulogenesis in vitro, suggesting that this agent also exhibits antiangiogenic properties.  PF-2341066 showed efficacy at well-tolerated doses, including marked cytoreductive antitumor activity, in several tumor models that expressed activated c-Met.  The antitumor efficacy of PF-2341066 was dose dependent and showed a strong correlation to inhibition of c-Met phosphorylation in vivo.  Near-maximal inhibition of c-Met activity for the full dosing interval was necessary to maximize the efficacy of PF-2341066.  Addnl. mechanism-of-action studies showed dose-dependent inhibition of c-Met-dependent signal transduction, tumor cell proliferation (Ki67), induction of apoptosis (caspase-3), and redn. of microvessel d. (CD31).  These results indicated that the antitumor activity of PF-2341066 may be mediated by direct effects on tumor cell growth or survival as well as antiangiogenic mechanisms.  Collectively, these results show the therapeutic potential of targeting c-Met with selective small-mol. inhibitors for the treatment of human cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEAWtGPOBHC7Vg90H21EOLACvtfcHk0lj36x68o_ODEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltVyrsbg%253D&md5=798bf93e6cf8d5e9897e27485cba9002</span></div><a href="/servlet/linkout?suffix=cit25b&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-4443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-4443%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DLi%26aufirst%3DQ.%2BH.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DArango%26aufirst%3DM.%2BE.%26aulast%3DMcDonnell%26aufirst%3DS.%2BR.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DKoudriakova%26aufirst%3DT.%2BB.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DKung%26aufirst%3DP.%2BP.%26aulast%3DNambu%26aufirst%3DM.%2BD.%26aulast%3DLos%26aufirst%3DG.%26aulast%3DBender%26aufirst%3DS.%2BL.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26atitle%3DAn%2520orally%2520available%2520small-molecule%2520inhibitor%2520of%2520c-met%252C%2520PF-2341066%252C%2520exhibits%2520cytoreductive%2520antitumor%2520efficacy%2520through%2520antiproliferative%2520and%2520antiangiogenic%2520mechanisms%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D4408%26epage%3D4417%26doi%3D10.1158%2F0008-5472.CAN-06-4443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Remsing Rix, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rix, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colinge, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hantschel, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stranzl, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumgartner, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valent, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Augustin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Till, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Superti-Furga, G.</span><span> </span><span class="NLM_article-title">Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">477</span><span class="NLM_x">–</span> <span class="NLM_lpage">485</span><span class="refDoi"> DOI: 10.1038/leu.2008.334</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1038%2Fleu.2008.334" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=19039322" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivVKhu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2009&pages=477-485&author=L.+L.+Remsing+Rixauthor=U.+Rixauthor=J.+Colingeauthor=O.+Hantschelauthor=K.+L.+Bennettauthor=T.+Stranzlauthor=A.+Mullerauthor=C.+Baumgartnerauthor=P.+Valentauthor=M.+Augustinauthor=J.+H.+Tillauthor=G.+Superti-Furga&title=Global+target+profile+of+the+kinase+inhibitor+bosutinib+in+primary+chronic+myeloid+leukemia+cells&doi=10.1038%2Fleu.2008.334"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells</span></div><div class="casAuthors">Remsing Rix, L. L.; Rix, U.; Colinge, J.; Hantschel, O.; Bennett, K. L.; Stranzl, T.; Mueller, A.; Baumgartner, C.; Valent, P.; Augustin, M.; Till, J. H.; Superti-Furga, G.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">477-485</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The detailed mol. mechanism of action of second-generation BCR-ABL tyrosine kinase inhibitors, including perturbed targets and pathways, should contribute to rationalized therapy in chronic myeloid leukemia (CML) or in other affected diseases.  Here, we characterized the target profile of the dual SRC/ABL inhibitor bosutinib employing a two-tiered approach using chem. proteomics to identify natural binders in whole cell lysates of primary CML and K562 cells in parallel to in vitro kinase assays against a large recombinant kinase panel.  The combined strategy resulted in a global survey of bosutinib targets comprised of over 45 novel tyrosine and serine/threonine kinases.  We have found clear differences in the target patterns of bosutinib in primary CML cells vs. the K562 cell line.  A comparison of bosutinib with dasatinib across the whole kinase panel revealed overlapping, but distinct, inhibition profiles.  Common among those were the SRC, ABL and TEC family kinases.  Bosutinib did not inhibit KIT or platelet-derived growth factor receptor, but prominently targeted the apoptosis-linked STE20 kinases.  Although in vivo bosutinib is inactive against ABL T315I, we found this clin. important mutant to be enzymically inhibited in the mid-nanomolar range.  Finally, bosutinib is the first kinase inhibitor shown to target CAMK2G, recently implicated in myeloid leukemia cell proliferation.  Leukemia (2009) 23, 477-485; doi:10.1038/leu.2008.334; published online 27 Nov. 2008.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8u0ixFotIMLVg90H21EOLACvtfcHk0lgWIA0kDsnASg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivVKhu7w%253D&md5=b0d56d468ef66ddc2a6f012d08f8c1a4</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fleu.2008.334&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2008.334%26sid%3Dliteratum%253Aachs%26aulast%3DRemsing%2BRix%26aufirst%3DL.%2BL.%26aulast%3DRix%26aufirst%3DU.%26aulast%3DColinge%26aufirst%3DJ.%26aulast%3DHantschel%26aufirst%3DO.%26aulast%3DBennett%26aufirst%3DK.%2BL.%26aulast%3DStranzl%26aufirst%3DT.%26aulast%3DMuller%26aufirst%3DA.%26aulast%3DBaumgartner%26aufirst%3DC.%26aulast%3DValent%26aufirst%3DP.%26aulast%3DAugustin%26aufirst%3DM.%26aulast%3DTill%26aufirst%3DJ.%2BH.%26aulast%3DSuperti-Furga%26aufirst%3DG.%26atitle%3DGlobal%2520target%2520profile%2520of%2520the%2520kinase%2520inhibitor%2520bosutinib%2520in%2520primary%2520chronic%2520myeloid%2520leukemia%2520cells%26jtitle%3DLeukemia%26date%3D2009%26volume%3D23%26spage%3D477%26epage%3D485%26doi%3D10.1038%2Fleu.2008.334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Blumenthal, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortazar, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sridhara, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murgo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Justice, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pazdur, R.</span><span> </span><span class="NLM_article-title">FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1108</span><span class="NLM_x">–</span> <span class="NLM_lpage">1113</span><span class="refDoi"> DOI: 10.1634/theoncologist.2012-0044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1634%2Ftheoncologist.2012-0044" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=1108-1113&author=G.+M.+Blumenthalauthor=P.+Cortazarauthor=J.+J.+Zhangauthor=S.+Tangauthor=R.+Sridharaauthor=A.+Murgoauthor=R.+Justiceauthor=R.+Pazdur&title=FDA+approval+summary%3A+sunitinib+for+the+treatment+of+progressive+well-differentiated+locally+advanced+or+metastatic+pancreatic+neuroendocrine+tumors&doi=10.1634%2Ftheoncologist.2012-0044"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.2012-0044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.2012-0044%26sid%3Dliteratum%253Aachs%26aulast%3DBlumenthal%26aufirst%3DG.%2BM.%26aulast%3DCortazar%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DJ.%2BJ.%26aulast%3DTang%26aufirst%3DS.%26aulast%3DSridhara%26aufirst%3DR.%26aulast%3DMurgo%26aufirst%3DA.%26aulast%3DJustice%26aufirst%3DR.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DFDA%2520approval%2520summary%253A%2520sunitinib%2520for%2520the%2520treatment%2520of%2520progressive%2520well-differentiated%2520locally%2520advanced%2520or%2520metastatic%2520pancreatic%2520neuroendocrine%2520tumors%26jtitle%3DOncologist%26date%3D2012%26volume%3D17%26spage%3D1108%26epage%3D1113%26doi%3D10.1634%2Ftheoncologist.2012-0044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Eder, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Appleman, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, A. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miles, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cancilla, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hitchcock-Bryan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCallum, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heath, E. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boerner, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LoRusso, P. M.</span><span> </span><span class="NLM_article-title">A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">3507</span><span class="NLM_x">–</span> <span class="NLM_lpage">3516</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-10-0574</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1158%2F1078-0432.CCR-10-0574" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=20472683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC3cXot1Wlt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=3507-3516&author=J.+P.+Ederauthor=G.+I.+Shapiroauthor=L.+J.+Applemanauthor=A.+X.+Zhuauthor=D.+Milesauthor=H.+Keerauthor=B.+Cancillaauthor=F.+Chuauthor=S.+Hitchcock-Bryanauthor=L.+Shermanauthor=S.+McCallumauthor=E.+I.+Heathauthor=S.+A.+Boernerauthor=P.+M.+LoRusso&title=A+phase+I+study+of+foretinib%2C+a+multi-targeted+inhibitor+of+c-Met+and+vascular+endothelial+growth+factor+receptor+2&doi=10.1158%2F1078-0432.CCR-10-0574"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2</span></div><div class="casAuthors">Eder, Joseph Paul; Shapiro, Geoffrey I.; Appleman, Leonard J.; Zhu, Andrew X.; Miles, Dale; Keer, Harold; Cancilla, Belinda; Chu, Felix; Hitchcock-Bryan, Suzanne; Sherman, Laurie; McCallum, Stewart; Heath, Elisabeth I.; Boerner, Scott A.; Lo Russo, Patricia M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3507-3516</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Foretinib is an oral multikinase inhibitor targeting Met, RON, Axl, and vascular endothelial growth factor receptor.  We conducted a phase I, first-time-in-human, clin. trial using escalating doses of oral foretinib.  The primary objectives are to identify a max. tolerated dose and det. the safety profile of foretinib.  Secondary objectives included evaluation of plasma pharmacokinetics, long-term safety after repeated administration, preliminary antitumor activity, and pharmacodynamic activity.  Exptl. Design: Patients had histol. confirmed metastatic or unresectable solid tumors for which no std. measures exist.  All patients received foretinib orally for 5 consecutive days every 14 days.  Dose escalation followed a conventional "3+3" design.  RESULTS: Forty patients were treated in eight dose cohorts.  The max. tolerated dose was defined as 3.6 mg/kg, with a max. administered dose of 4.5 mg/kg.  Dose-limiting toxicities included grade 3 elevations in aspartate aminotransferase and lipase.  Addnl. non-dose-limiting adverse events included hypertension, fatigue, diarrhea, vomiting, proteinuria, and hematuria.  Responses were obsd. in two patients with papillary renal cell cancer and one patient with medullary thyroid cancer.  Stable disease was identified in 22 patients.  Foretinib pharmacokinetics increased linearly with dose.  Pharmacodynamic evaluation indicated inhibition of MET phosphorylation and decreased proliferation in select tumor biopsies at submaximal doses.  CONCLUSIONS: The recommended dose of foretinib was detd. to be 240 mg, given on the first 5 days of a 14-day cycle.  This dose and schedule were identified as having acceptable safety and pharmacokinetics, and will be the dose used in subsequent phase II trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1LAL1xiRe-rVg90H21EOLACvtfcHk0lgWIA0kDsnASg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXot1Wlt74%253D&md5=d37b24383a08fdde5f78ed40b077963b</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-0574&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-0574%26sid%3Dliteratum%253Aachs%26aulast%3DEder%26aufirst%3DJ.%2BP.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DAppleman%26aufirst%3DL.%2BJ.%26aulast%3DZhu%26aufirst%3DA.%2BX.%26aulast%3DMiles%26aufirst%3DD.%26aulast%3DKeer%26aufirst%3DH.%26aulast%3DCancilla%26aufirst%3DB.%26aulast%3DChu%26aufirst%3DF.%26aulast%3DHitchcock-Bryan%26aufirst%3DS.%26aulast%3DSherman%26aufirst%3DL.%26aulast%3DMcCallum%26aufirst%3DS.%26aulast%3DHeath%26aufirst%3DE.%2BI.%26aulast%3DBoerner%26aufirst%3DS.%2BA.%26aulast%3DLoRusso%26aufirst%3DP.%2BM.%26atitle%3DA%2520phase%2520I%2520study%2520of%2520foretinib%252C%2520a%2520multi-targeted%2520inhibitor%2520of%2520c-Met%2520and%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%25202%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2010%26volume%3D16%26spage%3D3507%26epage%3D3516%26doi%3D10.1158%2F1078-0432.CCR-10-0574" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Yan, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peek, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ajamie, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchanan, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graff, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heidler, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hui, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huss, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konicek, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manro, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shih, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stout, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uhlik, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Um, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walgren, R. A.</span><span> </span><span class="NLM_article-title">LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">833</span><span class="NLM_x">–</span> <span class="NLM_lpage">844</span><span class="refDoi"> DOI: 10.1007/s10637-012-9912-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1007%2Fs10637-012-9912-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=23275061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOksLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=833-844&author=S.+B.+Yanauthor=V.+L.+Peekauthor=R.+Ajamieauthor=S.+G.+Buchananauthor=J.+R.+Graffauthor=S.+A.+Heidlerauthor=Y.+H.+Huiauthor=K.+L.+Hussauthor=B.+W.+Konicekauthor=J.+R.+Manroauthor=C.+Shihauthor=J.+A.+Stewartauthor=T.+R.+Stewartauthor=S.+L.+Stoutauthor=M.+T.+Uhlikauthor=S.+L.+Umauthor=Y.+Wangauthor=W.+Wuauthor=L.+Yanauthor=W.+J.+Yangauthor=B.+Zhongauthor=R.+A.+Walgren&title=LY2801653+is+an+orally+bioavailable+multi-kinase+inhibitor+with+potent+activity+against+MET%2C+MST1R%2C+and+other+oncoproteins%2C+and+displays+anti-tumor+activities+in+mouse+xenograft+models&doi=10.1007%2Fs10637-012-9912-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models</span></div><div class="casAuthors">Yan, S. Betty; Peek, Victoria L.; Ajamie, Rose; Buchanan, Sean G.; Graff, Jeremy R.; Heidler, Steven A.; Hui, Yu-Hua; Huss, Karen L.; Konicek, Bruce W.; Manro, Jason R.; Shih, Chuan; Stewart, Julie A.; Stewart, Trent R.; Stout, Stephanie L.; Uhlik, Mark T.; Um, Suzane L.; Wang, Yong; Wu, Wenjuan; Yan, Lei; Yang, Wei J.; Zhong, Boyu; Walgren, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">833-844</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The HGF/MET signaling pathway regulates a wide variety of normal cellular functions that can be subverted to support neoplasia, including cell proliferation, survival, apoptosis, scattering and motility, invasion, and angiogenesis.  MET over-expression (with or without gene amplification), aberrant autocrine or paracrine ligand prodn., and missense MET mutations are mechanisms that lead to activation of the MET pathway in tumors and are assocd. with poor prognostic outcome.  We report here preclin. development of a potent, orally bioavailable, small-mol. inhibitor LY2801653 targeting MET kinase.  LY2801653 is a type-II ATP competitive, slow-off inhibitor of MET tyrosine kinase with a dissocn. const. (Ki) of 2 nM, a pharmacodynamic residence time (Koff) of 0.00132 min-1 and t1/2 of 525 min.  LY2801653 demonstrated in vitro effects on MET pathway-dependent cell scattering and cell proliferation; in vivo anti-tumor effects in MET amplified (MKN45), MET autocrine (U-87MG, and KP4) and MET over-expressed (H441) xenograft models; and in vivo vessel normalization effects.  LY2801653 also maintained potency against 13 MET variants, each bearing a single-point mutation.  In subsequent nonclin. characterization, LY2801653 was found to have potent activity against several other receptor tyrosine oncokinases including MST1R, FLT3, AXL, MERTK, TEK, ROS1, DDR1/2 and against the serine/threonine kinases MKNK1/2.  The potential value of MET and other inhibited targets within a no. of malignancies (such as colon, bile ducts, and lung) is discussed.  LY2801653 is currently in phase 1 clin. testing in patients with advanced cancer (trial I3O-MC-JSBA, NCT01285037).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo04limPWxrHLVg90H21EOLACvtfcHk0ljzO0AO8ASKDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOksLzE&md5=9d80bcdb04ebec24e2516dcf26821ad3</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1007%2Fs10637-012-9912-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-012-9912-9%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DS.%2BB.%26aulast%3DPeek%26aufirst%3DV.%2BL.%26aulast%3DAjamie%26aufirst%3DR.%26aulast%3DBuchanan%26aufirst%3DS.%2BG.%26aulast%3DGraff%26aufirst%3DJ.%2BR.%26aulast%3DHeidler%26aufirst%3DS.%2BA.%26aulast%3DHui%26aufirst%3DY.%2BH.%26aulast%3DHuss%26aufirst%3DK.%2BL.%26aulast%3DKonicek%26aufirst%3DB.%2BW.%26aulast%3DManro%26aufirst%3DJ.%2BR.%26aulast%3DShih%26aufirst%3DC.%26aulast%3DStewart%26aufirst%3DJ.%2BA.%26aulast%3DStewart%26aufirst%3DT.%2BR.%26aulast%3DStout%26aufirst%3DS.%2BL.%26aulast%3DUhlik%26aufirst%3DM.%2BT.%26aulast%3DUm%26aufirst%3DS.%2BL.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DYan%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DW.%2BJ.%26aulast%3DZhong%26aufirst%3DB.%26aulast%3DWalgren%26aufirst%3DR.%2BA.%26atitle%3DLY2801653%2520is%2520an%2520orally%2520bioavailable%2520multi-kinase%2520inhibitor%2520with%2520potent%2520activity%2520against%2520MET%252C%2520MST1R%252C%2520and%2520other%2520oncoproteins%252C%2520and%2520displays%2520anti-tumor%2520activities%2520in%2520mouse%2520xenograft%2520models%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2013%26volume%3D31%26spage%3D833%26epage%3D844%26doi%3D10.1007%2Fs10637-012-9912-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Mori, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaneko, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueno, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saito, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondoh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimada, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuromitsu, S.</span><span> </span><span class="NLM_article-title">ASP2215, a novel FLT3/AXL inhibitor: preclinical evaluation in acute myeloid leukemia (AML)</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">7070</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=7070&author=M.+Moriauthor=N.+Kanekoauthor=Y.+Uenoauthor=R.+Tanakaauthor=K.+Choauthor=R.+Saitoauthor=Y.+Kondohauthor=I.+Shimadaauthor=S.+Kuromitsu&title=ASP2215%2C+a+novel+FLT3%2FAXL+inhibitor%3A+preclinical+evaluation+in+acute+myeloid+leukemia+%28AML%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMori%26aufirst%3DM.%26aulast%3DKaneko%26aufirst%3DN.%26aulast%3DUeno%26aufirst%3DY.%26aulast%3DTanaka%26aufirst%3DR.%26aulast%3DCho%26aufirst%3DK.%26aulast%3DSaito%26aufirst%3DR.%26aulast%3DKondoh%26aufirst%3DY.%26aulast%3DShimada%26aufirst%3DI.%26aulast%3DKuromitsu%26aufirst%3DS.%26atitle%3DASP2215%252C%2520a%2520novel%2520FLT3%252FAXL%2520inhibitor%253A%2520preclinical%2520evaluation%2520in%2520acute%2520myeloid%2520leukemia%2520%2528AML%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D32%26spage%3D7070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Burbridge, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bossard, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saunier, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fejes, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruno, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonce, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferry, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Da Violante, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouzom, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cattan, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacquet-Bescond, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comoglio, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boutin, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortuno, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierre, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cruzalegui, F. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Depil, S.</span><span> </span><span class="NLM_article-title">S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1749</span><span class="NLM_x">–</span> <span class="NLM_lpage">1762</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1158%2F1535-7163.MCT-13-0075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=23804704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtl2lur7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=1749-1762&author=M.+F.+Burbridgeauthor=C.+J.+Bossardauthor=C.+Saunierauthor=I.+Fejesauthor=A.+Brunoauthor=S.+Leonceauthor=G.+Ferryauthor=G.+Da+Violanteauthor=F.+Bouzomauthor=V.+Cattanauthor=A.+Jacquet-Bescondauthor=P.+M.+Comoglioauthor=B.+P.+Lockhartauthor=J.+A.+Boutinauthor=A.+Cordiauthor=J.+C.+Ortunoauthor=A.+Pierreauthor=J.+A.+Hickmanauthor=F.+H.+Cruzaleguiauthor=S.+Depil&title=S49076+is+a+novel+kinase+inhibitor+of+MET%2C+AXL%2C+and+FGFR+with+strong+preclinical+activity+alone+and+in+association+with+bevacizumab&doi=10.1158%2F1535-7163.MCT-13-0075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab</span></div><div class="casAuthors">Burbridge, Mike F.; Bossard, Celine J.; Saunier, Carine; Fejes, Imre; Bruno, Alain; Leonce, Stephane; Ferry, Gilles; Da Violante, Georges; Bouzom, Francois; Cattan, Valerie; Jacquet-Bescond, Anne; Comoglio, Paolo M.; Lockhart, Brian P.; Boutin, Jean A.; Cordi, Alex; Ortuno, Jean-Claude; Pierre, Alain; Hickman, John A.; Cruzalegui, Francisco H.; Depil, Stephane</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1749-1762</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Aberrant activity of the receptor tyrosine kinases MET, AXL, and FGFR1/2/3 has been assocd. with tumor progression in a wide variety of human malignancies, notably in instances of primary or acquired resistance to existing or emerging anticancer therapies.  This study describes the preclin. characterization of S49076, a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3.  S49076 potently blocked cellular phosphorylation of MET, AXL, and FGFRs and inhibited downstream signaling in vitro and in vivo.  In cell models, S49076 inhibited the proliferation of MET- and FGFR2-dependent gastric cancer cells, blocked MET-driven migration of lung carcinoma cells, and inhibited colony formation of hepatocarcinoma cells expressing FGFR1/2 and AXL.  In tumor xenograft models, a good pharmacokinetic/pharmacodynamic relationship for MET and FGFR2 inhibition following oral administration of S49076 was established and correlated well with impact on tumor growth.  MET, AXL, and the FGFRs have all been implicated in resistance to VEGF/VEGFR inhibitors such as bevacizumab.  Accordingly, combination of S49076 with bevacizumab in colon carcinoma xenograft models led to near total inhibition of tumor growth.  Moreover, S49076 alone caused tumor growth arrest in bevacizumab-resistant tumors.  On the basis of these preclin. studies showing a favorable and novel pharmacol. profile of S49076, a phase I study is currently underway in patients with advanced solid tumors.  Mol Cancer Ther; 12(9); 1749-62. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodE4VwyiV-HrVg90H21EOLACvtfcHk0lgEMwfbL70QcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtl2lur7O&md5=a53009f7a7b0601cf45598ca5b8775c2</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0075%26sid%3Dliteratum%253Aachs%26aulast%3DBurbridge%26aufirst%3DM.%2BF.%26aulast%3DBossard%26aufirst%3DC.%2BJ.%26aulast%3DSaunier%26aufirst%3DC.%26aulast%3DFejes%26aufirst%3DI.%26aulast%3DBruno%26aufirst%3DA.%26aulast%3DLeonce%26aufirst%3DS.%26aulast%3DFerry%26aufirst%3DG.%26aulast%3DDa%2BViolante%26aufirst%3DG.%26aulast%3DBouzom%26aufirst%3DF.%26aulast%3DCattan%26aufirst%3DV.%26aulast%3DJacquet-Bescond%26aufirst%3DA.%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26aulast%3DLockhart%26aufirst%3DB.%2BP.%26aulast%3DBoutin%26aufirst%3DJ.%2BA.%26aulast%3DCordi%26aufirst%3DA.%26aulast%3DOrtuno%26aufirst%3DJ.%2BC.%26aulast%3DPierre%26aufirst%3DA.%26aulast%3DHickman%26aufirst%3DJ.%2BA.%26aulast%3DCruzalegui%26aufirst%3DF.%2BH.%26aulast%3DDepil%26aufirst%3DS.%26atitle%3DS49076%2520is%2520a%2520novel%2520kinase%2520inhibitor%2520of%2520MET%252C%2520AXL%252C%2520and%2520FGFR%2520with%2520strong%2520preclinical%2520activity%2520alone%2520and%2520in%2520association%2520with%2520bevacizumab%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26spage%3D1749%26epage%3D1762%26doi%3D10.1158%2F1535-7163.MCT-13-0075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Schroeder, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">An, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, Z. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornelius, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gullo-Brown, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henley, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeyaseelan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manne, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oppenheimer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sack, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stefanski, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokarski, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trainor, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wautlet, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fargnoli, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borzilleri, R. M.</span><span> </span><span class="NLM_article-title">Discovery of <i>N</i>-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1251</span><span class="NLM_x">–</span> <span class="NLM_lpage">1254</span><span class="refDoi"> DOI: 10.1021/jm801586s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801586s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhvVCnsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1251-1254&author=G.+M.+Schroederauthor=Y.+Anauthor=Z.+W.+Caiauthor=X.+T.+Chenauthor=C.+Clarkauthor=L.+A.+Corneliusauthor=J.+Daiauthor=J.+Gullo-Brownauthor=A.+Guptaauthor=B.+Henleyauthor=J.+T.+Huntauthor=R.+Jeyaseelanauthor=A.+Kamathauthor=K.+Kimauthor=J.+Lippyauthor=L.+J.+Lombardoauthor=V.+Manneauthor=S.+Oppenheimerauthor=J.+S.+Sackauthor=R.+J.+Schmidtauthor=G.+Shenauthor=K.+Stefanskiauthor=J.+S.+Tokarskiauthor=G.+L.+Trainorauthor=B.+S.+Wautletauthor=D.+Weiauthor=D.+K.+Williamsauthor=Y.+Zhangauthor=Y.+Zhangauthor=J.+Fargnoliauthor=R.+M.+Borzilleri&title=Discovery+of+N-%284-%282-amino-3-chloropyridin-4-yloxy%29-3-fluorophenyl%29-4-ethoxy-1-%284-fluorophenyl%29-2-oxo-1%2C2-dihydropyridine-3-carboxamide+%28BMS-777607%29%2C+a+selective+and+orally+efficacious+inhibitor+of+the+Met+kinase+superfamily&doi=10.1021%2Fjm801586s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a Selective and Orally Efficacious Inhibitor of the Met Kinase Superfamily</span></div><div class="casAuthors">Schroeder, Gretchen M.; An, Yongmi; Cai, Zhen-Wei; Chen, Xiao-Tao; Clark, Cheryl; Cornelius, Lyndon A. M.; Dai, Jun; Gullo-Brown, Johnni; Gupta, Ashok; Henley, Benjamin; Hunt, John T.; Jeyaseelan, Robert; Kamath, Amrita; Kim, Kyoung; Lippy, Jonathan; Lombardo, Louis J.; Manne, Veeraswamy; Oppenheimer, Simone; Sack, John S.; Schmidt, Robert J.; Shen, Guoxiang; Stefanski, Kevin; Tokarski, John S.; Trainor, George L.; Wautlet, Barri S.; Wei, Donna; Williams, David K.; Zhang, Yingru; Zhang, Yueping; Fargnoli, Joseph; Borzilleri, Robert M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1251-1254</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Substituted N-(4-(2-aminopyridin-4-yloxy)-3-fluoro-phenyl)-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamides were identified as potent and selective Met kinase inhibitors.  Substitution of the pyridine 3-position gave improved enzyme potency, while substitution of the pyridone 4-position led to improved aq. soly. and kinase selectivity.  Analog 10 demonstrated complete tumor stasis in a Met-dependent GTL-16 human gastric carcinoma xenograft model following oral administration.  Because of its excellent in vivo efficacy and favorable pharmacokinetic and preclin. safety profiles, 10 has been advanced into phase I clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAHEvJXf0Fq7Vg90H21EOLACvtfcHk0lgEMwfbL70QcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhvVCnsLc%253D&md5=784623be820fcc8b931200ced3a476df</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm801586s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801586s%26sid%3Dliteratum%253Aachs%26aulast%3DSchroeder%26aufirst%3DG.%2BM.%26aulast%3DAn%26aufirst%3DY.%26aulast%3DCai%26aufirst%3DZ.%2BW.%26aulast%3DChen%26aufirst%3DX.%2BT.%26aulast%3DClark%26aufirst%3DC.%26aulast%3DCornelius%26aufirst%3DL.%2BA.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DGullo-Brown%26aufirst%3DJ.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DHenley%26aufirst%3DB.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DJeyaseelan%26aufirst%3DR.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DKim%26aufirst%3DK.%26aulast%3DLippy%26aufirst%3DJ.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DManne%26aufirst%3DV.%26aulast%3DOppenheimer%26aufirst%3DS.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DSchmidt%26aufirst%3DR.%2BJ.%26aulast%3DShen%26aufirst%3DG.%26aulast%3DStefanski%26aufirst%3DK.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DTrainor%26aufirst%3DG.%2BL.%26aulast%3DWautlet%26aufirst%3DB.%2BS.%26aulast%3DWei%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DD.%2BK.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DFargnoli%26aufirst%3DJ.%26aulast%3DBorzilleri%26aufirst%3DR.%2BM.%26atitle%3DDiscovery%2520of%2520N-%25284-%25282-amino-3-chloropyridin-4-yloxy%2529-3-fluorophenyl%2529-4-ethoxy-1-%25284-fluorophenyl%2529-2-oxo-1%252C2-dihydropyridine-3-carboxamide%2520%2528BMS-777607%2529%252C%2520a%2520selective%2520and%2520orally%2520efficacious%2520inhibitor%2520of%2520the%2520Met%2520kinase%2520superfamily%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1251%26epage%3D1254%26doi%3D10.1021%2Fjm801586s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Bonfils, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaulieu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fournel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ste-Croix, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besterman, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maroun, C. R.</span><span> </span><span class="NLM_article-title">The combination of MGCD265, a MET/VEGFR inhibitor in clinical development, and erlotinib potently inhibits tumor growth by altering multiple pathways including glycolysis</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">1790</span><span class="refDoi"> DOI: 10.1158/1538-7445.AM2012-1790</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1158%2F1538-7445.AM2012-1790" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=1790&author=C.+Bonfilsauthor=N.+Beaulieuauthor=M.+Fournelauthor=H.+Ste-Croixauthor=J.+M.+Bestermanauthor=C.+R.+Maroun&title=The+combination+of+MGCD265%2C+a+MET%2FVEGFR+inhibitor+in+clinical+development%2C+and+erlotinib+potently+inhibits+tumor+growth+by+altering+multiple+pathways+including+glycolysis&doi=10.1158%2F1538-7445.AM2012-1790"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2012-1790&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2012-1790%26sid%3Dliteratum%253Aachs%26aulast%3DBonfils%26aufirst%3DC.%26aulast%3DBeaulieu%26aufirst%3DN.%26aulast%3DFournel%26aufirst%3DM.%26aulast%3DSte-Croix%26aufirst%3DH.%26aulast%3DBesterman%26aufirst%3DJ.%2BM.%26aulast%3DMaroun%26aufirst%3DC.%2BR.%26atitle%3DThe%2520combination%2520of%2520MGCD265%252C%2520a%2520MET%252FVEGFR%2520inhibitor%2520in%2520clinical%2520development%252C%2520and%2520erlotinib%2520potently%2520inhibits%2520tumor%2520growth%2520by%2520altering%2520multiple%2520pathways%2520including%2520glycolysis%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D1790%26doi%3D10.1158%2F1538-7445.AM2012-1790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Rho, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoon, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bae, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. C.</span><span> </span><span class="NLM_article-title">MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">253</span><span class="NLM_x">–</span> <span class="NLM_lpage">262</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-13-1103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1158%2F0008-5472.CAN-13-1103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=24165158" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC2cXislKjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=253-262&author=J.+K.+Rhoauthor=Y.+J.+Choiauthor=S.+Y.+Kimauthor=T.+W.+Kimauthor=E.+K.+Choiauthor=S.+J.+Yoonauthor=B.+M.+Parkauthor=E.+Parkauthor=J.+H.+Baeauthor=C.+M.+Choiauthor=J.+C.+Lee&title=MET+and+AXL+inhibitor+NPS-1034+exerts+efficacy+against+lung+cancer+cells+resistant+to+EGFR+kinase+inhibitors+because+of+MET+or+AXL+activation&doi=10.1158%2F0008-5472.CAN-13-1103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">MET and AXL Inhibitor NPS-1034 Exerts Efficacy against Lung Cancer Cells Resistant to EGFR Kinase Inhibitors Because of MET or AXL Activation</span></div><div class="casAuthors">Rho, Jin Kyung; Choi, Yun Jung; Kim, Seon Ye; Kim, Tae Won; Choi, Eun Kyung; Yoon, Seon-Joo; Park, Bu Man; Park, Eunhye; Bae, Jong Hwan; Choi, Chang-Min; Lee, Jae Cheol</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">253-262</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">In non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations, acquired resistance to EGFR-tyrosine kinase inhibitors (EGFR-TK1) can occur through a generation of bypass signals such as MET or AXL activation.  In this study, we investigated the antitumor activity of NPS-1034, a newly developed drug that targets both MET and AXL, in NSCLC cells with acquired resistance to gefitinib or erlotinib (HCC827/GR and HCC827/ER, resp.).  Characterization of H820 cells and evaluation of NPS-1034 efficacy in these cells were also performed.  The resistance of HCC827/GR was mediated by MET activation, whereas AXL activation led to resistance in HCC827/ER.  The combination of gefitinib or erlotinib with NPS-1034 synergistically inhibited cell proliferation and induced cell death in both resistant cell lines.  Accordingly, suppression of Akt was noted only in the presence of treatment with both drugs.  NPS-1034 was also effective in xenograft mouse models of HCC827/GR.  Although the H820 cell line was reported previously to have T790M and MET amplification, we discovered that AXL was also activated in this cell line.  There were no antitumor effects of siRNA or inhibitors specific for EGFR or MET, whereas combined treatment with AXL siRNA or NPS-1034 and EGFR-TKIs controlled H820 cells, suggesting that AXL is the main signal responsible for resistance.  In addn., NPS-1034 inhibited cell proliferation as well as ROS1 activity in HCC78 cells with ROS1 rearrangement.  Our results establish the efficacy of NPS-1034 in NSCLC cells rendered resistant to EGFR-TKIs because of MET or AXL activation or ROS1 rearrangement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzVRl7xbUBLrVg90H21EOLACvtfcHk0lhOp3dZUsmRBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXislKjtA%253D%253D&md5=35929f2dcfd5d1502ba745f367dccd27</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-13-1103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-13-1103%26sid%3Dliteratum%253Aachs%26aulast%3DRho%26aufirst%3DJ.%2BK.%26aulast%3DChoi%26aufirst%3DY.%2BJ.%26aulast%3DKim%26aufirst%3DS.%2BY.%26aulast%3DKim%26aufirst%3DT.%2BW.%26aulast%3DChoi%26aufirst%3DE.%2BK.%26aulast%3DYoon%26aufirst%3DS.%2BJ.%26aulast%3DPark%26aufirst%3DB.%2BM.%26aulast%3DPark%26aufirst%3DE.%26aulast%3DBae%26aufirst%3DJ.%2BH.%26aulast%3DChoi%26aufirst%3DC.%2BM.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26atitle%3DMET%2520and%2520AXL%2520inhibitor%2520NPS-1034%2520exerts%2520efficacy%2520against%2520lung%2520cancer%2520cells%2520resistant%2520to%2520EGFR%2520kinase%2520inhibitors%2520because%2520of%2520MET%2520or%2520AXL%2520activation%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D253%26epage%3D262%26doi%3D10.1158%2F0008-5472.CAN-13-1103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Holland, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franci, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torneros, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heckrodt, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Apatira, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chua, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandt, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pine, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goff, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Payan, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hitoshi, Y.</span><span> </span><span class="NLM_article-title">R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">1544</span><span class="NLM_x">–</span> <span class="NLM_lpage">1554</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-09-2997</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1158%2F0008-5472.CAN-09-2997" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=1544-1554&author=S.+J.+Hollandauthor=A.+Panauthor=C.+Franciauthor=Y.+Huauthor=B.+Changauthor=W.+Liauthor=M.+Duanauthor=A.+Tornerosauthor=J.+Yuauthor=T.+J.+Heckrodtauthor=J.+Zhangauthor=P.+Dingauthor=A.+Apatiraauthor=J.+Chuaauthor=R.+Brandtauthor=P.+Pineauthor=D.+Goffauthor=R.+Singhauthor=D.+G.+Payanauthor=Y.+Hitoshi&title=R428%2C+a+selective+small+molecule+inhibitor+of+Axl+kinase%2C+blocks+tumor+spread+and+prolongs+survival+in+models+of+metastatic+breast+cancer&doi=10.1158%2F0008-5472.CAN-09-2997"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-2997&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-2997%26sid%3Dliteratum%253Aachs%26aulast%3DHolland%26aufirst%3DS.%2BJ.%26aulast%3DPan%26aufirst%3DA.%26aulast%3DFranci%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DChang%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DDuan%26aufirst%3DM.%26aulast%3DTorneros%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DHeckrodt%26aufirst%3DT.%2BJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DP.%26aulast%3DApatira%26aufirst%3DA.%26aulast%3DChua%26aufirst%3DJ.%26aulast%3DBrandt%26aufirst%3DR.%26aulast%3DPine%26aufirst%3DP.%26aulast%3DGoff%26aufirst%3DD.%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DPayan%26aufirst%3DD.%2BG.%26aulast%3DHitoshi%26aufirst%3DY.%26atitle%3DR428%252C%2520a%2520selective%2520small%2520molecule%2520inhibitor%2520of%2520Axl%2520kinase%252C%2520blocks%2520tumor%2520spread%2520and%2520prolongs%2520survival%2520in%2520models%2520of%2520metastatic%2520breast%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D1544%26epage%3D1554%26doi%3D10.1158%2F0008-5472.CAN-09-2997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Mollard, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warner, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Call, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wade, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bearss, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verma, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vankayalapati, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bearss, D. J.</span><span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of a series of novel AXL kinase inhibitors</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">907</span><span class="NLM_x">–</span> <span class="NLM_lpage">912</span><span class="refDoi"> DOI: 10.1021/ml200198x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200198x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=907-912&author=A.+Mollardauthor=S.+L.+Warnerauthor=L.+T.+Callauthor=M.+L.+Wadeauthor=J.+J.+Bearssauthor=A.+Vermaauthor=S.+Sharmaauthor=H.+Vankayalapatiauthor=D.+J.+Bearss&title=Design%2C+synthesis+and+biological+evaluation+of+a+series+of+novel+AXL+kinase+inhibitors&doi=10.1021%2Fml200198x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fml200198x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200198x%26sid%3Dliteratum%253Aachs%26aulast%3DMollard%26aufirst%3DA.%26aulast%3DWarner%26aufirst%3DS.%2BL.%26aulast%3DCall%26aufirst%3DL.%2BT.%26aulast%3DWade%26aufirst%3DM.%2BL.%26aulast%3DBearss%26aufirst%3DJ.%2BJ.%26aulast%3DVerma%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DVankayalapati%26aufirst%3DH.%26aulast%3DBearss%26aufirst%3DD.%2BJ.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520a%2520series%2520of%2520novel%2520AXL%2520kinase%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D907%26epage%3D912%26doi%3D10.1021%2Fml200198x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Feneyrolles, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spenlinhauer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guiet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fauvel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dayde-Cazals, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warnault, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheve, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasri, A.</span><span> </span><span class="NLM_article-title">Axl kinase as a key target for oncology: focus on small molecule inhibitors</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">2141</span><span class="NLM_x">–</span> <span class="NLM_lpage">2148</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-1083</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1158%2F1535-7163.MCT-13-1083" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=25139999" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVOitLrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=2141-2148&author=C.+Feneyrollesauthor=A.+Spenlinhauerauthor=L.+Guietauthor=B.+Fauvelauthor=B.+Dayde-Cazalsauthor=P.+Warnaultauthor=G.+Cheveauthor=A.+Yasri&title=Axl+kinase+as+a+key+target+for+oncology%3A+focus+on+small+molecule+inhibitors&doi=10.1158%2F1535-7163.MCT-13-1083"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Axl Kinase as a Key Target for Oncology: Focus on Small Molecule Inhibitors</span></div><div class="casAuthors">Feneyrolles, Clemence; Spenlinhauer, Aurelia; Guiet, Lea; Fauvel, Benedicte; Dayde-Cazals, Benedicte; Warnault, Pierre; Cheve, Gwenael; Yasri, Aziz</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2141-2148</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Receptor tyrosine kinases (RTK) are transmembrane receptors that regulate signal transduction in cells.  As a member of the TAM (Tyro-3, Axl, Mer) RTK subfamily, Axl regulates key processes such as cell growth, migration, aggregation, and apoptosis through several pathways.  Its overexpression/overactivation has been underlined in several conditions, esp. cancers, and in both chemotherapy and targeted therapy sensitivity loss.  In this review, we propose to highlight the therapeutic implication of Axl, starting with the pathways it regulates, validating its interest as a therapeutic target, and defining the tools available to develop strategies for its inhibition.  We esp. focus on small mol. inhibitors, their structure, inhibition profile, and development stages.  Mol Cancer Ther; 13(9); 2141-8. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRn5-b7gNJkLVg90H21EOLACvtfcHk0lhOp3dZUsmRBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVOitLrO&md5=6c569ae44113e6cae2f59e8ba462a787</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-1083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-1083%26sid%3Dliteratum%253Aachs%26aulast%3DFeneyrolles%26aufirst%3DC.%26aulast%3DSpenlinhauer%26aufirst%3DA.%26aulast%3DGuiet%26aufirst%3DL.%26aulast%3DFauvel%26aufirst%3DB.%26aulast%3DDayde-Cazals%26aufirst%3DB.%26aulast%3DWarnault%26aufirst%3DP.%26aulast%3DCheve%26aufirst%3DG.%26aulast%3DYasri%26aufirst%3DA.%26atitle%3DAxl%2520kinase%2520as%2520a%2520key%2520target%2520for%2520oncology%253A%2520focus%2520on%2520small%2520molecule%2520inhibitors%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D2141%26epage%3D2148%26doi%3D10.1158%2F1535-7163.MCT-13-1083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Wise, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrews, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, L. J.</span><span> </span><span class="NLM_article-title">In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1983</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">559</span><span class="NLM_x">–</span> <span class="NLM_lpage">564</span><span class="refDoi"> DOI: 10.1128/AAC.23.4.559</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1128%2FAAC.23.4.559" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1983&pages=559-564&author=R.+Wiseauthor=J.+M.+Andrewsauthor=L.+J.+Edwards&title=In+vitro+activity+of+Bay+09867%2C+a+new+quinoline+derivative%2C+compared+with+those+of+other+antimicrobial+agents&doi=10.1128%2FAAC.23.4.559"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38a&amp;dbid=16384&amp;doi=10.1128%2FAAC.23.4.559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.23.4.559%26sid%3Dliteratum%253Aachs%26aulast%3DWise%26aufirst%3DR.%26aulast%3DAndrews%26aufirst%3DJ.%2BM.%26aulast%3DEdwards%26aufirst%3DL.%2BJ.%26atitle%3DIn%2520vitro%2520activity%2520of%2520Bay%252009867%252C%2520a%2520new%2520quinoline%2520derivative%252C%2520compared%2520with%2520those%2520of%2520other%2520antimicrobial%2520agents%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1983%26volume%3D23%26spage%3D559%26epage%3D564%26doi%3D10.1128%2FAAC.23.4.559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit38b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Chin, N. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neu, H. C.</span><span> </span><span class="NLM_article-title">Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1984</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">319</span><span class="NLM_x">–</span> <span class="NLM_lpage">326</span><span class="refDoi"> DOI: 10.1128/AAC.25.3.319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1128%2FAAC.25.3.319" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1984&pages=319-326&author=N.+X.+Chinauthor=H.+C.+Neu&title=Ciprofloxacin%2C+a+quinolone+carboxylic+acid+compound+active+against+aerobic+and+anaerobic+bacteria&doi=10.1128%2FAAC.25.3.319"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38b&amp;dbid=16384&amp;doi=10.1128%2FAAC.25.3.319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.25.3.319%26sid%3Dliteratum%253Aachs%26aulast%3DChin%26aufirst%3DN.%2BX.%26aulast%3DNeu%26aufirst%3DH.%2BC.%26atitle%3DCiprofloxacin%252C%2520a%2520quinolone%2520carboxylic%2520acid%2520compound%2520active%2520against%2520aerobic%2520and%2520anaerobic%2520bacteria%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1984%26volume%3D25%26spage%3D319%26epage%3D326%26doi%3D10.1128%2FAAC.25.3.319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit38c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Pan, X. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehtar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, L. M.</span><span> </span><span class="NLM_article-title">Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in streptococcus pneumonia</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">2321</span><span class="NLM_x">–</span> <span class="NLM_lpage">2326</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1996&pages=2321-2326&author=X.+S.+Panauthor=J.+Amblerauthor=S.+Mehtarauthor=L.+M.+Fisher&title=Involvement+of+topoisomerase+IV+and+DNA+gyrase+as+ciprofloxacin+targets+in+streptococcus+pneumonia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DX.%2BS.%26aulast%3DAmbler%26aufirst%3DJ.%26aulast%3DMehtar%26aufirst%3DS.%26aulast%3DFisher%26aufirst%3DL.%2BM.%26atitle%3DInvolvement%2520of%2520topoisomerase%2520IV%2520and%2520DNA%2520gyrase%2520as%2520ciprofloxacin%2520targets%2520in%2520streptococcus%2520pneumonia%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1996%26volume%3D40%26spage%3D2321%26epage%3D2326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Fu, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lafredo, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foleno, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isaacson, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tobia, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenthale, M. E.</span><span> </span><span class="NLM_article-title">In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">860</span><span class="NLM_x">–</span> <span class="NLM_lpage">866</span><span class="refDoi"> DOI: 10.1128/AAC.36.4.860</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1128%2FAAC.36.4.860" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1992&pages=860-866&author=K.+P.+Fuauthor=S.+C.+Lafredoauthor=B.+Folenoauthor=D.+M.+Isaacsonauthor=J.+F.+Barrettauthor=A.+J.+Tobiaauthor=M.+E.+Rosenthale&title=In+vitro+and+in+vivo+antibacterial+activities+of+levofloxacin+%28l-ofloxacin%29%2C+an+optically+active+ofloxacin&doi=10.1128%2FAAC.36.4.860"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39a&amp;dbid=16384&amp;doi=10.1128%2FAAC.36.4.860&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.36.4.860%26sid%3Dliteratum%253Aachs%26aulast%3DFu%26aufirst%3DK.%2BP.%26aulast%3DLafredo%26aufirst%3DS.%2BC.%26aulast%3DFoleno%26aufirst%3DB.%26aulast%3DIsaacson%26aufirst%3DD.%2BM.%26aulast%3DBarrett%26aufirst%3DJ.%2BF.%26aulast%3DTobia%26aufirst%3DA.%2BJ.%26aulast%3DRosenthale%26aufirst%3DM.%2BE.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520antibacterial%2520activities%2520of%2520levofloxacin%2520%2528l-ofloxacin%2529%252C%2520an%2520optically%2520active%2520ofloxacin%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1992%26volume%3D36%26spage%3D860%26epage%3D866%26doi%3D10.1128%2FAAC.36.4.860" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit39b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Davis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bryson, H. M.</span><span> </span><span class="NLM_article-title">Levofloxacin. a review of its antibacterial activity, pharmacokinetics and therapeutic efficacy</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">677</span><span class="NLM_x">–</span> <span class="NLM_lpage">700</span><span class="refDoi"> DOI: 10.2165/00003495-199447040-00008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.2165%2F00003495-199447040-00008" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=1994&pages=677-700&author=R.+Davisauthor=H.+M.+Bryson&title=Levofloxacin.+a+review+of+its+antibacterial+activity%2C+pharmacokinetics+and+therapeutic+efficacy&doi=10.2165%2F00003495-199447040-00008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39b&amp;dbid=16384&amp;doi=10.2165%2F00003495-199447040-00008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-199447040-00008%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DR.%26aulast%3DBryson%26aufirst%3DH.%2BM.%26atitle%3DLevofloxacin.%2520a%2520review%2520of%2520its%2520antibacterial%2520activity%252C%2520pharmacokinetics%2520and%2520therapeutic%2520efficacy%26jtitle%3DDrugs%26date%3D1994%26volume%3D47%26spage%3D677%26epage%3D700%26doi%3D10.2165%2F00003495-199447040-00008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit39c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Bucaneve, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Micozzi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menichetti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martino, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dionisi, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinelli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allione, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Antonio, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nosari, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cilloni, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zuffa, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantaffa, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Specchia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amadori, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbiano, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deliliers, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lauria, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foa, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Del Favero, A.</span><span> </span><span class="NLM_article-title">Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">353</span><span class="NLM_x">, </span> <span class="NLM_fpage">977</span><span class="NLM_x">–</span> <span class="NLM_lpage">987</span><span class="refDoi"> DOI: 10.1056/NEJMoa044097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1056%2FNEJMoa044097" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=16148283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpvVOis7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2005&pages=977-987&author=G.+Bucaneveauthor=A.+Micozziauthor=F.+Menichettiauthor=P.+Martinoauthor=M.+S.+Dionisiauthor=G.+Martinelliauthor=B.+Allioneauthor=D.+D%E2%80%99Antonioauthor=M.+Buelliauthor=A.+M.+Nosariauthor=D.+Cilloniauthor=E.+Zuffaauthor=R.+Cantaffaauthor=G.+Specchiaauthor=S.+Amadoriauthor=F.+Fabbianoauthor=G.+L.+Deliliersauthor=F.+Lauriaauthor=R.+Foaauthor=A.+Del+Favero&title=Levofloxacin+to+prevent+bacterial+infection+in+patients+with+cancer+and+neutropenia&doi=10.1056%2FNEJMoa044097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39cR"><div class="casContent"><span class="casTitleNuber">39c</span><div class="casTitle"><span class="NLM_cas:atitle">Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia</span></div><div class="casAuthors">Bucaneve, Giampaolo; Micozzi, Alessandra; Menichetti, Francesco; Martino, Pietro; Dionisi, M. Stella; Martinelli, Giovanni; Allione, Bernardino; D'Antonio, Domenico; Buelli, Maurizio; Nosari, A. Maria; Cilloni, Daniela; Zuffa, Eliana; Cantaffa, Renato; Specchia, Giorgina; Amadori, Sergio; Fabbiano, Francesco; Deliliers, Giorgio Lambertenghi; Lauria, Francesco; Foa, Robin; Del Favero, Albano</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">977-987</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: The prophylactic use of fluoroquinolones in patients with cancer and neutropenia is controversial and is not a recommended intervention.  METHODS: We randomly assigned 760 consecutive adult patients with cancer in whom chemotherapy-induced neutropenia (<1000 neutrophils per cubic millimeter) was expected to occur for more than seven days to receive either oral levofloxacin (500 mg daily) or placebo from the start of chemotherapy until the resoln. of neutropenia.  Patients were stratified according to their underlying disease (acute leukemia vs. solid tumor or lymphoma).  RESULTS: An intention-to-treat anal. showed that fever was present for the duration of neutropenia in 65 % of patients who received levofloxacin prophylaxis, as compared with 85 % of those receiving placebo (243 of 375 vs. 308 of 363; relative risk, 0.76; abs. difference in risk, -20 %; 95 % confidence interval, -26 to -14 %; P = 0.001).  The levofloxacin group had a lower rate of microbiol. documented infections (abs. difference in risk, -17 %; 95 % confidence interval, -24 to -10 %; P < 0.001), bacteremias (difference in risk, -16 %; 95 % confidence interval, -22 to -9 %; P < 0.001), and single-agent gram-neg. bacteremias (difference in risk, -7 %; 95 % confidence interval, -10 to -2 %; P < 0.01) than did the placebo group.  Mortality and tolerability were similar in the two groups.  The effects of prophylaxis were also similar between patients with acute leukemia and those with solid tumors or lymphoma.  CONCLUSIONS: Prophylactic treatment with levofloxacin is an effective and well-tolerated way of preventing febrile episodes and other relevant infection-related outcomes in patients with cancer and profound and protracted neutropenia.  The long-term effect of this intervention on microbial resistance in the community is not known.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqb1q0PotP99LVg90H21EOLACvtfcHk0lg17S30QnBY4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpvVOis7k%253D&md5=0f5820d78f7928ed6c0267fbeb2b6e1c</span></div><a href="/servlet/linkout?suffix=cit39c&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa044097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa044097%26sid%3Dliteratum%253Aachs%26aulast%3DBucaneve%26aufirst%3DG.%26aulast%3DMicozzi%26aufirst%3DA.%26aulast%3DMenichetti%26aufirst%3DF.%26aulast%3DMartino%26aufirst%3DP.%26aulast%3DDionisi%26aufirst%3DM.%2BS.%26aulast%3DMartinelli%26aufirst%3DG.%26aulast%3DAllione%26aufirst%3DB.%26aulast%3DD%25E2%2580%2599Antonio%26aufirst%3DD.%26aulast%3DBuelli%26aufirst%3DM.%26aulast%3DNosari%26aufirst%3DA.%2BM.%26aulast%3DCilloni%26aufirst%3DD.%26aulast%3DZuffa%26aufirst%3DE.%26aulast%3DCantaffa%26aufirst%3DR.%26aulast%3DSpecchia%26aufirst%3DG.%26aulast%3DAmadori%26aufirst%3DS.%26aulast%3DFabbiano%26aufirst%3DF.%26aulast%3DDeliliers%26aufirst%3DG.%2BL.%26aulast%3DLauria%26aufirst%3DF.%26aulast%3DFoa%26aufirst%3DR.%26aulast%3DDel%2BFavero%26aufirst%3DA.%26atitle%3DLevofloxacin%2520to%2520prevent%2520bacterial%2520infection%2520in%2520patients%2520with%2520cancer%2520and%2520neutropenia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D353%26spage%3D977%26epage%3D987%26doi%3D10.1056%2FNEJMoa044097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Littke, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, G. C.</span><span> </span><span class="NLM_article-title">Versatile catalysts for the Suzuki cross-coupling of arylboronic acids with aryl and vinyl halides and triflates under mild conditions</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">4020</span><span class="NLM_x">–</span> <span class="NLM_lpage">4028</span><span class="refDoi"> DOI: 10.1021/ja0002058</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja0002058" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BD3cXisVKktb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2000&pages=4020-4028&author=A.+F.+Littkeauthor=C.+Y.+Daiauthor=G.+C.+Fu&title=Versatile+catalysts+for+the+Suzuki+cross-coupling+of+arylboronic+acids+with+aryl+and+vinyl+halides+and+triflates+under+mild+conditions&doi=10.1021%2Fja0002058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40aR"><div class="casContent"><span class="casTitleNuber">40a</span><div class="casTitle"><span class="NLM_cas:atitle">Versatile Catalysts for the Suzuki Cross-Coupling of Arylboronic Acids with Aryl and Vinyl Halides and Triflates under Mild Conditions</span></div><div class="casAuthors">Littke, Adam F.; Dai, Chaoyang; Fu, Gregory C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4020-4028</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Through the use of Pd2(dba)3/P(t-Bu)3 as a catalyst, a wide range of aryl and vinyl chlorides, bromides, and iodides undergo Suzuki cross-coupling with arylboronic acids in very good yield, typically at room temp.  In the presence of Pd(OAc)2 and PCy3, a diverse array of aryl and vinyl triflates react cleanly at room temp. with arylboronic acids.  The catalyst systems Pd2(dba)3/(Me3C)3P and Pd(OAc)2/PCy3 cover a broad spectrum of commonly encountered substrates for Suzuki couplings.  Selective cross-coupling of an aryl chloride in the presence of an aryl triflate was performed in the presence of Pd2(dba)3/P(t-Bu)3 while selective coupling of an aryl triflate in the presence of an aryl chloride was performed in the presence of Pd(OAc)2/PCy3.  Both Suzuki cross-coupling catalyst systems are effective at low loadings [as low as 0.005 mol% Pd2(dba)3/0.01 mol% P(Bu-t)3], even with aryl chloride substrates [0.05 - 3 mol% Pd2(dba)3/0.12 - 6 mol% P(Bu-t)3].  Preliminary mechanistic work indicates that a palladium monophosphine complex is the active catalyst in the cross-coupling of aryl halides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRwuDVqwRT-bVg90H21EOLACvtfcHk0liT5urSbPub9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXisVKktb4%253D&md5=1bd3a8daa7a9f110479a7d12520cc5fb</span></div><a href="/servlet/linkout?suffix=cit40a&amp;dbid=16384&amp;doi=10.1021%2Fja0002058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja0002058%26sid%3Dliteratum%253Aachs%26aulast%3DLittke%26aufirst%3DA.%2BF.%26aulast%3DDai%26aufirst%3DC.%2BY.%26aulast%3DFu%26aufirst%3DG.%2BC.%26atitle%3DVersatile%2520catalysts%2520for%2520the%2520Suzuki%2520cross-coupling%2520of%2520arylboronic%2520acids%2520with%2520aryl%2520and%2520vinyl%2520halides%2520and%2520triflates%2520under%2520mild%2520conditions%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2000%26volume%3D122%26spage%3D4020%26epage%3D4028%26doi%3D10.1021%2Fja0002058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit40b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kotha, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lahiri, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kashinath, D.</span><span> </span><span class="NLM_article-title">Recent applications of the Suzuki-Miyaura cross-coupling reaction in organic synthesis</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">9633</span><span class="NLM_x">–</span> <span class="NLM_lpage">9695</span><span class="refDoi"> DOI: 10.1016/S0040-4020(02)01188-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1016%2FS0040-4020%2802%2901188-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BD38XovVSmtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2002&pages=9633-9695&author=S.+Kothaauthor=K.+Lahiriauthor=D.+Kashinath&title=Recent+applications+of+the+Suzuki-Miyaura+cross-coupling+reaction+in+organic+synthesis&doi=10.1016%2FS0040-4020%2802%2901188-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40bR"><div class="casContent"><span class="casTitleNuber">40b</span><div class="casTitle"><span class="NLM_cas:atitle">Recent applications of the Suzuki-Miyaura cross-coupling reaction in organic synthesis</span></div><div class="casAuthors">Kotha, Sambasivarao; Lahiri, Kakali; Kashinath, Dhurke</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">9633-9695</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review including prepn. of boronic acids and their derivs.; catalyst development; reactions under green conditions; prepn. of biphenyls and related systems; dendrimer prepn.; prepn. of unusual amino acids and peptides; cross-coupling of sp3, sp2, and sp hybridized compds.; prepn. of natural and unnatural products; solid-supported synthesis; formation of C-N, C-O, and C-S bonds; prepn. of diaryl ketones via carbonylative cross-coupling; and rhodium- and nickel-catalyzed reactions of arylboronic acids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqifcXmma-5_bVg90H21EOLACvtfcHk0liT5urSbPub9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XovVSmtbg%253D&md5=e0060b7e3391257704c2ee55d07c2660</span></div><a href="/servlet/linkout?suffix=cit40b&amp;dbid=16384&amp;doi=10.1016%2FS0040-4020%2802%2901188-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4020%252802%252901188-2%26sid%3Dliteratum%253Aachs%26aulast%3DKotha%26aufirst%3DS.%26aulast%3DLahiri%26aufirst%3DK.%26aulast%3DKashinath%26aufirst%3DD.%26atitle%3DRecent%2520applications%2520of%2520the%2520Suzuki-Miyaura%2520cross-coupling%2520reaction%2520in%2520organic%2520synthesis%26jtitle%3DTetrahedron%26date%3D2002%26volume%3D58%26spage%3D9633%26epage%3D9695%26doi%3D10.1016%2FS0040-4020%2802%2901188-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Rodems, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamman, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heidary, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Makings, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stack, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollok, B. A.</span><span> </span><span class="NLM_article-title">A FRET-based assay platform for ultra-high density drug screening of protein kinases and phosphatases</span> <span class="citation_source-journal">Assay Drug Dev. Technol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">9</span><span class="NLM_x">–</span> <span class="NLM_lpage">19</span><span class="refDoi"> DOI: 10.1089/154065802761001266</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1089%2F154065802761001266" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=9-19&author=S.+M.+Rodemsauthor=B.+D.+Hammanauthor=C.+Linauthor=J.+Zhaoauthor=S.+Shahauthor=D.+Heidaryauthor=L.+Makingsauthor=J.+H.+Stackauthor=B.+A.+Pollok&title=A+FRET-based+assay+platform+for+ultra-high+density+drug+screening+of+protein+kinases+and+phosphatases&doi=10.1089%2F154065802761001266"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1089%2F154065802761001266&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252F154065802761001266%26sid%3Dliteratum%253Aachs%26aulast%3DRodems%26aufirst%3DS.%2BM.%26aulast%3DHamman%26aufirst%3DB.%2BD.%26aulast%3DLin%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DShah%26aufirst%3DS.%26aulast%3DHeidary%26aufirst%3DD.%26aulast%3DMakings%26aufirst%3DL.%26aulast%3DStack%26aufirst%3DJ.%2BH.%26aulast%3DPollok%26aufirst%3DB.%2BA.%26atitle%3DA%2520FRET-based%2520assay%2520platform%2520for%2520ultra-high%2520density%2520drug%2520screening%2520of%2520protein%2520kinases%2520and%2520phosphatases%26jtitle%3DAssay%2520Drug%2520Dev.%2520Technol.%26date%3D2002%26volume%3D1%26spage%3D9%26epage%3D19%26doi%3D10.1089%2F154065802761001266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Fabian, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biggs, W. H.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azimioara, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benedetti, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerlach, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grotzfeld, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lelias, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span> </span><span class="NLM_article-title">A small molecule-kinase interaction map for clinical kinase inhibitors</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">329</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span><span class="refDoi"> DOI: 10.1038/nbt1068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1038%2Fnbt1068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=15711537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=329-336&author=M.+A.+Fabianauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=C.+E.+Atteridgeauthor=M.+D.+Azimioaraauthor=M.+G.+Benedettiauthor=T.+A.+Carterauthor=P.+Ciceriauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=M.+Galvinauthor=J.+L.+Gerlachauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=M.+A.+Inskoauthor=A.+G.+Laiauthor=J.+M.+Leliasauthor=S.+A.+Mehtaauthor=Z.+V.+Milanovauthor=A.+M.+Velascoauthor=L.+M.+Wodickaauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=A+small+molecule-kinase+interaction+map+for+clinical+kinase+inhibitors&doi=10.1038%2Fnbt1068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42aR"><div class="casContent"><span class="casTitleNuber">42a</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule-kinase interaction map for clinical kinase inhibitors</span></div><div class="casAuthors">Fabian, Miles A.; Biggs, William H.; Treiber, Daniel K.; Atteridge, Corey E.; Azimioara, Mihai D.; Benedetti, Michael G.; Carter, Todd A.; Ciceri, Pietro; Edeen, Philip T.; Floyd, Mark; Ford, Julia M.; Galvin, Margaret; Gerlach, Jay L.; Grotzfeld, Robert M.; Herrgard, Sanna; Insko, Darren E.; Insko, Michael A.; Lai, Andiliy G.; Lelias, Jean-Michel; Mehta, Shamal A.; Milanov, Zdravko V.; Velasco, Anne Marie; Wodicka, Lisa M.; Patel, Hitesh K.; Zarrinkar, Patrick P.; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors show great promise as a new class of therapeutics.  Here the authors describe an efficient way to det. kinase inhibitor specificity by measuring binding of small mols. to the ATP site of kinases.  The authors have profiled 20 kinase inhibitors, including 16 that are approved drugs or in clin. development, against a panel of 119 protein kinases.  The authors find that specificity varies widely and is not strongly correlated with chem. structure or the identity of the intended target.  Many novel interactions were identified, including tight binding of the p38 inhibitor BIRB-796 to an imatinib-resistant variant of the ABL kinase, and binding of imatinib to the SRC-family kinase LCK.  The authors also show that mutations in the epidermal growth factor receptor (EGFR) found in gefitinib-responsive patients do not affect the binding affinity of gefitinib or erlotinib.  Our results represent a systematic small mol.-protein interaction map for clin. compds. across a large no. of related proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA0vNmMOXrnrVg90H21EOLACvtfcHk0liT5urSbPub9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D&md5=6aedd5ceb8f77cd26ee50425dcec7bdf</span></div><a href="/servlet/linkout?suffix=cit42a&amp;dbid=16384&amp;doi=10.1038%2Fnbt1068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1068%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DAzimioara%26aufirst%3DM.%2BD.%26aulast%3DBenedetti%26aufirst%3DM.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGalvin%26aufirst%3DM.%26aulast%3DGerlach%26aufirst%3DJ.%2BL.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DInsko%26aufirst%3DM.%2BA.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DLelias%26aufirst%3DJ.%2BM.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DA%2520small%2520molecule-kinase%2520interaction%2520map%2520for%2520clinical%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D329%26epage%3D336%26doi%3D10.1038%2Fnbt1068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit42b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Karaman, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallant, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faraoni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span> </span><span class="NLM_article-title">A quantitative analysis of kinase inhibitor selectivity</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">132</span><span class="refDoi"> DOI: 10.1038/nbt1358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1038%2Fnbt1358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=18183025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=127-132&author=M.+W.+Karamanauthor=S.+Herrgardauthor=D.+K.+Treiberauthor=P.+Gallantauthor=C.+E.+Atteridgeauthor=B.+T.+Campbellauthor=K.+W.+Chanauthor=P.+Ciceriauthor=M.+I.+Davisauthor=P.+T.+Edeenauthor=R.+Faraoniauthor=M.+Floydauthor=J.+P.+Huntauthor=D.+J.+Lockhartauthor=Z.+V.+Milanovauthor=M.+J.+Morrisonauthor=G.+Pallaresauthor=H.+K.+Patelauthor=S.+Pritchardauthor=L.+M.+Wodickaauthor=P.+P.+Zarrinkar&title=A+quantitative+analysis+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt1358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42bR"><div class="casContent"><span class="casTitleNuber">42b</span><div class="casTitle"><span class="NLM_cas:atitle">A quantitative analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-132</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets.  The biol. consequences of multikinase activity are poorly defined, and an important step toward understanding the relationship between selectivity, efficacy and safety is the exploration of how inhibitors interact with the human kinome.  The authors present interaction maps for 38 kinase inhibitors across a panel of 317 kinases representing >50% of the predicted human protein kinome.  The data constitute the most comprehensive study of kinase inhibitor selectivity to date and reveal a wide diversity of interaction patterns.  To enable a global anal. of the results, the authors introduce the concept of a selectivity score as a general tool to quantify and differentiate the obsd. interaction patterns.  The authors further investigate the impact of panel size and find that small assay panels do not provide a robust measure of selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiArJSq2_lPrVg90H21EOLACvtfcHk0lhsf4qK30rBjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D&md5=346265d412853ced636ad4128ed8a76f</span></div><a href="/servlet/linkout?suffix=cit42b&amp;dbid=16384&amp;doi=10.1038%2Fnbt1358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1358%26sid%3Dliteratum%253Aachs%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DChan%26aufirst%3DK.%2BW.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DMorrison%26aufirst%3DM.%2BJ.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DA%2520quantitative%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D127%26epage%3D132%26doi%3D10.1038%2Fnbt1358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Valencia, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ormazabal, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zandueta, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luis-Ravelo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anton, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pajares, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agorreta, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montuenga, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez-Canarias, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leitinger, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lecanda, F.</span><span> </span><span class="NLM_article-title">Inhibition of collagen receptor discoidin domain receptor-1 (DDR1) reduces cell survival, homing, and colonization in lung cancer bone metastasis</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">969</span><span class="NLM_x">–</span> <span class="NLM_lpage">980</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-1686</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1158%2F1078-0432.CCR-11-1686" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=22223527" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC38XisVGgs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=969-980&author=K.+Valenciaauthor=C.+Ormazabalauthor=C.+Zanduetaauthor=D.+Luis-Raveloauthor=I.+Antonauthor=M.+J.+Pajaresauthor=J.+Agorretaauthor=L.+M.+Montuengaauthor=S.+Martinez-Canariasauthor=B.+Leitingerauthor=F.+Lecanda&title=Inhibition+of+collagen+receptor+discoidin+domain+receptor-1+%28DDR1%29+reduces+cell+survival%2C+homing%2C+and+colonization+in+lung+cancer+bone+metastasis&doi=10.1158%2F1078-0432.CCR-11-1686"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43aR"><div class="casContent"><span class="casTitleNuber">43a</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Collagen Receptor Discoidin Domain Receptor-1 (DDR1) Reduces Cell Survival, Homing, and Colonization in Lung Cancer Bone Metastasis</span></div><div class="casAuthors">Valencia, Karmele; Ormazabal, Cristina; Zandueta, Carolina; Luis-Ravelo, Diego; Anton, Iker; Pajares, Maria J.; Agorreta, Jackeline; Montuenga, Luis M.; Martinez-Canarias, Susana; Leitinger, Birgit; Lecanda, Fernando</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">969-980</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: We investigated the role of the collagen-binding receptor discoidin domain receptor-1 (DDR1) in the initiation and development of bone metastasis.  Exptl. Design: We conducted immunohistochem. analyses in a cohort of 83 lung cancer specimens and examd. phosphorylation status in a panel of human lung cancer cell lines.  Adhesion, chemotaxis, invasiveness, metalloproteolytic, osteoclastogenic, and apoptotic assays were conducted in DDR1-silenced cells.  In vivo, metastatic osseous homing and colonization were assessed in a murine model of metastasis.  RESULTS: DDR1 was expressed in a panel of human lung cancer cell lines, and high DDR1 levels in human lung tumors were assocd. with poor survival.  Knockdown (shDDR1) cells displayed unaltered growth kinetics in vitro and in vivo.  In contrast, shDDR1 cells showed reduced invasiveness in collagen matrixes and increased apoptosis in basal conditions and induced apoptosis in vitro.  More importantly, conditioned media of DDR1-knockdown cells decreased osteoclastogenic activity in vitro.  Consequently, in a model of tumor metastasis to bone, lack of DDR1 showed decreased metastatic activity assocd. with reduced tumor burden and osteolytic lesions.  These effects were consistent with a substantial redn. in the no. of cells reaching the bone compartment.  Moreover, intratibial injection of shDDR1 cells significantly decreased bone tumor burden, suggesting impaired colonization ability that was highly dependent on the bone microenvironment.  CONCLUSIONS: Disruption of DDR1 hampers tumor cell survival, leading to impaired early tumor-bone engagement during skeletal homing.  Furthermore, inhibition of DDR1 crucially alters bone colonization.  We suggest that DDR1 represents a novel therapeutic target involved in bone metastasis.  Clin Cancer Res; 18(4); 969-80.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRyWFLZ7ytcbVg90H21EOLACvtfcHk0lhsf4qK30rBjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XisVGgs7s%253D&md5=34984329a0773cfff78cc244b0ea9a51</span></div><a href="/servlet/linkout?suffix=cit43a&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-1686&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-1686%26sid%3Dliteratum%253Aachs%26aulast%3DValencia%26aufirst%3DK.%26aulast%3DOrmazabal%26aufirst%3DC.%26aulast%3DZandueta%26aufirst%3DC.%26aulast%3DLuis-Ravelo%26aufirst%3DD.%26aulast%3DAnton%26aufirst%3DI.%26aulast%3DPajares%26aufirst%3DM.%2BJ.%26aulast%3DAgorreta%26aufirst%3DJ.%26aulast%3DMontuenga%26aufirst%3DL.%2BM.%26aulast%3DMartinez-Canarias%26aufirst%3DS.%26aulast%3DLeitinger%26aufirst%3DB.%26aulast%3DLecanda%26aufirst%3DF.%26atitle%3DInhibition%2520of%2520collagen%2520receptor%2520discoidin%2520domain%2520receptor-1%2520%2528DDR1%2529%2520reduces%2520cell%2520survival%252C%2520homing%252C%2520and%2520colonization%2520in%2520lung%2520cancer%2520bone%2520metastasis%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D969%26epage%3D980%26doi%3D10.1158%2F1078-0432.CCR-11-1686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit43b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Meshinchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Appelbaum, F. R.</span><span> </span><span class="NLM_article-title">Structural and functional alterations of FLT3 in acute myeloid leukemia</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">4263</span><span class="NLM_x">–</span> <span class="NLM_lpage">4269</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-08-1123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1158%2F1078-0432.CCR-08-1123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=19549778" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnvFajsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=4263-4269&author=S.+Meshinchiauthor=F.+R.+Appelbaum&title=Structural+and+functional+alterations+of+FLT3+in+acute+myeloid+leukemia&doi=10.1158%2F1078-0432.CCR-08-1123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43bR"><div class="casContent"><span class="casTitleNuber">43b</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Functional Alterations of FLT3 in Acute Myeloid Leukemia</span></div><div class="casAuthors">Meshinchi, Soheil; Appelbaum, Frederick R.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4263-4269</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Hematopoiesis is highly regulated through cytokine-induced stimulation of multiple signal transduction pathways in order to mediate appropriate differentiation and proliferation of specific progenitor populations.  Ligand-induced stimulation of the FMS-like tyrosine kinase 3 (FLT3) leads to activation of multiple downstream effector pathways resulting in differentiation and proliferation of specific progenitor cell populations.  Genomic alterations of the FLT3 gene, including FLT3 internal tandem duplication (FLT3/ITD) and FLT3 activation loop mutation (FLT3/ALM) lead to autonomous receptor activation, dysregulation of FLT3 signal transduction pathways, contribute to myeloid pathogenesis, and have been linked to response to therapy and clin. outcome.  Exploring the mechanisms by which these FLT3 alterations lead to dysregulated proliferation should provide a better understanding of the mol. pathogenesis of acute myeloid leukemia (AML) and may provide insights into potential therapeutic interventions.  FLT3 inhibitors are under evaluation for their efficacy in AML patients with FLT3 mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAErdWLDL077Vg90H21EOLACvtfcHk0lhTCR_HCTtsbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnvFajsb4%253D&md5=ddde20ad844268c1baf2df563604f40f</span></div><a href="/servlet/linkout?suffix=cit43b&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-1123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-1123%26sid%3Dliteratum%253Aachs%26aulast%3DMeshinchi%26aufirst%3DS.%26aulast%3DAppelbaum%26aufirst%3DF.%2BR.%26atitle%3DStructural%2520and%2520functional%2520alterations%2520of%2520FLT3%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D4263%26epage%3D4269%26doi%3D10.1158%2F1078-0432.CCR-08-1123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit43cc"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Belkina, N. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hao, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karasuyama, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, S.</span><span> </span><span class="NLM_article-title">LOK is a major ERM kinase in resting lymphocytes and regulates cytoskeletal rearrangement through ERM phosphorylation</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">4707</span><span class="NLM_x">–</span> <span class="NLM_lpage">4712</span><span class="refDoi"> DOI: 10.1073/pnas.0805963106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43cc&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1073%2Fpnas.0805963106" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=4707-4712&author=N.+V.+Belkinaauthor=Y.+Liuauthor=J.+J.+Haoauthor=H.+Karasuyamaauthor=S.+Shaw&title=LOK+is+a+major+ERM+kinase+in+resting+lymphocytes+and+regulates+cytoskeletal+rearrangement+through+ERM+phosphorylation&doi=10.1073%2Fpnas.0805963106"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43cc&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0805963106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0805963106%26sid%3Dliteratum%253Aachs%26aulast%3DBelkina%26aufirst%3DN.%2BV.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DHao%26aufirst%3DJ.%2BJ.%26aulast%3DKarasuyama%26aufirst%3DH.%26aulast%3DShaw%26aufirst%3DS.%26atitle%3DLOK%2520is%2520a%2520major%2520ERM%2520kinase%2520in%2520resting%2520lymphocytes%2520and%2520regulates%2520cytoskeletal%2520rearrangement%2520through%2520ERM%2520phosphorylation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2009%26volume%3D106%26spage%3D4707%26epage%3D4712%26doi%3D10.1073%2Fpnas.0805963106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit43c"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Mehta, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarthy, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thilak, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robson, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neal, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, H. Y.</span><span> </span><span class="NLM_article-title">MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1381</span><span class="NLM_x">–</span> <span class="NLM_lpage">1389</span><span class="refDoi"> DOI: 10.1038/sj.onc.1206154</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1038%2Fsj.onc.1206154" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2003&pages=1381-1389&author=P.+B.+Mehtaauthor=B.+L.+Jenkinsauthor=L.+McCarthyauthor=L.+Thilakauthor=C.+N.+Robsonauthor=D.+E.+Nealauthor=H.+Y.+Leung&title=MEK5+overexpression+is+associated+with+metastatic+prostate+cancer%2C+and+stimulates+proliferation%2C+MMP-9+expression+and+invasion&doi=10.1038%2Fsj.onc.1206154"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43c&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1206154&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1206154%26sid%3Dliteratum%253Aachs%26aulast%3DMehta%26aufirst%3DP.%2BB.%26aulast%3DJenkins%26aufirst%3DB.%2BL.%26aulast%3DMcCarthy%26aufirst%3DL.%26aulast%3DThilak%26aufirst%3DL.%26aulast%3DRobson%26aufirst%3DC.%2BN.%26aulast%3DNeal%26aufirst%3DD.%2BE.%26aulast%3DLeung%26aufirst%3DH.%2BY.%26atitle%3DMEK5%2520overexpression%2520is%2520associated%2520with%2520metastatic%2520prostate%2520cancer%252C%2520and%2520stimulates%2520proliferation%252C%2520MMP-9%2520expression%2520and%2520invasion%26jtitle%3DOncogene%26date%3D2003%26volume%3D22%26spage%3D1381%26epage%3D1389%26doi%3D10.1038%2Fsj.onc.1206154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit43d"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zejnullahu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsudomi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hyland, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gale, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappuzzo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mok, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantley, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">316</span><span class="NLM_x">, </span> <span class="NLM_fpage">1039</span><span class="NLM_x">–</span> <span class="NLM_lpage">1043</span><span class="refDoi"> DOI: 10.1126/science.1141478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1126%2Fscience.1141478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=17463250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltlOjt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=2007&pages=1039-1043&author=J.+A.+Engelmanauthor=K.+Zejnullahuauthor=T.+Mitsudomiauthor=Y.+C.+Songauthor=C.+Hylandauthor=J.+O.+Parkauthor=N.+Lindemanauthor=C.+M.+Galeauthor=X.+J.+Zhaoauthor=J.+Christensenauthor=T.+Kosakaauthor=A.+J.+Holmesauthor=A.+M.+Rogersauthor=F.+Cappuzzoauthor=T.+Mokauthor=C.+Leeauthor=B.+E.+Johnsonauthor=L.+C.+Cantleyauthor=P.+A.+Janne&title=MET+amplification+leads+to+gefitinib+resistance+in+lung+cancer+by+activating+ERBB3+signaling&doi=10.1126%2Fscience.1141478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43dR"><div class="casContent"><span class="casTitleNuber">43e</span><div class="casTitle"><span class="NLM_cas:atitle">MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling</span></div><div class="casAuthors">Engelman, Jeffrey A.; Zejnullahu, Kreshnik; Mitsudomi, Tetsuya; Song, Youngchul; Hyland, Courtney; Park, Joon Oh; Lindeman, Neal; Gale, Christopher-Michael; Zhao, Xiaojun; Christensen, James; Kosaka, Takayuki; Holmes, Alison J.; Rogers, Andrew M.; Cappuzzo, Federico; Mok, Tony; Lee, Charles; Johnson, Bruce E.; Cantley, Lewis C.; Jaenne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">316</span>
        (<span class="NLM_cas:issue">5827</span>),
    <span class="NLM_cas:pages">1039-1043</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR) kinase inhibitors gefitinib and erlotinib are effective treatments for lung cancers with EGFR activating mutations, but these tumors invariably develop drug resistance.  Here, we describe a gefitinib-sensitive lung cancer cell line that developed resistance to gefitinib as a result of focal amplification of the MET proto-oncogene. inhibition of MET signaling in these cells restored their sensitivity to gefitinib.  MET amplification was detected in 4 of 18 (22%) lung cancer specimens that had developed resistance to gefitinib or erlotinib.  We find that amplification of MET causes gefitinib resistance by driving ERBB3 (HER3)-dependent activation of PI3K, a pathway thought to be specific to EGFR/ERBB family receptors.  Thus, we propose that MET amplification may promote drug resistance in other ERBB-driven cancers as well.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr430gbvBeIoLVg90H21EOLACvtfcHk0lhTCR_HCTtsbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltlOjt7g%253D&md5=3da9383b4acb965f57529b095f8f4686</span></div><a href="/servlet/linkout?suffix=cit43d&amp;dbid=16384&amp;doi=10.1126%2Fscience.1141478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1141478%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DZejnullahu%26aufirst%3DK.%26aulast%3DMitsudomi%26aufirst%3DT.%26aulast%3DSong%26aufirst%3DY.%2BC.%26aulast%3DHyland%26aufirst%3DC.%26aulast%3DPark%26aufirst%3DJ.%2BO.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DGale%26aufirst%3DC.%2BM.%26aulast%3DZhao%26aufirst%3DX.%2BJ.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DKosaka%26aufirst%3DT.%26aulast%3DHolmes%26aufirst%3DA.%2BJ.%26aulast%3DRogers%26aufirst%3DA.%2BM.%26aulast%3DCappuzzo%26aufirst%3DF.%26aulast%3DMok%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DMET%2520amplification%2520leads%2520to%2520gefitinib%2520resistance%2520in%2520lung%2520cancer%2520by%2520activating%2520ERBB3%2520signaling%26jtitle%3DScience%26date%3D2007%26volume%3D316%26spage%3D1039%26epage%3D1043%26doi%3D10.1126%2Fscience.1141478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit43e"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Wadhwa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nag, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jindal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kushwaha, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahapatra, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarkar, C.</span><span> </span><span class="NLM_article-title">Expression of the neurotrophin receptors Trk A and Trk B in adult human astrocytoma and glioblastoma</span> <span class="citation_source-journal">J. Biosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">181</span><span class="NLM_x">–</span> <span class="NLM_lpage">188</span><span class="refDoi"> DOI: 10.1007/BF02706217</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1007%2FBF02706217" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=12711810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BD3sXislWitb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2003&pages=181-188&author=S.+Wadhwaauthor=T.+C.+Nagauthor=A.+Jindalauthor=R.+Kushwahaauthor=A.+K.+Mahapatraauthor=C.+Sarkar&title=Expression+of+the+neurotrophin+receptors+Trk+A+and+Trk+B+in+adult+human+astrocytoma+and+glioblastoma&doi=10.1007%2FBF02706217"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43eR"><div class="casContent"><span class="casTitleNuber">43f</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of the neurotrophin receptors Trk A and Trk B in adult human astrocytoma and glioblastoma</span></div><div class="casAuthors">Wadhwa, Shashi; Nag, Tapas C.; Jindal, Anupam; Kushwaha, Rahul; Mahapatra, Ashok K.; Sarkar, Chitra</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biosciences (Bangalore, India)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">181-188</span>CODEN:
                <span class="NLM_cas:coden">JOBSDN</span>;
        ISSN:<span class="NLM_cas:issn">0250-5991</span>.
    
            (<span class="NLM_cas:orgname">Indian Academy of Sciences</span>)
        </div><div class="casAbstract">Neurotrophins and their receptors of the Trk family play a crit. role in proliferation, differentiation and survival of the developing neurons.  There are reports on their expression in neoplasms too, namely, the primitive neuroectodermal tumors of childhood, and in adult astrocytic gliomas.  The involvement of Trk receptors in tumor pathogenesis, if any, is not known.  With this end in view, the present study has examd. 10 tumor biopsy samples (identified as astrocytoma, pilocytic astrocytoma and glioblastoma) and peritumoral brain tissue of adult patients, for the presence of Trk A and Trk B receptors, by immunohistochem.  The nature of the tumor samples was also confirmed by their immunoreactivity (IR) to glial fibrillary acidic protein.  In the peritumoral brain tissue, only neurons showed IR for Trk A and Trk B.  On the contrary, in the tumor sections, the IR to both receptors was localized in the vast majority of glia and capillary endothelium.  There was an obvious pattern of IR in these gliomas: high levels of IR were present in the low-grade (type I and II) astrocytoma; whereas in the advanced malignant forms (WHO grade IV giant cell glioblastoma and glioblastoma multiforme) the IR was very weak.  These findings suggest that Trk A and Trk B are involved in tumor pathogenesis, esp. in the early stage, and may respond to signals that elicit glial proliferation, and thus contribute to progression towards malignancy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriBJYe5VdXG7Vg90H21EOLACvtfcHk0ljS_AAVlK9ctw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXislWitb8%253D&md5=d5a14151772b6fa49dad99749273af5f</span></div><a href="/servlet/linkout?suffix=cit43e&amp;dbid=16384&amp;doi=10.1007%2FBF02706217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF02706217%26sid%3Dliteratum%253Aachs%26aulast%3DWadhwa%26aufirst%3DS.%26aulast%3DNag%26aufirst%3DT.%2BC.%26aulast%3DJindal%26aufirst%3DA.%26aulast%3DKushwaha%26aufirst%3DR.%26aulast%3DMahapatra%26aufirst%3DA.%2BK.%26aulast%3DSarkar%26aufirst%3DC.%26atitle%3DExpression%2520of%2520the%2520neurotrophin%2520receptors%2520Trk%2520A%2520and%2520Trk%2520B%2520in%2520adult%2520human%2520astrocytoma%2520and%2520glioblastoma%26jtitle%3DJ.%2520Biosci.%26date%3D2003%26volume%3D28%26spage%3D181%26epage%3D188%26doi%3D10.1007%2FBF02706217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Y.</span><span> </span><span class="NLM_article-title">Axl as a downstream effector of TGF-beta1 via PI3K/Akt-PAK1 signaling pathway promotes tumor invasion and chemoresistance in breast carcinoma</span> <span class="citation_source-journal">Tumor Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">1115</span><span class="NLM_x">–</span> <span class="NLM_lpage">1127</span><span class="refDoi"> DOI: 10.1007/s13277-014-2677-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1007%2Fs13277-014-2677-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=25327287" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVent7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2015&pages=1115-1127&author=Y.+Liauthor=L.+Jiaauthor=C.+Liuauthor=Y.+Gongauthor=D.+Renauthor=N.+Wangauthor=X.+Zhangauthor=Y.+Zhao&title=Axl+as+a+downstream+effector+of+TGF-beta1+via+PI3K%2FAkt-PAK1+signaling+pathway+promotes+tumor+invasion+and+chemoresistance+in+breast+carcinoma&doi=10.1007%2Fs13277-014-2677-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Axl as a downstream effector of TGF-β1 via PI3K/Akt-PAK1 signaling pathway promotes tumor invasion and chemoresistance in breast carcinoma</span></div><div class="casAuthors">Li, Yanyan; Jia, Li; Liu, Chen; Gong, Yanxin; Ren, Dongliang; Wang, Ning; Zhang, Xu; Zhao, Yongfu</div><div class="citationInfo"><span class="NLM_cas:title">Tumor Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1115-1127</span>CODEN:
                <span class="NLM_cas:coden">TUMBEA</span>;
        ISSN:<span class="NLM_cas:issn">1010-4283</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The invasion and chemoresistance are crucial causes of morbidity and death for cancer patients.  Axl is closely assocd. with malignant phenotype of breast tumor cells, including invasiveness and metastasis.  Both breast cancer cell line and tissue displayed increased expression of Axl, esp. in highly metastatic breast cancer.  On the contrary, exptl. inhibition of Axl or transforming growth factor beta 1 (TGF-β1) by RNAi assay could suppress cell invasion ability and chemoresistance.  Moreover, the up-regulation of Axl was induced by TGF-β1, further activated phosphatidylinositol 3-kinase (PI3K)/Akt and PAK1 translocation, and resulted in greater cell motility, invasion, and chemoresistance in vitro and in vivo.  After the detection and statistics in human breast cancer specimens, we found that the Axl expression was closely correlated with TGF-β1 level, tumor differentiation, lymph node metastasis, and clin. stage (p < 0.01).  Our findings support the possibility that Axl is a significant regulator of invasion and chemosensitivity, and it means by targeting Axl or its related signaling pathways, we can reduce the invasion and chemosensitivity of breast tumor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG6SCNfxukf7Vg90H21EOLACvtfcHk0ljS_AAVlK9ctw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVent7fF&md5=beb693147ee2a38c3113e98bf2beb0bc</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1007%2Fs13277-014-2677-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13277-014-2677-3%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DGong%26aufirst%3DY.%26aulast%3DRen%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DY.%26atitle%3DAxl%2520as%2520a%2520downstream%2520effector%2520of%2520TGF-beta1%2520via%2520PI3K%252FAkt-PAK1%2520signaling%2520pathway%2520promotes%2520tumor%2520invasion%2520and%2520chemoresistance%2520in%2520breast%2520carcinoma%26jtitle%3DTumor%2520Biol.%26date%3D2015%26volume%3D36%26spage%3D1115%26epage%3D1127%26doi%3D10.1007%2Fs13277-014-2677-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Sinha, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boysen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Secreto, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warner, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bearss, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesnick, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shanafelt, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kay, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, A. K.</span><span> </span><span class="NLM_article-title">Targeted Axl inhibition primes chronic lymphocytic leukemia B cells to apoptosis and shows synergistic/additive effects in combination with BTK inhibitors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">2115</span><span class="NLM_x">–</span> <span class="NLM_lpage">2126</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-1892</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1158%2F1078-0432.CCR-14-1892" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=25673699" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnvFaqs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=2115-2126&author=S.+Sinhaauthor=J.+Boysenauthor=M.+Nelsonauthor=C.+Secretoauthor=S.+L.+Warnerauthor=D.+J.+Bearssauthor=C.+Lesnickauthor=T.+D.+Shanafeltauthor=N.+E.+Kayauthor=A.+K.+Ghosh&title=Targeted+Axl+inhibition+primes+chronic+lymphocytic+leukemia+B+cells+to+apoptosis+and+shows+synergistic%2Fadditive+effects+in+combination+with+BTK+inhibitors&doi=10.1158%2F1078-0432.CCR-14-1892"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors</span></div><div class="casAuthors">Sinha, Sutapa; Boysen, Justin; Nelson, Michael; Secreto, Charla; Warner, Steven L.; Bearss, David J.; Lesnick, Connie; Shanafelt, Tait D.; Kay, Neil E.; Ghosh, Asish K.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2115-2126</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: B-cell chronic lymphocytic leukemia (CLL) is an incurable disease despite aggressive therapeutic approaches.  We previously found that Axl receptor tyrosine kinase (RTK) plays a crit. role in CLL B-cell survival.  Here, we explored the possibility of using a high-affinity Axl inhibitor as a single agent or in combination with Bruton's tyrosine kinase (BTK) inhibitors for future clin. trial to treat patients with CLL.  Exptl. Design: Expression/activation status of other members of the TAM (e.g., Tyro3, Axl, and MER) family of RTKs in CLL B cells was evaluated.  Cells were treated with a high-affinity orally bioavailable Axl inhibitor TP-0903 with or without the presence of CLL bone marrow stromal cells (BMSCs).  Inhibitory effects of TP-0903 on the Axl signaling pathway were also evaluated in CLL B cells.  Finally, cells were exposed to TP-0903 in combination with BTK inhibitors to det. any synergistic/additive effects of the combination.  Results: CLL B cells overexpress Tyro3, but not MER.  Of interest, Tyro3 remains as constitutively phosphorylated and forms a complex with Axl in CLL B cells.  TP-0903 induces massive apoptosis in CLL B cells with LD50 values of nanomolar ranges.  Importantly, CLL BMSCs could not protect the leukemic B cells from TP-0903-induced apoptosis.  A marked redn. of the antiapoptotic proteins Mcl-1, Bcl-2, and XIAP and upregulation of the proapoptotic protein BIM in CLL B cells was detected as a result of Axl inhibition.  Finally, combination of TP-0903 with BTK inhibitors augments CLL B-cell apoptosis.  Conclusions: Administration of TP-0903 either as a single agent or in combination with BTK inhibitors may be effective in treating patients with CLL.  Clin Cancer Res; 21(9); 2115-26. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmCcdSntQPu7Vg90H21EOLACvtfcHk0ljS_AAVlK9ctw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnvFaqs7o%253D&md5=2d7554e400d1d5e4bee347f43dea2762</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-1892&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-1892%26sid%3Dliteratum%253Aachs%26aulast%3DSinha%26aufirst%3DS.%26aulast%3DBoysen%26aufirst%3DJ.%26aulast%3DNelson%26aufirst%3DM.%26aulast%3DSecreto%26aufirst%3DC.%26aulast%3DWarner%26aufirst%3DS.%2BL.%26aulast%3DBearss%26aufirst%3DD.%2BJ.%26aulast%3DLesnick%26aufirst%3DC.%26aulast%3DShanafelt%26aufirst%3DT.%2BD.%26aulast%3DKay%26aufirst%3DN.%2BE.%26aulast%3DGhosh%26aufirst%3DA.%2BK.%26atitle%3DTargeted%2520Axl%2520inhibition%2520primes%2520chronic%2520lymphocytic%2520leukemia%2520B%2520cells%2520to%2520apoptosis%2520and%2520shows%2520synergistic%252Fadditive%2520effects%2520in%2520combination%2520with%2520BTK%2520inhibitors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D2115%26epage%3D2126%26doi%3D10.1158%2F1078-0432.CCR-14-1892" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Rodriguez, L. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, X. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guan, J. L.</span><span> </span><span class="NLM_article-title">Wound-healing assay</span> <span class="citation_source-journal">Methods Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">294</span><span class="NLM_x">, </span> <span class="NLM_fpage">23</span><span class="NLM_x">–</span> <span class="NLM_lpage">29</span><span class="refDoi"> DOI: 10.1385/1-59259-860-9:023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1385%2F1-59259-860-9%3A023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=15576902" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A280%3ADC%252BD2cngsVaksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=294&publication_year=2005&pages=23-29&author=L.+G.+Rodriguezauthor=X.+Y.+Wuauthor=J.+L.+Guan&title=Wound-healing+assay&doi=10.1385%2F1-59259-860-9%3A023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Wound-healing assay</span></div><div class="casAuthors">Rodriguez Luis G; Wu Xiaoyang; Guan Jun-Lin</div><div class="citationInfo"><span class="NLM_cas:title">Methods in molecular biology (Clifton, N.J.)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">294</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">23-9</span>
        ISSN:<span class="NLM_cas:issn">1064-3745</span>.
    </div><div class="casAbstract">The wound-healing assay is simple, inexpensive, and one of the earliest developed methods to study directional cell migration in vitro.  This method mimics cell migration during wound healing in vivo.  The basic steps involve creating a "wound" in a cell monolayer, capturing the images at the beginning and at regular intervals during cell migration to close the wound, and comparing the images to quantify the migration rate of the cells.  It is particularly suitable for studies on the effects of cell-matrix and cell-cell interactions on cell migration.  A variation of this method that tracks the migration of individual cells in the leading edge of the wound is also described in this chapter.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQl9QyTalxlY0odMGTatQ7LfW6udTcc2eaQi6h2FTnCt7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2cngsVaksA%253D%253D&md5=6e48b14b34d8f3e673795ba74c95a647</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1385%2F1-59259-860-9%3A023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1385%252F1-59259-860-9%253A023%26sid%3Dliteratum%253Aachs%26aulast%3DRodriguez%26aufirst%3DL.%2BG.%26aulast%3DWu%26aufirst%3DX.%2BY.%26aulast%3DGuan%26aufirst%3DJ.%2BL.%26atitle%3DWound-healing%2520assay%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2005%26volume%3D294%26spage%3D23%26epage%3D29%26doi%3D10.1385%2F1-59259-860-9%3A023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Marshall, J.</span><span> </span><span class="NLM_article-title">Transwell  invasion assays</span> <span class="citation_source-journal">Methods Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">769</span><span class="NLM_x">, </span> <span class="NLM_fpage">97</span><span class="NLM_x">–</span> <span class="NLM_lpage">110</span><span class="refDoi"> DOI: 10.1007/978-1-61779-207-6_8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1007%2F978-1-61779-207-6_8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=21748672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvValtL3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=769&publication_year=2011&pages=97-110&author=J.+Marshall&title=Transwell++invasion+assays&doi=10.1007%2F978-1-61779-207-6_8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Transwell invasion assays</span></div><div class="casAuthors">Marshall, John</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">769</span>
        (<span class="NLM_cas:issue">Cell Migration</span>),
    <span class="NLM_cas:pages">97-110</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1064-3745</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The need to identify inhibitors of cancer invasion has driven the development of quant. in vitro invasion assays.  The most common assays used are based on the original Boyden assay system.  Today com. available plastic inserts for multi-well plates, which possess a cell-permeable membrane, as typified by Transwell Permeable Supports, permit accurate repeatable invasion assays.  When placed in the well of a multi-well tissue culture plate these inserts create a two-chamber system sepd. by the cell-permeable membrane.  To create an invasion assay the pores in the membrane are blocked with a gel composed of extracellular matrix that is meant to mimic the typical matrixes that tumor cells encounter during the invasion process in vivo.  By placing the cells on one side of the gel and a chemoattractant on the other side of the gel, invasion is detd. by counting those cells that have traversed the cell-permeable membrane having invaded towards the higher concn. of chemoattractant.  In this chapter, in addn. to protocols for performing Transwell invasion assays, there is consideration of the limitations of current assay designs with regard to available matrixes and the absence of tumor microenvironment cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7zbRBB-kc5LVg90H21EOLACvtfcHk0lhsrQKjS07MfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvValtL3F&md5=0e1a7a2315e8891770ad14540bd8e9b5</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1007%2F978-1-61779-207-6_8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-61779-207-6_8%26sid%3Dliteratum%253Aachs%26aulast%3DMarshall%26aufirst%3DJ.%26atitle%3DTranswell%2520%2520invasion%2520assays%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2011%26volume%3D769%26spage%3D97%26epage%3D110%26doi%3D10.1007%2F978-1-61779-207-6_8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Chen, H. C.</span><span> </span><span class="NLM_article-title">Boyden chamber assay</span> <span class="citation_source-journal">Methods Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">294</span><span class="NLM_x">, </span> <span class="NLM_fpage">15</span><span class="NLM_x">–</span> <span class="NLM_lpage">22</span><span class="refDoi"> DOI: 10.1385/1-59259-860-9:015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=10.1385%2F1-59259-860-9%3A015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=15576901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;key=1%3ACAS%3A280%3ADC%252BD2cngsVaksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=294&publication_year=2005&pages=15-22&author=H.+C.+Chen&title=Boyden+chamber+assay&doi=10.1385%2F1-59259-860-9%3A015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Boyden chamber assay</span></div><div class="casAuthors">Chen Hong-Chen</div><div class="citationInfo"><span class="NLM_cas:title">Methods in molecular biology (Clifton, N.J.)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">294</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">15-22</span>
        ISSN:<span class="NLM_cas:issn">1064-3745</span>.
    </div><div class="casAbstract">The Boyden chamber assay, originally introduced by Boyden for the analysis of leukocyte chemotaxis, is based on a chamber of two medium-filled compartments separated by a microporous membrane.  In general, cells are placed in the upper compartment and are allowed to migrate through the pores of the membrane into the lower compartment, in which chemotactic agents are present.  After an appropriate incubation time, the membrane between the two compartments is fixed and stained, and the number of cells that have migrated to the lower side of the membrane is determined.  Therefore, the Boyden chamber-based cell migration assay has also been called filter membrane migration assay, trans-well migration assay, or chemotaxis assay.  A number of different Boyden chamber devices are available commercially.  The method described in this chapter is intended specifically for measuring the migration of Madin-Darby canine kidney cells using a 48-well chamber from Neuro Probe, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQl9QyTalxlY5w7prLlxLOzfW6udTcc2eaQi6h2FTnCt7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2cngsVaksw%253D%253D&md5=bc388c5231733596bc778c560437a3de</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1385%2F1-59259-860-9%3A015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1385%252F1-59259-860-9%253A015%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DH.%2BC.%26atitle%3DBoyden%2520chamber%2520assay%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2005%26volume%3D294%26spage%3D15%26epage%3D22%26doi%3D10.1385%2F1-59259-860-9%3A015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i77"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00608">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_78427"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.6b00608">10.1021/acs.jmedchem.6b00608</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Biological data, assay details, and <sup>1</sup>H and <sup>13</sup>C NMR spectra for final compounds and intermediates (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00608/suppl_file/jm6b00608_si_001.pdf">PDF</a>)</p></li><li><p class="inline">(<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00608/suppl_file/jm6b00608_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00608/suppl_file/jm6b00608_si_001.pdf">jm6b00608_si_001.pdf (8.93 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00608/suppl_file/jm6b00608_si_002.csv">jm6b00608_si_002.csv (4.41 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-14%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b00608" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b00608" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67996e722ed1d93a","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
